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Abstract 
The aggregation of peptides or proteins to form amyloid fibrils and plaques is associated with the 
pathologies of a range of neurological disorders and metabolic diseases, including Alzheimer’s 
disease (AD), Parkinson’s disease (PD) and type II diabetes mellitus (T2D). Human islet amyloid 
polypeptide (IAPP), specifically, contributes to glycemic control but also mediates the dysfunction 
of insulin-producing pancreatic β-cells in T2D. Furthermore, IAPP in circulation is capable of 
cross-seeding amyloid-beta and alpha-synuclein, associated with AD and PD respectively. Given no 
current anti-amyloid treatment is currently commercially available, fundamental understanding of 
amyloidosis within the complex cellular environment is required against amyloid diseases. 
In this thesis, conditions to slow down the rapid fibrillization of IAPP to reduce or eliminate 
intermediate toxic aggregates have been identified in vitro. IAPP intermediate species were 
characterized and a novel ‘biannular’ morphology identified, with two distinct fibrillating 
populations then eliciting differential cytotoxicity to mature amyloids in primary cells in vitro. The 
behavior of fibrillating and fibrillar amyloid species in the presence of model proteins, lipids and 
ultrasmall lipid membranes was investigated, with regards to their effects on amyloid fibrillization, 
morphology and associated cytotoxicity in vitro, progressing then towards an in-depth study into 
the ‘protein corona’ formation of amyloid fibrils within complex biological media. Proteomic 
analysis identified amyloid-enriched proteins that are known to play significant roles in mediating 
cellular machinery and processing, potentially leading to pathological outcomes and therapeutic 
targets. Finally, a biocompatible star polymer (‘PHEA’) was synthesized to mimic the anti-
amyloidosis properties of natural polyphenols and effectively rescue IAPP toxicity in mouse islets. 
Surprisingly, the relatively rigid and amphiphilic PHEA stars induced the formation of novel 
amyloid morphologies through promoting fibrillization, and accelerated amyloidogenesis to 
eliminate toxic intermediates in a fashion reminiscent of melanin production. This thesis outlines a 
logical progression towards the development of effective anti-amyloid strategies: whereby through 
first gaining insight into amyloidosis, this knowledge can be then applied to ameliorate amyloid 
pathologies. 
3 
Publications during enrolment* 
*Journal articles written and published during candidature wherein experimentation was completed prior to
start date are not included here.
(1) Pilkington, E. H.; Lai, M.; X. Ge, Stanley, W. J.; Wang, B.; Wang, M.; Kakinen, A.; Sani,
M-A.; Whittaker, M. R.; Gurzov, E. N.; Ding, F.; Quinn, J. F.; Davis, T. P.; Ke, P. C., Star
Polymers Reduce Islet Amyloid Polypeptide Toxicity via Accelerated Amyloid Aggregation,
Biomacromolecules 2017, 18, 4249-4260.
(2) Pilkington, E. H.; Xing, Y.; Wang, B.; Käkinen, A.; Wang, M.; Davis, T. P.; Ding, F.; Ke, P.
C., Effects of Protein Corona on IAPP Amyloid Aggregation, Fibril Remodelling, and Cytotoxicity.
Sci. Rep. 2017, 7, 2455.
(3) Wang, B.; Pilkington, E. H.; Sun, Y.; Davis, T. P.; Ke, P. C.; Ding, F., Modulating protein
amyloid aggregation with nanomaterials, Environ. Sci. Nano 2017, 4, 1772-1783.
(4) Xing, Y.; Pilkington, E. H.; Wang, M.; Nowell, C. J.; Käkinen, A.; Sun, Y.; Wang, B.;
Davis, T. P.; Ding, F.; Ke, P. C., Lysophosphatidylcholine modulates the aggregation of human
islet amyloid polypeptide. Phys. Chem. Chem. Phys. 2017, 19, 30627-30635.
(5) Wang, M.; Käkinen, A.; Pilkington, E. H.; Davis, T. P.; Ke, P. C., Differential Effects of
Silver and Iron Oxide Nanoparticles on IAPP Aggregation and Toxicity. Biomater. Sci. 2017, 5,
485-493.
(6) Javed, I.; Sun, Y.; Adamcik, J.; Wang, B.; Käkinen, A.; Pilkington, E. H.; Ding, F.;
Mezzenga, R.; Davis, T. P.; Ke, P. C., Cofibrillization of Pathogenic and Functional Amyloid
Proteins with Gold Nanoparticles against Amyloidogenesis. Biomacromolecules 2017, 18, 4316-
4322.
(7) Wang, M.; Gustafsson, O. J. R.; Pilkington, E. H.; Kakinen, A.; Javed, I.; Faridi, A.; Davis,
T. P.; Ke, P. C., Nanoparticle-proteome in vitro and in vivo, J. Mat. Chem. B 2018, 6, 6026-6041.
(8) Tanaka, J.; Tani, S.; Peltier, R.; Pilkington, E. H.; Kerr, A.; Davis, T. P.; Wilson, P.,
Synthesis, aggregation and responsivity of block copolymers containing organic arsenicals, Polym.
Chem. 2018, 9, 1551-1556.
(9) Pilkington, E. H.; Gustaffson, O. J. R.; Xing, Y.; Hernandez-Fernaud, J.; Zampronio, C.;
Kakinen, A.; Faridi, A.; Ding, F.; Wilson, P.; Ke, P. C.; Davis, T. P., Profiling the Serum Protein
Corona of Fibrillar Human Islet Amyloid Polypeptide, ACS Nano 2018, 12, 6066-6078.
(10) Sun, Y.; Käkinen, A.; Xing, Y.; Pilkington, E. H.; Davis, T. P.; Ke, P. C.; Ding, F.,
Nucleation of β-rich oligomers and β-barrels in the early aggregation of human islet amyloid
polypeptide. Biochim. Biophys. Mol. Basis Dis. 2019, 1865, 434-444.
4 
(11) Kakinen, A.; Sun, Y.; Javed, I.; Faridi, A.; Pilkington, E. H.; Faridi, P.; Purcell, A. W.;
Zhou, R.; Ding, F.; Lin, S.; Ke, P. C.; Davis, T. P., Physical and toxicological profiles of human
IAPP amyloids and plaques, Sci. Bull. 2019, 64, 26-35.
(12) Ke, P. C.; Pilkington, E. H., Sun, Y., Javed, I.; Kakinen, A.; Peng, G.; Ding, F.; Davis, T. P.,
Mitigation of Amyloidosis with Nanomaterials, Adv. Mater. 2019, 1901690.
Conference presentations
Pilkington, E. H.; Blin, T.; Käkinen, A.; Ding, F.; Ke, P. C.; Davis, T. P.; Nanotechnologies for 
IAPP Aggregation Inhibition and Anti-Protein Fouling, Warwick Polymer Conference, Coventry, 
UK, 2016. 
Pilkington, E. H.; Gustafsson, O. J. R.; Ding, F.; Wilson, P.; Ke, P. C.; Davis, T. P.; Protein Corona, 
in a New Context of Amyloidogenesis, International Conference on Nanoscience and 
Nanotechnology (ICONN), Wollongong, Australia, 2018. 
Pilkington, E. H.; Gustafsson, O. J. R.; Ding, F.; Wilson, P.; Ke, P. C.; Davis, T. P.; Protein Corona, 
in a New Context of Amyloidogenesis, Macro Group UK Young Researcher’s Meeting (YRM), 
Dublin, Ireland, 2018. 
Pilkington, E. H.; Gustafsson, O. J. R.; Ding, F.; Wilson, P.; Ke, P. C.; Davis, T. P.; Protein Corona, 
in a New Context of Amyloidogenesis, EuCheMS, Liverpool, UK, 2018. 
Pilkington, E. H.; Gustafsson, O. J. R.; Ding, F.; Wilson, P.; Ke, P. C.; Davis, T. P.; Protein Corona, 
in a New Context of Amyloidogenesis, PolymerVic, Melbourne, Australia, 2018. 
5 
Thesis including published works declaration 
I hereby declare that this thesis contains no material which has been accepted for the award of any other 
degree or diploma at any university or equivalent institution and that, to the best of my knowledge and belief, 
this thesis contains no material previously published or written by another person, except where due 
reference is made in the text of the thesis.  
This thesis includes two original papers published in peer reviewed journals. The core theme of the thesis is 
amyloidosis. The ideas, development and writing up of all the papers in the thesis were the principal 
responsibility of myself, the student, working within the Monash Institute of Pharmaceutical Sciences 
(Monash University) and the Faculty of Chemistry (University of Warwick) under the supervision of Dr Pu 
Chun Ke, Dr Paul Wilson & Prof Tom Davis.  
The inclusion of co-authors reflects the fact that the work came from active collaboration between 
researchers and acknowledges input into team-based research. 






























50%. Concept and 
collecting data and 
analyses, writing 
first draft and 
additional editing 



































































50%. Concept and 
collecting data and 
analyses, writing 
first draft and 
additional editing 




























































11. John F. Quinn:
concept, input into
manuscript 2%










I have renumbered sections of submitted or published papers in order to generate a consistent presentation 
within the thesis. 
Student signature: Date: 26/11/2019 
The undersigned hereby certify that the above declaration correctly reflects the nature and extent of the 
student’s and co-authors’ contributions to this work. In instances where I am not the responsible author I 
have consulted with the responsible author to agree on the respective contributions of the authors. 





This research was supported by an Australian Government Research Training Program (RTP) 
Scholarship, and additionally by the 2018 Vaughan Scholarship and an Australian Bicentennial 
Scholarship (2016). I am also thankful for a travel bursary from the Monash-Warwick Alliance. 
First and foremost, to my brilliant supervisors – Dr Paul Wilson, Prof Tom Davis and especially to 
my primary supervisor, Dr Pu Chun Ke, who has worked with me tirelessly every step of the way. I 
am exceptionally fortunate to have had the guidance and wealth of experience each of you have 
brought behind me during the past four years. I am so grateful for the opportunities you have given 
me, from attending and presenting at international conferences to lab visits with collaborators, 
access to resources and facilities that developed my skills as an experimentalist, to workshops, 
seminars, and soft-skills training that enabled my growth as a well-rounded researcher. To be able 
to publish over twenty papers within these last few years is a privilege many candidates aren’t 
afforded, and for all the hard work I put in, you were willing to work twice as hard to get me there. 
Through your efforts, I go forward knowing my future is bright, and I could not be more thankful. 
Thank you to my panel, Prof Colin Pouton, Dr Esteban Gurzov and Dr Nghia Truong, for their 
guidance and insight throughout my candidature. I also could not have had the incredibly 
productive PhD that I had without fantastic collaborators: Dr Feng Ding and the Ding group at 
Clemson University, USA, provided computational simulations that have complemented and 
elevated so much of the experimental work I have been involved in thus far. To Dr Esteban Gurzov 
and his team at St Vincent Institute for excellent ex vivo mouse work. Dr Johan Gustafsson, who 
took 40 GB of proteomic data sent from England and turned it into gold down in sunny Adelaide, 
and to Drs John Quinn and Michael Whittaker, and May Lai at MIPS, all-stars of star polymer 
synthesis. It has been such a pleasure to know and work with all of you, and I hope we can continue 
to do so for years to come. 
To members of the Ke group, past and present – Dr Aleksandr Kakinen, Dr Miaoyi Wang, Dr 
Ibrahim Javed, Ava Faridi, Aparna Nandakumar, Nikolaos Andrikopoulos, Kairi Koppel – thank 
you for all of your support in the lab, the office and beyond. I am honoured to have known each of 
you for the brilliant scientists you are, and your dedication and drive inspires me to be a better 
scientist myself. To the lovely lads in the Haddleton/Wilson groups at the University of Warwick 
for always being supportive and accommodating to the migratory researcher in their midst, and 
who, as I was the lone amyloid scientist, gave me the nickname ‘Emyloid’ – with a particular thank 
9 
you to Chris and Gavin, who helped me through a very difficult period. To the admin and staff at 
the CBNS/MIPS Nanomed, who have each been endlessly helpful and generous through the years. 
To great scientists and greater friends in the wider Nanomed group, past and present, for their 
advice and encouragement – in particular to Ayaat, Carlos, Cheng, James, Jo, John, Lars, May, and 
Song-and-Elly, who went from friends to marriage within my candidature (and I got to catch the 
bouquet!) 
It’s been a long journey to get here – and I’m not just referring to the 24 hour UK-Australia flights 
I’ve been taking twice a year! To my long-suffering friends outside of work, who I might actually 
now see more than once every few months, and particularly to Ronnie, who might actually now see 
me in our own apartment – you mean the world to me, thank you for sticking with me through it all. 
And, finally, to Mum, Dad, and Meg, my wonderful, generous family, who don’t quite understand 
what I do (and to my sweet cat, who definitely doesn’t), but support me unconditionally anyway. I 
love you dearly, and could not have done this without you. 
10 
Table of contents. 
0. Preliminary pages (incl. Abstract, Declarations, Acknowledgments, ToC) 1-11
1. Introduction 12
1.1.  Protein aggregation: an overview 12
1.1.1. Defining protein aggregation: species and mechanics 12
1.1.2. Pathological amyloid and dysfunctional aggregation 15
1.2.  Islet amyloid polypeptide: type II diabetes as an amyloid disease 22
1.2.1. Overview 22
1.2.2. IAPP within pancreatic cells 24
1.2.3. IAPP amyloidosis 26
1.2.4. IAPP pathologies beyond the pancreas 28
1.3.  Amyloid in the extracellular environment 29
1.3.1. Modulation of amyloidosis by extracellular biomolecules 29
1.3.2. Amyloid and the ‘protein corona’ 31
1.4.  Anti-amyloidosis strategies: from nano to micro 34
1.4.1. Overview and models 34
1.4.2. Small molecules 36
1.4.3. Metallic and semi-conducting nanomaterials 37
1.4.4. Carbon-based and inorganic nanomaterials 39
1.4.5. Biomimetic nanomaterials 41
1.4.6. Polymeric nanomaterials 42
1.5.  State-of-the-art and current paradigms in amyloid science 44
1.5.1. State-of-the-art in amyloid technologies and anti-amyloidosis strategy 44
1.5.2. Prevailing issues and future directions in amyloid science 47
1.6.  Context of thesis 48
1.7.  References 50
2. Model Interactions of Amyloid Protein Species 75
2.1.  Chapter abstract 75
2.2.  Introduction 77
2.3.  Results and discussion 80
2.3.1. Profiling IAPP fibrillization species and their associated toxicity in
vitro 80
2.3.1.1.  Characterization of IAPP intermediate species 80
11 
2.3.1.2.  Cytotoxicity and fibrillization kinetics of IAPP species in primary 
endothelial cells 84 
2.3.2. Biophysical characterizations of protein and lipid binding on IAPP
aggregation and fibril remodeling 88 
2.3.2.1.  Effects of LPC binding on IAPP fibrillization and remodeling 88 
2.3.2.2.  ThT and CD assay quantifications of IAPP fibrillization inhibition 
by proteins 90 
2.3.2.3.  High resolution TEM imaging of IAPP fibrillization inhibition and 
remodeling by proteins 91 
2.3.3. Effects of protein binding on viabilities of fresh IAPP and IAPP
amyloids 92 
2.4.  Conclusions 93 
2.5.  Materials and Methods 95 
2.5.1. Materials 95 
2.5.2. Thioflavin T (ThT) assays 96 
2.5.3. Transmission electron microscopy (TEM) and analysis 96 
2.5.3.1.  Morphological and statistical analysis of IAPP species imaged
using TEM 97 
2.5.4. Circular dichroism (CD) spectroscopy 98 
2.5.5. In vitro biological assays 98 
2.5.5.1.  Cell culture 98 
2.5.5.2.  Propidium iodide live-dead assay 98 
2.5.5.3.  Calcein-AM viability assay 99 
2.5.5.4.  Statistical analysis 99 
2.6.  References 101 
3. Profiling the Serum Protein Corona of Human Islet Amyloid Polypeptide 107 
4. Star Polymers Reduce Islet Amyloid Polypeptide via Accelerated Amyloid
Aggregation 122 
5. Conclusions 136 
5.1.  References 139 
6. Appendices 140 
6.1.  Supporting Information 140 
6.1.1. Model Interactions of Amyloid Protein Species 140 
6.1.2. Profiling the Serum Protein Corona of Human Islet Amyloid 
Polypeptide 142 
6.1.3. Star Polymers Reduce Islet Amyloid Polypeptide via Accelerated 
Amyloid Aggregation 186 
6.2.  Complete Bibliography 195 
12 
Chapter One: Introduction 
1.1 Protein aggregation: an overview 
1.1.1 Defining protein aggregation: species and mechanics 
Protein aggregation can be defined as the interfacing of misfolded proteins to form micro- to 
macrostructures with either regular or amorphous morphology. Due to the large number of 
possible conformations a protein can take, the process of protein folding can be highly complex 
and heterogeneous, and reliant on weak, non-covalent interactions to correctly assume the 
native state.1 Modulation of a native protein’s net charge, for example, could destabilize 
electrostatic interactions and result in misfolding.2 Overarchingly, however, intramolecular 
folding of protein and protein aggregation are both driven by hydrophobic interactions: for 
soluble protein, folding mechanisms ensure hydrophobic residues are buried in the protein 
interior, and are particularly prescient for proteins 100 amino acids or larger (comprising 
around ~90% of all cellular proteins), which have a propensity for rapid hydrophobic collapse 
to compact, globular morphology.3 In aggregating species, these moieties – in the context of 
Figure 1: Physical aspects of amyloid aggregation. A: Free energy landscape of protein aggregation, 
visually demonstrating the energy requirements for the transition of a protein from its native state to different 
aggregation species, and how molecular chaperones attempt to return early aggregates to their native state 
while preventing further aggregation. Reproduced with permission from Hartl et al. 2011.1 B: Simplified 
scheme of amyloid aggregation pathway, revealing the relationships between native states, intermediate 
and endpoint aggregates, in addition to which cellular mechanisms (molecular chaperones, post-translational 
modifications and degradation) can modify each pathway or off-pathway species. Reproduced with 
permission from Knowles et al. 2014.4  
A B 
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amyloid aggregation, referred to as ‘amyloidogenic regions’ – promoting intermolecular 
hydrophobic contacts in a concentration-dependent manner.4-5 Accordingly, protein misfolding 
is surprisingly common – folding efficiency in secretory pathways frequently won’t exceed 
50%, and it has been estimated that up to 30% of all newly synthesized cellular proteins are 
defective ribosomal products, targeted for degradation shortly after synthesis.6  
Figure 1A depicts the protein folding funnel model as a simplified representation of the free 
energy landscape of protein aggregation, with unfolded conformations populating the broad 
top of the funnel and the native protein structure situated at the narrow bottom.1 Typically, 
aggregation occurs over several stages, each requiring a certain energy threshold to be met for 
the transition between different states to take place (Fig. 1B), with the process often 
conforming to sigmoidal kinetics (Fig. 2): these pertain to a lag phase, wherein negligible 
aggregate populations are present, to an exponential phase, where aggregation proceeds 
rapidly, and finally to the saturation phase, as populations of ‘seeding’ species required to 
propagate further aggregation are exhausted. Numerous intermediate species can be produced 
during aggregation, and can be generally classed as either low-order species (dimers, trimers, 
low molecular weight oligomers), or higher-order species, (high molecular weight oligomers 
and protofibrils), towards the formation of endpoint aggregates, typically either amorphous or 
amyloid structures. Rarely, crystalline conformations7 (the absolute free-energy ground state 
with regards to protein conformation8) or superstructures such as protein particulates and 
spherulites9 can be formed as endpoint species of protein aggregation under certain 
environmental conditions. However, amorphous aggregates, i.e. with no regular macroscopic 
structure, are the most common fate of aggregating protein. These aggregates are generally 
nontoxic, but result in loss-of-function of the protein.10  
In contrast to amorphous aggregates, amyloid fibrils are highly ordered: constructed of 
typically two or more stacked protofilaments and defined by their cross-β structure, wherein β-
sheets run perpendicular to the long fibril axis. Mesoscopically polymorphic, the morphology 
of fibrils can range from flat tapes to twisted or helical ribbons and nanotubes, dependent on 
fibrillization conditions.8, 11 Nearly all proteins are capable of forming amorphous aggregates, 
yet only a fraction of human proteins – known as ‘amyloidogenic’ proteins and peptides – are 
capable of forming amyloid within a physiological environment,10 though some metabolites 
can form ‘amyloid-like’ structures under certain conditions.12 Though the amyloid state is 
defined by β-sheet-rich fibrils, amyloidogenic proteins and peptides can have a diversity of 
native structures – from the β-sheet sandwich structures of β2-microglobulin (β2m), 
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immunoglobulin light chain and transthyretin to the α+β structure of lysozyme and even α-rich, 
in the case of serum amyloid A.13 Remarkably, it has been demonstrated that ultrashort peptides 
of two14 to three15 residues, down to single amino acids (i.e. phenylalanine)16 are capable of 
amyloidosis. Furthermore, endpoint products of aggregation are not necessarily conserved for 
amyloidogenic species: for example, β2m forms either amyloid fibrils or amorphous aggregates 
at pH 2.5 depending on local NaCl concentration.7 
Amyloidosis has been modelled as a process of secondary nucleation for most major amyloid 
species. In secondary nucleation, amyloid fibrils provide a scaffold for new amyloid nuclei or 
‘seeds’ to assemble, subsequently continuing to grow and provide catalytic surfaces for more 
nuclei to form.17 Under these parameters, the rate of amyloid fibrillization is highly dependent 
on concentration, and a large and varied population of intermediate aggregates18-19 are 
generated during the exponential phase of aggregation. For major amyloid species such as 
amyloid-beta (Aβ) and alpha-synuclein (αSyn), complete amyloidosis under physiological 
conditions takes place over days in vitro,20-21 allowing more granular explorations of 
fibrillization kinetics and the categorization of intermediates to be feasibly achieved. This has 
perpetuated the ‘oligomer hypothesis’, pertaining to the theory that oligomers and intermediate 
aggregate species are the arbiters of amyloid-associated cytotoxicity rather than mature 
fibrils.19 However, for amyloidogenic species with rapid fibrillization kinetics, such as human 
islet amyloid polypeptide (IAPP), where amyloidosis can reach the saturation phase within 
minutes in vitro dependent on concentration,22 the transition point from majority lower order 
to higher order aggregate populations cannot be easily delineated, and their elicited toxicity 
less clearly defined.23  
Figure 2: Fibrillization kinetics of amyloidogenesis as they pertain to solution populations of 
amyloid pathway species. Reproduced with permission from Raleigh et al. 2017.117  
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1.1.2 Pathological amyloid and dysfunctional aggregation 
Aggregation can be a vital, functional process, with the generation of various protein 
aggregates along the pathway contributing to integral cellular and metabolic functions. It has 
been theorized that amyloidogenesis in humans could be an evolutionarily flawed attempt at 
an antimicrobial defense mechanism,24-25 or that, in a primordial earth, amyloids could have 
even functioned as a primitive extracellular matrix.26 These concepts can be reflected in the 
roles of functional amyloid in bacteria: both acting as antimicrobial agents against competing 
bacteria and utilized in biofilm formation, in addition to facilitating pathogen-host interactions 
and rendering ‘stealth’ status of the bacterium against host immune processes.27-28 Indeed, 
proteinaceous oligomers form the blocks of key biological machinery, from bacterial 
membrane channels 29-30 to human vision,31 and large, complex amyloid-like aggregate 
structures, including Balbiani bodies and nuclear amyloid bodies, have crucial roles in cellular 
health and maintenance.32-33 Furthermore, the rapid amyloidogenesis of pmel17 (Fig. 3) within 
melanosomes to form nontoxic, functional fibrils is a key step in melanogenesis, i.e. 
pigmentation of the skin.34  
Ultimately, however, the majority of amyloidogenic processes in humans are found to be 
pathological. There are 22 different amyloidogenic proteins and peptides in the human body, 
which are implicated in over 50 diseases,5 with the misfolding that accompanies their 
pathologies generally correlating to a toxic ‘gain of function’ of the aggregating protein. A 
selection of amyloidogenic species in amyloid-associated disease are outlined in Table 1. 
Figure 3: Rapid pmel17 fibrillization during melanogenesis. Left panel:  ThT fluorescence of 
pmel17 fibrillization at pH 7.4 (black line), 6.0 (dark grey line) and 4.85 (light grey line). Inset: 
ThT fluorescence of pmel17 compared to major pathogenic amyloid species up to 24 h of 
fibrillization. Right panels: TEM imagery of pmel17 amyloid fibrils (top) and melanosomes with 
stored melanin. Adapted with permission from Fowler et al. 2005.34 
1 µm 
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Major amyloid-associated diseases include Alzheimer’s disease (AD), type II diabetes mellitus 
(T2D), and Parkinson’s disease (PD); these are associated, respectively, with the 
amyloidogenic peptides Aβ, IAPP, tau and the amyloidogenic protein αSyn. 
Table 1: Selected amyloidogenic species and associated diseases* 
*Adapted with permission from Knowles et al. 2014.4 A comprehensive list of amyloid-associated diseases in
humans can be found in Chiti & Dobson, 2006.5
Disease Aggregating species Polypeptide length 
(number of residues) 
Native structure 
Neurodegenerative diseases 
Alzheimer’s disease (AD) 
Amyloid-beta (Aβ) 37-43 Intrinsically disordered 
Tau 352-441 Intrinsically disordered Frontotemporal dementia 
with Parkinsonism 
Parkinson’s disease (PD) 
Alpha-synuclein (αSyn) 140 Intrinsically disordered Frontotemporal dementia 
with Lewy bodies 
Spongiform 
encephalopathies 





Huntington’s disease (HD) Huntingtin fragments Variable 
Mostly intrinsically 
disordered 
Amyotrophic lateral sclerosis Superoxide dismutase 1 153 β-sheets, Ig-like 
Non-neuropathic systemic amyloidosis 
Amyloid light chain (AL) 
amyloidosis 
Immunoglobulin (Ig) light 
chains or fragments 
90 β-sheets, Ig-like 
Amyloid A (AA) amyloidosis 
Serum amyloid A1 
fragments 
76-104 α-helical, unknown fold 









β2-microglobulin (β2m) 99 β-sheets, Ig-like 
Lysozyme amyloidosis Lysozyme mutants 130 α-helical and β-sheets 
Non-neuropathic localized amyloidosis 
Type II diabetes mellitus 
(T2D) 
Human islet amyloid 
polypeptide (IAPP; 
amylin) 
37 Intrinsically disordered 
Apolipoprotein A1 (ApoA1) 
amyloidosis 
ApoA1 fragments 80-93 Intrinsically disordered 
Injection-localized 
amyloidosis 
Insulin 21 and 30 α-helical, insulin-like 
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Dysfunctional aggregation can be triggered by various factors. In an in silico study of human 
sequence variations that may potentiate aggregation, mutations in human disease were found 
more likely to induce aggregation than non-disease associated mutations.35 In the context of 
protein aggregation, the introduction of mutant sequences can result in either loss- or gain-of-
function for the aggregating species. With ‘loss-of-function’ mutations, excessive aggregation 
of a key protein is nontoxic but its consequent deficiency is the major burden of disease, e.g. 
in cystic fibrosis and α1-antitrypsin deficiency.1 In contrast, ‘gain-of-function’ mutations allow 
the aggregating species to elicit new biological effects unavailable to the wild-type monomer, 
often found to be highly deleterious. For example, non-amyloid aggregation of mutant p53 
prevents apoptosis and allows cancerous cells to proliferate,36-37 and aggregating mutant α-
galactosidase acquires resistance to the chemical chaperone DGJ-1, limiting the treatment of 
familial Fabry disease.38 In amyloid-associated disease, the acquired ‘gain-of-function’ is 
typically pathogenic: huntingtin is only capable of amyloidosis upon mutation to introduce a 
polyglutamine sequence near its N-terminus, thus conferring pathogenicity in HD.39 Chiti et 
al. examined sixteen mutated forms of amyloidogenic species (Aβ, ApoA1, tau and the 
fibrinogen α-chain) and found that mutation induced a reduction in net charge of fourteen of 
these species, leading to enhanced aggregation and pathogenicity.2 Indeed, in Aβ1-42, the 
Arctic mutation (E22G) induces enhanced amyloidogenesis of Aβ, with mutant aggregate 
species found highly resistant to intracellular degradation mechanisms in vitro40 and 
additionally capable of enhancing the misfolding of  Aβ1-40 through cross-amyloid seeding.41 
Mutation in amyloidogenesis may present as a double-edged sword: mutant amyloid species 
overarchingly display enhanced pathogenicity, but, in some cases, their specific recognition by 
monoclonal antibodies42 or allele-selective compounds43 could provide more direct avenues of 
treatment. 
Faulty post-translational processing of polypeptides can also readily generate aggregating 
species. The hyperphosphorylation of tau, for example, is known to be a hallmark in its 
fibrillization and pathology.44 Phosphorylation of Aβ at Ser845-46 or Ser2647 or nitration at 
Tyr1048 have each been demonstrated to promote amyloid aggregation while extending the 
lifetime of oligomeric intermediates, resulting in increased pathogenicity. Interestingly, 
phosphorylation of tau at Thr205 was shown to confer a protective role against Aβ cytotoxicity 
in vivo.49 ‘Unwanted’ post-translational modifications, such as protein glycation, also 
contribute to protein misfolding. Glycated αSyn50 and tau51 form globule-like deposits, and the 
methylglyoxal-mediated glycation of Aβ enhanced its neurotoxicity in vitro.52 Though the roles 
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of glycation and advanced glycation endproducts (AGEs) in aggregation are yet to be fully 
elucidated, AGE-associated aggregation has been implicated in the pathologies of 
neurodegenerative diseases and a number of cancers.53  
Disruptions to the physiological environment can induce or promote protein aggregation, and 
can even induce amyloid formation without initial unfolding and destabilization of its native 
state.54 Oxidative stress, and the generation of radical oxygen species (ROS), facilitate residue 
oxidation-induced aggregation of proteins such as γD-crystallin,55 linked to cataract formation, 
and tryptophan hydroxylase 2 (TPH2),56 associated with pathologies of PD, under 
physiological conditions. High temperature and low pH are required to induce protein 
misfolding towards amyloid aggregation in naturally non-amyloidogenic proteins, such as 
cow’s milk-derived β-lactoglobulin (bLg).57 Small changes in physiological temperature 
(which can range from 33.4 – 42°C under certain conditions, such as within tumors and 
neurological disease) can also accelerate aggregation of amyloidogenic species: the 
amyloidogenic region of Aβ monomers was shown to be increasingly exposed, i.e. allowing 
more amyloid contact, when increasing environmental temperature from 37 to 42 °C.58 With 
regards to pH, human pmel17 fibrillates only under the mildly acidic conditions present within 
the melanosome, with the formed amyloid fibrils solubilizing at neutral pH.59  
Lastly, the intracellular environment is densely crowded, with 30-40% of its volume taken up 
by biomolecules60 – the roles of biomolecules, and proteins in particular, in amyloidosis is 
discussed in Section 1.3. In general, macromolecular crowding has been shown to accelerate 
the aggregation of αSyn61-62 and apolipoprotein C-II.63 The ionic strength of the milieu also 
contributes to amyloidogenesis, driving β2m aggregation from amorphous to toxic 
amyloidosis.7 Furthermore, the coordination of metal ions such as Cu2+, Zn2+ and Fe3+ with 
amyloidogenic species can trigger aggregation through destabilization of the native protein 
structure and/or facilitating intermolecular amyloid contact through cross-linking with the 
incorporated metal ion.64 As would be expected, environmental stressors can intersect or even 
impede their respective promotional actions on aggregation. Interfacing amyloid species with 
redox-active ions, i.e. Cu2+ and Fe3+, can facilitate ROS-induced aggregation – for example, 
Cu2+ drives the formation of dityrosine dimers of IAPP65 and Aβ,66 – but the phosphorylation 
of Aβ actually limits the action of Cu2+.67 Interestingly, the selection pressure induced by 
aggregate-causing environmental stressors can, in some cases, be advantageous:  exposing E. 
coli to stressors (heat, oxidative stress and antibiotic treatment) that induced the formation of 
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intracellular protein aggregates could instill increased resistance in subsequent generations to 
these conditions comparative to aggregate-free bacteria.68  
In the absence of a strong genetic link to their onset, some amyloid diseases – most prominently 
late-onset diseases such as AD, PD and HD – are ultimately considered diseases of ageing.69 
The triggers of protein misfolding listed above – mutation, post-translational processing, and 
environmental interactions – can be generated or their effects enhanced by the breakdown and 
dysfunction of biological machinery typical of ageing. In yeast, for instance, approximately 
480 proteins have recently been identified as age-related aggregators.70 Weids and colleagues 
screened proteins in S. cerevisiae triggered to aggregate by stressful conditions – oxidative 
stress, heavy metal exposure, and amino acid stressors – significantly overlapped with proteins 
known to aggregate due to ageing; and, additionally, that these stress-induced aggregators also 
aligned with ageing-induced aggregators in C. elegans.71 There is some debate, however, as to 
whether protein aggregation is causative of ageing, or a consequence therein, and thus this 
relationship warrants further investigation. 
Deleterious aggregation is further spurred by the failure of systems designed to correct protein 
misfolding, and remove harmful aggregation species from the circulation. Protein aggregation 
can be ostensibly ‘kept in check’ so long as it is controllable, reversible, and localized 
temporally and spatially – so that, ultimately, local protein concentrations are always kept 
below their critical aggregation-concentration threshold.72 The conservation of this equilibrium 
is known as proteostasis – a complex collection of cellular mechanisms to employ the 
functional benefits of protein aggregation and limit associated pathologies (Fig. 4). Amyloid 
species can build up to overwhelm the cellular systems that maintain proteostasis, but can also 
actively interfere with certain components of these systems, further accelerating their 
cytotoxicity. A cell can attempt to quarantine toxic aggregates within intracellular 
compartments, such as inclusion bodies6 and the Insoluble Protein Deposit (IPOD) in yeast73 – 
ultimately, however, if all internal systems fail and the cell is unable to restore proteostasis, the 
cell can decide to self-terminate to minimize further damage mediated to the local environment 
by uncontrolled protein aggregation.69 
Proteostasis can be essentially grouped into maintenance at two levels: the ‘nucleic acid’ level 
and the ‘protein’ level. At the regulatory level, it is estimated that over 75% of proteins contain 
hydrophobic regions that significantly promote aggregation nucleation74 – consequently, amino 
acids can be encoded adjacent to these regions to counteract aggregation through charge 
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repulsion (arginine, lysine, aspartate, glutamate), the entropic penalty relating to aggregate 
formation (arginine and lysine) or inability to conform to β-sheet structure (proline).75 Two or 
more of these so-called ‘gatekeeping’ residues have been predicted to flank up to 60% of 
aggregation-prone regions in a multiproteome study, with some guarded by up to six.74 
Gatekeeping residues have been identified in amyloid-forming bacterial proteins such as the E. 
coli curli protein CsgA76 and microcin E492 in Klebsiella pneumoniae.77 Interestingly, it has 
been shown that employing this tactic at the regulatory level can provide a ‘barcode’ to be read 
by protein-mediated quality control processes: namely, that chaperones can recognize a pattern 
of charged residues before a hydrophobic region, aiding in the efficacy of processing misfolded 
protein.74 Similarly, the encoding of a KFERQ motif, known as a consensus sequence, directs 
chaperone-mediated autophagy (CMA) for amyloid precursor protein (APP),78 αSyn79 and 
huntingtin (associated with pathologies in HD),80 among others. Tight control can also be 
elicited over the translation of αSyn and APP through an iron response element (IRE) in their 
respective 5’UTR.81-83  
Figure 4: Cellular mechanisms in which to maintain proteostasis, i.e. amelioration or elimination 
of misfolded protein, and how the failure of these systems can result in aggregation-based 
pathologies. Basal state mechanisms associated with proteostasis are represented by green arrows, with 
red arrows representing the pathological state – dashed arrows are impaired processes, and bold arrows 
are increased protein aggregation. Hsp70, heat shock protein of 70 kDa; Ub, ubiquitin; CMA, chaperone-
mediated autophagy; ERAD, endoplasmic reticulum-associated protein degradation; UPS, ubiquitin-
proteasome system; UPR, unfolded protein response; mtUPR, mitochondrial unfolded protein response. 
Reproduced with permission from Trigo et al., 2019.69  
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At the ‘protein’ level, defensive strategies to maintain proteostatic equilibrium fall into three 
main categories: disaggregation and refolding of misfolded protein by molecular chaperones,1 
and, if the chaperone system becomes overwhelmed, targeted destruction of protein aggregates 
by the ubiquitin-proteasome system (UPS)84 or the autophagy-lysosome system (ALS).85 
Within the UPS – predominantly responsible for the removal of short-lived proteins (which, 
on average, have a high aggregation propensity86) and over 90% of oxidatively damaged 
protein within the cytosol – damaged and dysfunctional proteins are tagged for destruction with 
ubiquitin and subsequently recognized and degraded by the proteasome. Comparatively, the 
ALS, which disposes of longer-lived proteins and aggregates, involves the activation protein 
complexes encoded by autophagic genes (ATG) to form the autophagosome, which in turn 
leads to lysosomal degradation of dysfunctional protein cargo. In both normal and pathological 
proteostasis, combinations of these pathways are possible, such as in the case of CMA. The 
chaperone system majorly consists of heat shock proteins (Hsp) and small heat shock proteins 
(smHsps), delineated by their kilodalton molecular weight, i.e. Hsp70, Hsp90 and Hsp100,87 
and typically interact with longer-lived, low turnover proteins.86 Hsp70, in particular, has a 
central role in protein folding and proteostasis control – its increased expression has been 
shown to ameliorate toxicity associated with the aggregation of αSyn in an in vivo PD model.88 
However, buildup of αSyn oligomers can conversely limit the chaperone action of Hsp70, 
rendering it unable to functionally fold other protein.89 Hyperphosphorylated tau also facilitates 
the displacement of TDP-43 from cdc37, a co-chaperone of Hsp90, resulting in accumulation 
of TDP-43 fragments in the cytosol which subsequently form inclusions typically associated 
with the pathologies of amyotrophic lateral sclerosis and frontotemporal dementia.90 Though 
tau aggregates can subsequently be cleared by the ALS,91 the presence of autophagic vacuoles 
in dystrophic neurites of AD patient brains, a disease also subject to tauopathies, implicates 
that the process is overall malfunctional in the disease state.92 Similarly, there is a tight 
relationship between Aβ and the UPS that contributes to the pathologies in AD, wherein the 
UPS readily degrades Aβ aggregates under endogenous conditions but Aβ species 
competitively inhibit proteasome activity under disease conditions.93 
Individual organelles additionally have their own mechanisms in place to mitigate protein-
misfolding under stress-response, such as the unfolded protein response (UPR) system within 
the endoplasmic reticulum (ER) and mitochondria (denoted as the mtUPR). The UPR follows 
the aforementioned dual strategies: corrective refolding of proteins mediated by chaperones, or 
their enforced degradation via the ER-associated protein degradation pathway (ERAD). 
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Concordantly, increased Aβ deposition in the brain of mouse models was correlated with the 
downregulation of membralin, a component of the ERAD system.94 Sorrentino and colleagues 
demonstrated cross-species conservation, from C. elegans to human models, of mtUPR-
mediated suppression of Aβ toxicity, and posit that strategies to enhance the mtUPR may rescue 
aggregation-based pathologies in amyloid diseases.95  
1.2 Islet amyloid polypeptide: type II diabetes as an amyloid disease 
1.2.1 Overview 
T2D is a metabolic disease currently affecting approximately 5% of the global adult 
population,96 with prevalence expected to double by 2035.97 Though the major burden of the 
disease is largely preventable through healthy diet and exercise, T2D is predicted to become 
the seventh leading cause of death by 2030.98 A key hallmark during the onset of T2D is 
dysfunction and death of pancreatic β-cells, located within the islets of Langerhans (Fig. 5).99-
101 Once β-cell mass decreases by 40-60%, development of T2D is irreversible.99 
The 37-residue peptide IAPP, also known as amylin, is directly correlated with β-cell loss in 
T2D.102-108 In its native state, IAPP is positively charged and hydrophobic, due to an amidated 
C-terminus and lack of acidic residues, and is ‘intrinsically disordered’ i.e. does not conform
to a rigid, globular morphology. Endogenously, IAPP is co-secreted with insulin by pancreatic
β-cells and has a number of both established and purported functions: centrally, in glycemic
control and energy balance, though new evidence indicates there may be further roles for
amylin in neurodegeneration and cognition.109-110 However, it is highly amyloidogenic, and can
aggregate in a concentration-dependent manner through intermolecular amyloid contact at its
amyloidogenic region, known to be primarily at residues 20-29 (Fig. 6).111 Rodent IAPP
(rIAPP), which does not naturally fibrillate, differs in six amino acids in this region, with the
most important substitutions considered the three proline residues at positions 25, 28 and 29 of
rIAPP,112 due to the capacity of proline to disrupt H-bonding and β-sheet formation.75
Additionally, a His18 residue in IAPP that is replaced by Arg increases the positive charge of
the sidechain in rIAPP under physiological conditions, likely further limiting aggregation.113
Ultimately, the insoluble amyloid fibrils and plaques formed in IAPP amyloidogenesis, present
in 90% of T2D patients, are implicated in the development, progression and burden of the
disease.114 A deviation in IAPP secretion within a single cell could be capable of initiating
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amyloid fibrillation,115 and recent evidence has also suggested that amyloidosis in monomeric 
IAPP can be triggered by existing amyloid species in a prion-like mechanism.116 
Figure 5: Mechanisms of pancreatic β-cell dysfunction as the hallmark of T2D. Reproduced with 
permission from Park & Woo, 2019.101  
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1.2.2 IAPP within pancreatic β-cells 
IAPP is generated via the translational processing of proIAPP, a propeptide whose expression 
is regulated by the glucose-responsive IAPP gene promoter.117 IAPP is capable of undergoing 
further ‘unwanted’ post-translational modifications, such as glycation, which may enhance its 
pathogenicity. For example, glycated IAPP has been shown to undergo more rapid fibrillization 
than IAPP lacking AGEs, and was further capable of expediting the fibrillization of non-
glycated IAPP.118 Gong et al. observed increased local plasma concentration of IAPP and 
amyloid deposition in the kidneys of T2D patients with diabetic nephropathy (DN), 
hypothesizing that IAPP could bind AGE receptors (RAGEs) and potentially trigger 
inflammatory signal transduction pathways, thus contributing to localized cell death.119 
Concordantly, in a study conducted by Abedini and colleagues, RAGEs were shown to be 
upregulated in response to a human IAPP challenge in the islets of transgenic, human IAPP-
producing mouse models ex vivo. Interestingly, RAGEs demonstrated selective binding of 
IAPP intermediate species over fibrillar amyloid, with isolated extracellular ligand-binding 
domains of soluble RAGE (sRAGE) capable of inhibiting IAPP amyloid formation and 
associated cytotoxicity.120 
ER stress has been shown to have a role in β-cell death and dysfunction in diabetes, and has 
been specifically linked to pathological IAPP fibrillization.121-123 IAPP upregulation in vitro 
was associated with the inhibition of autophagy signaling and, in particular, mitophagy – 
resulting in accumulation of damaged mitochondria, ROS production, and rendering β-cells 
more prone to dysfunction and apoptosis induced by ER stress.124 Concordantly, molecular 
Figure 6: Sequence of human IAPP compared to other mammals. The amyloidogenic region of 
human IAPP (20-29) is highlighted, and residue substitutions across species (as compared to human 
IAPP) are in red. Bolded, starred species indicate IAPP can natively form amyloids. The disulfide 
bridge between C2 and C7 is indicated, with the amidated C-terminus denoted in purple and His18 in 
human IAPP labeled in blue. Relative overall sequence conservation across all species, including those 
omitted from this figure, is illustrated below. Adapted with permission from Raleigh et al. 2017.117   
25 
(GRP78, protein disulfide isomerase: PDI) and chemical (taurine-conjugated ursodeoxycholic 
acid, 4-phenylbutyrate) chaperones have been shown to mitigate IAPP-induced ER stress in 
vitro.125-126 A proteomic study into the contents of the β-cell granules identified a number of 
molecular chaperones sequestered within, including Hsps 5, 70, 72 and 90, in addition to PDIs 
and GRP58.127 In a follow-up study, Chien and co-workers demonstrated that Hsp70 and the 
co-chaperone Hsp40 inhibit IAPP fibrillization in vitro;126 Hsp72 has additionally been shown 
capable of rescuing IAPP pathology in vivo in C. elegans.128 Recently, in fact, a hybrid of 
Hsp70 grafted with IAPP demonstrated cytoprotective effects in pancreatic β-cells against 
IAPP-mediated toxicity in vitro.129 Press and colleagues recently reviewed the current literature 
regarding the role of IAPP in proteostasis, specifically concerning the UPS and ALS.130 There 
is little or conflicting evidence regarding the relationship between IAPP and the UPS, though 
there is some consensus that IAPP can act to impair it – more specifically, inhibiting 
proteasomal activity in addition to downregulating expression of Hsp90 and UCH-L1, a 
deubiquitination enzyme. Similarly, though the ALS plays a role in IAPP clearance, 
fundamental understanding of the impact IAPP in the disease state elicits on ALS is limited – 
though IAPP may interfere with autophagic pathways, the increase in dysfunctional autophagy 
with age may exacerbate IAPP-mediated toxicity. Furthermore, it is not currently known if 
IAPP-associated autophagosome accumulation is due to an increased response to IAPP 
challenge, or, as IAPP aggregates are resistant to proteolytic degradation,131 due to IAPP 
burden impairing lysosomal degradation. 
Upon completion of processing through the ER and Golgi, IAPP is natively stored at millimolar 
concentrations within the high pH environment of the β-cell granules, under conditions which 
favor the retention of monomeric IAPP over amyloidogenesis.132 It has been previously thought 
that insulin, co-stored in β-cell granules at a 100:1 molar ratio to IAPP, is the major inhibitor 
of intracellular IAPP fibrillation.133 Though insulin has been shown to be a potent IAPP 
aggregation inhibitor in vitro,134 hyper-production or -secretion of IAPP is often not 
complemented by upregulation of insulin in vivo, and intercellular concentrations of IAPP have 
been shown to be comparatively heterogeneous.115 Additionally, IAPP is localized nearly 
exclusively in the soluble halo fraction of β-cell granules, whereas insulin forms insoluble 
hexameric crystals within the core.135 Consequently, it is more plausible to postulate that 
additional granule components, co-localized with IAPP, contribute to this crucial role within 
β-cells. Two such candidates include C-peptide, a part of the proinsulin sequence which 
precursors insulin synthesis, and zinc ions (Zn2+).136 Interestingly, Zn2+ concentration within 
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pancreatic β-cells represents one of the highest in the human body, and is maintained by a zinc 
transporter (ZnT8) specific to β-cells.137 Zn2+ is known to form hexamers with insulin, and as 
such is important in effective insulin storage within the β-cell granules.138 It has been recently 
demonstrated that C-peptide, Zn2+, and IAPP form a stable, heteromolecular complex that is 
capable of preventing IAPP fibrillation in vitro, and thus potentially maintain the IAPP native 
state within β-cell granular storage.139  
1.2.3 IAPP amyloidogenesis 
The initiation of IAPP amyloid fibrillation remains a debate of ‘chicken versus egg’: whether 
intracellular amyloidogenesis triggers death of the β-cell and provides a ‘seed’ for larger plaque 
formation extracellularly,115 or if IAPP fibrillation occurs post-secretion within the 
extracellular space, and subsequently leads to β-cell death.104 Conclusive evidence to support 
either hypothesis remains forthcoming. In addition to the question of intracellular versus 
extracellular amyloidogenesis, there has been considerable debate in the literature as to the 
primary IAPP conformation that induces β-cell toxicity23 – namely, monomeric IAPP, 
intermediate species or mature amyloids – and, additionally, the mechanisms thereof. Within 
an in vitro aqueous environment, IAPP fibrillates rapidly, and multiple forms can co-exist at 
any given stage until the amyloid saturation point has been long reached.4 When compared to 
the well-characterized Aβ, which has a slower aggregation rate of days in vitro, isolation of 
different IAPP species to examine their cytotoxic effects has thus far been difficult to 
accomplish,23 further contributing to ambiguity with regards to IAPP toxicity.  
Mature IAPP amyloids have been historically favored as a causative agent of β-cell failure, 
with physical association between plaques and cells posited to result in membrane perturbation, 
production of ROS, and/or apoptosis.22 A Japanese population who produced a mutated form 
of IAPP with an increased aggregation propensity showed that they subsequently developed 
T2D in clinical studies.140-141 Lorenzo et al. identified amyloid-membrane contact triggering 
apoptosis as the primary mechanism of toxicity (Fig. 7A), proposing that β-cell viability is only 
reduced when IAPP concentration is high enough to mediate fibrillization.104 Additionally, 
Schubert and colleagues screened a number of amyloid peptides in B12 cells for production of 
ROS with 2,7-dichlorofluorescin diacetate (DCFDA), and determined that IAPP was correlated 
with ROS production and subsequent loss of β-cell viability, while no such species were 
measured with the non-amyloidogenic rIAPP.108 Furthermore, exposure of pancreatic β-cells 
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to sublethal levels of IAPP aggregates in vitro resulted in ROS-independent upregulation of 
antioxidant enzymes, indicating an in-built defensive mechanism to IAPP-mediated oxidative 
stress.142 There is evidence that amphiphilic amyloid can mediate formation of ion channels or 
pores in the β-cell membrane through its high propensity for contacting and integrating 
phospholipids into growing fibrils, i.e. ‘lipid stripping’, leading to cell death by unregulated 
calcium ion influx or cytosol leakage (Fig. 7B-C).143-147 IAPP fibrils can be phagocytosed in 
vitro but amyloid-associated factors may limit the capacity of macrophages to clear localized 
plaques in vivo, potentiating long-term perturbation of the tissues they are deposited within.131 
In more recent years, however, the focus has shifted to the soluble oligomeric form of IAPP as 
the main toxic species, but considering similar mechanisms of toxicity as were postulated for 
IAPP amyloids. As such, many working paradigms concerning IAPP toxicity have been 
influenced by mechanistic studies of Aβ toxicity in AD – known to be mediated by Aβ 
oligomers23 – in light of the biophysical and biochemical connections between IAPP and Aβ 
fibrillization. This approach remains to be validated, though evidence to suggest a toxic role 
for IAPP oligomers is abundant. Ritzel and coworkers observed that IAPP oligomers mediated 
a disruption in islet architecture ex vivo, impairing cell coupling and insulin secretion and 
inducing apoptosis.107 Research from Kayed et al. and Meier et al. described cell membrane 
permeation induced by IAPP oligomers (Fig. 7B-C), while monomeric IAPP or amyloid fibrils 
showed no adverse effects,105 and prevention of amyloid fibrillization did not mitigate 
toxicity.106 Rifampicin was utilized in the latter study to inhibit the formation of amyloid 
plaques, demonstrating its anti-aggregation properties through Thioflavin-T (ThT) staining – 
an established method to detect amyloid protein. However, Meng and colleagues refuted this, 
revealing that rifampicin had no effect on IAPP fibrillization and demonstrating that the ligand 
could interfere with ThT fluorescence.148 Furthermore, studies interrogating the toxicity of 
Figure 7: Proposed mechanisms of lipid membrane damage elicited by amyloid pathway 
species such as IAPP. A: Non-specific membrane disruption by fibril growth and physical 
perturbation. B: Detergent-like membrane disruption and ‘lipid stripping’ by oligomeric and 
fibrillating species. C: Pore formation by low-order intermediate species. Adapted with permission 
from Owen et al. 2019.147  
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different IAPP species in vivo are predominantly conducted with antibodies, e.g. anti-oligomer 
antibodies such as A11, which can be problematic when applied in a complex environment as 
these antibodies are not sequence-specific – rather, they recognize conformational shape.149 
Given the polymorphic nature of oligomers, and the wealth of biomolecules in vivo that share 
β-rich conformations, the reliability of antibodies to delineate IAPP aggregation species in the 
context of their associated pathogenicity is called into question.23 Collectively, this illustrates 
the limitations of current methodology to characterize IAPP species, and warrants a more 
comprehensive approach towards establishing fundamental tenets of IAPP pathogenicity.  
1.2.4 IAPP pathologies beyond the pancreas 
Per its role in glycemic control, IAPP is capable of crossing the blood-brain barrier (BBB), and 
is ubiquitously present in the circulation. Lack of confinement to the pancreas becomes 
problematic in the context of T2D, as IAPP amyloid deposits have been reported in the 
kidneys,119 heart,150 and brain151 of T2D patients, with associated tissue degradation and health 
complications observed in each case. Srodulski et al. proposed a mechanism for IAPP wherein 
oligomerized IAPP translocated from the pancreas to the brain, mediating damage to the BBB, 
which subsequently allowed diffusion of IAPP oligomers into the brain tissue.151 Indeed, IAPP 
amyloid deposition has been reported in brain blood vessels and perivascular spaces of AD 
patients with or without T2D, causing extensive damage to the surrounding tissue.152 
Interestingly, unchanged or decreased blood plasma concentrations of IAPP have been reported 
in T2D patients, likely due to increasing amyloid accumulation in the pancreas inhibiting the 
translocation of monomeric IAPP.153-154 The reason for this disparity, i.e. between IAPP plasma 
concentration and increased systematic amyloid deposition in T2D, has not been fully 
elucidated. Oskarsson and colleagues posit that IAPP could be expressed within the brain, 
which could contribute to the formation of local Aβ-IAPP co-amyloids.155 Though there is 
some evidence that extra-pancreatic expression of IAPP occurs in several animal models,156-157 
there is no current evidence to suggest a similar mechanism in humans.152  
Compared to other amyloid protein species, including Aβ and αSyn, IAPP is understudied, with 
fundamental knowledge of its endogenous and pathogenic behavior found lacking: further 
interrogation into IAPP at the biological interface should thus be pursued, particularly in light 
of the significant proportion of the global population that are affected by T2D. 
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1.3 Amyloid in the extracellular environment 
1.3.1 Modulation of amyloidosis by extracellular biomolecules 
Post-secretion, amyloid species are introduced to a complex extracellular milieu, with various 
circulating species likely to elicit significant effects on amyloid morphology and cytotoxicity. 
For instance, nucleic acids can mediate aggregation of αSyn, prion protein and Aβ, among 
others,158 and lipids additionally impact amyloid aggregation of various species, from small 
peptides such as Aβ and IAPP to apolipoprotein B, one of the largest proteins present in 
nature.159 How lipids, and more specifically, phospholipids, play a role in amyloidogenesis is 
of particular interest, given the deleterious seeding and conformational change of amyloid 
species on synthetic and endogenous phospholipid bilayers.105, 144-145, 160 In the presence of 
unimolecular lysophosphatidylcholine (LPC), a product of lipid peroxidation and the most 
abundant single-tailed phospholipid in the blood,161 fibrillization of Aβ1-40 was repressed – 
but, surprisingly, a promotional effect was observed on the aggregation of Aβ1-42,162 further 
augmenting its cytotoxicity in vitro.163 Contrastingly, IAPP fibrillization was inhibited in the 
presence of both unimolecular and micellar LPC, with micellar LPC driving IAPP to adopt a 
majority α-helical conformation, as has been reported in the presence of sodium dodecyl sulfate 
(SDS) micelles.164 The stark contrast in the elicited effect of singular lipids and model 
biomembranes between different amyloid species highlights the necessity to examine amyloid 
interactions at the biological interface on a case-by-case basis, in order to fully reflect the 
complex endogenous environments they inhabit. 
Concordantly, though thousands of proteins have been identified in the circulation,165 few have 
been investigated as non-specific interactors or aggregation inhibitors of amyloid species. 
Human serum albumin (HSA), as the most abundant protein in blood plasma, has been reported 
to bind >90% of circulating Aβ and up to half of Aβ within the cerebrospinal fluid, and act to 
inhibit its fibrillization.166 Recently, HSA also demonstrated the capacity to inhibit amyloid 
aggregation of IAPP and αSyn, in addition to mitigating amyloid-associated hemolysis in 
vitro.167 Extracellular proteins α-casein, lysozyme (Lys), alpha-lactalbumin (aLac), bLg, 
albumin, pyruvate kinase and catalase have been shown to bind non-specifically to Aβ1-40 and 
inhibit its fibrillization in vitro.168-170 Various amyloidogenic species, including Aβ1-40 and 
Aβ1-42 peptides, pulmonary lung surfactant protein C171 and the ageing-associated arterial 
amyloid medin,172 were inhibited through in vitro interactions with proteins with the BRICHOS 
domain (sequence alignments related to BRI proteins associated with British and Danish 
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dementia, in addition to chondromodulin and proSP-C) such as proSP-C,173-174 Bri2,174-175 and 
gastrokine 1.176  
Non-chaperone specific interference of molecular chaperones with amyloidogenesis has also 
been described. α2-Macroglobulin (α2M) and haptoglobin (Hp), glycoproteins with the 
capacity to rescue proteins from stress-induced amorphous aggregation, demonstrated anti-
amyloidosis properties through their association with Aβ1-42, in addition to various other 
aggregating proteins.177 Concordantly, smHsps such as αB-crystallin and Hsp27 prevented 
amyloidogenesis and/or amyloid-associated toxicity through transient interactions with Aβ1-
42,178-179 Aβ1-40 in wild type and a mutant with higher pathogenicity,179 in addition to αSyn.180 
With regards to IAPP, interactions with intracellular components beyond the granular space 
have been reported,181 but, surprisingly, little is known so far concerning the association of 
IAPP with extracellular proteins and their biological and pathological implications. Several co-
factors, including serum amyloid P (SAP) component,182 apolipoprotein E (ApoE)183 and 
glycosaminoglycans (GAGs), in particular heparan sulfate proteoglycans,184 have been shown 
to associate with IAPP amyloid deposits in vivo. GAGs are also known to enhance fibrillization 
of IAPP185-186 and can promote aggregation of incompletely processed IAPP.187 Secretory 
chaperones have additionally demonstrated some capacity to prevent IAPP fibrillation in 
vitro.188 However, association with IAPP does not necessarily affect residual IAPP-mediated 
cytotoxicity – in the cases of ApoE and GAGs, only the latter is implicated in IAPP toxicity.189-
190 This paradigm was further highlighted via the exposure of fibrillating IAPP to aLac and Lys 
as two model protein interactors, with analogous molecular weight and morphology but 
opposing charges, to gauge how their presence impacted IAPP aggregation and associated 
cytotoxicity in vitro.191 Net positively-charged Lys inhibited IAPP aggregation while net 
negatively charged aLac elicited a promotional effect, yet the application of neither protein was 
able to significantly mitigate the cytotoxicity of IAPP.  
Lastly, amyloidogenic peptides have also been found to co-localize, with Aβ, tau and αSyn 
frequently reported to interact and generate enhanced pathologies within in vivo 
neurodegenerative disease models.192-193 Accordingly, circulating IAPP species have been 
shown capable of forming co-amyloids with other extra-pancreatic amyloidogenic peptides. 
For example, residues within the amyloidogenic region of IAPP show a strong binding affinity 
for Aβ.194 IAPP-Aβ cross-seeding and co-amyloid generation has been widely reported,195-197 
particularly in the context of T2D at the interface of neurological disorders and AD. How IAPP 
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contributes to the overall toxicity of these co-amyloids, however, remains unclear. IAPP-Aβ 
co-aggregates have been shown to contain properties intermediate to each respective 
amyloidogenic peptide; Seeliger et al. demonstrated that IAPP-Aβ permeabilized β-cell lipid 
membranes at a slower rate than IAPP alone, but more rapidly than Aβ species.196 Clearance 
of toxic Aβ amyloids in the brain by circulating low order IAPP species has actually been 
proposed as a therapeutic effect of their association.152, 197 However, though IAPP was found 
to co-localize with cerebral and vascular Aβ plaques, Aβ was not detected in IAPP plaques 
isolated from T2D patients.155 Elucidating the interplay of IAPP with extracellular 
biomolecules, in addition to other amyloidogenic species, would shed further light on IAPP 
pathologies, towards developing targeted, effective treatment strategies against T2D. 
1.3.2 Amyloid and the ‘protein corona’ 
The ‘protein corona’ was first coined in 2007 by Dawson, Linse and colleagues to describe the 
fouling of synthetic nanomaterials when exposed to a biological environment, defined therein 
as “proteins compete for the nanoparticle ‘surface,’ leading to a protein ‘corona’ that largely 
defines the biological identity of the particle.”198 In this sense, the enrichment of nanomaterial 
surface-exposed proteins leads to an in vivo response which may not necessarily align with the 
applied nanomaterial’s intended target. In the decade since, elucidating the protein corona of a 
given nanomaterial has become a key point of characterization in order to more accurately 
predict its in vivo behavior.199 Recently, it has been proposed that so-called ‘native’ 
nanomaterials, i.e. biomolecular structures naturally present in vivo, likely form a protein 
corona in the complex extracellular environment, which may have additional implications on 
their biological fate. As of writing, protein corona formation has been reported on virions,200 
collagen matrices,201 unfolded fibronectin,202 protofibrils of a synthetic Aβ1-42 variant,203 and, 
recently, per the author, mature IAPP amyloid fibrils (Fig. 8).191, 204  
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As an emerging field, the general literature on protein-amyloid species interactions do not 
ascribe a ‘coronal’ effect to protein interactors in the case that they have inhibitory action on 
amyloidosis but specific binding mechanics are not elucidated: rather, ‘non-specific’, 
‘transient’ or ‘unknown’ protein-amyloid interactions are reported. Potential coronal 
interference in amyloidogenesis is exemplified in many studies pertaining to amyloid-
molecular chaperone associations. Clusterin, known also as apolipoprotein J and found in all 
disease-associated extracellular amyloid deposits, was capable of inhibiting amyloidogenesis 
of multiple aggregating species in vitro, including Aβ1-42 and αSyn.205 It has been posited that 
the interaction of clusterin with Aβ species enhances its amyloid-associated pathogenicity, as 
loss of clusterin directed amyloid deposition to the cerebrovasculature and relieved hemorrhage 
and inflammation in an AD mouse model in vivo.206 Concordantly, clusterin associated with 
engineered Aβ1-42 protofibrils as a component of its protein corona,203 potentiating clusterin 
as an alternative target for anti-amyloidosis treatment strategies. Aβ1-42 oligomers formed in 
the presence of the chaperone prefoldin (PFD) were shown to elicit approximately 30-40% less 
100 nm 
100 nm 
Figure 8: Formation of the amyloid-protein corona within biological media. Left panels: 
Transmission electron microscopy (TEM) images of IAPP amyloid in the absence (top) and presence 
(bottom) of complex biological media in vitro. Right panels: docking simulations of amyloid fibrils 
(dark blue) with identified coronal proteins of IAPP amyloids after exposure to fetal bovine serum 
in vitro. A: alpha-actinin-4; B: protein AMBP; C: neuropilin, in both ‘open’ and ‘closed’ 
conformations; D: serum albumin; E: thrombospondin-1; F: cartilage oligomeric matrix protein. 
Adapted with permission from Pilkington et al. 2018.204  
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cytotoxicity to PC12 cells and murine primary cortical neurons in vitro comparative to 
oligomers generated in its absence, suggesting the interfacing of PFD with Aβ1-42 aggregates 
to form a corona may prevent cytotoxic contact.207 Lastly, DNAJB6, a member of the Hsp40 
family, did not interact with unfolded Aβ1-42 monomers but was able to truncate the 
fibrillization of aggregated species;208 similarly, Hsp104 was also capable of arresting Aβ1-42 
aggregation at multiple stages, but unable to mediate disaggregation of formed aggregates.209 
In this context, the changed identity of the amyloid surface via corona formation presents two 
key paradigms: firstly, limiting amyloid fibrillization through obfuscation of nucleation sites, 
but, antithetically, rendering chaperones unable to interact and perform amyloid 
disaggregation. This underscores the need to interrogate the amyloid-protein corona within 
different environments, and how applied conditions may act to both help and hinder treatment 
strategies.  
Towards a more comprehensive understanding of proteins enriched within the amyloid plaque 
microenvironment in vivo, Liao et al. isolated plaques from clinical patients with AD and 
described the co-localization of 488 proteins with senile plaques from postmortem brain 
tissues, with 26 found conserved between two patients.210 Proteomic analysis characterized the 
plaques as majorly Aβ-based, with tau also identified as a co-amyloid. Non-amyloid proteins 
such as cystatin C, capable of binding soluble Aβ peptides,211 and 14-3-3 proteins, which 
comprise of up to 1% of soluble protein within the brain,212 were identified in the plaques, with 
the zeta isoform found to be the most enriched. As 14-3-3 ζ is known to bind and promote the 
phosphorylation of tau,213 and, accordingly, has been found enriched in tau neurofibrillary 
tangles,214 the presence of tau within these plaques may have influenced its localization, 
indicating that co-amyloids – and their relative makeup, with regards to ratios of different 
amyloid species – likely impact the diversity of enriched ligands. Furthermore, the increased 
localization of a number of lysosomal ATPases and cathepsin D to the AD plaques comparative 
to the surrounding tissue implicated the plaque interior as an area of high proteolytic activity. 
Overarchingly, the AD plaque-localized proteins Liao and colleagues identified pertained to a 
number of biological processes, including cell adhesion, inflammation, membrane trafficking 
and proteolysis, thus potentiating interference in these mechanisms elicited by these plaques 
through artificial enrichment of specific proteins within the local microenvironment.  
The first in vitro characterization of amyloid-protein corona formation in biological media, 
wherein corona formation was tracked under different environmental conditions and coronal 
proteins identified through proteomic analysis, was performed on IAPP amyloid fibrils in vitro 
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by the author and colleagues,204 as a follow-up study to an initial examination of protein corona 
formation of IAPP fibrils in the presence of single model protein interactors.191 Singular protein 
interactors were able to induce fibril conformational change and mitigate low-level cytotoxicity 
elicited in primary cells in vitro;191 accordingly, the amyloid-protein corona in complex media 
was found extensive and nonuniform, and further induced changes in morphology of cultured 
pancreatic β-cells.204 Concordantly, proteins from the amyloid corona formed in complex 
media generally favored fibrillar conformations and structural plasticity (Fig. 8), and pertained 
to roles in a variety of biological processes, including focal adhesion, ECM-receptor 
interaction, the PI3K-Akt signaling pathway and metabolism. Remarkably, exposure of 
amyloids to the same biological media under different conditions, i.e. flow, generated divergent 
coronae, further illustrating how factors within the local microenvironment may influence 
plaque composition. Interestingly, the enrichment of APP was conserved under these 
parameters, a continued testament to the high propensity of amyloid-fated species to co-
localize. Further examination of enriched proteins in plaques in vivo in tandem with the 
controlled interrogation of amyloid-corona formation conditions in vitro can build a 
fundamental understanding of how amyloid, as a scaffold for protein interactors, may elicit a 
biological impact beyond the scope of short-term cytocidal action, and further reveal as-yet 
undiscovered pathologies of amyloid-associated disease. 
1.4 Anti-amyloidosis strategies: from nano to micro 
1.4.1 Overview and models 
Amyloid inhibition is essentially achieved through the introduction of exogenous ligands or 
chaperones to disrupt and/or outcompete the self-assembly of amyloid proteins from initiating 
nucleation, driving toxic intermediate species off-pathway or sequestering them for 
degradation, and, lastly, the disaggregation or remodeling of mature fibrils into nontoxic 
amorphous aggregates. In principle, this can be accomplished by introducing engineered 
nanoparticles (NPs) that mediate – in no particular order – hydrogen bonding (H-bonding), 
hydrophobic and electrostatic interactions, as well as π stacking, either individually or in 
combination with amyloid proteins. In practice, however, controlling such an array of 
interactions through nanomaterials design (for both the core and the surface) and synthesis 
remains a major challenge, further complicated by the necessity of installing the nanoparticles 
with good dispersity, biocompatibility and bioavailability in vitro and in vivo.  
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Over the last decade, there has been an active search for efficacious anti-amyloidosis agents. 
A myriad of nanomaterials and small molecules, from simple polyphenols to complex 
nanostructures with a range of different surface chemistries, have been screened in vitro for 
their capacity to mitigate amyloidosis, with the majority of anti-amyloidosis studies – from 
benchtop to clinic – focused on Aβ aggregation.215 An overview of nanomaterials utilized to 
combat amyloid aggregation, in addition to prototypical experimental models to which they 
are applied, is shown in Figure 9. Recent efforts have not shown a trend towards a particular 
material – rather, multiple species are still being explored in vitro towards their application in 
vivo.  
Assessing anti-amyloidosis candidates in vitro involves immortalized and primary cell lines 
from humans, mice, and sometimes bacteria, frequently undertaken in static, 2D conditions, 
but additionally can be performed under flow216 and/or in a 3D microenvironment.217-218 Cells 
can also be co-cultured to generate organoids, towards a more realistic biological environment 
– for example, mimicking pancreatic islet biology through the co-culture of α-cells, β-cells and
epithelial cells in a specific ratio to investigate IAPP-elicited cytotoxicity and its amelioration
by a given treatment strategy.219
Figure 9: Selected anti-amyloidosis agents and model systems of amyloidosis. Reproduced with 
permission from Ke et al. 2019.215   
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In vivo models exploited to investigate amyloidosis can range from the nematode C. elegans to 
recent studies utilizing zebrafish (Danio rerio),215 and, more rarely, non-human primates.220 
Rodent models, primarily mice and occasionally rats, are the most frequently utilized in vivo 
platform for anti-amyloidosis research. However, these models can differ from human biology 
in key areas that are essential to mimic human disease – for instance, the non-amyloidogenic 
nature of rIAPP.117 Consequently, to best approximate the conditions of human disease, two 
overarching strategies are utilized: firstly, generating transgenic (tg) mice to overexpress 
human amyloidogenic proteins or peptides, optionally excising affected organs and applying 
treatment strategies ex vivo; secondly, direct injection of human amyloid species into the 
circulation or specific tissues of wild-type (WT) animals to produce disease pathologies. To 
evaluate the burden of disease in these models, animal behavior is assessed in addition to tissue 
damage and amyloid deposition, and, specifically, the presence of neurotransmitters such as 
acetylcholine esterase, serum glutamate and GABA (γ-amino butyric acid) for AD, tyrosine 
hydroxylase for PD, and insulin levels for T2D can be monitored as indicators for each 
respective disease.221-222  
1.4.2 Small molecules 
Small molecules, both natural and synthetic, are capable of complexing with amyloid proteins 
or intercalating into the amyloidogenic regions of aggregating species, resulting in effective 
inhibition of amyloid aggregation.11, 223 Plant-derived polyphenols, including resveratrol, 
curcumin and epigallocatechin gallate (EGCG), are additionally cytoprotective due to their 
antioxidant properties, capable of scavenging amyloid-associated ROS and thereby preventing 
lipid peroxidation of cell membranes. 
Discrete molecular dynamics simulations indicate that resveratrol and curcumin are capable of 
forming IAPP-polyphenol nanoassemblies.224 EGCG has been shown to intercalate between 
beta sheets of fibrillating IAPP via π-π stacking and hydrophobic interactions, and capable of 
driving amyloid aggregation off-pathway.11 How their anti-aggregation properties correlate to 
mitigation of IAPP toxicity, however, can vary – resveratrol-stabilized IAPP oligomers were 
found toxic to β-cells in vitro,225 whereas a reduction in cytotoxicity was reported for IAPP and 
other amyloidogenic peptides stabilized by the polyphenols 1,2,3,4,6-penta-O-galloyl-β-D-
glucose226 and EGCG227 respectively. Polyphenols have additionally been investigated for 
amyloid-remodelling properties: EGCG has been shown to cleave IAPP fibrils without 
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changing their morphology,11 with remodelled species delegated off-pathway and so unable to 
refibrillate.228 Bieschke et al. demonstrated that EGCG-mediated remodelling of Aβ and αSyn 
rendered them unable to reform fibrils, and conferred reduced cytotoxicity in vitro.227  
The molecular promiscuity229 and poor aqueous solubility of polyphenols, however, limit their 
direct application in vivo – consequently, polyphenolic compounds are frequently utilized as 
anti-amyloidosis agents in the context of a payload delivered by a carrier nanoparticle. For 
example, in an APPswe/PS1dE9 AD mouse model, EGCG loaded into polyethylene glycol 
(PEG)-functionalized poly(lactic-co-glycolic acid) (PLGA) NPs, ostensibly intended to target 
the brain, was able to cross the BBB when given orally to mice – but was additionally found 
present in every other organ. Furthermore, no specific pathway was shown to be employed by 
the EGCG-loaded NPs to cross the BBB. Regardless, treatment did result in significant 
amelioration of spatial learning and memory and other AD pathologies, including a notable 
rise in synapses and decreased neuroinflammation in addition to a reduced presence of Aβ(1-
42) species and overall plaque load.230 Synthesis of biocompatible, targeted nanostructures with
analogous properties to small molecules, e.g. aromatic and tertiary hydroxyl groups, may
present superior efficacy as anti-amyloidosis agents.
1.4.3 Metallic and semi-conducting nanomaterials 
Metallic and semi-conducting NPs, including gold (AuNPs),231 silver (AgNPs),232 cadmium 
telluride (CdTe),233 iron oxides (IONPs),232 zinc oxides (ZnO NPs)234 and ceria nanocrystals,235 
among others, have been widely applied in anti-amyloidosis treatment strategies. Gold 
nanoparticles (AuNPs), in particular, have been frequently exploited, given both their inert 
nature and their capacity to bind amyloid cysteines, potentiating their development as both 
inhibitors and indicators of amyloid aggregation.231 For example, improved acquisition and 
retention of special learning and memory in addition to neural survival was observed in Aβ-
treated mice after the application of citrate-coated AuNPs.236 Zhang et al. examined the anti-
amyloidosis capacity of AuNPs coated with a metal-phenolic network, comprising of tannic 
acid coordinated with various metal ions (Al3+, Fe3+, Co2+, Ni2+, Cu2+, Zn2+), and demonstrated 
that AuNPs coated with a cobalt-tannic acid network were most effective in inhibiting Aβ1-40 
fibrillization in vitro, likely due to the specific geometry of the cobalt-tannic acid network 
favoring interactions with histidine and methionine residues in Aβ peptides.237 Recently, 
AuNPs functionalized with sonicated β-sheet rich bLg amyloid acted as probes for fibrillating 
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IAPP, wherein dark-field microscopy visualized the T-cell mediated phagocytosis of AuNP-
decorated fibrils through the intrinsic surface plasmon resonance (SPR) property of gold.238 
Similarly, quercetin-modified gold-palladium NPs promoted clearance of Aβ through inducing 
autophagy in SH-SY5Y cells.239 Gladytz et al. have recently interfaced AuNPs with amyloid 
proteins, hypothesizing that the amyloid aggregation of IAPP and prion protein SUP35 hinged 
on a balance between peptide-nanoparticle and peptide-peptide interactions.240 Specifically, 
anionic citrate-coated AuNPs intercalated with cationic IAPP through stronger Coulombic 
interactions, while PEG-coated AuNPs adsorbed onto IAPP fibrils via binding forces weaker 
than those involved in IAPP self-assembly.  
Magnetic NPs (MNPs), such as superparamagnetic IONPs, NPs with a metallic core (i.e. 
nickel, zinc, cobalt) or magnetic doping agent (e.g. gadolinium; Gd), are effective T2 contrast 
agents for magnetic resonance imaging (MRI).241 The complexation of MNPs with a targeting 
motif can allow them to act as theranostics, for both the detection and mitigation of 
amyloidoses. Gd-based NPs grafted with the nanobody B10AP specifically targeted IAPP, Aβ 
and TTR amyloid deposits ex vivo in murine pancreas, brain and stomach tissue sections, 
respectively.242 PEGylated superparamagnetic IONPs were conjugated with an oligomer-
specific scFv antibody (W20) and, after intravenous injection into PD and HD mouse models, 
were demonstrated by MRI to be capable of targeting amyloid oligomers in the brain.243 In 
separate studies, IONPs222 and Gd-doped PLGA NPs with a curcumin cargo and cationic 
carrier peptide (K16ApoE)244 were complexed with the plaque-binding antibody IgG4.1, and 
visualized through MRI to penetrate the BBB and localize to Aβ plaques in the murine 
cerebrovasculature. In the latter work, however, nonspecific immune reactions and 
meningoencephalitis were observed during human pre-clinical studies.245 Bypassing extra-
circulatory in vivo contact may present a more biocompatible route for anti-amyloidosis 
treatment: Kim and colleagues utilized an innovative ‘magnetic dialysis’ methodology to 
cleanse toxic Aβ species from the blood of 5XFAD mice.246 Blood was first extracted from the 
femoral artery, and circulating Aβ species captured by magnetite/ceria NPs within in a closed 
system – subsequently, with the aid of a magnet and peristaltic pump, magnetite/ceria NPs with 
bound Aβ were sequestered, allowing ‘cleansed’ blood to return to the mouse via the jugular 
vein. Treated mice demonstrated decreased levels of circulating Aβ and additionally did not 
develop spatial working memory deficits.  
Physiological metals are known to have key roles in both regular and dysfunctional cellular 
biology. Cysteines, for example, can complex with heavy metal ions – exploited in functional 
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amyloid-based biomaterials for wastewater purification and iron fortification247-248 – and recent 
studies have demonstrated the potential for amyloids to act as pseudo-enzymes via the 
sequestration of metal ions,249 potentially altering materials that interface with the amyloid 
surface. Polyoxometalates (POMs) have been demonstrated to effectively inhibit Aβ in 
vitro,250-251 with POM-Dawson derivatives functionalized with histidine-chelating metals (Cu, 
Fe, Ni, Co, Mn) shown further capable of crossing the BBB in rodent models in vivo.251 
However, as metallic and metal oxide NPs have the capacity to release metal ions, several of 
which – notably, Fe3+, Cu2+ and Zn2+ – are known to impact amyloidosis in vivo, further 
investigation is warranted to assess whether ion leakage may be exploited to combat amyloid-
associated pathologies. A recent study demonstrated that, while IONPs stabilized by PEG and 
phosphorylcholine (PC) had little impact on IAPP fibrillization in vitro, Fe3+ ions strongly 
inhibited amyloid aggregation.232 On the other hand, limiting ion release or leaching through 
particle surface coating can be beneficial: consider the case of zinc, where Zn2+ ions have been 
shown to promote formation of toxic oligomers during amyloidosis.252 Utilizing hen’s egg 
white lysozyme (HEWL) as the amyloid model, Ban & Paul demonstrated that ZnO NPs 
capped with starch induced less β-sheet formation and reduced amyloid-associated cytotoxicity 
in vitro comparative to bare NPs.234 Consequently, amyloid aggregation inhibition achieved 
through concentration-dependent application of certain metallic or semi-conducting NPs may 
be induced through increased local ion concentration, rather than mediated by the surface 
properties of the particles themselves.  
1.4.4 Carbon-based and inorganic nanomaterials 
Carbon-based nanomaterials, comprised of infinitely repeating aromatic structures and 
including fullerenes,253 graphene oxide (GO),254-255 carbon nanotubes (CNTs)256-257 and 
quantum dots (QDs),258-259 have shown efficacy in sequestering amyloid species and reducing 
amyloid-associated cytotoxicity in vitro.256 Surface functionalization of carbonaceous 
materials is generally required, however, to improve their biocompatibility and provide stable 
dispersion within the aqueous in vivo environment. Accordingly, aqueous solubility was 
conferred to fullerene derivatives via functionalization with phenylbutyric acid, aminocaproic 
acid and thiocarboxylic acid, with each construct demonstrating effective anti-amyloidosis 
properties and low acute toxicity in mouse models in vivo.253 Concordantly, graphene or GO 
nanosheets can provide scaffolds for effective scavenging of toxic amyloid species255 and/or 
surface functionalizations260 to enhance anti-amyloidosis detection, targeting and delivery. For 
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example, He et al. interfaced fluorescently-tagged resveratrol with GO to create a FRET-based 
probe for effectively detecting Aβ amyloid species in vitro, towards a potential method to 
screen for AD.260 Though not carbon-based, MoS2 and WS2 nanosheets are graphene-like in 
their physical structure, i.e. composed of vertically-stacked 2D layers: MoS2 was able to 
modulate the aggregation of amyloidogenic Aβ33-42 and IAPP20-29 fragments,261 while WS2 
scavenged Aβ1-40 monomers and permitted dissolution of bound aggregates upon near-
infrared radiation.262 The large size of these nanomaterials can, however, limit their practicality 
at the biological interface.  
Recently, multi-walled CNTs functionalized with bLg amyloid fragments were able to form a 
bLg-IAPP double protein corona through H-bonding and hydrophobic interactions by 
sequestering toxic IAPP species pre-injected into zebrafish embryos, effectively neutralizing 
their pathogenicity.257 Hybridization of carbon-based materials with amyloids even has 
applications outside the scope of nanomedicine and into biotechnology, e.g. for developing 
conductive nanowires256 and the selective removal of fluoride from contaminated 
waterways.263 CNTs require careful design and functionalization to be effective at the 
biological interface, however, given the capacity for longer, rigid structures (i.e. with a high 
aspect ratio) to induce ‘frustrated phagocytosis’ – thus pertaining to a long circulation lifetime 
– in addition to oxidative stress caused by the partitioning of CNTs through the lipid cell
membrane.264-265 Shorter, tangled CNTs may thus be more biocompatible, but, due to a smaller
available surface area, likely pose less effective amyloid scavengers.
On the other hand, graphene QDs, due to their small size, good biocompatibility and intrinsic 
photoluminescent properties, provide promising candidates for the development of anti-
amyloidosis biosensors. Huang and colleagues demonstrated that graphene QDs were able to 
track Aβ aggregation in vitro, providing an analogous kinetic profile to ThT for probing 
amyloid fibrillization.266 Furthermore, nonfunctionalized graphene QDs were able to 
translocate across the BBB and induced the clearance of amyloid from αSyn-treated WT 
mice,221 additionally mitigating IAPP-associated toxicity in zebrafish larvae in vivo.259 
However, given that the surface of carbon-based materials is highly fouling in lieu of stealth 
polymer functionalization,256 consideration should be taken to protein corona formation when 
materials are introduced to the biological interface, and how it may impact their trafficking and 
behavior in vivo. 
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Given the left-handedness of most major amyloid species under physiological conditions,267 
chirality presents a novel mesoscopic target for anti-amyloidosis strategies. Direct chiral 
modulation of Aβ1-42 aggregation and associated in vitro cytotoxicity was demonstrated by 
enantiomeric carbon dots synthesized from L-lysine over those synthesized by D-lysine.268 
Accordingly, right-handed silica nanoribbons provided a nucleation site for IAPP, allowing 
fibrillization to occur perpendicularly to the ribbon axis, consequently rescuing zebrafish larvae 
from IAPP-associated toxicity.269 In addition to nanoribbons, mesoporous silica NPs (MSNs) 
are well-established as vehicles for drug delivery in nanomedicine, and have recently been 
explored for their capacity to mitigate amyloidosis.270 For example, defect-related luminescent 
MSNs, surface-modified by chitosan and conjugated to the small peptide NF(NMe)GA(N-
Me)IL, inhibited IAPP fibrillization and associated generation of ROS, further demonstrating 
intervention of this nanocomposite stabilized the mitochondrial membrane potential in INS-1 
cells in vitro.271  
1.4.5 Biomimetic nanomaterials 
The utilization of nanostructures either directly constructed of or synthetically mimicking 
native biomolecular components can ensure robust biocompatibility and low immunogenicity, 
thus allowing safe passage of so-called ‘biomimetic’ nanomaterials through complex biological 
milieu. Chitosan NPs, derived from the degradation of crustacean chitin shells, were conjugated 
with the peptide KLVFF via a PEG cross-linker, with a Beclin-1 protein also attached to induce 
autophagy.272 KLVFF, a ‘β-sheet breaker’ derived from Aβ1-42, selectively targeted Aβ 
plaques in APPswe/PS1dE9 mice via H-bonding between NP-bound KVLFF and the twin 
sequence inherent in Aβ aggregates. The NP-amyloid complex was then effectively 
endocytosed and degraded through the ALS, resulting in the clearance of approximately 59% 
of insoluble and 32% of soluble Aβ in vivo, respectively, and restored memory deficits within 
the mice. Mirror image phage display identified two peptides, TGNYKALHPHNG (TGN) and 
QSHYRHISPAQV (QSH), predicted to target the BBB and Aβ fibrils. Conjugation of the 
peptides to PEGylated polylactic acid NPs resulted in concentration of the NPs at Aβ plaques 
in the hippocampus after intravenous injection into Aβ-treated nude adult mice.273 Mitigation 
of AD-associated behavioral and memory deficits, however, was not assessed in this approach. 
HSA nanoparticles were used to encapsulate and deliver the drug andrographolide, derived 
from the Asian medicinal plant Andrographis paniculate, across the BBB to target Aβ plaques 
42 
in the brain of TgCRND8 mice. Though this approach did not succeed in counteracting Aβ 
aggregation and toxicity, significantly reduced oxidative stress levels were reported in treated 
mice.274 Ma and colleagues developed a xenograft mouse model of immunoglobulin light-chain 
amyloidosis (LC), and, selecting 306-O18B3 lipidoid nanoparticles as model candidates for 
anti-LC gene therapy, they demonstrated that NP-encapsulated siRNA targeting κ LC constant 
region-encoding mRNA was capable of reducing circulating LC in the mice after 8 days of 
daily injections.275 Lastly, bridging the gap between lipid and protein, apolipoprotein E3 
(ApoE3) and high-density lipoproteins (HDLs) were complexed to generate biomimetic 
‘nanodiscs’. These nanodiscs demonstrated stealth properties upon intravenous administration 
into Aβ-treated WT mice, avoiding the accumulation of a protein corona within the plasma and 
cerebrospinal fluid as they crossed the BBB via ApoE3 specific receptors, and specifically 
targeted low order Aβ species, subsequently promoting clearance of Aβ from astrocytes and 
microglial cells.276  
1.4.6 Polymeric nanomaterials 
Polymeric NPs have facilely tuneable structures, allowing the generation of NPs with a diverse 
range of properties. Given the propensity for cationic nanomaterials to undergo protein fouling 
and inflict membrane damage, anionic or neutrally charged polymeric materials may prove 
superior agents for combating amyloidosis. For example, Aso and colleagues functionalized 
poly(propylene imine) core dendrimers with a maltose-histidine shell, neutralizing the positive 
charge of the amino groups and subsequently demonstrating improved biocompatibility and 
BBB penetration in APP/PS1 mice, in addition to mediating neuroprotectivity against AD 
pathologies.277 Tuning the hydrophobicity of polymeric NPs is also necessary to both (1) 
promote hydrophobic interactions of the NP with the amyloidogenic region of aggregating 
species while (2) allowing effective dispersion of the NPs in aqueous solution, as posited by 
Evgrafova and colleagues, who demonstrated that inhibition of Aβ1-40 was best achieved 
through balancing the hydrophobic and hydrophilic properties of polymeric anti-amyloidosis 
candidates.278 
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Though several types of polymeric NPs have been investigated as for the inhibition of 
amyloidogenic peptides,277-282 a paucity of data exists for IAPP. Poly-ε-caprolactone NPs were 
designed with an IAPP cargo towards an in vivo system of controlled IAPP release, allowing 
the endogenous functions of IAPP to be performed while maintaining its localized 
concentration below the aggregation threshold, and were able to regulate glycemia in fasting 
mice over 36 h.283 As IAPP aggregation-inhibition agents, hydrophobic, neutrally charged 
NiPAM:BAM co-polymers have shown some efficacy in inhibiting IAPP fibrillization,284 and 
OH-terminated polyamidoamine (PAMAM-OH) dendrimers were recently shown to interact 
with IAPP within the amyloidogenic region, preventing IAPP fibrillization through amyloid 
contact and mitigating cytotoxicity in vitro and in mouse islets.285 Interestingly, some neutral 
polymers have been shown to promote amyloid aggregation, particularly at higher 
concentrations, likely due to molecular crowding – recently, for example, PEG 12 polymer was 
shown to promote fibrillization of αSyn, increasing with increasing concentration of PEG in 
solution.280 The promotion of amyloid aggregation, however, is not necessarily correlated with 
increased cytotoxicity – through reducing the lifetime of toxic oligomeric species via their 
Figure 10: Star polymers sequester IAPP and provide a scaffold to promote fibrillization, 
generating ‘stelliform’ amyloids. Top panel: simplified cartoon scheme of poly (2-hydroxyl ethyl 
acrylate) stars interacting with IAPP monomers. Bottom panel: TEM imagery of stelliform amyloids, 
as nanostructures with compact cores and radiating fibrils, highlighted in green with the diameter of 
the core indicated. Upper panel reproduced with permission from Pilkington et al. 2017.290  
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conversion to fibrils, a net reduction in amyloid-associated toxicity may be observed, and could 
provide an alternative treatment strategy for amyloidosis. Accordingly, anionic sulfated 
dendrimers prevented IAPP-associated cytotoxicity in β-cells in vitro, with dendrimer-
mediated modulation of the amyloid pathway dependent on dendrimer morphology: G0 
dendrimers were shown to inhibit amyloidogenesis, whereas G1 dendrimers enhanced it, 
through providing a scaffold that promoted IAPP amyloid contact and aggregation.286  
Despite the potential of dendrimers as effective anti-amyloidosis agents, their synthesis is 
expensive and labour intensive, limiting their practical application in IAPP research. 
Hyperbranched and star polymers, on the other hand, lack the cost and difficulty of synthesis 
of dendrimers and other polymeric species, yet are capable of analogous structural complexity, 
potentiating their development as treatment agents for amyloid-associated pathologies. For 
example, a hyperbranched PEG polymer containing a dopamine moiety was effective in 
inhibiting the fibrillization of αSyn in vitro.280 Star polymers have historically been utilized for 
engineering and materials science applications, while their usage in a biological context is 
relatively new287 – a frequent application within the scope of nanomedicine being the delivery 
of interference RNA for anti-cancer purposes288 and for diabetic-related wound healing289 in 
vivo. In pancreatic β-cells in vitro, and additionally ex vivo in mouse islets, poly (2-hydroxyl 
ethyl acrylate) star polymers were shown to accelerate IAPP fibrillization through formation 
of a polymer-IAPP ‘stelliform amyloid’ complex (Fig. 10), resulting in a significant reduction 
of IAPP-mediated cytotoxicity.290 This reflects the aforementioned rapid fibrillization kinetics 
of pmel17 in melanogenesis, as an endogenous mechanism to reduce the lifetime of toxic 
intermediate species.34 Thus, the development of hyperbranched and star polymers with 
aromatic or hydroxyl terminal moieties as novel anti-IAPP agents may provide an effective 
approach for mitigating the toxic effect of IAPP in T2D.  
1.5 State-of-the-art and current paradigms in amyloid science 
1.5.1 State-of-the-art in amyloid technologies and anti-amyloidosis strategy 
Amyloid science represents a diverse field, and encapsulates not only the interrogation of 
amyloid pathologies, but additionally harnessing amyloids for use in engineering and 
nanotechnology beyond the scope of associated disease – namely, taking the pathological and 
rendering it functional. Reches & Gazit pioneered the use of modified amyloidogenic peptides 
as scaffolding for nanomaterial production, utilizing Aβ-diphenylalanine ultrashort peptides 
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assembled into nanotubes to internally cast silver nanowires, subsequently 'breaking' the cast 
via enzymatic digestion and revealing discrete nanowires with long persistence length.14 
Fifteen years later, Jain et al. fibrillized ultrashort dipeptides into an amyloid-like hydrogel 
which was utilized as a staging area for the synthesis of rectangular platonic gold nanoparticles, 
attaining size control through tuning pH.291 Bacillus subtilis biofilms generated through tunable 
TasA amyloid fibrillization can be 3D printed into diverse shapes for a wide variety of 
applications in biomedicine;292 similarly, fibrillization under certain conditions allows αSyn to 
form flat sheets that may have potential in biosensing.293 Amyloid oligomers have even been 
exploited as NPs to target macrophages.294 With regards to IAPP, a synthetic nanovaccine for 
Chikungunya fever was generated by merging the amyloidogenic region (20-29) of IAPP with 
an 18mer antigenic sequence from a glycoprotein exposed on the Chikungunya viral envelope. 
The fibrillization of the synthetic nanovaccine, facilitated by IAPP20-29, provided superior 
surface area for IgG response and macrophage uptake in immunized mice.295 Increased 
manipulation of the intrinsic properties of amyloid species comes hand in hand with new 
insight into fundamental aspects of their fibrillogenesis and toxic states, towards understanding 
and combating amyloid pathologies. 
Within the biomedical context of amyloid science, a theory recently gaining traction is that 
bacteria may contribute to the development and/or pathologies of a number of amyloid-
associated diseases.296 Of particular interest is how bacterial infection and the microbiota 
contribute to AD development,297 but these could also have implications in T2D.298-299 The 
capacity for bacterial toxins to interface with neurodegenerative disorder was recently 
illustrated through the delivery of superparamagnetic IONPs and thioflavin S – neither capable 
of crossing the BBB under normal circumstances – to Aβ plaques within the brain of mouse 
models, as facilitated by their complexation with the toxin lipopolysaccharide (LPS).300 LPS 
was able to induce inflammation at the BBB of 5XFAD mice, consequently allowing uptake 
of the Aβ-targeting materials – however, this effect was only seen in ageing mice, not in young 
or wild-type mice, potentiating that the BBB in older models is more susceptible to leakiness 
upon inflammation. Accordingly, systemic inflammation induced by LPS also impacted the 
health of older models: highlighting both the risk of the approach and the implications of the 
role of bacteria in neurodegenerative disease. Anti-amyloidosis, on the other hand, may offer 
new solutions to multi-drug resistance (MDR), a paramount challenge for modern medicine 
due to the antibiotic-focused global pharmaceutical industry.  
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CRISPR-Cas9 presents a new frontier for a wide range of gene therapy applications, and has 
found recent application in the field of amyloid science. Sun et al. demonstrated that β-cleavage 
of APP to generate toxic Aβ species can be redirected to neuroprotective α-cleavage through 
the editing of APP at the extreme C-terminus, and that this methodology is well-tolerated in 
human iPSC-derived neuronal cells and in vivo within mouse models. CRISPR-Cas9 
amphiphilic nanocomplexes were further utilized by Park and colleagues to target β-secretase 
1 (Bace1), an enzyme required for the production of Aβ peptides through APP cleavage. This 
approach was able to rescue AD pathologies in two mouse models (5XFAD and App knock-in 
mice) of AD.301 Harnessing nanotechnology to target the source of protein aggregation rather 
than the outcome could be highly effective in ameliorating the pathologies of amyloid diseases, 
particularly for mutation-induced amyloidoses.43 
Overall, the development and application of novel and innovative anti-amyloidosis agents, 
from molecular tweezers302 to plasmon-activated water,303 generates a broad catalogue of 
treatment strategies to potentially bring to the market. Exploiting the propensity for amyloids 
to sequester other amyloid species and co-fibrillate presents such a venture: from prion-
functionalized AuNPs304 and Aβ1-40 tethered to MNPs305 for Aβ-sensing, to protein-capped 
NPs against tau,306 and recent work with inexpensive, biocompatible bLg amyloid fragments 
absorbed to NPs that, when administered to the circulation of zebrafish, crossed the BBB to 
sequester Aβ in the brain and mitigate its toxicity.307 Further utilizing the promotion of amyloid 
protein fibrillization to combat its associated toxicity could provide a new treatment strategy 
for amyloid-associated pathologies, particularly for IAPP. Though the application of NPs to 
deliberately enhance amyloid aggregation in order to decrease toxic oligomer lifetime has been 
explored for Aβ,223, 308-309 anti-amyloidosis candidate design has trended overarchingly towards 
inhibition strategies for IAPP. This strategy was applied successfully via the application of 
poly (2-hydroxyl ethyl acrylate) star polymers to promote IAPP fibrillization, wherein the 
formation of polymer-IAPP complexes mitigated IAPP-associated cytotoxicity in pancreatic 
β-cells and mouse islets.290 Biocompatible polymeric nanostructures with facile synthesis 
therefore represent an understudied class of nanomaterials with potential development as 
effective agents against IAPP pathologies in T2D.  
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1.5.2 Prevailing issues and future directions in amyloid science 
As of 2016, 51 FDA-approved medicinal NPs and 77 NP products were in clinical trials for a 
wide range of applications,310 yet decades of research has produced only one candidate against 
amyloid disease to clear the clinic and seek FDA approval to enter the market.311 
Overarchingly, efforts to develop anti-amyloidosis technologies are likely stymied by two key 
issues: a lack of fundamental knowledge of how amyloid species and NPs interact with each 
other and the surrounding milieu at the biological interface, and, furthermore, a lack of 
appropriate models for the interrogation of these conditions at pre-clinical stages.  
Firstly, in light of recent failures of antibody-based strategies to promote the clearance of 
amyloid species in clinical trials,312 it was hypothesized that the amyloid surface may prove 
highly heterogeneous and thus difficult to specifically target due to obfuscation by circulating 
proteins. Indeed, the first investigations into the amyloid-protein corona191, 204 revealed that 
amyloid species form a nonuniform, viscoelastic corona capable of remodeling mature fibrils, 
and that proteins absorbed to the amyloid surface have roles in a number of key metabolic and 
biological functions. These insights were supported by proteomic profiling of in vivo 
plaques,210 and provide new implications for the endogenous state of mature amyloid fibrils 
and plaques within different areas of the body, in addition to how enriched proteins may 
influence the biological processes of the local environment. Consequently, further 
characterization of amyloid plaques in different microenvironments could provide novel 
targeting strategies for anti-amyloidosis treatment agents. 
Autosomal dominant mutations in APP, PSEN1 or PSEN2 are causative of early onset familial 
AD (FAD), and represent < 1% of AD cases – yet these mutated forms of APP and PS1 are 
expressed in all major transgenic rodent models of AD.220 Similarly, in rodent models 
transgenic for human IAPP, multiple copies of the transgene can be expressed – in one case, 
up to 74 copies were recorded313 – with the IAPP gene promoter found 2-5× more responsive 
to glucose challenge than under endogenous conditions, causing artificial overexpression of 
IAPP.314-315 3D cultures, including spheroids and organoids, represent an alternative to the use 
of animal models. Recently, Choi and coworkers developed a human neural stem cell 3D model 
of FAD supported by a gel matrix, demonstrating that the bioengineered tissue deposited Aβ 
into the gel, with plaques forming after 5-6 weeks.218 Remarkably, tau neurofibrillary tangles 
were also observed a week later, representative of clinical pathologies in human AD yet never 
replicated in animal models of the disease. Low volume microfluidic platforms further reduce 
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waste while providing a highly controlled platform to investigate the behavior of amyloid 
species and NPs under flow. For example, a dynamic flow sandwich immunoassay utilizing 
antibody-conjugated AuNPs to detect captured protein within multi-channel microfluidic chips 
allowed detection of Aβ and tau at femtomolar levels.216  
Ultimately, in order to attain successful translation of anti-amyloidosis agents from in vitro to 
in vivo, fundamental aspects of the nature and behavior of amyloid in complex biological 
environments must be elucidated. Providing a complex microenvironment that more accurately 
approximates human biology, while benefiting from the tight control of an in vitro platform, 
endogenous amyloid and/or NP interactions can be more effectively addressed.  
1.6 Context of thesis 
In this introduction, it has been established that elucidating the mechanics of IAPP amyloid 
aggregation and associated pathologies in their native context has, for decades, been obfuscated 
by the complexity of the biological milieu to which they are introduced post-secretion from 
pancreatic β-cells – from the pancreatic extracellular space to the circulation, and beyond, to 
pathologies in tissues and organs throughout the body that contribute to the symptomatic 
burden of T2D. Though oligomers have been cited as the key mediators of amyloid-associated 
cytotoxicity for other amyloids, this paradigm is still contested for IAPP. Moreover, the rapid 
fibrillization of IAPP has presented a challenge for the characterization of intermediate species, 
with morphologies described in theory but not in practice. Given, further, that fibrillating and 
mature IAPP amyloid interface with a complex extracellular environment – consisting of 
numerous circulating proteins and lipids – its impact on the structure and biological behavior 
of IAPP species has been found lacking. For example, the ‘protein corona’ described for 
synthetic nanomaterials interfacing with a biological environment had yet to be demonstrated 
for an endogenously generated, proteinaceous nanomaterial such as amyloid. 
As a result of knowledge gaps regarding IAPP at the biological interface, numerous studies 
utilizing a wide variety of nanomaterials towards mitigating IAPP pathologies have not, at the 
time of writing, succeeded in clinical translation. The majority of anti-amyloid research utilizes 
inhibition of fibrillization as a strategy, with a ‘fibrillization promotion’ approach far less 
frequently employed. Considering the effective application of this strategy in nature through 
nontoxic melanogenesis, an approach utilizing a biocompatible polymeric nanostructure, e.g. 
a star polymer, designed with aromatic and hydroxyl moieties to effectively sequester IAPP 
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species and, additionally, acting to promote IAPP fibrillization, could present a new agent and 
a new strategy to be employed towards mitigating IAPP-mediated toxicity in T2D.   
Concordantly, this thesis aims to bridge the gap between fundamental knowledge and practical 
application in the context of IAPP aggregation and associated cytotoxicity, through gaining 
deeper understanding of an understudied amyloidogenic peptide towards strategies to mitigate 
its pathologies. Herein, fundamental mechanisms and biological interactions of IAPP 
amyloidosis and associated pathway species are established, and this knowledge utilized to 
advise the design and application of an anti-amyloidosis agent. These paradigms are explored 
over three experimental chapters, as outlined in two key aims: 
1. Establish fundamental paradigms of IAPP species at the biological interface
a. Characterize the morphology and associated cytotoxicity of IAPP species in
vitro
b. Examine the modulation of IAPP fibrillization and biological behavior by the
extracellular environment utilizing model proteins, lipids and ultrasmall
membranes in vitro
c. Explore the formation of an ‘amyloid-protein corona’ within a model complex
biological milieu in vitro
2. Explore a new strategy and agent for mitigation of IAPP-mediated cytotoxicity
a. Design and assess the efficacy of a star polymer to inhibit IAPP-mediated
toxicity in vitro and ex vivo
The experimental section of this thesis is thus structured as follows: first, the fibrillization 
pathway of IAPP is interrogated and intermediate species characterized (Chapter Two, Aim 
1A). Second, IAPP amyloid pathway species are explored at the in vitro biological interface: 
with regards to their cytotoxic impact on primary cells and their interactions with model 
proteins, lipids and ultrasmall membranes (Chapter Two, Aim 1B). The formation of the 
‘amyloid-protein corona’ in a complex in vitro environment (Aim 1C) is then explored in-depth, 
through a biophysical and proteomics-based study published in ACS Nano (Chapter Three). 
Lastly, the novel synthesis of a poly (2-hydroxyl ethyl acrylate) ‘PHEA’ star polymer and its 
capacity to mitigate IAPP-mediated cytotoxicity in pancreatic β-cells in vitro, in addition to 
mouse islets ex vivo (Aim 2), is described in Chapter Four, as published in 




(1) Hartl, F. U.; Bracher, A.; Hayer-Hartl, M., Molecular chaperones in protein folding and
proteostasis. Nature 2011, 475, 324-332.
(2) Chiti, F.; Calamai, M.; Taddei, N.; Stefani, M.; Ramponi, G.; Dobson, C. M., Studies of the
aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc.
Natl. Acad. Sci. U.S.A. 2002, 99, 16419-16426.
(3) Bartlett, A. I.; Radford, S. E., An expanding arsenal of experimental methods yields an
explosion of insights into protein folding mechanisms. Nat. Struc. Mol. Biol. 2009, 16, 582-588.
(4) Knowles, T. P. J.; Vendruscolo, M.; Dobson, C. M., The amyloid state and its association with
protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 2014, 15, 384-396.
(5) Chiti, F.; Dobson, C. M., Protein Misfolding, Functional Amyloid, and Human Disease. Annu.
Rev. Biochem. 2006, 75, 333-366.
(6) Kopito, R. R., Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000,
10, 524-530.
(7) Yoshimura, Y.; Lin, Y.; Yagi, H.; Lee, Y.-H.; Kitayama, H.; Sakurai, K.; Masatomo, S.; Ogi,
H.; Naiki, H.; Goto, Y., Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates
from their kinetics of formation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 14446-14451.
(8) Adamcik, J.; Mezzenga, R., Amyloid Polymorphism in the Protein Folding and Aggregation
Energy Landscape. Angew. Chem., Int. Ed. Engl. 2018, 57, 8370-8382.
(9) Vetri, V.; Foderà, V., The route to protein aggregate superstructures: Particulates and amyloid-
like spherulites. FEBS Lett. 2015, 589, 2448-2463.
(10) Dobson, C. M., Principles of protein folding, misfolding and aggregation. Semin. Cell Dev.
Biol. 2004, 15, 3-16.
(11) Käkinen, A.; Adamcik, J.; Wang, B.; Ge, X.; Mezzenga, R.; Davis, T. P.; Ding, F.; Ke, P. C.,
Nanoscale inhibition of polymorphic and ambidextrous IAPP amyloid aggregation with small
molecules. Nano Res. 2017, 11, 3636-3647.
(12) Sade, D.; Shaham-Niv, S.; Arnon, Z. A.; Tavassoly, O.; Gazit, E., Seeding of proteins into
amyloid structures by metabolite assemblies may clarify certain unexplained epidemiological
associations. Open Biol. 2018, 8, 170229.
(13) Sipe, J. D.; Benson, M. D.; Buxbaum, J. N.; Ikeda, S.-I.; Merlini, G.; Saraiva, M. J. M.;
Westermark, P., Nomenclature 2014: Amyloid fibril proteins and clinical classification of the
amyloidosis. Amyloid 2014, 21, 221-224.
(14) Reches, M.; Gazit, E., Casting metal nanowires within discrete self-assembled peptide
nanotubes. Science 2003, 300, 625-627.
51 
(15) Tamamis, P.; Adler-Abramovich, L.; Reches, M.; Marshall, K.; Sikorski, P.; Serpell, L.; Gazit,
E.; Archontis, G., Self-Assembly of Phenylalanine Oligopeptides: Insights from Experiments and
Simulations. Biophys. J. 2009, 96, 5020-5029.
(16) Adler-Abramovich, L.; Vaks, L.; Carny, O.; Trudler, D.; Magno, A.; Caflisch, A.; Frenkel, D.;
Gazit, E., Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat.
Chem. Biol. 2012, 8, 701-706.
(17) Törnquist, M.; Michaels, T. C. T.; Sanagavarapu, K.; Yang, X.; Meisl, G.; Cohen, S. I. A.;
Knowles, T. P. J.; Linse, S., Secondary nucleation in amyloid formation. Chem. Commun. 2018, 54,
8667-8684.
(18) van Diggelen, F.; Tepper, A. W. J. W.; Apetri, M. M.; Otzen, D. E., α-Synuclein Oligomers: A
Study in Diversity. Isr. J. Chem. 2016, 57, 699-723.
(19) Walsh, D. M.; Selkoe, D. J., Aβ Oligomers - a decade of discovery. J. Neurochem. 2007, 101,
1172-1184.
(20) Bellomo, G.; Bologna, S.; Gonnelli, L.; Ravera, E.; Fragai, M.; Lelli, M.; Luchinat, C.,
Aggregation kinetics of the Aβ1–40 peptide monitored by NMR. Chem. Commun. 2018, 54, 7601-7604.
(21) Wördehoff, M. M.; Bannach, O.; Shaykhalishahi, H.; Kulawik, A.; Schiefer, S.; Willbold, D.;
Hoyer, W.; Birkmann, E., Single Fibril Growth Kinetics of α-Synuclein. J. Mol. Biol. 2015, 427, 1428-
1435.
(22) Pillay, K.; Govender, P., Amylin Uncovered: A Review on the Polypeptide Responsible for
Type II Diabetes. Biomed Res. Int. 2013, 2013, 826706.
(23) Zraika, S.; Hull, R. L.; Verchere, C. B.; Clark, A.; Potter, K. J.; Fraser, P. E.; Kahn, S. E., Toxic
oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?
Diabetologia 2010, 53, 1046-1056.
(24) Kumar, D. K. V.; Choi, S. H.; Washicosky, K. J.; Eimer, W. A.; Tucker, S.; Ghofrani, J.;
Lefkowitz, A.; McColl, G.; Goldstein, L. E.; Tanzi, R. E.; Moir, R. D., Amyloid-β peptide protects
against microbial infection in mouse and worm models of Alzheimer's disease. Sci. Transl. Med. 2016,
8, 340ra72.
(25) Moir, R. D.; Lathe, R.; Tanzi, R. E., The antimicrobial protection hypothesis of Alzheimer's
disease. Alzheimers Dement. 2018, 14, 1602-1614.
(26) Jacob, R. S.; Das, S.; Singh, N.; Patel, K.; Datta, D.; Sen, S.; Maji, S. K., Amyloids Are Novel
Cell-Adhesive Matrices. In Biochemical and Biophysical Roles of Cell Surface Molecules,
Chattopadhyay, K.; Basu, S., Eds. Springer: Singapore, 2018.
(27) Blanco, L. P.; Evans, M. L.; Smith, D. R.; Badtke, M. P.; Chapman, M. R., Diversity, biogenesis
and function of microbial amyloids. Trends Microbiol. 2012, 20, 66-73.
(28) Romero, D.; Kolter, R., Functional amyloids in bacteria. Int. Microbiol. 2014, 17, 65-73.
52 
(29) Nakae, T.; Ishii, J.; Tokunaga, M., Subunit Structure of Functional Porin Oligomers That Form
Permeability Channels in the Outer Membrane of Escherichia coli. J. Biol. Chem. 1978, 254, 1457-
1461.
(30) Pyle, E.; Kalli, A. C.; Amillis, S.; Hall, Z.; Lau, A. M.; Hanyaloglu, A. C.; Diallinas, G.; Byrne,
B.; Politis, A., Structural Lipids Enable the Formation of Functional Oligomers of the Eukaryotic Purine
Symporter UapA. Cell Chem. Biol. 2018, 25, 840-848.
(31) Filipek, S.; Krzysko, K. A.; Fotiadis, D.; Liang, Y.; Saperstein, D. A.; Engel, A.; Palczewski,
K., A concept for G protein activation by G protein-coupled receptor dimers: the transducin/rhodopsin
interface. Photochem. Photobiol. Sci. 2004, 3, 628-638.
(32) Woodruff, J. B.; Hyman, A. A.; Boke, E., Organization and Function of Non-dynamic
Biomolecular Condensates. Trends Biochem. Sci. 2018, 43, 81-94.
(33) Audas, T. E.; Audas, D. E.; Jacob, M. D.; Ho, J. J. D.; Khacho, M.; Wang, M.; Perera, J. K.;
Gardiner, C.; Bennett, C. A.; Head, T.; Kryvenko, O. N.; Jorda, M.; Daunert, S.; Malhotra, A.; Trinkle-
Mulcahy, L.; Gonzalgo, M. L.; Lee, S., Adaptation to Stressors by Systemic Protein Amyloidogenesis.
Dev. Cell 2016, 39, 155-168.
(34) Fowler, D. M.; Koulov, A. V.; Alory-Jost, C.; Marks, M. S.; Balch, W. E.; Kelly, J. W.,
Functional Amyloid Formation within Mammalian Tissue. PLoS Biol. 2006, 4, 0100-0107.
(35) De Baets, G.; Van Doorn, L.; Rousseau, F.; Shymkowitz, J., Increased Aggregation Is More
Frequently Associated to Human Disease-Associated Mutations Than to Neutral Polymorphisms. PLoS
Comput. Biol. 2015, 11, e1004374.
(36) Xu, J.; Reumers, J.; Couceiro, J. R.; De Smet, F.; Gallardo, R.; Rudyak, S.; Cornelis, A.;
Rozenski, J.; Zwolinska, A.; Marine, J.-C.; Lambrechts, D.; Suh, Y.-A.; Rousseau, F.; Schymkowitz,
J., Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol.
2011, 7, 285-295.
(37) Jang, H. H., Regulation of Protein Degradation by Proteasomes in Cancer. J. Cancer Prev.
2018, 23, 153-161.
(38) Siekierska, A.; De Baets, G.; Reumers, J.; Gallardo, R.; Rudyak, S.; Broersen, K.; Couceiro, J.;
Van Durme, J.; Schymkowitz, J.; Rousseau, F., α-Galactosidase Aggregation Is a Determinant of
Pharmacological Chaperone Efficacy on Fabry Disease Mutants. J. Biol. Chem. 2012, 287, 28386-
28397.
(39) Huang, C. C.; Faber, P. W.; Persichetti, F.; Mittal, V.; Vonsattel, J.-P.; MacDonald, M. E.;
Gusella, J. F., Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of
Normal Polyglutamine Proteins. Somatic Cell Mol. Genet. 1998, 24, 217-233.
(40) Lu, M.; Williamson, N.; Mishra, A.; Michel, C. H.; Kaminski, C. F.; Tunnacliffe, A.; Schierle,
G. S. K., Structural progression of amyloid-β Arctic mutant aggregation in cells revealed by
multiparametric imaging. J. Biol. Chem. 2018, 294, 1478-1487.
53 
(41) Yoo, B. K.; Xiao, Y.; McElheny, D.; Ishii, Y., E22G Pathogenic Mutation of β‐Amyloid (Aβ)
Enhances Misfolding of Aβ40 by Unexpected Prion-like Cross Talk between Aβ42 and Aβ40. J. Am.
Chem. Soc. 2018, 140, 2781-2784.
(42) Hatami, A.; Monjazeb, S.; Milton, S.; Glabe, C. G., Familial Alzheimer's Disease Mutations
within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β
Peptide. J. Biol. Chem. 2017, 292, 3172-3185.
(43) Li, Z.; Wang, C.; Wang, Z.; Zhu, C.; Li, J.; Sha, T.; Ma, L.; Gao, C.; Yang, Y.; Sun, Y.; Wang,
J.; Sun, X.; Lu, C.; Difiglia, D.; Mei, Y.; Ding, C.; Luo, S.; Dang, Y.; Ding, Y.; Fei, Y.; Lu, B., Allele-
selective lowering of mutant HTT protein by HTT–LC3 linker compounds. Nature 2019, 575, 203-209.
(44) Noble, W.; Hanger, D. P.; Miller, C. C. J.; Lovestone, S., The Importance of Tau
Phosphorylation for Neurodegenerative Diseases. Front. Neurol. 2013, 4, 83.
(45) Rezaei-Ghaleh, N.; Amininasab, M.; Kumar, S.; Walter, J.; Zweckstetter, M., Phosphorylation
modifies the molecular stability of β-amyloid deposits. Nat. Commun. 2016, 7, 11359.
(46) Kumar, S.; Walter, J., Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation
of toxic aggregates in Alzheimer's disease. Aging 2011, 3, 803-812.
(47) Kumar, S.; Wirths, O.; Stüber, K.; Wunderlich, P.; Koch, P.; Theil, S.; Rezaei-Ghaleh, N.;
Zweckstetter, M.; Bayer, T. A.; Brüstle, O.; Thal, D. R.; Walter, J., Phosphorylation of the amyloid β-
peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol. 2016,
131, 525-537.
(48) Guivernau, B.; Bonet, J.; Valls-Comamala, V.; Bosch-Morató, M.; Godoy, J. A.; Inestrosa, N.
C.; Perálvarez-Martin, A.; Fernández-Busquets, X.; Andreu, D.; Oliva, B.; Muñoz, F. J., Amyloid-β
Peptide Nitrotyrosination Stabilizes Oligomers and Enhances NMDAR-Mediated Toxicity. J. Neurosci.
2016, 36, 11693-11703.
(49) Ittner, A.; Chua, S. W.; Bertz, J.; Volkerling, A.; van der Hoven, J.; Gladbach, A.; Przybyla,
M.; Bi, M.; van Hummel, A.; Stevens, C. H.; Ippati, S.; Suh, L. S.; Macmillan, A.; Sutherland, G.; Kril,
J. J.; Silva, A. P. G.; Mackay, J. P.; Poljak, A.; Delerue, F.; Ke, Y. D.; Ittner, L. M., Site-specific
phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice. Science 2016, 354, 904-908.
(50) Chen, L.; Wei, Y.; Wang, X.; He, R., Ribosylation Rapidly Induces α-Synuclein to Form Highly
Cytotoxic Molten Globules of Advanced Glycation End Products. PLoS ONE 2010, 5, e9052.
(51) Chen, L.; Wei, Y.; Wang, X.; He, R., d-Ribosylated Tau forms globular aggregates with high
cytotoxicity. Cell. Mol. Life Sci. 2009, 66, 2559-2571.
(52) Li, X.-H.; Du, L.-L.; Cheng, X.-S.; Jiang, X.; Zhang, Y.; Lv, B.-L.; Liu, R.; Wang, J.-Z.; Zhou,
X.-W., Glycation exacerbates the neuronal toxicity of β-amyloid. Cell Death Dis. 2013, 4, e673.
(53) Haque, E.; Kamil, M.; Hasan, A.; Irfan, S.; Sheikh, S.; Khatoon, A.; Nazir, A.; Mir, S. S.,
Advanced Glycation End Products (AGEs), Protein Aggregation and their Crosstalk: New Insight in
Tumorigenesis. Glycobiology 2019, cwz073.
54 
(54) Soldi, G.; Bemporad, F.; Torrassa, S.; Relini, A.; Ramazzotti, M.; Taddei, N.; Chiti, F.,
Amyloid Formation of a Protein in the Absence of Initial Unfolding and Destabilization of the Native
State. Biophys. J. 2005, 89, 4234-4244.
(55) Serebryany, E.; Woodard, J. C.; Adkar, B. V.; Shabab, M.; King, J. A.; Shakhnovich, E. I., An
Internal Disulfide Locks a Misfolded Aggregation-prone Intermediate in Cataract-linked Mutants of
Human γD-Crystallin. J. Biol. Chem. 2016, 291, 19172-19183.
(56) Kuhn, D. M.; Sykes, C. E.; Geddes, T. J.; Jaunarajs, K. L. E.; Bishop, C., Tryptophan
hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin
deficits and non-motor symptoms in Parkinson's disease. J. Neurochem. 2011, 116, 426-437.
(57) Bolisetty, S.; Harnau, L.; Jung, J.; Mezzenga, R., Gelation, Phase Behavior, and Dynamics of
β-Lactoglobulin Amyloid Fibrils at Varying Concentrations and Ionic Strengths. Biomacromolecules
2012, 13, 3241-3252.
(58) Ghavami, M.; Rezaei, M.; Ejtehadi, R.; Lofti, M.; Shokrgozar, M. A.; Emamy, B. A.; Raush,
J.; Mahmoudi, M., Physiological Temperature Has a Crucial Role in Amyloid Beta in the Absence and
Presence of Hydrophobic and Hydrophilic Nanoparticles. ACS Chem. Neurosci. 2013, 4, 375-378.
(59) McGlinchey, R. P.; Shewmaker, F.; McPhie, P.; Monterroso, B.; Thurber, K.; Wickner, R. B.,
The repeat domain of the melanosome fibril protein Pmel17 forms the amyloid core promoting melanin
synthesis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 13731-13736.
(60) Zimmerman, S. B.; Trach, S. O., Estimation of macromolecule concentrations and excluded
volume effects for the cytoplasm of Escherichia coli. J. Mol. Biol. 1991, 222, 599-620.
(61) Uversky, V. N.; Cooper, M. E.; Bower, K. S.; Li, J.; Fink, A. L., Accelerated α-synuclein
fibrillation in crowded milieu. FEBS Lett. 2002, 515, 99-103.
(62) Shtilerman, M. D.; Ding, T. D.; Lansbury, P. T., Molecular Crowding Accelerates Fibrillization
of α-Synuclein:  Could an Increase in the Cytoplasmic Protein Concentration Induce Parkinson's
Disease? Biochemistry 2002, 41, 3855-3860.
(63) Hatters, D. M.; Minton, A. P.; Howlett, G. J., Macromolecular Crowding Accelerates Amyloid
Formation by Human Apolipoprotein C-II. J. Biol. Chem. 2002, 277, 7824-7830.
(64) Viles, J. H., Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper,
zinc and iron in Alzheimer's, Parkinson's and prion diseases. Coord. Chem. Rev. 2012, 256, 2271-2284.
(65) Dong, X.; Svantesson, T.; Sholts, S. B.; Wallin, C.; Jarvet, J.; Gräslund, A.; Wärmländer, S. K.
T. S., Copper ions induce dityrosine-linked dimers in human but not in murine islet amyloid polypeptide
(IAPP/amylin). Biochem. Biophys. Res. Communs. 2019, 510, 520-524.
(66) Smith, D. P.; Ciccotosto, G. D.; Tew, D. J.; Fodero-Tavoletti, M. T.; Johanssen, T.; Masters,
C. L.; Barnham, K. J.; Cappai, R., Concentration Dependent Cu2+ Induced Aggregation and Dityrosine
Formation of the Alzheimer's Disease Amyloid-β Peptide. Biochemistry 2007, 46, 2881-2891.
55 
(67) Zhao, J.; Gao, W.; Yang, Z.; Li, H.; Gao, Z., Nitration of amyloid-β peptide (1–42) as a
protective mechanism for the amyloid-β peptide (1–42) against copper ion toxicity. J. Inorg. Biochem.
2019, 190, 15-23.
(68) Govers, S. K.; Mortier, J.; Adam, A.; Aertsen, A., Protein aggregates encode epigenetic
memory of stressful encounters in individual Escherichia coli cells. PLoS Biol. 2018, 16, e2003853.
(69) Trigo, D.; Nadais, A.; da Cruz e Silva, O. A. B., Unravelling protein aggregation as an ageing
related process or a neuropathological response. Ageing Res. Rev. 2019, 51, 67-77.
(70) Peters, T. W.; Rardin, M. J.; Czerwieniec, G.; Evani, U. S.; Reis-Rodrigues, P.; Lithgow, G. J.;
Mooney, S. D.; Gibson, B. W.; Hughes, R. E., Tor1 regulates protein solubility in Saccharomyces
cerevisiae. Mol. Biol. Cell 2012, 23, 4679-4688.
(71) Weids, A. J.; Ibstedt, S.; Tamás, M. J.; Grant, C. M., Distinct stress conditions result in
aggregation of proteins with similar properties. Sci. Rep. 2016, 6, 24554.
(72) Gsponer, J.; Babu, M. M., Cellular Strategies for Regulating Functional and Nonfunctional
Protein Aggregation. Cell Reports 2012, 2, 1425-1437.
(73) Rothe, S.; Prakash, A.; Tyedmers, J., The Insoluble Protein Deposit (IPOD) in Yeast. Front.
Mol. Neurosci. 2018, 11, 237.
(74) Reumers, J.; Maurer-Stroh, S.; Schymkowitz, J.; Rousseau, F., Protein sequences encode
safeguards against aggregation. Hum. Mutat. 2009, 30, 431-437.
(75) Rousseau, F.; Schymkowitz, J.; Serrano, L., Protein aggregation and amyloidosis: confusion of
the kinds? Curr. Opin. Struct. Biol. 2006, 16, 118-126.
(76) Wang, X.; Zhou, Y.; Ren, J.-J.; Hammer, N. D.; Chapman, M. R., Gatekeeper residues in the
major curlin subunit modulate bacterial amyloid fiber biogenesis. Proc. Natl. Acad. Sci. U.S.A. 2010,
107, 163-168.
(77) Aguilera, P.; Marcoleta, A.; Lobos-Ruiz, P.; Arranz, R.; Valpuesta, J. M.; Monasterio, O.;
Lagos, R., Identification of Key Amino Acid Residues Modulating Intracellular and In vitro Microcin
E492 Amyloid Formation. Front. Microbiol. 2016, 7, 35.
(78) Park, J.-S.; Kim, D.-H.; Yoon, S.-Y., Regulation of amyloid precursor protein processing by its
KFERQ motif. BMB Rep. 2016, 49, 337-342.
(79) Vogiatzi, T.; Xilouri, M.; Vekrellis, K.; Stefanis, L., Wild Type α-Synuclein Is Degraded by
Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells. J. Biol. Chem. 2008, 283,
23542-23556.
(80) Bauer, P. O.; Goswami, A.; Wong, H. K.; Kurosawa, M.; Yamada, M.; Miyazaki, H.;
Matsumoto, G.; Kino, Y.; Nagai, Y.; Nukina, N., Harnessing chaperone-mediated autophagy for the
selective degradation of mutant huntingtin protein. Nat. Biotechnol. 2010, 28, 256-263.
(81) Friedlich, A. L.; Tanzi, R. E.; Rogers, J. T., The 5'-untranslated region of Parkinson's disease
α-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry 2007, 12,
222-223.
56 
(82) Rogers, J. T.; Randall, J. D.; Cahill, C. M.; Eder, P. S.; Huang, X.; Gunshin, H.; Leiter, L.;
McPhee, J.; Sarang, S. S.; Utsuki, T.; Greig, N. H.; Lahiri, D. K.; Tanzi, R. E.; Bush, A. I.; Giordani,
T.; Gullans, S. R., An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's
amyloid precursor protein transcript. J. Biol. Chem. 2002, 277, 45518-45528.
(83) Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Weinreb, O.; Youdim, M. B. H., Physiological
and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic
use of iron-chelators. BMC Neurosci. 2008, 9 (Suppl 2), S2.
(84) Glickman, M. H.; Ciechanover, A., The Ubiquitin-Proteasome Proteolytic Pathway:
Destruction for the Sake of Construction. Physiol. Rev. 2001, 82, 373-428.
(85) Dikic, I.; Elazar, Z., Mechanism and medical implications of mammalian autophagy. Nat. Rev.
Mol. Cell Biol. 2018, 19, 349-364.
(86) De Baets, G.; Reumers, J.; Blanco, J. D.; Dopazo, J.; Schymkowitz, J.; Rousseau, F., An
Evolutionary Trade-Off between Protein Turnover Rate and Protein Aggregation Favors a Higher
Aggregation Propensity in Fast Degrading Proteins. PLoS Comput. Biol. 2011, 7, e1002090.
(87) Liberek, K.; Lewandowska, A.; Zietkiewicz, S., Chaperones in control of protein
disaggregation. EMBO J. 2008, 27, 328-335.
(88) Auluck, P. K.; Chan, H. Y. E.; Trojanowski, J. Q.; Lee, V. M. Y.; Bonini, N. M., Chaperone
Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease. Science 2002, 295,
865-868.
(89) Hinault, M.-P.; Cuendet, A. F. H.; Mattoo, R. U. H.; Mensi, M.; Dietler, G.; Lashuel, H. A.;
Goloubinoff, P., Stable α-Synuclein Oligomers Strongly Inhibit Chaperone Activity of the Hsp70
System by Weak Interactions with J-domain Co-chaperones. J. Biol. Chem. 2010, 285.
(90) Zhang, Y.-J.; Gendron, T. F.; Xu, Y.-F.; Ko, L.-W.; Yen, S.-H.; Petrucelli, L., Phosphorylation
regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal
fragments. Mol. Neurodegener. 2010, 5, 33.
(91) Wang, Y.; Mandelkow, E., Degradation of tau protein by autophagy and proteasomal pathways.
Biochem. Soc. Trans. 2012, 40, 644-652.
(92) Liu, J.; Li, L., Targeting Autophagy for the Treatment of Alzheimer’s Disease: Challenges and
Opportunities. Front. Mol. Neurosci. 2019, 12, 203.
(93) Hong, L.; Huang, H.-C.; Jiang, Z.-F., Relationship between amyloid-beta and the ubiquitin–
proteasome system in Alzheimer’s disease. Neurol. Res. 2014, 36, 276-282.
(94) Zhu, B.; Jiang, L.; Huang, T.; Zhao, Y.; Liu, T.; Li, X.; Campos, A.; Pomeroy, K.; Masliah, E.;
Zhang, D.; Xu, H., ER-associated degradation regulates Alzheimer's amyloid pathology and memory
function by modulating γ-secretase activity. Nat. Commun. 2017, 8, 1472.
(95) Sorrentino, V.; Romani, M.; Mouchiroud, L.; Beck, J. S.; Zhang, H.; D'Amico, D.; Moullan,
N.; Potenza, F.; Schmid, A. W.; Rietsch, S.; Counts, S. E.; Auwerx, J., Enhancing mitochondrial
proteostasis reduces amyloid-β proteotoxicity. Nature 2017, 552, 187-193.
57 
(96) Mendis, S. Global status report on noncommunicable diseases 2014; World Health
Organisation: Geneva, 2014.
(97) Guariguata, L.; Whiting, D. R.; Hambleton, I.; Beagley, J.; Linnenkamp, U.; Shaw, J. E., Global
estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 2014,
103, 137-149.
(98) Mathers, C. D.; Loncar, D., Projections of Global Mortality and Burden of Disease from 2002
to 2030. PLoS Med. 2006, 3, 2011-2030.
(99) Leahy, J. L., Pathogenesis of Type 2 Diabetes Mellitus. Arch. Med. Res. 2005, 36, 197-209.
(100) Kahn, S. E.; Zraika, S.; Utzschneider, K. M.; Hull, R. L., The beta cell lesion in type 2 diabetes:
there has to be a primary functional abnormality. Diabetologia 2009, 52, 1003-1012.
(101) Park, Y. J.; Woo, M., Pancreatic β cells: Gatekeepers of type 2 diabetes. J. Cell Biol. 2019, 218,
1094.
(102) Kamata, K.; Mizukami, H.; Inaba, W.; Tsuboi, K.; Tateishi, Y.; Yoshida, T.; Yagihashi, S.,
Islet amyloid with macrophage migration correlates with augmented β-cell deficits in type 2 diabetic
patients. Amyloid 2014, 21, 191-201.
(103) Jurgens, C. A.; Toukatly, M. N.; Fligner, C. L.; Udayasankar, J.; Subramanian, S. L.; Zraika,
S.; Aston-Mourney, K.; Carr, D. B.; Westermark, P.; Westermark, G. T., β-Cell Loss and β-Cell
Apoptosis in Human Type 2 Diabetes Are Related to Islet Amyloid Deposition. Am. J. Pathol. 2011,
178, 2632-2640.
(104) Lorenzo, A.; Razzaboni, B.; Weir, G. C.; Yankner, B. A., Pancreatic islet cell toxicity of amylin
associated with type-2 diabetes mellitus. Nature 1994, 368, 756-760.
(105) Kayed, R.; Sokolov, Y.; Edmonds, B.; McIntire, T. M.; Milton, S. C.; Hall, J. E.; Glabe, C. G.,
Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid
Oligomers in Protein Misfolding Diseases. J. Biol. Chem. 2004, 279, 46363-46366.
(106) Meier, J. J.; Kayed, R.; Lin, C.-Y.; Gurlo, T.; Haataja, L.; Jajasinghe, S.; Langen, R.; Glabe, C.
G.; Butler, P. C., Inhibition of human IAPP fibril formation does not prevent β-cell death: evidence for
distinct actions of oligomers and fibrils of human IAPP. Am. J. Physiol. Endocrinol. Metab. 2006, 291,
E1317-E1324.
(107) Ritzel, R. A.; Meier, J. J.; Lin, C.-Y.; Veldhuis, J. D.; Butler, P. C., Human Islet Amyloid
Polypeptide Oligomers Disrupt Cell Coupling, Induce Apoptosis, and Impair Insulin Secretion in
Isolated Human Islets. Diabetes 2007, 56, 65-71.
(108) Schubert, D.; Behl, C.; Lesley, R.; Brack, A.; Dargusch, R.; Sagara, Y.; Kimura, H., Amyloid
peptides are toxic via a common oxidative mechanism. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1989-
1993.
(109) Scherbaum, W. A., The role of amylin in the physiology of glycemic control. Exp. Clin.
Endocrinol. Diabetes 1998, 106, 97-102.
58 
(110) Mietlick-Baase, E. G., Amylin-mediated control of glycemia, energy balance, and cognition.
Physiol. Behav. 2016, 162, 130-140.
(111) Zhang, S.; Andreasen, M.; Nielson, J. T.; Liu, L.; Nielson, E. H.; Song, J.; Ji, G.; Sun, F.;
Skrydstrup, T.; Besenbacher, F.; Nielson, N. C.; Otzen, D. E.; Dong, M., Coexistence of ribbon and
helical fibrils originating from hIAPP20-29 revealed by quantitative nanomechanical atomic force
microscopy. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 2798-2803.
(112) Betsholtz, C.; Christmansson, L.; Engström, U.; Rorsman, F.; Svensson, V.; Johnson, K. H.;
Westermark, P., Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains
differences in islet amyloid formation between species. FEBS Lett. 1989, 251, 261-264.
(113) Abedini, A.; Raleigh, D. P., The Role of His-18 in Amyloid Formation by Human Islet Amyloid
Polypeptide. Biochemistry 2005, 44, 16284-16291.
(114) Kahn, S. E., The Importance of the β-Cell in the Pathogenesis of Type 2 Diabetes Mellitus. Am.
J. Med. 2000, 108, 2S-8S.
(115) Westermark, P.; Andersson, A.; Westermark, G. T., Islet Amyloid Polypeptide, Islet Amyloid,
and Diabetes Mellitus. Physiol. Rev. 2011, 91, 795-826.
(116) Moreno-Gonzalez, I.; Soto, C., Misfolded Protein Aggregates: Mechanisms, Structures and
Potential for Disease Transmission. Semin. Cell Dev. Biol. 2011, 22, 482-487.
(117) Raleigh, D.; Zhang, X.; Hastoy, B.; Clark, A., The β-cell assassin: IAPP cytotoxicity. J. Mol.
Endocrinol. 2017, 59, R121-R140.
(118) Hsu, Y.-H.; Chen, Y.-W.; Wu, M.-H.; Tu, L.-H., Protein Glycation by Glyoxal Promotes
Amyloid Formation by Islet Amyloid Polypeptide. Biophys. J. 2019, 116, 2304-2313.
(119) Gong, W.; Liu, Z. H.; Zeng, C. H.; Peng, A.; Chen, H. P.; Zhou, H.; Li, L. S., Amylin deposition
in the kidney of patients with diabetic nephropathy. Kidney Int. 2007, 72, 213-218.
(120) Abedini, A.; Cao, P.; Plesner, A.; He, M.; Derk, J.; Patil, S. A.; Rosario, R.; Lonier, J.; Song,
F.; Koh, H.; Li, H.; Raleigh, D. P.; Schmidt, A. M., RAGE binds preamyloid IAPP intermediates and
mediates pancreatic β cell proteotoxicity. J. Clin. Invest. 2018, 128, 682-698.
(121) Huang, C. J.; Haataja, L.; Gurlo, T.; Butler, A. E.; Wu, X.; Soeller, W. C.; Butler, P. C.,
Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of
polyubiquitinated proteins by human islet amyloid polypeptide. Am. J. Physiol. Endocrinol. Metab.
2007, 293, E1656-E1662.
(122) Huang, C.-J.; Lin, C.-Y.; Haataja, L.; Gurlo, T.; Butler, A. E.; Rizza, R. A.; Butler, P. C., High
Expression Rates of Human Islet Amyloid Polypeptide Induce Endoplasmic Reticulum Stress–
Mediated β-Cell Apoptosis, a Characteristic of Humans With Type 2 but Not Type 1 Diabetes. Diabetes
2007, 56, 2016-2027.
(123) Casas, S.; Gomis, R.; Gribble, F. M.; Altirriba, J.; Knuutila, S.; Novials, A., Impairment of the
Ubiquitin-Proteasome Pathway is a Downstream Endoplasmic Reticulum Stress Response Induced by
59 
Extracellular Human Islet Amyloid Polypeptide and Contributes to Pancreatic β-cell Apoptosis. 
Diabetes 2007, 56, 2284-2294. 
(124) Hernández, M. G.; Aguilar, A. G.; Burillo, J.; Oca, R. G.; Manca, A. M.; Novials, A.; Alcarraz-
Vizan, G.; Guillén, C.; Benito, M., Pancreatic β cells overexpressing hIAPP impaired mitophagy and
unbalanced mitochondrial dynamics. Cell Death Dis. 2018, 9, 481.
(125) Cadavez, L.; Montane, J.; Alzarraz-Vizán, G.; Visa, M.; Vidal-Fàbrega, L.; Servitja, M.;
Novials, A., Chaperones Ameliorate Beta Cell Dysfunction Associated with Human Islet Amyloid
Polypeptide Overexpression. PLoS ONE 2014, 9, e101797.
(126) Chien, V.; Aitken, J. F.; Zhang, S.; Buchanan, C. E.; Hickey, A.; Brittain, T.; Cooper, G. J.;
Loomes, K. M., The chaperone proteins HSP70, HSP40/DnaJ and GRP78/BiP suppress misfolding and
formation of β-sheet-containing aggregates by human amylin: a potential role for defective chaperone
biology in Type 2 diabetes. Biochem. J. 2010, 432, 113-121.
(127) Hickey, A. J. R.; Bradley, J. W. I.; Skea, G. L.; Middleditch, M. J.; Buchanan, C. M.; Phillips,
A. R. J.; Cooper, G. J. S., Proteins Associated with Immunopurified Granules from a Model Pancreatic
Islet β-Cell System: Proteomic Snapshot of an Endocrine Secretory Granule. J. Proteome Res. 2009, 8,
178-186.
(128) Rosas, P. C.; Nagaraja, G. M.; Kaur, P.; Panossia, A.; Wickman, G.; Garcia, L. R.; Al-Khamis,
F. A.; Asea, A. A. A., Hsp72 (HSPA1A) Prevents Human Islet Amyloid Polypeptide Aggregation and
Toxicity: A New Approach for Type 2 Diabetes Treatment. PLoS ONE 2016, 11, e0149409.
(129) Bongiovanni, M. N.; Aprile, F. A.; Sormanni, P.; Vendruscolo, M., A Rationally Designed
Hsp70 Variant Rescues the Aggregation-Associated Toxicity of Human IAPP in Cultured Pancreatic
Islet β-Cells. Int. J. Mol. Sci. 2018, 19, 1443.
(130) Press, M.; Jung, T.; König, J.; Grune, T.; Höne, A., Protein aggregates and proteostasis in aging:
Amylin and β-cell function. Mech. Ageing Dev. 2019, 177, 46-54.
(131) Badman, M. K.; Pryce, R. A.; Chargé, S. B. P.; Morris, J. F.; Clark, A., Fibrillar islet amyloid
polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation. Cell Tissue
Res. 1998, 291, 285-294.
(132) Khemtémourian, L.; Doménech, E.; Doux, J. P. F.; Koorengevel, M. C.; Killian, J. A., Low pH
Acts as Inhibitor of Membrane Damage Induced by Human Islet Amyloid Polypeptide. J. Am. Chem.
Soc. 2011, 133, 15598-15604.
(133) Jaikaran, E. T. A. S.; Nilsson, M. R.; Clark, A., Pancreatic β-cell granule peptides form
heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem. J. 2004,
377, 709-716.
(134) Larson, J. L.; Miranker, A. D., The Mechanism of Insulin Action on Islet Amyloid Polypeptide
Fiber Formation. J. Mol. Biol. 2004, 335, 221-231.
60 
(135) Westermark, P.; Li, Z.-C.; Westermark, G. T.; Leckström, A.; Steiner, D. F., Effects of beta
cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett. 1996, 379,
203-206.
(136) DeToma, A. S.; Salamekh, S.; Ramamoorthy, A.; Lim, M. H., Misfolded Proteins in
Alzheimer's Disease and Type II Diabetes. Chem. Soc. Rev. 2012, 41, 608-621.
(137) Chimienti, F.; Favier, A.; Seve, M., ZnT-8, a pancreatic beta-cell-specific zinc transporter.
BioMetals 2005, 18, 313-317.
(138) Lemaire, K.; Ravier, M. A.; Schraenen, A.; Creemers, J. W. M.; Van de Plas, R.; Granvik, M.;
Van Lommel, L.; Waelkens, E.; Chimienti, F.; Rutter, G. A.; in't Veld, P. A.; Schuit, F. C., Insulin
crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose
homeostasis in mice. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 14872-14877.
(139) Ge, X.; Kakinen, A.; Gurzov, E. N.; Pang, L.; Pilkington, E. H.; Separovic, F.; Davis, T. P.;
Ke, P. C.; Ding, F., Zinc-coordination and C-peptide complexation: a potential mechanism for the
endogenous inhibition of IAPP aggregation. Chem. Commun. 2017, 53, 9394-9397.
(140) Sakagashira, S.; Hiddinga, H. J.; Tateishi, K.; Sanke, T.; Hanabusa, T.; Nanjo, K.; Eberhardt,
N. L., S20G Mutant Amylin Exhibits Increased in Vitro Amyloidogenicity and Increased Intracellular
Cytotoxicity Compared to Wild-Type Amylin. Am. J. Pathol. 2000, 157, 2101-2109.
(141) Seino, S.; Study Group of Comprehensive Analysis of Genetic Factors in Diabetes Mellitus, T.,
S20G mutation of the amylin gene is associated with Type II diabetes in Japanese. Diabetologia 2001,
44, 906-909.
(142) Borchi, E.; Bargelli, V.; Guidotti, V.; Berti, A.; Stefani, M.; Nediani, C.; Rigacci, S., Mild
exposure of RIN-5F β-cells to human islet amyloid polypeptide aggregates upregulates antioxidant
enzymes via NADPH oxidase-RAGE: An hormetic stimulus. Redox Biol. 2014, 2, 114-122.
(143) Kawahara, M.; Kuroda, Y.; Arispe, N.; Rojas, E., Alzheimer's β-Amyloid, Human Islet Amylin,
and Prion Protein Fragment Evoke Intracellular Free Calcium Elevations by a Common Mechanism in
a Hypothalamic GnRH Neuronal Cell Line. J. Biol. Chem. 2000, 275, 14077-14083.
(144) Mirzabekov, T. A.; Lin, M.-C.; Kagan, B. L., Pore Formation by the Cytotoxic Islet Amyloid
Peptide Amylin. J. Biol. Chem. 1996, 271, 1988-1992.
(145) Sparr, E.; Engel, M. F. M.; Sakharov, D. V.; Sprong, M.; Jacobs, J.; de Kruijff, B.; Höppener,
J. W. M.; Killian, J. A., Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids
by forming amyloid fibres. FEBS Lett. 2004, 577, 117-120.
(146) Engel, M. F. M.; Khemtémourian, L.; Kleijer, C. C.; Meeldijk, H. J. D.; Jacobs, J.; Verkleij, A.
J.; de Kruijff, B.; Killian, J. A.; Höppener, J. W. M., Membrane damage by human islet amyloid
polypeptide through fibril growth at the membrane. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 6033-6038.
(147) Owen, M. C.; Gnutt, D.; Gao, M.; Wärmländer, S. K. T. S.; Jarvet, J.; Gräslund, A.; Winter, R.;
Ebbinghaus, S.; Strodel, B., Effects of in vivo conditions on amyloid aggregation. Chem. Soc. Rev.
2019, 48, 3946-3996.
61 
(148) Meng, F.; Marek, P.; Potter, K. J.; Verchere, C. B.; Raleigh, D. P., Rifampicin Does Not Prevent
Amyloid Fibril Formation by Human Islet Amyloid Polypeptide but Does Inhibit Thioflavin-T
Interactions: Implications for Mechanistic Studies of β-cell Death. Biochemistry 2008, 47, 6016-6024.
(149) Glabe, C. G., Structural Classification of Toxic Amyloid Oligomers. J. Biol. Chem. 2008, 283,
29639-29643.
(150) Despa, S.; Margulies, K. B.; Chen, L.; Knowlton, A. A.; Havel, P. J.; Taegtmeyer, H.; Bers, D.
M.; Despa, F., Hyperamylinemia Contributes to Cardiac Dysfunction in Obesity and Diabetes: A Study
in Humans and Rats. Circ. Res. 2012, 110, 598-608.
(151) Srodulski, S.; Sharma, S.; Bachstetter, A. B.; Brelsford, J. M.; Pascual, C.; Xie, X. S.; Saatman,
K. E.; Van Eldik, L. J.; Despa, F., Neuroinflammation and neurologic deficits in diabetes linked to brain
accumulation of amylin. Mol. Neurodegener. 2014, 9.
(152) Jackson, K.; Barisone, G. A.; Diaz, E.; Jin, L.-W.; DeCarli, C.; Despa, F., Amylin Deposition
in the Brain: A Second Amyloid in Alzheimer Disease? Ann. Neurol. 2013, 74, 517-526.
(153) Mäkimattila, S.; Fineman, M. S.; Yki-Järvinen, H., Deficiency of Total and Nonglycosylated
Amylin in Plasma Characterizes Subjects with Impaired Glucose Tolerance and Type 2 Diabetes. J.
Clin. Endocrinol. Metab. 2000, 85, 2822-2827.
(154) Sanke, T.; Hanabusa, T.; Nakano, Y.; Oki, C.; Okai, K.; Nishimura, S.; Kondo, M.; Nanjo, K.,
Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in Type 2 (non-
insulin-dependent) diabetic patients. Diabetologia 1991, 34, 129-132.
(155) Oskarsson, M. E.; Paulsson, J. F.; Schultz, S. W.; Ingelsson, M.; Westermark, P.; Westermark,
G. T., In Vivo Seeding and Cross-Seeding of Localized Amyloidosis. Am. J. Pathol. 2015, 185, 834-
846.
(156) Ferrier, G. J. M.; Pierson, A. M.; Bloom, S. R.; Girgis, S. I.; Legon, S., Expression of the rat
amylin (IAPP/DAP) gene. J. Mol. Endocrinol. 1989, 3, R1-4.
(157) D'Este, L.; Wimalawansa, S. J.; Renda, T. G., Distribution of Amylin-Immunoreactive Neurons
in the Monkey Hypothalamus and their Relationships with the Histaminergic System. Arch. Histol.
Cytol. 2001, 64, 295-303.
(158) Liu, C.; Zhang, Y., Nucleic acid-mediated protein aggregation and assembly. Adv. Protein
Chem. Struct. Biol. 2011, 84, 1-40.
(159) Gursky, O., Lipids in Protein Misfolding. Springer: Cham, Switzerland, 2015; Vol. 855.
(160) Grey, M.; Linse, S.; Nilsson, H.; Brundin, P.; Sparr, E., Membrane Interaction of α-Synuclein
in Different Aggregation States. J. Parkinsons Dis. 2011, 1, 359-371.
(161) Kishimoto, T.; Soda, Y.; Matsuyama, Y.; Mizuno, K., An enzymatic assay for
lysophosphatidylcholine concentration in human serum and plasma. Clin. Biochemistry 2002, 35, 411-
416.
(162) Sheikh, A. M.; Nagai, A., Lysophosphatidylcholine modulates fibril formation of amyloid beta
peptide. FEBS J. 2011, 278, 634-642.
62 
(163) Sheikh, A. M.; Michikawa, M.; Kim, S. U.; Nagai, A., Lysophosphatidylcholine increases the
neurotoxicity of Alzheimer’s amyloid β1-42 peptide: Role of oligomer formation. Neuroscience 2015,
292, 159-169.
(164) Xing, Y.; Pilkington, E. H.; Wang, M.; Nowell, C. J.; Käkinen, A.; Sun, Y.; Wang, B.; Davis,
T. P.; Ding, F.; Ke, P. C., Lysophosphatidylcholine modulates the aggregation of human islet amyloid
polypeptide. Phys. Chem. Chem. Phys. 2017, 19, 30627-30635.
(165) Ponomarenko, E. A.; Poverennaya, E. V.; Ilgisonis, E. V.; Pyatnitskiy, M. A.; Kopylov, A. T.;
Zgoda, V. G.; Lisitsa, A. V.; Archakov, A. I., The Size of the Human Proteome: The Width and Depth.
Int. J. Anal. Chem. 2016, 2016, 7436849.
(166) Stanyon, H. F.; Viles, J. H., Human Serum Albumin Can Regulate Amyloid-β Peptide Fiber
Growth in the Brain Interstitium. J. Biol. Chem. 2012, 2012, 28163-28168.
(167) Käkinen, A.; Javed, I.; Faridi, A.; Davis, T. P.; Ke, P. C., Serum albumin impedes the amyloid
aggregation and hemolysis of human islet amyloid polypeptide and alpha synuclein. Biochim. Biophys.
Acta, Biomembranes 2018, 1860, 1803-1809.
(168) Luo, J.; Wärmländer, S. K. T. S.; Gräslund, A.; Abrahams, J. P., Human lysozyme inhibits the
in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease. Chem.
Commun. 2013, 49, 6507-6509.
(169) Luo, J.; Wärmländer, S. K. T. S.; Gräslund, A.; Abrahams, J. P., Non-chaperone Proteins Can
Inhibit Aggregation and Cytotoxicity of Alzheimer Amyloid β Peptide. J. Biol. Chem. 2014, 289,
27766-27775.
(170) Carrotta, R.; Canale, C.; Diaspro, A.; Trapani, A.; Biagio, P. L. S.; Bulone, D., Inhibiting effect
of α(s1)-casein on Aβ(1-40) fibrillogenesis. Biochim. Biophys. Acta 2012, 1820, 124-132.
(171) Gustafsson, M.; Thyberg, J.; Näslund, J.; Eliasson, E.; Johansson, J., Amyloid fibril formation
by pulmonary surfactant protein C. FEBS Lett. 1999, 464, 138-142.
(172) Peng, S.; Glennert, J.; Westermark, P., Medin-amyloid: A recently characterized age-associated
arterial amyloid form affects mainly arteries in the upper part of the body. Amyloid 2005, 12, 96-102.
(173) Nerelius, C.; Gustafsson, M.; Nordling, K.; Larsson, A.; Johansson, J., Anti-Amyloid Activity
of the C-Terminal Domain of proSP-C against Amyloid β-Peptide and Medin. Biochemistry 2009, 48,
3778-3786.
(174) Willander, H.; Presto, J.; Askarieh, G.; Biverstal, H.; Frohm, B.; Knight, S. D.; Johansson, J.;
Linse, S., BRICHOS domains efficiently delay fibrillation of amyloid β-peptide. J. Biol. Chem. 2012,
287, 31608-31617.
(175) Peng, S.; Fitzen, M.; Jörnvall, H.; Johansson, J., The extracellular domain of Bri2 (ITM2B)
binds the ABri peptide (1–23) and amyloid β-peptide (Aβ1–40): Implications for Bri2 effects on
processing of amyloid precursor protein and Aβ aggregation. Biochem. Biophys. Res. Commun. 2010,
393, 356-361.
63 
(176) Altieri, F.; Di Stadio, C. S.; Severino, V.; Sandomenico, A.; Minopoli, G.; Miselli, G.; Di Maro,
A.; Ruvo, M.; Chambery, A.; Quagliariello, V.; Masullo, M.; Rippa, E.; Arcari, P., Anti-amyloidogenic
property of human gastrokine 1. Biochimie 2014, 106, 91-100.
(177) Yerbury, J. J.; Kumita, J. R.; Meehan, S.; Dobson, C. M.; Wilson, M. R., α2-Macroglobulin
and Haptoglobin Suppress Amyloid Formation by Interacting with Prefibrillar Protein Species. J. Biol.
Chem. 2009, 284, 4246-4254.
(178) Raman, B.; Ban, T.; Sakai, M.; Pasta, S. Y.; Ramakrishna, T.; Naiki, H.; Goto, Y.; Rao, C. M.,
αB-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid β-peptide
and β2-microglobulin. Biochem. J. 2005, 392, 573-581.
(179) Wilhelmus, M. M. M.; Boelens, W. C.; Otte-Höller, I.; Kamps, B.; de Waal, R. M. W.; Verbeek,
M. M., Small heat shock proteins inhibit amyloid-β protein aggregation and cerebrovascular amyloid-
β protein toxicity. Brain Res. 2006, 1089, 67-78.
(180) Cox, D.; Selig, E.; Griffin, M. D. W.; Carver, J. A.; Ecroyd, H., Small Heat-shock Proteins
Prevent α-Synuclein Aggregation via Transient Interactions and Their Efficacy Is Affected by the Rate
of Aggregation. J. Biol. Chem. 2016, 291, 22618-22629.
(181) Gao, M.; Estel, K.; Seeliger, J.; Friedrich, R. P.; Dogan, S.; Wanker, E. E.; Winter, R.;
Ebbinghaus, S., Modulation of human IAPP fibrillation: cosolutes, crowders and chaperones. Phys.
Chem. Chem. Phys. 2015, 17, 8338-8348.
(182) Westermark, P.; Skinner, M.; Cohen, A. S., The P-Component of Amyloid of Human Islets of
Langerhans. Scand. J. Immunol. 1975, 4, 95-97.
(183) Chargé, S. B. P.; Esiri, M. M.; Bethune, C. A.; Hansen, B. C.; Clark, A., Apolipoprotein E is
Associated With Islet Amyloid and Other Amyloidoses: Implications for Alzheimer's Disease. J.
Pathol. 1996, 179, 443-447.
(184) Young, I. D.; Ailles, L.; Narindrasorasak, S.; Tan, R.; Kisilevsky, R., Localization of the
basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus.
Arch. Pathol. Lab. Med. 1992, 116, 951-954.
(185) Jha, S.; Patil, S. M.; Gibson, J.; Nelson, C. E.; Alder, N. N.; Alexandrescu, A. T., Mechanism
of Amylin Fibrillization Enhancement by Heparin. J. Biol. Chem. 2011, 286, 22894-22904.
(186) Li, Y.; Wang, L.; Lu, T.; Wei, Y.; Li, F., The effects of chondroitin sulfate and serum albumin
on the fibrillation of human islet amyloid polypeptide at the phospholipid membranes. Phys. Chem.
Chem. Phys. 2016, 18, 12000-12008.
(187) Meng, F.; Abedini, A.; Song, B.; Raleigh, D. P., Amyloid Formation by Pro-Islet Amyloid
Polypeptide Processing Intermediates: Examination of the Role of Protein Heparan Sulfate Interactions
and Implications for Islet Amyloid Formation in Type 2 Diabetes. Biochemistry 2007, 46, 12091-12099.
(188) Peinado, J. R.; Sami, F.; Rajpurohit, N.; Lindberg, I., Blockade of islet amyloid polypeptide
fibrillation and cytotoxicity by the secretory chaperones 7B2 and proSAAS. FEBS Lett. 2013, 587,
3406-3411.
64 
(189) Oskarsson, M. E.; Singh, K.; Wang, J.; Vlodavsky, I.; Li, J.-P.; Westermark, G. T., Heparan
Sulfate Proteoglycans are important for Islet Amyloid Formation and Islet Amyloid Polypeptide-
Induced Apoptosis. J. Biol. Chem. 2015, 290, 15121-15132.
(190) Vidal, J.; Verchere, C. B.; Andrikopoulos, S.; Wang, F.; Hull, R. L.; Cnop, M.; Olin, K. L.;
LeBoeuf, R. C.; O'Brien, K. D.; Chait, A.; Kahn, S. E., The effect of apolipoprotein E deficiency on
islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Diabetologia 2003, 46,
71-79.
(191) Pilkington, E. H.; Xing, Y.; Wang, B.; Käkinen, A.; Wang, M.; Davis, T. P.; Ding, F.; Ke, P.
C., Effects of Protein Corona on IAPP Amyloid Aggregation, Fibril Remodelling, and Cytotoxicity.
Sci. Rep. 2017, 7, 2455.
(192) Masliah, E.; Rockenstein, E.; Veinbergs, I.; Sagara, Y.; Mallory, M.; Hashimoto, M.; Mucke,
L., β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse
model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98,
12245-12250.
(193) Clinton, L. K.; Blurton-Jones, M.; Myczek, K.; Trojanowski, J. Q.; LaFerla, F. M., Synergistic
Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive
Decline. J. Neurosci. 2010, 30, 7281-7289.
(194) Andreetto, E.; Yan, L.-M.; Tatarek-Nossol, M.; Velkova, A.; Frank, R.; Kapurniotu, A.,
Identification of Hot Regions of the Aβ–IAPP Interaction Interface as High-Affinity Binding Sites in
both Cross- and Self-Association. Angew. Chem. Int. Ed., Engl. 2010, 49, 3081-3085.
(195) O'Nuallain, B.; Williams, A. D.; Westermark, P.; Wetzel, R., Seeding Specificity in Amyloid
Growth Induced by Heterologous Fibrils. J. Biol. Chem. 2004, 279, 17490-17499.
(196) Seeliger, J.; Weise, K.; Opitz, N.; Winter, R., The effect of Aβ on IAPP aggregation in the
presence of an isolated β-cell membrane. J. Mol. Biol. 2012, 421, 348-363.
(197) Qiu, W. Q.; Wallack, M.; Dean, M.; Liebson, E.; Mwamburi, M.; Zhu, H., Association between
Amylin and Amyloid-β Peptides in Plasma in the Context of Apolipoprotein E4 Allele. PLoS ONE
2014, 9, e88063.
(198) Cedervall, T.; Lynch, I.; Lindman, S.; Berggård, T.; Thulin, E.; Nilsson, H.; Dawson, K. A.;
Linse, S., Understanding the nanoparticle-protein corona using methods to quantify exchange rates and
affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 2050-2055.
(199) Ke, P. C.; Lin, S.; Parak, W. J.; Davis, T. P.; Caruso, F., A Decade of the Protein Corona. ACS
Nano 2017, 11, 11773-11776.
(200) Ezzat, K.; Pernemalm, M.; Palsson, S.; Roberts, T. C.; Jarver, P.; Dondalska, A.; Bestas, B.;
Sobkowiak, M. J.; Levanen, B.; Skold, M.; Thompson, E. A.; Saher, O.; Kari, O. K.; Lajunen, T.;
Ekström, E. S.; Nilsson, C.; Ischenko, Y.; Malm, T.; Wood, M. J. A.; Power, U. F.; Masich, S.; Linden,
A.; Sandberg, J. K.; Lehtio, J.; Spetz, A.-L.; Andaloussi, S. E. L., The viral protein corona directs viral
pathogenesis and amyloid aggregation. Nat. Commun. 2018, 10, 2331.
65 
(201) Serpooshan, V.; Mahmoudi, M.; Zhao, M.; Wei, K.; Sivanesan, S.; Motamedchaboki, K.;
Malkovskiy, A. V.; Goldstone, A. B.; Cohen, J. E.; Yang, P. C.; Rajadas, J.; Bernstein, D.; Woo, Y. J.;
Ruiz-Lozano, P., Protein Corona Influences Cell–Biomaterial Interactions in Nanostructured Tissue
Engineering Scaffolds. Adv. Funct. Mater. 2015, 25, 4379-4389.
(202) Little, W. C.; Schwartlander, R.; Smith, M. L.; Gourdon, D.; Vogel, V., Stretched Extracellular
Matrix Proteins Turn Fouling and Are Functionally Rescued by the Chaperones Albumin and Casein.
Nano Lett. 2009, 9, 4158-4167.
(203) Rahman, M.; Zetterberg, H.; Lendel, C.; Härd, T., Binding of Human Proteins to Amyloid-β
Protofibrils. ACS Chem. Biol. 2015, 10, 766-774.
(204) Pilkington, E. H.; Gustafsson, O. J. R.; Xing, Y.; Hernandez-Fernaud, J.; Zampronio, C.;
Käkinen, A.; Faridi, A.; Ding, F.; Wilson, P.; Ke, P. C.; Davis, T. P., Profiling the Serum Protein Corona
of Fibrillar Human Islet Amyloid Polypeptide. ACS Nano 2018, 12, 6066-6078.
(205) Yerbury, J. J.; Poon, S.; Meehan, S.; Thompson, B.; Kumita, J. R.; Dobson, C. M.; Wilson, M.
R., The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with
prefibrillar structures. FASEB J. 2007, 21, 2312-2322.
(206) Wojtas, A. M.; Kang, S. S.; Olley, B. M.; Gatherer, M.; Shinohara, M.; Loranzo, P. A.; Liu, C.
C.; Kurti, A.; Baker, K. E.; Dickson, D. W.; Yue, M.; Petrucelli, L.; Bu, G.; Carare, R. O.; Fryer, J. D.,
Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular
drainage pathways. Proc. Natl. Acad. Sci. U.S.A. 2017, 114, E6962-E6971.
(207) Sörgjerd, K. M.; Zako, T.; Sakono, M.; Stirling, P. C.; Leroux, M. R.; Saito, T.; Nilsson, P.;
Sekimoto, M.; Saido, T. C.; Maeda, M., Human Prefoldin Inhibits Amyloid-β (Aβ) Fibrillation and
Contributes to Formation of Nontoxic Aβ Aggregates. Biochemistry 2013, 52, 3532-3542.
(208) Mansson, C.; Arosio, P.; Hussein, R.; Kampinga, H. H.; Hashem, R. M.; Boelens, W. C.;
Dobson, C. M.; Knowles, T. P. J.; Linse, S.; Emanuelsson, C., Interaction of the molecular chaperone
DNAJB6 with growing amyloid-beta 42 (Aβ42) aggregates leads to sub-stoichiometric inhibition of
amyloid formation. J. Biol. Chem. 2014, 289, 31066-31076.
(209) Arimon, M.; Grimminger, V.; Sanz, F.; Lashuel, H. A., Hsp104 Targets Multiple Intermediates
on the Amyloid Pathway and Suppresses the Seeding Capacity of Aβ Fibrils and Protofibrils. J. Mol.
Biol. 2008, 384, 1157-1173.
(210) Liao, L.; Cheng, D.; Wang, J.; Duong, D. M.; Losik, T. G.; Gearing, M.; Rees, H. D.; Lah, J.
J.; Levey, A. I.; Peng, J., Proteomic Characterization of Postmortem Amyloid Plaques Isolated by Laser
Capture Microdissection. J. Biol. Chem. 2004, 279, 37061-37068.
(211) Mi, W.; Pawlik, M.; Sastre, M.; Jung, S. S.; Radvinsky, D. S.; Klein, A. M.; Sommer, J.;
Schmidt, S. D.; Nixon, R. A.; Mathews, P. M.; Levy, E., Cystatin C inhibits amyloid-β deposition in
Alzheimer's disease mouse models. Nat. Genet. 2007, 39, 1440-1442.
(212) Foote, M.; Zhou, Y., 14-3-3 proteins in neurological disorders. Int. J. Biochem. Mol. Biol. 2012,
3, 152-164.
66 
(213) Sadik, G.; Tanaka, T.; Kato, K.; Yamamori, H.; Nessa, B. N.; Morihara, T.; Takeda, M.,
Phosphorylation of tau at Ser214 mediates its interaction with 14‐3‐3 protein: implications for the
mechanism of tau aggregation. J. Neurochem. 2009, 108, 33-43.
(214) Umahara, T.; Uchihara, T.; Tsuchiya, K.; Nakamura, A.; Iwamoto, T.; Ikeda, K.; Takasaki, M.,
14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer’s disease.
Acta Neuropathol. 2004, 108, 279-286.
(215) Ke, P. C.; Pilkington, E. H.; Sun, Y.; Javed, I.; Käkinen, A.; Peng, G.; Ding, F.; Davis, T. P.,
Mitigation of Amyloidosis with Nanomaterials. Adv. Mater. 2019, 1901690.
(216) Kim, H. S.; Lee, S. H.; Choi, I., On-chip plasmonic immunoassay based on targeted assembly
of gold nanoplasmonic particles. Analyst 2019, 144, 2820-2826.
(217) Choi, S. H.; Kim, Y. H.; Quinti, L.; Tanzi, R. E.; Kim, D. Y., 3D culture models of Alzheimer’s
disease: a road map to a “cure-in-a-dish”. Mol. Neurodegener. 2016, 11, 75.
(218) Choi, S. H.; Kim, Y. H.; Hebisch, M.; Sliwinski, C.; Lee, S.; D'Avanzo, C.; Chen, H.; Hooli,
B.; Asselin, C.; Muffat, J.; Klee, J. B.; Zhang, C.; Wainger, B. J.; Peitz, M.; Kovacs, D. M.; Woolf, C.
J.; Wagner, S. L.; Tanzi, R. E.; Kim, D. Y., A three-dimensional human neural cell culture model of
Alzheimer's disease. Nature 2014, 515, 274-278.
(219) Jo, Y. H.; Jang, I. J.; Nemeno, J. G.; Lee, S.; Kim, B. Y.; Nam, B. M.; Yang, W.; Lee, K. M.
K., H.; Takebe, T.; Kim, Y. S.; Lee, J. I., Artificial Islets From Hybrid Spheroids of Three Pancreatic
Cell Lines. Transplant. Proc. 2014, 46, 1156-1160.
(220) Drummond, E.; Wisniewski, T., Alzheimer’s disease: experimental models and reality. Acta
Neuropathol. 2017, 133, 155-175.
(221) Kim, H. Y.; Kim, H. V.; Jo, S.; Lee, J.; Choi, S. Y.; Kim, D. J.; Kim, Y., EPPS rescues
hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers
and plaques. Nat. Commun. 2015, 6, 8997.
(222) Poduslo, J. F.; Hultman, K. L.; Curran, G. L.; Preboske, G. M.; Chamberlain, R.; Marjanska,
M.; Garwood, M.; Jack Jr., C. R.; Wengenack, T. M., Targeting vascular amyloid in arterioles of
Alzheimer disease transgenic mice with amyloid β protein antibody-coated nanoparticles. J.
Neuropathol. Exp. Neurol. 2011, 70, 653-661.
(223) Bieschke, J.; Herbst, M.; Wiglenda, M.; Friedrich, R. P.; Boeddrich, A.; Schiele, F.; Kleckers,
D.; del Amo, J. M. L.; Grüning, B. A.; Wang, Q.; Schmidt, M. R.; Lurz, R.; Anwyl, R.; Schnoegl, S.;
Fändrich, M.; Frank, R. F.; Reif, B.; Günther, S.; Walsh, D. M.; Wanker, E. E., Small-molecule
conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils. Nat. Chem. Biol. 2011, 8, 93-
101.
(224) Govindan, P. N.; Käkinen, A.; Pilkington, E. H.; Davis, T. P.; Ke, P. C.; Ding, F., Stabilizing
Off-pathway Oligomers by Polyphenol Nanoassemblies for IAPP Aggregation Inhibition. Sci. Rep.
2016, 6, 19463.
67 
(225) Pilkington, E. H.; Gurzov, E. N.; Käkinen, A.; Litwak, S. A.; Stanley, W. J.; Davis, T. P.; Ke,
P. C., Pancreatic β-Cell Membrane Fluidity and Toxicity Induced by Human Islet Amyloid Polypeptide
Species. Sci. Rep. 2016, 6, 21274.
(226) Bruno, E.; Pereira, C.; Roman, K. P.; Takiguchi, M.; Kao, P.-Y.; Nogaj, L. A.; Moffet, D. A.,
IAPP aggregation and cellular toxicity are inhibited by 1,2,3,4,6-penta-O-galloyl-β-D-glucose. Amyloid
2013, 20, 34-38.
(227) Bieschke, J.; Russ, J.; Friedrich, R. P.; Ehrnhoefer, D. E.; Wobst, H.; Neugebauer, K.; Wanker,
E. E., EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc.
Natl. Acad. Sci. U.S.A. 2010, 107, 7710-7715.
(228) Cao, P.; Raleigh, D. P., Analysis of the Inhibition and Remodeling of Islet Amyloid Polypeptide
Amyloid Fibers by Flavanols. Biochemistry 2012, 51, 2670-2683.
(229) Barrajón-Catalán, E.; Herranz-López, M.; Joven, J.; Segura-Carretero, A.; Alonso-Villaverde,
C.; Menéndez, J. A.; Micol, V., Molecular Promiscuity of Plant Polyphenols in the Management of
Age-Related Diseases: Far Beyond Their Antioxidant Properties. Adv. Exp. Med. Biol. 2014, 824, 141-
159.
(230) Cano, A.; Ettcheto, M.; Chang, J.-H.; Barroso, E.; Espina, M.; Kühne, B. A.; Barenys, M.;
Auladell, C.; Folch, J.; Souto, E. B.; Camins, A.; Turowski, P.; García, M. L., Dual-drug loaded
nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of
EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. J. Control. Release 2019, 301, 62-75.
(231) John, T.; Gladytz, A.; Kubeil, C.; Martin, L. L.; Risselada, H. J.; Abel, B., Impact of
nanoparticles on amyloid peptide and protein aggregation: a review with a focus on gold nanoparticles.
Nanoscale 2018, 10, 20894-20913.
(232) Wang, M.; Käkinen, A.; Pilkington, E. H.; Davis, T. P.; Ke, P. C., Differential Effects of Silver
and Iron Oxide Nanoparticles on IAPP Aggregation and Toxicity. Biomater. Sci. 2017, 5, 485-493.
(233) Yoo, S. I.; Yang, M.; Brender, J. R.; Subramanian, V.; Sun, K.; Joo, N. E.; Jeong, S.-H.;
Ramamoorthy, A.; Kotov, N. A., Inhibition of Amyloid Peptide Fibrillation by Inorganic Nanoparticles:
Functional Similarities with Protein. Angew. Chem. Int. Ed. Engl. 2011, 50, 5110-5115.
(234) Ban, D. K.; Paul, S., Nano Zinc Oxide Inhibits Fibrillar Growth and Suppresses Cellular
Toxicity of Lysozyme Amyloid. ACS Appl. Mater. Interfaces 2016, 8, 31587-31601.
(235) Dowding, J. M.; Song, W.; Bossy, K.; Karakoti, A.; Kumar, A.; Kim, A.; Bossy, B.; Seal, S.;
Ellisman, M. H.; Perkins, G.; Self, W. T.; Bossy-Wetzel, E., Cerium oxide nanoparticles protect against
Aβ-induced mitochondrial fragmentation and neuronal cell death. Cell Death Differ. 2014, 21, 1622-
1632.
(236) Sanati, M.; Khodagholi, F.; Ghasemi, F.; Gholami, M.; Kebriaeezadeh, A.; Sabzevari, O.;
Hajipour, M. J.; Imani, M.; Mahmoudi, M.; Sharifzadeh, M., Impact of Gold Nanoparticles on Amyloid
β-Induced Alzheimer’s Disease in a Rat Animal Model: Involvement of STIM Proteins. ACS Chem.
Neurosci. 2019, 10, 2299-2309.
68 
(237) Zhang, W.; Christofferson, A. J.; Besford, Q. A.; Richardson, J. J.; Guo, J.; Ju, Y.; Kempe, K.;
Yarovsky, I.; Caruso, F., Metal-dependent inhibition of amyloid fibril formation: synergistic effects of
cobalt–tannic acid networks. Nanoscale 2019, 11, 1921-1928.
(238) Javed, I.; Sun, Y.; Adamcik, J.; Wang, B.; Käkinen, A.; Pilkington, E. H.; Ding, F.; Mezzenga,
R.; Davis, T. P.; Ke, P. C., Cofibrillization of Pathogenic and Functional Amyloid Proteins with Gold
Nanoparticles against Amyloidogenesis. Biomacromolecules 2017, 18, 4316-4322.
(239) Liu, Y.; Zhou, H.; Yin, T.; Gong, Y.; Yang, G.; Chen, L.; Liu, J., Quercetin-modified gold-
palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer's disease. J.
Colloid Interface Sci. 2019, 552, 388-400.
(240) Gladytz, A.; Abel, B.; Risselada, H. J., Gold-Induced Fibril Growth: The Mechanism of
Surface-Facilitated Amyloid Aggregation. Angew. Chem. Int. Ed., Engl. 2016, 55, 11242-11246.
(241) Pansierei, J.; Gerstenmayer, M.; Lux, F.; Mériaux, S.; Tillement, O.; Forge, V.; Larrat, B.;
Marquette, C., Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review.
Nanomaterials 2018, 8, 740.
(242) Pansierei, J.; Plissonneau, M.; Stransky-Heilkron, N.; Dumoulin, M.; Heinrich-Balard, L.;
Rivory, P.; Morfin, J.-F.; Toth, E.; Saraiva, M. J.; Allémann, E.; Tillement, O.; Forge, V.; Lux, F.;
Marquette, C., Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a
nanobody for amyloid plaques targeting. Nanomedicine 2017, 12, 1675-1687.
(243) Liu, X. G.; Lu, S.; Liu, D. Q.; Zhang, L.; Zhang, L. X.; Yu, X. L.; Liu, R. T., ScFv-conjugated
superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of
Parkinson's and Huntington's diseases. Brain Res. 2019, 1707, 141-153.
(244) Ahlschwede, K. M.; Curran, G. L.; Rosenberg, J. T.; Grant, S. C.; Sarkar, G.; Jenkins, R. B.;
Ramakrishnan, S.; Poduslo, J. F.; Kandimalla, K. K., Cationic carrier peptide enhances cerebrovascular
targeting of nanoparticles in Alzheimer's disease brain. Nanomedicine 2019, 16, 258-266.
(245) Dodart, J.-C.; Bales, K. R.; Paul, S. M., Immunotherapy for Alzheimer's disease: will
vaccination work? Trends Mol. Med. 2003, 9, 85-87.
(246) Kim, D.; Kwon, H. J.; Hyeon, T., Magnetite/Ceria Nanoparticle Assemblies for Extracorporeal
Cleansing of Amyloid-β in Alzheimer's Disease. Adv. Mater. 2019, 31, e1807965.
(247) Bolisetty, S.; Mezzenga, R., Amyloid-carbon hybrid membranes for universal water
purification. Nat. Nanotechnol. 2016, 11, 365-372.
(248) Shen, Y.; Posavec, L.; Bolisetty, S.; Hilty, F. M.; Nyström, G.; Kohlbrecher, J.; Hilbe, M.;
Rossi, A.; Baumgartner, J.; Zimmermann, M. B.; Mezzenga, R., Amyloid fibril systems reduce,
stabilize and deliver bioavailable nanosized iron. Nat. Nanotechnol. 2017, 12, 642-647.
(249) Al-Garawi, Z. S.; McIntosh, B. A.; Neill-Hall, D.; Hatimy, A. A.; Sweet, S. M.; Bagley, M. C.;
Serpell, L. C., The amyloid architecture provides a scaffold for enzyme-like catalysts. Nanoscale 2017,
9, 10773-10783.
69 
(250) Geng, J.; Li, M.; Ren, J.; Wang, E.; Qu, X., Polyoxometalates as Inhibitors of the Aggregation
of Amyloid β Peptides Associated with Alzheimer's Disease. Angew. Chem. Int Ed., Engl. 2011, 50,
4184-4188.
(251) Gao, N.; Sun, H.; Dong, K.; Ren, J.; Duan, T.; Xu, C.; Qu, X., Transition-metal-substituted
polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer’s disease. Nat. Commun.
2014, 5, 3422.
(252) Lee, M.-C.; Yu, W.-C.; Shih, Y.-H.; Chen, C.-Y.; Guo, Z.-H.; Huang, S.-J.; Chan, J. C. C.;
Chen, Y.-R., Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β
derived diffusible ligands in Alzheimer’s disease. Sci. Rep. 2018, 8, 4772.
(253) Bobylev, A. G.; Kraevaya, O. A.; Bobyleva, L. G.; Khakina, E. A.; Fadeev, R. S.; Zhilenkov,
A. V.; Mishchenko, D. V.; Penkov, N. V.; Teplov, I. Y.; Yakupova, E. I.; Vikhlyantsev, I. M.; Troshin,
P. A., Anti-amyloid activities of three different types of water-soluble fullerene derivatives. Colloids
Surf. B Biointerfaces 2019, 183, 110426.
(254) Mahmoudi, M.; Akhavan, O.; Ghavami, M.; Rezaee, F.; Ghiasi, S. M. A., Graphene oxide
strongly inhibits amyloid beta fibrillation. Nanoscale 2012, 4, 7322-7325.
(255) Govindan, P. N.; Gurzov, E. N.; Chen, P.; Pilkington, E. H.; Stanley, W. J.; Litwak, S. A.;
Davis, T. P.; Ke, P. C.; Ding, F., Graphene Oxide Inhibits hIAPP Amyloid Fibrillation and Toxicity in
Insulin-Producing NIT-1 Cells. Phys. Chem. Chem. Phys. 2015, 18, 94-100.
(256) Li, C.; Mezzenga, R., The interplay between carbon nanomaterials and amyloid fibrils in bio-
nanotechnology. Nanoscale 2013, 5, 6207-6218.
(257) Javed, I.; Yu, T.; Peng, G.; Sánchez-Ferrer, A.; Faridi, A.; Käkinen, A.; Zhao, M.; Mezzenga,
R.; Davis, T. P.; Lin, S.; Ke, P. C., In Vivo Mitigation of Amyloidogenesis through
Functional−Pathogenic Double-Protein Coronae. Nano Lett. 2018, 18, 5797-5804.
(258) Liu, Y.; Xu, L.-P.; Dai, W.; Dong, H.; Wen, Y.; Zhang, X., Graphene quantum dots for the
inhibition of β amyloid aggregation. Nanoscale 2015, 7, 19060-19065.
(259) Wang, M.; Sun, Y.; Cao, X.; Peng, G.; Javed, I.; Käkinen, A.; Davis, T. P.; Lin, S.; Liu, J.;
Ding, F.; Ke, P. C., Graphene quantum dots against human IAPP aggregation and toxicity in vivo.
Nanoscale 2018, 10, 19995-20006.
(260) He, X.-P.; Deng, Q.; Cai, L.; Wang, C.-Z.; Zang, Y.; Li, J.; Chen, G.-R.; Tian, H., Fluorogenic
Resveratrol-Confined Graphene Oxide For Economic and Rapid Detection Of Alzheimer's Disease.
ACS Appl. Mater. Interfaces 2014, 6, 5379-5382.
(261) Wang, J.; Liu, L.; Ge, D.; Zhang, H.; Feng, Y.; Zhang, Y.; Chen, M.; Dong, M., Differential
Modulating Effect of MoS2 on Amyloid Peptide Assemblies. Chem. Eur. J. 2018, 24, 3397-3402.
(262) Li, M.; Zhao, A.; Dong, K.; Li, W.; Ren, J.; Qu, X., Chemically exfoliated WS2 nanosheets
efficiently inhibit amyloid β-peptide aggregation and can be used for photothermal treatment of
Alzheimer’s disease. Nano Res. 2015, 8, 3216-3227.
70 
(263) Zhang, Q.; Bolisetty, S.; Cao, Y.; Handschin, S.; Adamcik, J.; Peng, Q.; Mezzenga, R.,
Selective and Efficient Removal of Fluoride from Water: In Situ Engineered Amyloid Fibril/ZrO2
Hybrid Membranes. Angew. Chem. Int. Ed., Engl. 2019, 58, 6012-6016.
(264) Kostarelos, K., The long and short of carbon nanotube toxicity. Nat. Biotechnol. 2008, 26, 774-
776.
(265) Ke, P. C.; Qiao, R., Carbon nanomaterials in biological systems. J. Phys. Condens. Matter
2007, 19, 373101.
(266) Huang, H.; Li, P.; Zhang, M.; Yu, Y.; Huang, Y.; Gu, H.; Wang, C.; Yang, Y., Graphene
quantum dots for detecting monomeric amyloid peptides. Nanoscale 2017, 9, 5044-5048.
(267) Dzwolak, W., Chirality and Chiroptical Properties of Amyloid Fibrils. Chirality 2014, 26, 580-
587.
(268) Malishev, R.; Arad, E.; Bhunia, S. K.; Shaham-Niv, S.; Kolusheva, S.; Gazit, E.; Jelinek, R.,
Chiral modulation of amyloid beta fibrillation and cytotoxicity by enantiomeric carbon dots. Chem.
Commun. 2018, 54, 7762-7765.
(269) Faridi, A.; Sun, Y.; Okazaki, Y.; Peng, G.; Gao, J.; Käkinen, A.; Faridi, P.; Zhao, M.; Javed, I.;
Purcell, A. W.; Davis, T. P.; Lin, S.; Oda, R.; Ding, F.; Ke, P. C., Mitigating Human IAPP
Amyloidogenesis In Vivo with Chiral Silica Nanoribbons. Small 2018, 14, 1802825.
(270) Tang, F.; Li, L.; Chen, D., Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and
Drug Delivery. Adv. Mater. 2012, 24, 1504-1534.
(271) Zhu, X.; Wen, Y.; Zhao, Y.; Liu, Y.; Sun, J.; Liu, J.; Chen, L., Functionalized chitosan-modified
defect-related luminescent mesoporous silica nanoparticles as new inhibitors for hIAPP aggregation.
Nanotechnology 2019, 30, 315705.
(272) Luo, Q.; Lin, Y.-X.; Yang, P.-P.; Wang, Y.; Qi, G.-B.; Qiao, Z.-Y.; Li, B.-N.; Zhang, K.; Zhang,
J.-P.; Wang, L.; Wang, H., A self-destructive nanosweeper that captures and clears amyloid β-peptides.
Nat. Commun. 2018, 9, 1802.
(273) Zhang, C.; Wan, X.; Zheng, X.; Shao, X.; Liu, Q.; Zhang, Q.; Qian, Y., Dual-functional
nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials 2014,
35, 456-465.
(274) Bilia, A. R.; Nardiello, P.; Piazzini, V.; Leri, M.; Bergonzi, M. C.; Bucciantini, M.; Casamenti,
F., Successful Brain Delivery of Andrographolide Loaded in Human Albumin Nanoparticles to
TgCRND8 Mice, an Alzheimer's Disease Mouse Model. Front. Pharmacol. 2019, 10, 910.
(275) Ma, X.; Zhou, P.; Kugelmass, A.; Toskic, D.; Warner, M.; Lee, L.; Fogaren, T.; Godara, A.;
Wang, M.; Li, Y.; Yang, L.; Xu, Q.; Comenzo, R. L., A novel xenograft mouse model for testing
approaches targeting human kappa light-chain diseases. Gene Ther. 2019, 26, 187-197.
(276) Song, Q.; Huang, M.; Yao, L.; Wang, X.; Gu, X.; Chen, J.; Chen, J.; Huang, J.; Hu, Q.; Kang,
T.; Rong, Z.; Qi, H.; Zheng, G.; Chen, H.; Gao, X., Lipoprotein-Based Nanoparticles Rescue the
71 
Memory Loss of Mice with Alzheimer’s Disease by Accelerating the Clearance of Amyloid-Beta. ACS 
Nano 2014, 8, 2345-2359. 
(277) Aso, E.; Martinsson, I.; Appelhans, D.; Effenberg, C.; Benseny-Cases, N.; Cladera, J. C.;
Gouras, G.; Ferrer, I.; Klementieva, O., Poly(propylene imine) dendrimers with histidine-maltose shell
as novel type of nanoparticles for synapse and memory protection. Nanomedicine 2019, 17, 198-209.
(278) Evgrafova, Z.; Voigt, B.; Roos, A. H.; Hause, G.; Hinderberger, D.; Balbach, J.; Binder, W. H.,
Modulation of amyloid β peptide aggregation by hydrophilic polymers. Phys. Chem. Chem. Phys. 2019,
21, 20999-21006.
(279) Cabaleiro-Lago, C.; Quinlan-Pluck, F.; Lynch, I.; Lindman, S.; Minogue, A. M.; Thulin, E.;
Walsh, D. M.; Dawson, K. A.; Linse, S., Inhibition of Amyloid β Protein Fibrillation by Polymeric
Nanoparticles. J. Am. Chem. Soc. 2008, 130, 15437-15443.
(280) Breydo, L.; Newland, B.; Zhang, H.; Rosser, A.; Werner, C.; Uversky, V. N.; Wang, W., A
hyperbranched dopamine-containing PEG-based polymer for the inhibition of α-synuclein fibrillation.
Biochem. Biophys. Res. Commun. 2016, 469, 830-835.
(281) Chowdhury, S. R.; Agarwal, M.; Meher, N.; Muthuraj, B.; Iyer, P. K., Modulation of Amyloid
Aggregates into Nontoxic Coaggregates by Hydroxyquinoline Appended Polyfluorene. ACS Appl.
Mater. Interfaces 2016, 8, 13309-13319.
(282) Debnath, K.; Shekhar, S.; Kumar, V.; Jana, N. R.; Jana, N. R., Efficient Inhibition of Protein
Aggregation, Disintegration of Aggregates, and Lowering of Cytotoxicity by Green Tea Polyphenol-
Based Self-Assembled Polymer Nanoparticles. ACS Appl. Mater. Interfaces 2016, 8, 20309-20318.
(283) Guerreiro, L. H.; Da Silva, D.; Ricci-Junior, E.; Girard-Dias, W.; Mascarenhas, C. M.; Sola-
Penna, M.; Miranda, K.; Lima, L. M. T. R., Polymeric particles for the controlled release of human
amylin. Colloids Surf. B Biointerfaces 2012, 94, 101-106.
(284) Cabaleiro-Lago, C.; Lynch, I.; Dawson, K. A.; Linse, S., Inhibition of IAPP and IAPP(20-29)
Fibrillation by Polymeric Nanoparticles. Langmuir 2009, 26, 3453-3461.
(285) Gurzov, E. N.; Wang, B.; Pilkington, E. H.; Chen, P.; Käkinen, A.; Stanley, W. J.; Litwak, S.
A.; Hanssen, E. G.; Davis, T. P.; Ding, F.; Ke, P. C., Inhibition of hIAPP Amyloid Aggregation and
Pancreatic β-Cell Toxicity by OH-Terminated PAMAM Dendrimer. Small 2016, 12, 1615-1626.
(286) Nguyen, P. T.; Sharma, R.; Rej, R.; De Carufel, C. A.; Roy, R.; Bourgault, S., Low generation
anionic dendrimers modulate islet amyloid polypeptide self-assembly and inhibit pancreatic β-cell
toxicity. RSC Adv. 2016, 6, 76360-76369.
(287) Ren, J. M.; McKenzie, T. G.; Fu, Q.; Wong, E. H. H.; Xu, J.; An, Z.; Shanmugam, S.; Davis,
T. P.; Boyer, C.; Qiao, G. C., Star Polymers. Chem. Rev. 2016, 116, 6743-6836.
(288) Teo, J.; McCarroll, J. A.; Boyer, C.; Youkhana, J.; Sagnella, S. M.; Duong, H. T. T.; Liu, J.;
Sharbeen, G.; Goldstein, D.; Davis, T. P.; Kavallaris, M.; Phillips, A. P., A Rationally Optimized
Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in
Vivo. Biomacromolecules 2016, 17, 2337-2351.
72 
(289) Li, N.; Luo, H.-C.; Yang, C.; Deng, J.-J.; Ren, M.; Xie, X.-Y.; Lin, D.-Z.; Yan, L.; Zhang, L.-
M., Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast
cells and promoting wound healing in diabetic rats. Int. J. Nanomedicine 2014, 9, 3377-3387.
(290) Pilkington, E. H.; Lai, M.; Ge, X.; Stanley, W. J.; Wang, B.; Wang, M.; Käkinen, A.; Sani, M.-
A.; Whittaker, M. R.; Gurzov, E. N.; Ding, F.; Quinn, J. F.; Davis, T. P.; Ke, P. C., Star Polymers
Reduce Islet Amyloid Polypeptide Toxicity via Accelerated Amyloid Aggregation. Biomacromolecules
2017, 18, 4249-4260.
(291) Jain, R.; Khandelwal, G.; Roy, S., Unraveling the Design Rules in Ultrashort Amyloid-Based
Peptide Assemblies toward Shape-Controlled Synthesis of Gold Nanoparticles. Langmuir 2019, 35,
5878-5889.
(292) Huang, J.; Liu, S.; Zhang, C.; Wang, X.; Pu, J.; Ba, F.; Xue, S.; Ye, H.; Zhao, T.; Li, K.; Wang,
Y.; Zhang, J.; Wang, L.; Fan, C.; Lu, T. K.; Zhong, C., Programmable and printable Bacillus subtilis
biofilms as engineered living materials. Nat. Chem. Biol. 2019, 15, 34-41.
(293) Lee, S.; Lee, D.; Hong, C.-S.; Yang, J. E.; Kang, J. S.; Sung, Y.-E.; Paik, S. R., Alternative
Assembly of α-Synuclein Leading to Protein Film Formation and Its Application for Developing
Polydiacetylene-Based Sensing Materials. Langmuir 2019, 35, 11923-11931.
(294) Kumar, S. T.; Meinhardt, J.; Fuchs, A.-K.; Aumüller, T.; Leppert, J.; Büchele, B.; Knüpfer, U.;
Ramachandran, R.; Yadav, J. K.; Prell, E.; Morgado, I.; Ohlenschläger, O.; Horn, U.; Simmet, T.;
Görlach, M.; Fändrich, M., Structure and Biomedical Applications of Amyloid Oligomer Nanoparticles.
ACS Nano 2014, 8, 11042-11052.
(295) Babych, M.; Bertheau-Mailhot, G.; Zottig, X.; Dion, J.; Gauthier, L.; Archambault, D.;
Bourgault, S., Engineering and evaluation of amyloid assemblies as a nanovaccine against the
Chikungunya virus. Nanoscale 2018, 10, 19547-19556.
(296) Mayer, E. A.; Knight, R.; K., M. S.; Cryan, J. F.; Tillisch, K., Gut Microbes and the Brain:
Paradigm Shift in Neuroscience. J. Neurosci. 2014, 34, 15490-15496.
(297) Dominy, S. S.; Lynch, C.; Ermini, F.; Benedyk, M.; Marczyk, A.; Konradi, A.; Nguyen, M.;
Haditsch, U.; Raha, D.; Griffin, C.; Holsinger, L. J.; Arastu-Kapur, S.; Kaba, S.; Lee, A.; Ryder, M. I.;
Potempa, B.; Mydel, P.; Hellvard, A.; Adamowicz, K.; Hasturk, H.; Walker, G. D.; Reynolds, E. C.;
Faull, R. L. M.; Curtis, M. A.; Dragunow, M.; Potempa, J., Porphyromonas gingivalis in Alzheimer’s
disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv.
2019, 5, eaau3333.
(298) Koh, A.; Molinaro, A.; Ståhlman, M.; Khan, M. T.; Schmidt, C.; Mannerås-Holm, L.; Wu, H.;
Carreras, A.; Jeong, H.; Olofsson, L. E.; Bergh, P.-O.; Gerdes, V.; Hartstra, A.; de Brauw, M.; Perkins,
R.; Nieuwdorp, M.; Bergström, G.; Bäckhed, F., Microbially Produced Imidazole Propionate Impairs
Insulin Signaling through mTORC1. Cell 2018, 175, 947-961.
(299) Meijnikman, A. S.; Gerdes, V. E.; Nieuwdorp, M.; Herrema, H., Evaluating Causality of Gut
Microbiota in Obesity and Diabetes in Humans. Endocr. Rev. 2018, 39, 133-153.
73 
(300) Barton, S. M.; Janve, V. A.; McClure, R.; Anderson, A.; Matsubara, J. A.; Gore, J. C.; Pham,
W., Lipopolysaccharide Induced Opening of the Blood Brain Barrier on Aging 5XFAD Mouse Model.
J. Alzheimers Dis. 2019, 67, 503-513.
(301) Park, H.; Oh, J.; Shim, G.; Cho, B.; Chang, Y.; Kim, S.; Baek, S.; Kim, H. S.; Shin, J.; Choi,
H.; Yoo, J.; Kim, J.; Jun, W.; Lee, M.; Lengner, C.; Oh, Y.-K.; Kim, J., In vivo neuronal gene editing
via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's
disease. Nat. Neurosci. 2019, 22, 524-528.
(302) Lopes, D. H. J.; Attar, A.; Nair, G.; Hayden, E. Y.; Du, Z.; McDaniel, K.; Dutt, S.; Bandmann,
H.; Bravo-Rodriguez, K.; Mittal, S.; Klärner, F.-G.; Wang, C.; Sanchez-Garcia, E.; Schrader, T.; Bitan,
G., Molecular Tweezers Inhibit Islet Amyloid Polypeptide Assembly and Toxicity by a New
Mechanism. ACS Chem. Biol. 2015, 10, 1555-1569.
(303) Cheng, C.-H.; Lin, K.-J.; Hong, C.-T.; Wu, D.; Chang, H.-M.; Liu, C.-H.; Hsiao, I.-T.; Yang,
C.-P.; Liu, Y.-C.; Hu, C.-J., Plasmon-Activated Water Reduces Amyloid Burden and Improves Memory
in Animals with Alzheimer's Disease. Sci. Rep. 2019, 9, 13252.
(304) Qin, J.; Cho, M.; Lee, Y., Ultrasensitive Detection of Amyloid-β Using Cellular Prion Protein
on the Highly Conductive Au Nanoparticles–Poly(3,4-ethylene dioxythiophene)–Poly(thiophene-3-
acetic acid) Composite Electrode. Anal. Chem. 2019, 91, 11259-11265.
(305) Wadghiri, Y. Z.; Sigurdsson, E. M.; Sadowski, M.; Elliott, J. I.; Li, Y.; Scholtzova, H.; Tang,
C. Y.; Aguinaldo, G.; Pappolla, M.; Duff, K.; Wisniewski, T.; Turnbull, D. H., Detection of Alzheimer's
amyloid in transgenic mice using magnetic resonance microimaging. Magn. Res. Med. 2003, 50, 293-
302.
(306) Sonawane, S. K.; Ahmad, A.; Chinnathambi, S., Protein-Capped Metal Nanoparticles Inhibit
Tau Aggregation in Alzheimer's Disease. ACS Omega 2019, 4, 12833-12840.
(307) Javed, I.; Peng, G.; Xing, Y.; Yu, T.; Zhao, M.; Käkinen, A.; Faridi, A.; Parish, C. L.; Ding, F.;
Davis, T. P.; Ke, P. C.; Lin, S., Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold
nanoparticle dual strategy. Nat. Commun. 2019, 10, 3780.
(308) Chen, J.; Armstrong, A. H.; Koehler, A. N.; Hecht, M. H., Small Molecule Microarrays Enable
the Discovery of Compounds that Bind the Alzheimer's Aβ Peptide and Reduce its Cytotoxicity. J. Am.
Chem. Soc. 2010, 132, 17015-17022.
(309) Limbocker, R.; Chia, S.; Ruggeri, F. S.; Perni, M.; Cascella, R.; Heller, G. T.; Meisl, G.;
Mannini, B.; Habchi, J.; Michaels, T. C. T.; Challa, P. K.; Ahn, M.; Casford, S. T.; Fernando, N.; Xu,
C. K.; Kloss, N. D.; Cohen, S. I. A.; Kumita, J. R.; Cecchi, F.; Zasloff, M.; Linse, S.; Knowles, T. P. J.;
Chiti, F.; Vendruscolo, M.; Dobson, C. M., Trodusquemine enhances Aβ42 aggregation but suppresses
its toxicity by displacing oligomers from cell membranes. Nat. Commun. 2019, 10, 225.
(310) Van der Munnik, N. P.; Moss, M. A.; Uline, M. J., Obstacles to translating the promise of
nanoparticles into viable amyloid disease therapeutics. Phys. Biol. 2019, 16, 021002.
74 
(311) Wadman, M.; Servick, K., Alzheimer’s drug resurrected, as company claims clinical benefits.
Science 2019.
(312) Abbott, A.; Dolgin, E., Leading Alzheimer's theory survives drug failure. Nature 2016, 540,
15-16.
(313) Zhang, S.; Liu, H.; Chuang, C. L.; Li, X.; Au, M.; Zhang, L.; Phillips, A. R. J.; Scott, D. W.;
Cooper, G. J. S., The pathogenic mechanism of diabetes varies with the degree of overexpression and
oligomerization of human amylin in the pancreatic islet β cells. FASEB J. 2014, 28, 5083-5096.
(314) Fox, N.; Schrementi, J.; Nishi, M.; Ohagi, S.; Chan, S. J.; Heisserman, J. A.; Westermark, G.
T.; Leckström, A.; Westermark, P.; Steiner, D. F., Human islet amyloid polypeptide transgenic mice as
a model of non‐insulin‐dependent diabetes mellitus (NIDDM). FEBS Lett. 1993, 323, 40-44.
(315) Matveyenko, A. V.; Butler, P. C., Islet Amyloid Polypeptide (IAPP) Transgenic Rodents as
Models for Type 2 Diabetes. ILAR J. 2006, 47, 225-233.
75 
Chapter Two: Model Interactions of Amyloid Protein Species 
Preamble: Fundamental insight into IAPP amyloid aggregation in model environments in vitro 
(Aims 1A & 1B) was first sought to provide context for further studies of amyloid behavior 
within complex environments (Chapter Three) and how nanomaterials might be designed to 
mimic endogenous mechanisms of IAPP amyloidosis inhibition (Chapter Four). Selected data 
in this chapter has been published as Xing, Y.; Pilkington, E. H. et al. Phys. Chem. Chem. Phys. 
2017, 19, 30627 (Fig. 4), reproduced by permission of the PCCP Owner Societies; and 
Pilkington, E. H. et al. Sci. Rep. 2017, 7, 2455 (Figs. 5 & 6), as indicated in respective figure 
captions. All experiments and analyses presented herein were undertaken by the candidate, 
excepting FibreApp fibril persistence length analysis in Figure 5E, which was performed by 
Dr. Aleksandr Kakinen. 
2.1. Chapter abstract 
The amyloid aggregation of islet amyloid polypeptide (IAPP) is associated with dysfunction 
and death of pancreatic β-cells, a hallmark of type 2 diabetes (T2D), but is capable of further 
damage to extra-pancreatic tissues due to the propensity of circulating IAPP species to 
translocate throughout the body. Though studies have been conducted with Alzheimer’s-
associated amyloid-beta (Aβ) and Parkinson’s-associated alpha-synuclein (αSyn), the rapid 
amyloidosis of IAPP has previously limited characterization of amyloid pathway species, with 
respect to their morphology and associated cytotoxicity. Through timepoint-based high 
resolution transmission electron microscopy (TEM), a diverse profile of IAPP intermediate 
species was generated, including a biannular oligomer morphology that has not been previously 
reported. A cytotoxicity assay, utilizing primary human umbilical vein endothelial cells 
(HUVECs) to provide a more accurate approximation of vascular tissue encountered by 
circulating IAPP in vivo, demonstrated differential cytotoxic effects of thioflavin T (ThT)-
probed IAPP species, with early and intermediate IAPP species proving highly deleterious in 
both ‘fresh’ and preincubated states regardless of different fibrillization kinetics, and mature 
amyloid plaques eliciting low-level cytotoxicity.  
A number of biophysical studies have highlighted membranes, both biological and synthetic, 
as eliciting a promotional effect on Aβ, αSyn and IAPP, through electrostatic and hydrophobic 
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interactions between amyloidogenic species and the lipid membranes. Utilizing a ThT kinetic 
assay, TEM and circular dichroism (CD) spectroscopy, micellar lysophosphatidylcholine 
(LPC), the most abundant lysophospholipid in the blood, is shown to inhibit IAPP amyloid 
aggregation through nonspecific interactions while elevating α-helical peptide secondary 
structure. This surprising finding suggests a native protective mechanism against IAPP 
aggregation in vivo.  
The ubiquity of extracellular proteins in both the pancreatic islets of Langerhans and the 
vascular circulation belies an impact on fibrillating and amyloid IAPP, though the effects of 
protein association with IAPP species are largely unknown. Two homologous proteins, cationic 
lysozyme (Lys) and anionic alpha-lactalbumin (aLac), both of which can be found in the 
circulation, were examined for their capacity to modulate IAPP behavior in a controlled in vitro 
environment. Biophysical characterizations and a cell viability assay revealed distinct effects 
of Lys and aLac on IAPP amyloid aggregation, fibril remodeling and associated cytotoxicity, 
pointing to the role of a protein ‘corona’ in conferring the biological impact of amyloidogenic 
peptides. Collectively, this chapter provides fundamental characterizations and interactions of 
IAPP aggregation species individually and with model proteins, lipids, and ultrasmall 
membranes within a controlled in vitro environment, towards understanding endogenous 
behaviors of IAPP and its associated pathologies in vivo. 
Figure 1. Simplified scheme of the amyloid fibrillization pathway (blue), in addition to off-
pathway or native/unfolded species (red). 
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2.2. Introduction 
IAPP is a 37-residue peptide hormone that, along with insulin, plays an essential role in 
glycemic control.1 The soluble, monomeric peptide is stored at millimolar concentrations in 
the islets of Langerhans before being released to the bloodstream. However, IAPP is 
aggregation prone sans the stabilization of insulin, physiological metal ions, low pH,2-7 or their 
complexation with zinc and C-peptide8 per endogenous inhibitory measures employed by 
pancreatic β-cells.9 Lacking a stabilizing microenvironment, in vitro studies have revealed that, 
at micromolar concentrations, IAPP can readily fibrillate into amyloids within hours – 
accumulating evidence has implicated IAPP amyloid aggregation as a key causative agent of 
pancreatic β-cell death and, subsequently, the development of T2D, a debilitating disease 
impairing 368 million people worldwide.10  
Earlier studies ascribed IAPP amyloids as the toxic species,11-12 while more recent studies 
pointed to IAPP oligomers as the causative toxic agent for β-cell loss.13 The ambiguities 
surrounding IAPP toxicity largely stem from the difficulty in isolating IAPP monomers from 
oligomers, protofibrils and amyloids due to the rapid fibrillization kinetics of the peptide, as 
well as the complex intra- and extra-cellular environments of the IAPP species where peptides, 
proteins, lipids and fatty acids occur in abundance.13 Intermediate species, spanning the breadth 
of the amyloid fibrillization pathway from monomer to fibril (Fig. 1), further complicate IAPP-
induced pathogenicity. The structural diversity in IAPP oligomeric species,14 wherein < 10% 
are predicted to have the β-rich secondary structure associated with eliciting cytotoxicity,15 in 
addition to the rapid rate in which they progress from low order structures into higher order 
fibrils and protofibrils, dynamically changing conformation16-17 and facilitating the nucleation 
of other fibrillating species,9, 18 all present particular challenges for their characterization. The 
presence of IAPP fibrils and plaques in the extracellular space of the islets of Langerhans 
further suggests a role of cell membranes in inducing aberrant IAPP aggregation. Cell 
membranes as well as lipid vesicles have generally been shown to promote IAPP 
aggregation,19-30 as also observed for Aβ and αSyn in neurodegenerative disorders.31-32 
Conversely, IAPP disrupts membrane integrity through lipid extraction or pore formation.24, 26, 
30-31 On the molecular level, the binding between IAPP and a lipid interface is initiated by the 
N-terminus of the peptide, through electrostatic interaction with the anionic lipids and
facilitated by hydrophobic interaction engaging the lipid bilayer and the amphiphilic peptide
oligomers, protofibrils and fibrils.16-17, 19-23, 25
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In consideration of the changing conformation and hydrophobicity of IAPP during its 
fibrillization process, it is reasonable to postulate that the molecular ligands encountered by 
IAPP from cradle to grave may exert effects on the physical and biological identities of the 
IAPP species. Surprisingly, little is known concerning IAPP-protein interactions and their 
biological and pathological implications. IAPP amyloid deposition in vivo has been associated 
with various co-factors, including apolipoprotein E (ApoE),33 serum amyloid P (SAP) 
component,34 and glycosaminoglycans (GAGs), in particular heparan sulfate proteoglycans.35 
The fibrillization of IAPP has been shown to be enhanced by GAGs,36-37 which can further 
augment aggregation of incompletely processed IAPP.38 IAPP fibrillization in vitro has also 
been inhibited, to varying extents, by secretory chaperones and serum albumins.37, 39-40 Protein-
IAPP association is not necessarily correlated with mitigation of IAPP-mediated cytotoxicity, 
as is evidenced with ApoE and GAGs, wherein only the latter is implicated in IAPP toxicity.41-
42
In this chapter, fundamental questions into the native state and behaviors of IAPP amyloid 
species are explored, utilizing controlled in vitro environments as a platform for elucidating 
endogenous processes in complex in vivo milieu. Firstly, a structure-based analysis of 
intermediate fibrillar species generated during a 24-hour period in aqueous solution was 
undertaken using TEM. Four distinct morphologies were identified – spherical, annular, 
biannular and complex aggregates – and additionally profiled by diametric size. Furthermore, 
by lowering the reaction temperature, the progression of intermediates to a predominantly 
fibrillar state was delayed, allowing for selection of reaction conditions that favor 
predominantly oligomeric species (e.g., 4 h at 4 oC) for use in comparative studies. 
Concordantly, an in vitro toxicity study was performed on three IAPP populations: monomeric 
IAPP, oligomeric/fibrillating IAPP, and mature IAPP amyloid. Utilizing HUVECs, a primary 
endothelial cell line corresponding to cells present in the vasculature that may interface with 
circulating IAPP, fibrillization and associated cytotoxicity of each IAPP species was compared. 
Under the applied conditions, monomeric and fibrillating IAPP species had near-identical 
toxicity profiles, demonstrating sigmoidal kinetics and an endpoint toxicity value of ~60%, 
despite notable differentiation in their fibrillization behavior. IAPP amyloid elicited around 
~20% cytotoxicity, giving precedence to early and intermediate species of IAPP as causative 
of the majority of cell damage and death within an initial period of exposure.  
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In order to assess the impact of circulating proteins and lipids on IAPP behavior, model proteins 
and lipids were introduced to early (‘fibrillating’ or ‘fresh’) IAPP and mature amyloid IAPP, 
and their impact on IAPP fibrillization, morphology and associated cytotoxicity were explored 
for the first time.43-44 In the first study, the effects of zwitterionic LPC on IAPP aggregation at 
both below and above its critical micelle concentration (CMC, 40-50 μM)45 were examined. 
LPC, a product of lipid peroxidation, is the most abundant single-tailed phospholipid in the 
blood (234 μM)46 as well as a signaling molecule in the cell membrane. At concentrations 
above the CMC, such as in the blood, LPC molecules render ultra-small micelles (~4 nm in 
diameter)47-48 in size similar to that of sodium dodecyl sulfate (SDS). From the perspective of 
a model membrane the zwitterionic LPC micelles mimic the largely neutral pancreatic β-cell 
membranes (97.5% neutral, plus 2.5% anionic lipids)49 more closely than the anionic SDS that 
has been used as a model system for examining protein-membrane interactions. The 
fibrillization of IAPP in the presence of linear and micellar LPC was quantified by a ThT 
kinetic assay and high-resolution TEM, with the changing secondary structure of IAPP in the 
presence of linear and micellar forms of the lipid probed with CD spectroscopy. A surprising 
inhibition effect of LPC micelles on IAPP amyloid aggregation was revealed, characterized by 
a prolonged lag time, a reduction in the β-sheet content at saturation in favor of majority α-
helical conformations, and sparse formation of soft, braided IAPP fibrils.  
Lastly, the interactions of the two IAPP populations with two model proteins, Lys and aLac, 
was examined, in order to determine how the binding of amyloid species with model circulatory 
proteins affects their biological fate. Lys and aLac are homologous proteins with similar 
tertiary structures (14 kDa, 41% helical and 9% β-sheets) while carrying opposite net charges. 
Lys is an enzyme commonly found in saliva and tears responsible for hydrolyzing 
peptidoglycans in bacterial cell wall, while aLac from mammal milk regulates lactose 
biosynthesis. Both Lys50 and aLac51 can also be found in circulation. ThT assay and high-
resolution TEM were used to assess IAPP aggregation and fibril remodeling, and a viability 
assay with HUVECs was performed to evaluate the toxicities of fresh IAPP and IAPP amyloids 
in the presence of the model proteins. Specifically, co-incubated with IAPP peptides at a 1:1 
molar ratio, Lys inhibited IAPP aggregation with no visible fibril formation while aLac induced 
amorphous aggregation containing significant β-sheet content. TEM imaging revealed that 
both aLac and Lys bound mature fibrils and binding of aLac led to fibril softening. Surprisingly, 
the cell viability study indicated that Lys enhanced but aLac reduced the cytotoxicity of IAPP 
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peptides, whereas binding of either Lys or aLac with mature IAPP fibrils mitigated the fibril 
toxicity.  
This controlled in vitro study has revealed the polymorphic nature of intermediate IAPP 
aggregation species in addition to the contrasting effects of proteins and lipids on IAPP 
amyloidogenesis, fibril remodeling and cytotoxicity, depending on the physicochemical 
properties as well as the relative concentrations between the proteins and IAPP peptides – 
pointing to a natural defense mechanism of biological systems in mitigating the toxicities 
elicited by amyloidogenic species.  
2.3. Results and discussion 
2.3.1. Profiling IAPP fibrillization species and their associated toxicity in vitro 
2.3.1.1. Characterization of IAPP intermediate species 
Kinetic fluorescence-based studies of IAPP aggregation can indicate increasing β-sheet content 
over time but do not provide information about aggregate species morphology, particularly 
which populations are dominant at a given point in time. This study utilized TEM to 
characterize the formation of nonfibrillar IAPP aggregates, with regards to their size and 
morphology, during amyloidosis in a controlled environment. When monomeric IAPP was 
applied to aqueous solution at room temperature, nonfibrillar, globular aggregates were initially 
generated (Fig. 2A; 30 min) but a transition to fibrillar species was observed after 2 h of 
incubation, concordant with ThT assays of IAPP fibrillization kinetics (Figs. 4A & 5A). Non-
fibrillar aggregates were gated into four categories based on their morphology: spherical, 
annular, biannular and complex aggregates (Fig. 2B). Spherical aggregates averaged around 
22 nm in diameter, with annular and biannular species doubling in size to 44 nm and 48 nm 
respectively. Complex aggregates exhibited the broadest range of species, averaging a diameter 
of 63 nm, though the diametric variation of spherical species represented the largest 
proportional standard deviation (± 10 nm). Interestingly, some larger (100-400 nm) species 
with complex surface structure were observed across multiple timepoints at both 4 oC and RT, 
potentially corresponding to off-pathway amyloid ‘particulates’52 (Fig. S1A). Given the 
extensive and heterogeneous population of oligomers predicated by secondary nucleation in 
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amyloidosis,18 reports of oligomer formation in vitro with regards to size have varied – one 
review defines oligomers as smaller than 50 nm, generally consisting of under 50 misfolded 
monomer units.52 Sedimentation velocity experiments have previously failed to detect IAPP 
oligomeric species under 100 units associating with mature fibrils, positing that IAPP 
intermediates form larger structures than those observed for Aβ1-42.53 Indeed, the observation 
of aggregates > 50 nm here supports this hypothesis, and further investigation in vivo will 
determine if endogenous IAPP aggregates pertain to an analogous profile.  
Annular oligomers, pertaining to ‘doughnut’ or ‘cylinder-like’ morphologies, have been 
previously reported for IAPP in addition to a number of amyloidogenic54-55 and artificially 
Figure 2. Characterization of IAPP intermediate aggregates by TEM. A: Fibrillization of IAPP 
(25 µM) in aqueous solution over time at either RT or 4 oC. Scale = 200 nm. B: Identification of 




fibrillated56 species under various conditions. Previous in vitro studies of annular IAPP 
oligomer formation have either been investigated in a surface-mediated context, i.e. at a lipid 
membrane interface,55 or omitted their morphological characterization.57 Herein annular 
oligomeric IAPP is characterized in vitro in the absence of lipid membrane catalyzation. The 
presence of annular structures is in line with the observance of so-called ‘β-barrel’ oligomers,15 
which are purported to instigate pore formation when interfaced at the cell membrane and thus 
contribute to amyloid-associated pathologies. The low sample size of these morphologies in 
the population, comparative to spherical and complex aggregates (see section 2.5.3.1, Materials 
and Methods) correlates with the low abundance of β-barrel species within an aggregate 
population predicted by computational studies, estimated to comprise less than 10% of 
aggregates.15 Biannular oligomers, to the candidate’s knowledge, have not been previously 
reported elsewhere. Oligomerizing Aβ1-42 generated a few biannular oligomers by 24-28 
hours (Fig. S1B), implicating these structures are not unique to IAPP.  
Ultimately, the lack of nonfibrillar aggregate populations by 24 h at room temperature (Fig. 
2A; RT), where fibrillar species overwhelmingly dominate, likely indicates that the observed 
aggregate morphologies are on-pathway species, given the saturation point of IAPP 
fibrillization is reached within several hours in aqueous solution at room temperature.58 The 
wealth of diversity of IAPP intermediate species revealed in this study potentiates that a 
thorough, fine-grained approach to their characterization in further studies could provide 
further insight into computational and theoretically predicted amyloid aggregation mechanics. 
Finally, reducing the environmental temperature to 4 oC favored the production of lower-order 
aggregate species (Fig. 2A; 4 oC), extending the observable ‘lag’ period of amyloidosis up to 
7 h before fibrillar aggregates were observed as the majority population. These observations 
are concordant with the energy landscape for amyloidosis: specifically, that a reduction in 
temperature and thus a reduction in the kinetic energy facilitating intermolecular interactions 
between lower-order oligomeric species limits their further transition into mature fibrils. 
Though detailed methodologies for the preparation of different pathway species of Aβ have 
been published,59-60 efforts to generate discrete populations of IAPP aggregates have often 
relied on the introduction of a foreign stabilizing agent.61 Pre-incubating IAPP at a low 
temperature thus presents a facile, practical approach for curating intermediate populations.   
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Figure 3. Visualizing and quantifying in vitro fibrillization and cytotoxicity of IAPP species. 
A: Fluorescence microscopy of IAPP species (25 µM), either fresh (lyophilized monomers), oligos 
(low order aggregates, pre-incubated for 4 h in aqueous at 4 oC) and amyloid (mature fibrils, pre-
incubated for ~2 weeks in aqueous at room temperature) incubated with HUVECs after 24 h. 
Propidium iodide (PI) indicates dead cell nuclei, and the formation of β-rich amyloid is probed by 
thioflavin T (ThT), as then quantified in the right-hand panels. Scale = 100 µm. Statistical 
significance, as calculated by a 2-way ANOVA with Tukey’s correction, is comparative to control: 
** p < 0.01, **** p < 0.0001. Error bars represent standard error of mean (SEM), n = 3. B: 
Fibrillization of fresh and oligomeric IAPP over 24 h demonstrating the kinetic profile of endpoint 
data seen in A, i.e. β-rich amyloid formation (ThT fluorescence intensity) juxtaposed against cell 




2.3.1.2. Cytotoxicity and fibrillization kinetics of IAPP species in primary endothelial cells 
Given the diversity of IAPP pathway species able to be generated, the impact of different 
populations on in vitro primary cell viability and how it correlates with IAPP fibrillization over 
time was assessed. Fibrillating IAPP species were delineated as ‘fresh’ IAPP, i.e. lyophilized, 
monomeric IAPP directly dissolved into solution, and ‘oligomeric’ IAPP, i.e. majority-
intermediate populations generated through the pre-incubation of IAPP in aqueous solution for 
4 h at 4 oC, in addition to non-fibrillating, mature IAPP amyloids (at least one week old to 
eliminate oligomers and protofibrils). ThT was utilized as a probe for the generation of β-sheet 
rich aggregates, indicative of amyloid fibrillization (Fig. 3, in green). Both fibrillating IAPP 
populations demonstrated a significantly increased ThT fluorescence by 24 h comparative to 
the control (Fig. 3A), each displaying a prototypical sigmoidal increase in fluorescence over 
time (Fig. 3B). Though endpoint ThT fluorescence was conserved across the populations, 
notable differentiation was observed in their kinetic profiles. ‘Fresh’ IAPP underwent a lag 
phase of 5 h before progressing to exponential aggregation, and finally achieving saturation at 
~18 h; contrastingly, oligomeric IAPP had a lag time of only 1 h, reaching saturation by 
approximately 16 h. As IAPP intermediate populations pertain to amyloid ‘seeds’ that can be 
utilized to propagate fibril growth and initiate the nucleation of further seed aggregates (Fig. 
1), the unfavorable energetics of the lag phase were more readily overcome, allowing the IAPP 
oligomer samples to proceed more rapidly into the saturation phase compared to IAPP 
monomers. As expected, mature IAPP amyloid, in the absence of nucleating ‘seeds’, did not 
undergo further fibrillization, and maintained a steady fluorescence value of ~600 AU over 24 
h (Fig. S2A). Though multiple ThT-labeled plaques are clearly visible in solution (Figs. S3 & 
3A), statistical analysis did not deem the overall fluorescence significantly differentiated from 
background levels, potentially due to some free-floating aggregates not interfacing with cells 
at the analysis focal plane.  
Membrane-impermeable propidium iodide (PI) traffics to the nucleus upon disruption of the 
cell membrane and complexes with fragmented DNA as an indicator of cell apoptosis (Fig. 3, 
in red). Overall, fibrillating species, i.e. fresh and intermediate populations, elicited the most 
toxic effect in vitro. IAPP amyloid did not display evolving cytocidal action on HUVECs over 
24 h, maintaining a consistent value of PI-positive cells at 15-20% of the population (Fig. S2), 
found significantly differentiated to the untreated cells in the ThT- control group (Fig. S2A; p 
< 0.05 by two-way ANOVA). Fibrillating IAPP species, on the other hand, were highly 
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Figure 4. Effects of micellar (> CMC) and non-micellar (< CMC) LPC on IAPP fibrillization and 
amyloid remodeling. Concentrations of IAPP (25 µM), LPC < CMC (25 µM) and > CMC (2 mM) were 
fixed in all experiments. (A) ThT fluorescence assay of IAPP and LPC alone (both above and below the 
CMC) or as mixed samples, with sigmoidal least-squares fit (dotted lines); error = SEM. (B) TEM imaging
of IAPP and IAPP amyloids after 24 h incubation with or without LPC, scale = 100 nm. (C) IAPP secondary
structures in the presence and absence of LPC as determined through circular dichroism spectroscopy. Lines
are intended to guide the eye. (D) Diameter frequencies of IAPP amyloid fibrils with Gaussian least-squares
fit, ****p < 0.0001 (one-way ANOVA, n = 100). Reproduced with permission from Xing, Pilkington et al.
2017.44
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deleterious, and appeared to seed and propagate along the cell membranes, accumulating for 
several hours prior to the death of the associated cells (Fig. 3B, images). Interestingly, 
monomeric IAPP appeared to form more concentrated deposits comparative to a more even 
distribution of the IAPP intermediate population across sampled areas (Fig. 3A, images), 
highlighting the role of cell membranes in accelerating amyloid fibrillization of localized 
aggregating species. Given that preformed seeds may not necessarily permeabilize the cell 
membrane,57 the fibrillization of IAPP intermediate populations herein potentially represents a 
balance between surface-assisted nucleation at the interface of the intermediate species 
themselves (i.e., secondary nucleation) in addition to at the lipid cell membrane.  
Assessing cell death over time rather than taking an endpoint value allowed the kinetics of 
IAPP-associated cytotoxicity to be visualized and compared between species. Accordingly, 
though fibrillization progressed more rapidly for the preincubated oligomeric IAPP, cell death 
kinetics were conserved between fresh IAPP and IAPP oligomers (Fig. 3B), with exponential 
death rates reached ~ 6 h post IAPP-exposure and both stabilizing at around 60% by ~ 18 h. 
The good correlation between IAPP fibrillization and cell death, particularly with regards to 
‘fresh’ IAPP, leads further credence to membrane disruption as a major mechanism of IAPP-
induced cytotoxicity – indeed, previous studies have demonstrated that monomeric IAPP 
elicited the largest shift in membrane fluidity in pancreatic β-cells in vitro comparative to 
oligomeric and mature amyloid IAPP.62 Conversely, for oligomeric IAPP, as a mixed 
population of complex intermediate species (Fig. 2), the mechanisms of its elicited cytotoxicity 
at the cell membrane may be similarly diverse. Pore formation, ‘lipid stripping’ and physical 
perturbation have all been proposed as mechanisms of amyloid-associated cytotoxicity at the 
interface of lipid membranes,24, 26, 30-31 as facilitated by different aggregate species:63 
accordingly, intermediate population demographics15 likely determine which mechanism 
predominates. For example, preformed annular oligomers of αSyn and Aβ elicited less 
membrane permeabilization than spherical aggregates, though the effect of IAPP annular 
species was not reported.57 Consequently, the generation of intermediate species under 
different conditions may have different roles in IAPP-associated pathologies, in particular 
given the propensity for extra-pancreatic translocation of toxic IAPP species, and merits further 
investigation in vivo.  
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Figure 5. IAPP fibrillization inhibition and amyloid remodeling by lysozyme (Lys) and α-lactalbumin 
(aLac). (A) Thioflavin T (ThT) fluorescence assay shows IAPP fibrillization in the presence of Lys and 
aLac over 14 h. (B) TEM images of IAPP fibrillization inhibition (upper panel) and IAPP amyloid 
remodeling (lower panel) mediated by Lys and aLac at a 1:1 molar ratio after incubation in Milli-Q water 
for 24 h at 25 
o
C. Formation of a visible IAPP-aLac precipitate (upper middle panel, inset) and soft aLac-
amyloids (lower middle panel, white circles) are shown. Scale = 200 nm. (C) Circular dichroism (CD) 
shows β-sheet content of IAPP in the presence of aLac and Lys, in addition to aLac and Lys controls, over 
48 h. (D, E) Analysis of IAPP amyloid fibril diameter (D) and persistence length (E) in the presence or 
absence of Lys and aLac. IAPP concentration = 25 μM for all experiments. **** p < 0.0001 (unpaired t-
test, n = 100). Reproduced with permission from Pilkington et al. 2017.43 
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2.3.2. Biophysical characterizations of protein and lipid binding on IAPP aggregation and 
fibril remodeling 
2.3.2.1. Effects of LPC binding on IAPP fibrillization and remodeling 
Biophysical characterizations revealed the differential effects of micellar and non-micellar 
LPC on IAPP fibrillization, and additionally, their capacities in remodeling of mature IAPP 
amyloids (Fig. 4). Native fibrillization of IAPP, which formed semi-flexible amyloid fibrils in 
aqueous solution over 24 h, was notably inhibited by micellar LPC (Fig. 4B). ThT fluorescence 
indicated a reduction in the β-sheet content formed by IAPP in the presence of micellar LPC 
by 24 h, compared to the IAPP control (Fig. 4A). Non-micellar LPC induced a lag time of only 
~10 min and the saturation point was reached ~2 h before the IAPP control. This effect has also 
been observed with Aβ, where LPC below the CMC was capable of reducing the fibril lag and 
elongation times of Aβ1-42, yet showed no notable increase in fibrillization after saturation 
was reached in each case.64 Anionic non-micellar lipids, including SDS65 and lysophosphatidic 
acid (LPA),66 have demonstrated the capacity to promote fibrillization and fibril elongation of 
β2-microglobulin (β2M) at a neutral pH, though zwitterionic LPC did not mediate any 
significant effect.  
The interaction of micellar LPC with IAPP, in contrast, greatly reduced IAPP fibrillization, 
both in terms of fibrillization kinetics and overall amyloid formation by 24 h. CD spectroscopy 
revealed the transition of peptide secondary structure from random coils to β-sheets over 24 h 
(Fig. 4C). In the presence of non-micellar LPC, an increase in β-sheet content of ~15% was 
observed for IAPP by 24 h, while the α-helical content (< 10%) showed negligible variations 
over the experimental period. In contrast, interactions of IAPP with LPC micelles induced an 
immediate transition from β-sheets to α-helices (39.2%). Within the IAPP-LPC micelle 
complex, IAPP random coils remained stable over 24 h (~ 33%). In contrast, Patil et al. 
observed that upon complexation with SDS micelles, IAPP residues 5-28 were present in the 
α-helical conformation, with residues 5-19 embedded in the hydrophobic core, and the known 
amyloidogenic region (residues 20-29) positioned on the surface of the micelle at the lipid-
solvent interface.25  
Given the limited capacity for inter-peptide interactions between micelle-bound IAPP, 
disruption of IAPP fibrillization is expected. Indeed, visualization of IAPP amyloid fibrils after 
24 h in aqueous solution demonstrated significant structural polymorphism of IAPP fibrils in 
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the presence of micellar LPC by TEM imaging (Fig. 4B) and subsequent analysis of fibril 
diameter (Fig. 4D). Large, braided amyloid fibrils larger than 30 nm in diameter were observed 
(Fig. 4B), displaying a significantly broadened distribution compared with the IAPP control or 
IAPP treated with non-micellar LPC (Fig. 4D), though fewer fibrils were seen. The fibrils 
appeared softer, with a persistence length of 458 ± 13 nm based on FiberApp statistical 
Figure 6. Viability of HUVECs exposed to 25 μM IAPP and amyloids in the presence of α-
lactalbumin (aLac) and lysozyme (Lys) after 24 h. (A) Bright-field images reveal extensive cell death 
in the presence of fibrillating IAPP, and some loss of cells with IAPP amyloids. (B) The calcein-AM 
viability assay demonstrates high toxicity of IAPP (left) and, to a lesser extent, IAPP amyloids (right). 
Significant mitigation of toxicity in amyloids was observed when pre-treated with aLac and Lys. Scale = 




analysis,67 compared with that of 2,885 ± 60 nm for the IAPP control.68 Below the CMC, LPC 
remodeled amyloid fibrils into filaments of thinner width (Fig. 4D). Micellar LPC (Fig. S4, 4-
5 nm in size) did not remodel pre-formed fibrils, but similarly to their effect on fibrillating 
IAPP, individual fibrils were observed to closely associate, belying the 'glue-like' effect of LPC 
micelles on mature amyloids. The strong LPC-fibril binding suggests that LPC could coat the 
fibril and bundle multiple fibrils into a braided structure as observed in TEM (Fig. 4B). This 
can also explain the slightly reduced ThT intensity but increased β-sheet content observed for 
IAPP fibrillization in the presence and absence of LPC < CMC (Fig. 4A vs. 4C, middle panel), 
as the strong binding of LPC monomers onto IAPP fibrils and protofibrils would sterically 
hinder ThT dye from binding thereby reducing its fluorescence. Concordantly, the combined 
ThT, CD and TEM results suggest that unimolecular LPC accelerated IAPP binding.    
2.3.2.2. ThT and CD assay quantifications of IAPP fibrillization inhibition by proteins 
IAPP, aLac and Lys were incubated with the amyloid-sensitive ThT dye to quantify the rate 
and kinetics of IAPP fibrillization over 14 h (Fig. 5A), in addition to visualizing change in 
protein secondary structure up to 48 h through CD spectroscopy (Fig. 5C). It was demonstrated 
that IAPP alone remained in the energetically unfavorable nucleation, or lag, phase up to 5 h, 
before entering the elongation phase, and by 14 h was within the saturation phase (Fig. 5A). 
This is in turn was complemented by an increase of IAPP β-sheet content from 35.4% at 0 h to 
50.7% after 48 h (Fig. 5C), indicative of increasing prevalence of β-sheet rich amyloid species. 
The secondary structure of IAPP mixed with aLac showed analogous increase in β-sheets to 
the IAPP control after 48 h (Fig. 5C), which was not complemented in aLac in the absence of 
IAPP. Comparative to IAPP alone, however, IAPP-aLac did not show evidence of sigmoidal 
fibrillization, and the increase in ThT fluorescence followed a more linear trend (Fig. 5A). 
IAPP-aLac also attained the largest increase in ThT fluorescence overall, indicating a 
promotional effect of aLac on IAPP aggregation. The non-sigmoidal fibrillization trend, 
however, was consistent in all experiments, with the combined intensity and kinetics 
observations therefore suggesting formation of unstructured, amorphous IAPP aggregates in 
the presence of aLac. In contrast, complete inhibition of IAPP was observed in the presence of 
Lys over the 14 h sampling period for ThT (Fig. 5A); concordantly, no increase in percentage 
of IAPP β-sheet structure in IAPP:Lys was seen after 48 h (Fig. 5C). Each protein consequently 
mediated opposing effects on IAPP fibrillization, both in terms of β-sheet content and kinetic 
behavior. 
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2.3.2.3. High-resolution TEM imaging of IAPP fibrillization inhibition and remodeling by 
proteins 
TEM imaging was performed to complement ThT analysis through visualization of the 
aggregation products (Fig. 5B, upper panel), and also to examine IAPP amyloid remodeling 
mediated by aLac or Lys (Fig. 5B, lower panel). The TEM images were further analyzed with 
statistical software to determine the morphological and mesoscopic changes of mature IAPP 
amyloid fibrils incubated with aLac or Lys, including fibril diameter (Fig. 5D) and persistence 
length (fibril stiffness) (Fig. 5E).  
By 24 h incubation of IAPP alone, both long fibrils and smaller protofibrillar aggregates 
appeared (Fig. 5B, upper panel). Neither of these structures were observed in the presence of 
aLac or Lys, however. Specifically, IAPP fibrillization was completely inhibited by Lys, with 
only a few small, worm-like structures present after 24 h. Electrostatic repulsion between the 
positively charged IAPP and Lys likely compromised IAPP-IAPP interactions. In comparison, 
the IAPP-aLac mixture was mainly present as large amorphous aggregates after 24 h, which 
were also observed as off-white precipitates in solution (Fig. 5B upper panel, inset). Based on 
the ThT assay (Fig. 5A), the amorphous aggregates were significantly β-sheet rich. 
Considering the opposing charges of IAPP and aLac, it is likely that electrostatic attraction 
with aLac strongly perturbed IAPP self-assembly into fibrils, while favored formation of 
amorphous structures. Alternatively, formation of non-fibrillar species has been observed in 
both IAPP and Aβ amyloidogenesis when monomers interact with hydrophobic surfaces.69-70 
This suggests that IAPP-aLac could act as a seed, promoting contact between monomeric or 
low-order oligomeric IAPP species, yet directing aggregation off-pathway.  
Mature IAPP amyloids formed by IAPP alone after 30-60 days of incubation were long and 
semi-flexible (Fig. 5B, lower panel). The presence of some shorter species is attributed to the 
cross-linking and subsequent gelation of mature IAPP amyloids,71 which can result in some 
fibril breakage during pipetting from the stock. Statistical analysis of these fibrils revealed an 
average diameter of ~ 8.9 nm (Fig. 5D) and an average persistence length of ~2,100 nm (Fig. 
5E). When incubated with aLac and Lys, IAPP amyloids underwent remodeling, as indicated 
by changes in fibril diameter and morphology compared to IAPP amyloids alone (Fig. 5B, 
lower panels). Both aLac and Lys interacted with the fibrils, mediating a significant shift in 
average fibril diameter (Fig. 5D) from approximately 9 nm (IAPP amyloid control) to 12 nm 
(aLac) and 15 nm (Lys), correspondingly. Interestingly, interaction with aLac halved the 
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persistence length of amyloid fibrils (Fig. 5E) indicating significant fibril softening, while no 
difference was seen in IAPP stiffness with Lys binding.  
The endogenous inhibition of Aβ1-40 fibrillization mediated by several non-chaperone 
proteins, including aLac and Lys, has been previously reported.72 It was shown that 
fibrillization of the negatively charged Aβ was inhibited by aLac and Lys at a ~ 1:1 molar ratio, 
yet both proteins were unable to promote disaggregation of pre-formed Aβ fibrils. In the case 
of IAPP, although both aLac and Lys inhibited the fibrillization, aLac promoted the formation 
of large amorphous aggregates with significant β-sheet content while Lys prevented any 
formation of aggregates that could be detected by either ThT and TEM imaging. The 
differential impact on IAPP amyloid aggregation and remodeling of IAPP amyloids by aLac 
and Lys suggests that both electrostatic and hydrophobic interactions between proteins and 
IAPP can alter the intrinsic properties of IAPP amyloids. As such, it is likely that IAPP 
amyloids can facilitate interactions with a multitude of components in the environmental 
milieu. Formation of a ‘protein corona’73-74 on IAPP amyloids in vivo is likely to have a 
significant effect on IAPP amyloid toxicity, and merits further investigation. 
2.3.3. Effects of protein binding on the viabilities of fresh IAPP and IAPP amyloids 
Bright-field imaging (Fig. 6A) showed healthy control HUVECs as highly confluent and 
endothelial-like in morphology. Microscopic examination was additionally complemented by 
the calcein-AM assay (Fig. 6B) for quantitative measurement of cell viability against an 
untreated control. Large-scale cell damage and death was observed with IAPP, regardless of 
the presence or absence of aLac or Lys (Fig. 6A, middle row). Viability data (Fig. 6B, left 
panel) for IAPP (22% viability), IAPP-aLac (29%) and IAPP-Lys (7%) further demonstrated 
that aLac and Lys, though capable of inhibiting IAPP fibrillization, had no mitigating effect on 
the peptide toxicity. In fact, the IAPP-Lys mixture showed notably higher toxicity in HUVECs 
compared to IAPP alone, suggesting that Lys binding might increase the half-life of toxic low-
order IAPP species towards eliciting further damage to exposed cells (Fig. 5). The reduced 
toxicity of IAPP-aLac mixture was likely due to the fact that the formed amorphous aggregates 
were very large and precipitated (Fig. 6B, IAPP-aLac inset), reducing their exposure and 
subsequent toxic effects to cells.  
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Interestingly, different phenomena were observed when aLac and Lys were incubated with 
IAPP amyloids. Large deposits of mature amyloid aggregates were seen with each condition 
(Fig. 6A, lower row); however, extensive cell destruction, as visualized with IAPP, was not 
present. In amyloid-aLac and amyloid-Lys, healthy cells were observed. This effect is 
corroborated by the viability data (Fig. 6B, right panel); the relatively lower level of toxicity 
mediated by IAPP amyloids (47% viability) was significantly reduced in the presence of both 
aLac (81% viability) and Lys (85% viability). Therefore, these results suggest that the 
formation of aLac or Lys ‘corona’ on the amyloid fibril surface likely screened the amyloid-
cell interactions and thus reduced the low levels of amyloid fibril-induced cytotoxicity.  
2.4. Conclusions 
It is often said that one is a product of their environment. Collectively, these studies aimed to 
elucidate the behavior of IAPP fibrillization species within a model environment, and how 
representative lipids and proteins therein can impact the structure, morphology and induced 
cytotoxicity of these aggregation products, towards a more complete understanding of IAPP at 
the biological interface.  
Amyloidosis, as a complex process with a variety of intermediate species produced in the 
exponential phase of fibrillization before fibrillar species dominate the saturation phase, is 
further complicated in the case of IAPP – given its rapid fibrillization in aqueous media, 
characterization of intermediate aggregates is challenging. A high-resolution electron 
microscopy-focused study into IAPP fibrillization within a controlled environment revealed a 
wide variety of intermediate aggregates, including spherical and annular morphologies 
prototypical of amyloidosis in various species,54-56 but additionally biannular aggregates, 
revealing a new conformational morphology to be explored. Furthermore, monomeric and 
oligomeric IAPP demonstrated near-identical cytotoxicity profiles in primary endothelial cells 
in vitro regardless of the more rapid fibrillization kinetics of the intermediate population: 
potentiating that the known capacity of IAPP to mediate cytotoxic cell membrane disruption at 
the lipid interface is likely facilitated by diverse mechanisms, directed by proportions of 
different intermediate conformations adopted by IAPP in a given population. In a previous 
study, the candidate and co-workers explored the complex nature of IAPP fibrillization species 
and their associated toxicities.62 It was demonstrated that fibrillating, stabilized oligomeric and 
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mature amyloid IAPP species played different roles in eliciting toxicity to pancreatic β-cells in 
vitro. This study supports this narrative with a different cell line and hence a different in vitro 
IAPP environment, and additionally provides new insight. 
The uncovered phenomenon of IAPP aggregation inhibition by micellar LPC offers a new 
mechanism to the existing models of IAPP intracellular stabilization by insulin, low pH, metal 
ions,2 or by zinc-C-peptide-IAPP complexation.8 Unlike cell membranes and SDS micelles, 
which are net negatively charged, zwitterionic LPCs readily disperse in water as ultrasmall 
micelles which are then shown to interface with IAPP, subsequently inhibiting its aggregation. 
Some LPC species have been demonstrated to be five times more concentrated within β-cell 
secretory granules comparative to other cellular compartments – these are then downregulated 
40-60% after glucose stimulation,75 potentiating a connection between LPC abundance and
IAPP activity. Consequently, these unique physicochemical characteristics exhibited by LPC
may be crucial to IAPP stabilization in vivo, and could further advise the design and
development of small molecules and nanoparticles against amyloidosis.
The binding of cationic IAPP to both cationic Lys and anionic aLac further illustrates the 
capacity for extracellular, circulating protein to differentially impact amyloid pathologies. 
Thousands of circulating proteins have been identified in vivo;76 consequently, given the 
intrinsically disordered nature and high conformational flexibility of IAPP peptides, IAPP 
likely has the capacity to interface with numerous plasma proteins through electrostatic and 
hydrophobic interactions. Furthermore, depending on their physicochemical properties, 
proteins binding to IAPP may have drastically different effects on IAPP amyloidosis. For 
example, aLac and IAPP co-aggregated forming a large IAPP-aLac molecular complex driven 
by strong binding affinity and opposite charges. The large aggregates formed by IAPP and 
aLac mixture elicited low toxicity to HUVECs – Lys, on the other hand, could bind and 
stabilize IAPP intermediate species, where increased electrostatic repulsion prevented further 
aggregation of these clusters.43 Stabilization of low molecular weight oligomers of IAPP by 
their associations with Lys resulted in increased toxicity of IAPP as toxic oligomers were 
transiently formed. Interestingly, protein binding of IAPP fibrils – i.e. formation of amyloid 
coronae – always reduced the relatively low toxicity of the fibril, suggesting a new mechanism 
for mitigating IAPP toxicity in vivo.  
Despite the general binding of IAPP with globular proteins and the potential of proteins in 
promoting toxic IAPP species at comparable protein/IAPP concentrations, a crowded 
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environment with abundant globular proteins may inhibit the formation of IAPP oligomers. 
Interestingly, although not directly related to this study, it has been shown in the literature that 
whey protein α or β caseins, usually present in the form of micelles through mutual 
hydrophobic and electrostatic interactions, show a chaperone-like activity in inhibiting Aβ and 
insulin from aggregation through mechanisms not yet understood.77-79 Conversely, however, 
IAPP has recently been shown to form toxic oligomers in plasma through interactions with 
glucose and low-density lipoproteins.80 Further exploration is necessary to fully elucidate 
environmental proteins that may contribute to IAPP toxicity both in the pancreas and in 
circulation. Together, this new protein corona paradigm facilitates our understanding of the 
fate and transformation of IAPP in vivo, which may have consequential bearings on IAPP 
glycemic control and T2D pathology. 
2.5. Materials and Methods 
2.5.1 Materials 
Human islet amyloid polypeptide (IAPP) (disulfide bridge: 2-7; MW: 3,906; 37-residue: 
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY; > 95% pure by HPLC) was 
obtained as lyophilized powder from AnaSpec. Lysozyme (Lys) (from chicken egg white; MW: 
14,300), α-lactalbumin (aLac) (calcium depleted, from bovine milk; MW: 14,178), and L-α-
Lysophosphatidylcholine (LPC; from Glycine max, >99% pure by TLC) were purchased from 
Sigma-Aldrich. LPC derived from soybean is primarily composed of unsaturated C-18 fatty 
acids; typically, 40-60% linoleic, 25-30% palmitic, 10-12% oleic, 7-10% stearic and 4-6% 
linolenic acid. IAPP, aLac and Lys were weighed on a Cubis MSE balance (Sartorius, 0.01 mg 
resolution), dissolved in Milli-Q water (pH 6.5) to a concentration of 200 µM and used 
immediately for zeta potential, ThT, TEM and viability assay sample preparations. Pre-formed 
IAPP amyloids (30-60 days old in Milli-Q water, room temperature) were kept at a stock 
concentration of 200 μM. The stock solution of LPC was 16 mM in Milli-Q water. Thioflavin 
T (ThT) dye (Sigma) was dissolved in Milli-Q water to form a 250 μM stock solution 
immediately prior to use in ThT sample preparations unless otherwise specified. Calcein-AM 
(Sigma) and propidium iodide (PI) dyes (Thermo Fisher) were kept in a 1 mM stock solution 
in DMSO and 1.5 mM stock in water, respectively, and stored at -20 oC. 
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2.5.2. Thioflavin T (ThT) assays 
IAPP alone (25 µM) or in the presence of micellar (25 µM) and non-micellar (2 mM) LPC, 
aLac (25 µM) or Lys (25 µM), was mixed with 25 µM ThT dye in a black/clear bottom 96-
well plate (Costar), with the remaining volume made up to 100 µL with Milli-Q water where 
necessary. ThT fluorescence (excitation: 440 nm/emission: 485 nm) was then read every 10 
min for 24 h (144 time points) on an EnVision plate reader (Perkin Elmer) for IAPP-LPC 
studies, a Flexstation 3 plate reader (Molecular Devices) every 5 min for a total of 14 h (169 
time points) for IAPP-protein studies (both at 25 oC), and hourly on an Operetta High-Content 
Imaging System (Perkin Elmer) for 24 h (24 time points) at 37 oC for IAPP characterization 
studies, as paired with an in vitro viability assay (see Propidium iodide live-dead assay, section 
2.5.5.2). Error represents the standard error of mean of two (IAPP-LPC, IAPP-proteins) or 
three independent (IAPP characterization studies) experiments. Data was fit to a sigmoidal 
curve (least squares) using Prism (GraphPad) where required. 
2.5.3. Transmission electron microscopy (TEM) and analysis 
Carbon-coated formvar copper grids (400 mesh, ProSciTech) were glow discharged to promote 
hydrophilicity. A 10 µL aliquot of the sample to be imaged was placed on the grid and allowed 
to adsorb for 60 s. The remaining solution was then drawn off and the grid washed twice in 10 
µL of Milli-Q water. The grid was then touched to 5 µL 1% uranyl acetate (in Milli-Q water), 
the solution immediately drawn off, and the grid then placed onto a 5 µL droplet of 1% uranyl 
acetate to stain for 15 s. Any remaining liquid was then drawn off and the sample allowed to 
dry. Grids were imaged using Tecnai TF20 (FEI), Talos L120C (FEI) and JEOL 2000FX 
transmission electron microscopes.  
For IAPP characterization experiments, lyophilized monomeric IAPP (25 µM) was incubated 
in aqueous solution (PBS, pH 7) at either 4 oC or room temperature for 24 h, with samples 
taken for imaging at 0 min (data not shown), 30 min, 2 h, 4 h, 7 h, and 24 h. Grids were not 
glow-discharged for these studies. For the experiments concerning IAPP and model interactors, 
IAPP, IAPP amyloids, aLac, Lys, monomeric LPC (25 μM; all materials 1:1 by mass) and 
micellar LPC (2 mM; IAPP:LPC = 1:40 by mass) were incubated in Milli-Q water at 25 oC for 
24 h prior to imaging.  
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2.5.3.1. Morphological and statistical analysis of IAPP species imaged using TEM 
The size distribution profiles of IAPP aggregate species were generated using Digital 
Micrograph software (GMS3, Gatan), and Gaussian modelling of size distributions was applied 
in Prism (GraphPad, v. 7.01). For IAPP characterization experiments, lower order aggregates 
were gated into four distinct categories based on their morphologies – spherical (sphere shaped, 
no ‘pores’ or irregular structures), annular (pertaining to a singular pore), biannular (pertaining 
to two distinct pores), and complex (multipore, and/or demonstrating irregular globular 
structure). Size analysis was performed for each group, with sampling capped at 200 individual 
aggregates (spherical); for less common species, the sample pool was 126 (complex) 60 
(annular) and 19 (biannular), respectively. 
The distributions of fibril diameters for IAPP amyloids, IAPP-aLac, IAPP-Lys and IAPP-LPC 
were determined through randomly sampling > 100 points on the amyloid fibrils. Statistical 
significance was calculated via unpaired t-tests, utilizing the Holm-Sidak method for multiple 
comparisons, for protein binding experiments, and a one-way ANOVA with Tukey’s correction 
was utilized for IAPP-LPC. Values wherein p < 0.05 were considered to be statistically 
significant. 
The mesoscopic parameters of fibril persistence length (λ) and contour length (l) in the presence 
and absence of the proteins were analyzed with software FiberApp67 by Dr. Aleksandr Kakinen. 
The FiberApp open-source code was developed from statistical polymer physics for the 
structural analysis of filamentous and macromolecular objects. The persistence length λ reflects 
the rigidity of a polymer and is mathematically defined via the bond correlation function (BCF) 
in 3D or 2D as the length over which angular correlations in the tangential direction decrease 
by a factor of e. Here the λ values of IAPP fibrils were estimated from the average values 
determined by the BCF, mean-squared end-to-end distance (MSED) and mean-squared 
midpoint displacement (MSMD) methods. The contour length corresponds to the end-to-end 
length of a polymer along its contour. The values of persistence length and contour length were 
obtained based on statistical analysis of 290 fibrils.  
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2.5.4. Circular dichroism (CD) spectroscopy 
Experiments were performed on a Chirascan CD spectrometer (Applied Photophysics), with 
spectra read from 190-260 nm. Prior to sample loading, a baseline with no cuvette was run. 
300 µL of 25 µM IAPP in Milli-Q water, alone or in the presence of LPC above (2 mM) and 
below (25 µM) the CMC, aLac (25 µM) or Lys (25 µM) was placed in a cuvette with a 0.1 cm 
pathlength and CD analysis was run at 0 h, 2.5 h and 24 h (LPC) or 0 and 48 h (aLac, Lys) time 
points after incubation at room temperature. Between samples, cuvettes were washed more 
than 5× with distilled water. Final spectra were an average of three reads, which were then 
normalized against background signal and, for IAPP:protein or IAPP:LPC samples, against 
individual protein/LPC controls at each respective timepoint. Data were then de-convoluted 
with CDNN software to give a final relative percentage content of secondary structure. 
2.5.5. In vitro biological assays 
2.5.5.1. Cell culture 
Primary human umbilical vein endothelial cells (HUVECs), sourced from pooled donors and 
available commercially through Lonza, were seeded into a black/clear bottom 96 well plate 
(Corning) at a density of 1.0 x 105 cells/well in 200 μL EGM (Lonza) and incubated overnight 
(37 oC, 95% humidity, 5% CO2) or until 70-80% confluency was reached. Media was refreshed 
every 24-48 h during cell growth, with old media then removed before experimentation. 
2.5.5.2. Propidium iodide live-dead assay 
For IAPP characterization studies, 150 µL of media containing 1 µM propidium iodide (PI; 
Thermo Fisher) was added to wells and allowed to equilibrate with cells in the dark at 37 oC, 
5% CO2, 95% humidity for ~ 30 min. IAPP stock solutions (200 µM) were mixed 1:1 with ThT 
(200 µM) and allowed to equilibrate before 50 µL of each sample was then added to each well 
to make a final volume of 200 µL (final concentration IAPP and ThT = 25 µM). ‘Fresh’ IAPP 
was lyophilized monomers dissolved directly into solution; IAPP ‘oligos’ was lyophilized 
monomers pre-incubated at 4 oC for 4 h with gentle shaking; IAPP amyloid was lyophilized 
monomers pre-incubated for > 1 week at room temperature. The plate was then imaged on an 
Operetta High-Content Imaging System (PerkinElmer) at 37 oC, 5% CO2, 95% humidity for 
99 
24 h, with 5 readings at regions of interest in each well taken with a 20× lens every hour. PI 
was read at 535 nm excitation/617 nm emission, and 430 nm excitation/460-480 emission was 
utilized for ThT (refer to Thioflavin T (ThT) assays, section 2.5.2).  
2.5.5.3. Calcein-AM viability assay 
The calcein-AM live cell assay was used to provide quantitative data on cell viability. Calcein-
AM is a colorless dye in aqueous solution, but fluoresces brightly in the green spectrum when 
cellular esterases cleave off the AM group. IAPP, IAPP amyloids, aLac and Lys (100 μM) were 
incubated in Milli-Q water for 24 h at 25 oC prior to addition to cells. Media was refreshed and 
pre-incubated IAPP, IAPP amyloids, aLac and Lys were added to final concentrations of 25 
μM. For control cells, an equal volume of Milli-Q water was added to each well. Samples were 
added to wells in triplicate and incubated for 24 h (37 oC, 95% humidity, 5% CO2). Bright-
field images were taken prior to calcein-AM viability testing with a Nikon TS100 bright-field 
microscope, equipped with a DS-Fi1 CCD camera (Nikon) and Digital Sight software (Nikon). 
Media was then aspirated from wells, cells were gently washed 3× in warm HBSS (Gibco), and 
100 μL aliquots of 2 μM calcein-AM dye in HBSS were added to each well. The dye was 
incubated with cells for 30 min at 37 oC before endpoint fluorescence was read (excitation: 485 
nm/emission: 538 nm) on a Flexstation 3 plate reader (Molecular Devices). Though lysozyme 
is capable of non-specific esterase activity,81 a separate control confirmed the fluorescence of 
calcein-AM was not affected. 
2.5.5.4. Statistical analysis 
All data were analyzed using Prism (GraphPad, v. 7.01), with values considered statistically 
significant if p < 0.05. 
For the PI live-dead assay, PI positive cells were calculated within sampling areas as an 
estimate of total well counts from total cell count vs PI-positive nuclei, utilizing digital phase 
contrast mapping to define nuclear and cell boundaries. A two-way ANOVA was performed 
utilizing Tukey's correction for multiple comparisons to compare cytotoxicity elicited by IAPP 
species at 24 h, and unpaired t-tests were performed (24 h timepoint) using the Holm-Sidak 
method for multiple comparisons to confirm the presence of ThT did not impact overall 
viability of control and IAPP-treated cells (refer to Fig S2).  
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For the calcein-AM viability assay, percentage viability of cells was calculated through direct 
comparison of calcein-AM fluorescence intensity with control cells (100% viable) after 
correcting for background fluorescence. Error bars represent the standard error of mean. A one-
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Chapter Three: Profiling the Serum Protein Corona of Fibrillar 
Human Islet Amyloid Polypeptide 
This chapter pertains to a published work, reprinted with permission from Pilkington, E. H.; 
Gustafsson, O. J. R.; Xing, Y.; Hernandez-Fernaud, J.; Zampronio, C.; Käkinen, A.; Faridi, 
A.; Ding, F.; Wilson, P.; Ke, P. C.; Davis, T. P., Profiling the Serum Protein Corona of 
Fibrillar Human Islet Amyloid Polypeptide. ACS Nano 2018, 12, 6066-6078. Copyright 2018 
American Chemical Society. 
https://doi.org/10.1021/acsnano.8b02346 
Preamble: In Chapter Two, it was demonstrated that IAPP aggregation species interact with 
model proteins, lipids and lipid micelles in vitro, and the capacity of these biomolecules to 
impact intrinsic physicochemical properties and biological behaviors of these species was 
established. In particular, proteins and lipids exerted conformational remodeling and reduced 
associated cytotoxicity upon binding to mature amyloid fibrils, resulting in the first report of 
the ‘amyloid-protein corona’. In this chapter, these initial findings are further expanded 
through the interrogation of the amyloid-protein corona in vitro in complex biological media 
(Aim 1C), as fibrils and plaques would be natively exposed to within the extracellular milieu 
in vivo.  
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ABSTRACT: Amyloids may be regarded as native nanomaterials that
form in the presence of complex protein mixtures. By drawing an
analogy with the physicochemical properties of nanoparticles in
biological fluids, we hypothesized that amyloids should form a protein
corona in vivo that would imbue the underlying amyloid with a
modified biological identity. To explore this hypothesis, we charac-
terized the protein corona of human islet amyloid polypeptide (IAPP)
fibrils in fetal bovine serum using two complementary methodologies
developed herein: quartz crystal microbalance and “centrifugal
capture”, coupled with nanoliquid chromatography tandem mass
spectroscopy. Clear evidence for a significant protein corona was
obtained. No trends were identified for amyloid corona proteins based
on their physicochemical properties, whereas strong binding with IAPP
fibrils occurred for linear proteins or multidomain proteins with
structural plasticity. Proteomic analysis identified amyloid-enriched proteins that are known to play significant roles in
mediating cellular machinery and processing, potentially leading to pathological outcomes and therapeutic targets.
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Chapter Four: Star Polymers Reduce Islet Amyloid Polypeptide 
Toxicity via Accelerated Amyloid Aggregation 
This chapter pertains to a published work, reprinted with permission from Pilkington, E. H.; 
Lai, M.; Ge, X.; Stanley, W. J.; Wang, B.; Wang, M.; Käkinen, A.; Sani, M.-A.; Whittaker, 
M. R.; Gurzov, E. N.; Ding, F.; Quinn, J. F.; Davis, T. P.; Ke, P. C., Star Polymers Reduce
Islet Amyloid Polypeptide Toxicity via Accelerated Amyloid Aggregation. 
Biomacromolecules 2017, 18, 4249-4260. Copyright 2017 American Chemical Society. 
https://doi.org/10.1021/acs.biomac.7b01301 
Preamble: In Chapters Two and Three, fundamental understanding of IAPP species at the 
biological interface was achieved through characterizing the aggregation pathway and 
exploring the interactions of pathway species with natively circulating biomolecules in both 
model and complex environments. Drawing specifically on knowledge gained in Chapter 
Two, wherein fibrillating IAPP species demonstrated significantly higher cytotoxicity in vitro 
cytotoxicity in primary human endothelial cells comparative to mature IAPP amyloid (Aim 
1A), with the charge of model interactors providing no significant differentiation to the toxic 
effect of oligomeric IAPP (Aim 1B), Chapter Four highlights the application of ‘fibrillization 
promotion’ as an effective strategy for mitigating IAPP-associated cytotoxicity. Herein, the 
design and synthesis of a polymer-based anti-amyloidosis agent – poly (2-hydroxyl ethyl 
acrylate) ‘PHEA’ stars – is described (Aim 2), comprised of aromatic moieties and terminal 
hydroxyls towards the sequestration of fibrillating IAPP, and carrying a neutral charge to 
enhance its biocompatibility. The cytoprotective capabilities of the PHEA stars against IAPP 
in vitro and ex vivo are demonstrated, through sequestering toxic intermediate IAPP species 
and enhancing their fibrillization towards noncytotoxic mature IAPP amyloid – presenting a 
new agent and new strategy towards mitigating IAPP pathologies in T2D.  
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ABSTRACT: Protein aggregation into amyloid fibrils is a
ubiquitous phenomenon across the spectrum of neuro-
degenerative disorders and type 2 diabetes. A common
strategy against amyloidogenesis is to minimize the popula-
tions of toxic oligomers and protofibrils by inhibiting protein
aggregation with small molecules or nanoparticles. However,
melanin synthesis in nature is realized by accelerated protein
fibrillation to circumvent accumulation of toxic intermediates.
Accordingly, we designed and demonstrated the use of star-
shaped poly(2-hydroxyethyl acrylate) (PHEA) nanostructures for promoting aggregation while ameliorating the toxicity of
human islet amyloid polypeptide (IAPP), the peptide involved in glycemic control and the pathology of type 2 diabetes. The
binding of PHEA elevated the β-sheet content in IAPP aggregates while rendering a new morphology of “stelliform” amyloids
originating from the polymers. Atomistic molecular dynamics simulations revealed that the PHEA arms served as rodlike
scaffolds for IAPP binding and subsequently accelerated IAPP aggregation by increased local peptide concentration. The tertiary
structure of the star nanoparticles was found to be essential for driving the specific interactions required to impel the accelerated
IAPP aggregation. This study sheds new light on the structure−toxicity relationship of IAPP and points to the potential of
exploiting star polymers as a new class of therapeutic agents against amyloidogenesis.
■ INTRODUCTION
Type 2 diabetes mellitus (T2D) is a metabolic disease affecting
5% of the global population.1 Extensive research indicates that a
major factor in the development and pathogenesis of T2D is
dysfunction of human islet amyloid polypeptide (IAPP), a 37-
residue peptide cosecreted with insulin from pancreatic β-cells,
which undergoes fibrillization to form amyloid plaques found in
90% of T2D patients.2,3 The toxic IAPP aggregation products
are also capable of eliciting systemic damage in T2D patients
with evidence of cardiac dysfunction and neurological deficits
mediated by IAPP deposition increasing the burden of
disease.4,5 Concordantly, there is a crucial need for the
development of treatment agents that are capable of mitigating
IAPP-associated toxicity in vivo to reduce the morbidity of T2D
and prevent its development in prediabetics.
Aggregation inhibition with the use of small molecules as
well as metal, carbon, and polymeric nanoparticles (NPs)6−9
has been a major strategy against amyloid-mediated toxicity.
Polymeric NPs, specifically, have been explored as protein
aggregation inhibitors utilizing their tunable hydrophobicity as
well as their capacity for initiating H-bonding.10−13 For
example, antiprion activity has been demonstrated by
phosphorus dendrimers, maltose-based glycodendrimers
(mPPI), poly(propyleneimine) PPI, and poly(ethylenimine)
hyperbranched polymers.12−20 Of the myriad forms of
polymeric NPs, hyperbranched polymers and dendrimers
have demonstrated strong efficacies as antiamyloid
agents,11,12,15,21−26 though anti-IAPP applications have only
been explored recently. PPI glycodendrimers and lysine
dendrimers have been investigated as anti-Aβ aggregation
agents,22,23 and hyperbranched PEG-based polymers with a
dopamine moiety were found to be capable of inhibiting α-
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synuclein (αS) aggregation.11 Anionic low-generation den-
drimers have been shown to modulate IAPP fibrillization and
associated toxicity,24 and inhibition of IAPP fibrillization and
toxicity in vitro and ex vivo has recently been demonstrated by
our team with OH-terminated polyamidoamine dendrimers
(PAMAM-OH).26
Curiously, the amyloidogenesis of melanocyte protein
Pmel17 in the human system is entirely nonpathogenic.27
The rapid fibrillization of Pmel17, which transitions from
monomeric form to mature amyloid fibrils within 3 s, is a
cytoprotective mechanism, namely, through reducing the half-
life of toxic intermediate products (i.e., oligomers and
protofibrils) to favor the formation of nontoxic, mature
amyloid fibrils. Indeed, this effect has been shown to extend
to pathogenic amyloids; mice overexpressing the Alzheimer’s-
related amyloidogenic peptide amyloid-β (Aβ) with the “Artic”
mutation, correlated with the acceleration of Aβ fibrillization,
demonstrated higher plaque loading with lower or negligible
impact on behavioral function comparable to mice expressing
wild-type Aβ.28 The concept of fibrillization promotion, rather
than inhibition, thus provides a biomimetic and perhaps
counterintuitive strategy in the mitigation of amyloid
cytotoxicity.
Amyloid aggregation promotion as a strategy for mitigating
cytotoxicity has thus far only been reported for a selected few
small molecules.29,30 Specifically, high-throughput screening
identified aromatic small molecules capable of promoting Aβ
fibrillization to provide a cytoprotective effect, including the
orcein-related molecule O430 and the compound 2002-H20.29
Small molecules, however, are imperfectly suited as antiamyloid
agents when utilized without modifications to confer targeting
specificity, as they frequently display molecular promiscuity.31
In this study, we synthesized and demonstrated the use of
poly(2-hydroxyethyl acrylate) (PHEA) star polymers32 as an
anti-IAPP agent capable of cytoprotective rescue of pancreatic
β-cells through the promotion of amyloid aggregation. PHEA
stars were synthesized using a reversible addition-fragmentation
chain-transfer (RAFT) polymerization methodology and were
designed to mimic the chemistry of small molecule aggregation
promoters through the incorporation of hydroxyls and aromatic
rings via the RAFT end-groups.33,34 The PHEA stars were
weakly negatively charged, each possessing a hydrodynamic size
of ∼12 nm and containing on average 12 arms. Through
biophysical characterizations, we demonstrated a significant,
positive correlation between amyloid aggregation promotion
induced by PHEA stars and reduction in IAPP-mediated
cytotoxicity both in vitro and ex vivo and additionally identified
a new amyloid morphology, named “stelliform amyloids”,
formed by coaggregation of IAPP and PHEA stars at a molar
ratio of 5:1. Atomistic discrete molecular dynamics (DMD)35
simulations revealed that the PHEA stars possessed rigid arms
different from the porous and micellar PAMAM dendrimers.
The rodlike arms served as linear scaffolds for IAPP binding
and further accelerated the nucleation of β-sheet aggregates by
increased local peptide concentration. Each arm of the PHEA
stars could nucleate the fibrillization of IAPP resulting in the
stelliform amyloid morphology. This study opens the door to
the design and application of a new class of agents against
amyloid diseases.
■ EXPERIMENTAL METHODS
Materials. 2-Hydroxyethyl acrylate (HEA) was purchased from
Sigma-Aldrich and deinhibited by passing through a column of basic
alumina. S,S′-Dibenzyl trithiocarbonate (DBTC), N,N′-methylenebis-
(acrylamide) (X) was purchased from Sigma-Aldrich. Azobis-
(isobutyronitrile) (AIBN) was purified by recrystallization from
methanol before use. Dimethyl sulfoxide (DMSO) was purchased
from Merck Millipore and used as received. Human islet amyloid
polypeptide monomers (IAPP; disulfide bridge: 2−7; MW: 3,906; 37
residue: KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY;
>95% pure by HPLC) were obtained in lyophilized powder form
from AnaSpec and were made up to a 200 μM stock immediately prior
to an experiment or allowed to fibrillate at 25 °C for >5 days to
produce mature IAPP amyloids. All materials were weighed out on a
Cubis MSE balance (Sartorius, 0.01 mg resolution) and made up fresh
in Milli-Q water prior to experiments unless otherwise specified.
Thioflavin T (ThT) dye (Sigma-Aldrich) was prepared fresh for each
experiment at a 250 μM stock solution. Propidium iodide (PI) dye
stock solution (1 mg/mL in water) was stored at −20 °C.
RAFT Synthesis of Poly(2-hydroxyl ethyl acrylate) Stars.
Synthesis of Poly(2-hydroxyl ethyl acrylate) (p(HEA)) Homopol-
ymer. Three homopolymers of PHEA were prepared by RAFT
polymerization with molecular weights of 4,000, 8,000, and 16 000 g/
mol.
The synthesis of PHEA 1 (Mn = 4000 g/mol) was carried out using
the following stoichiometry: [DBTC]:[HEA]:[AIBN] = 1:38:0.1. In
brief, 2-hydroxyethyl acrylate (4.00 g, 0.034 mol), DBTC RAFT agent
(0.27 g, 9.12 × 10−4 mol), AIBN (15.4 × 10−3 g, 9.38 × 10−5 mol),
and DMSO (26 mL) were placed into a 50 mL round-bottom flask
equipped with a magnetic stirrer bar and capped with a rubber septum.
The reaction mixture was deoxygenated for 1 h at 0 °C with nitrogen
gas. The sealed deoxygenated reaction vessel was placed in a preheated
oil bath at 70 °C, and the polymerization was carried for 4 h with
stirring. Polymerization was stopped by placing the vessel in ice to
cool. The product was analyzed by 1H NMR and GPC. The monomer
conversion was determined to be approximately 88% by NMR, thus
resulting in a Mw of 4141 g/mol. By integrating the peaks associated
with the benzyl group (7.1−7.4 ppm) and the hydroxyl group in the
PHEA repeat unit (δ = 4.8 ppm), the Mn(NMR) is found to be 4374 g/
mol. Per arm, there are 32 units of the PHEA monomer because the
homopolymer constitutes 64 units. The molecular number and
polydispersity index were determined by GPC to be 8,276 Mn and
1.30, respectively.
A similar procedure was employed for the synthesis of PHEA 2 (Mn
= 8000 g/mol) using the following stoichiometry: [DBTC]:[HEA]:
[AIBN] = 1:75:0.1. In brief, 2-hydroxyethyl acrylate (4.00 g, 0.034
mol), DBTC RAFT agent (0.13 g, 4.58 × 10−4 mol), AIBN (7.2 ×
10−3 g, 4.38 × 10−5 mol), and DMSO (26 mL) were placed into a 50
mL round-bottom flask equipped with a magnetic stirrer bar and
capped with a rubber septum. The reaction mixture was deoxygenated
for 1 h at 0 °C with nitrogen gas. The sealed deoxygenated reaction
vessel was placed in a preheated oil bath at 70 °C, and the
polymerization was carried for 4 h with stirring. Polymerization was
stopped by placing the vessel in ice to cool. The product was analyzed
by 1H NMR and GPC. The monomer conversion was determined to
be approximately 85% by NMR, thus resulting in an Mn(th) of 7716 g/
mol. By integrating the peaks associated with the benzyl group (7.1−
7.4 ppm) and the hydroxyl group in the PHEA repeat unit (δ = 4.8
ppm), the Mn(NMR) is found to be 7729 g/mol. Per arm, there are 32
units of the PHEA monomer; therefore, the homopolymer constitutes
64 units. The molecular number and polydispersity index were
determined by GPC to be 14,688 Mn and 1.24, respectively.
The synthesis of PHEA 3 (Mn = 16,000 g/mol) was achieved in a
similar method as above using the following stoichiometry: [DBTC]:
[HEA]:[AIBN] = 1:144:0.1. In brief, 2-hydroxyethyl acrylate (4.91 g,
0.042 mol), DBTC RAFT agent (0.085 g, 2.93 × 10−4 mol), AIBN (5
× 10−3 g, 3.04 × 10−5 mol), and DMSO (32 mL) were placed into a
50 mL round-bottom flask equipped with a magnetic stirrer bar and
capped with a rubber septum. The reaction mixture was deoxygenated
for 1 h at 0 °C with nitrogen gas. The sealed deoxygenated reaction
vessel was placed in a preheated oil bath at 70 °C and the
polymerization was carried for 6 h with stirring. Polymerization was
terminated by placing the vessel in ice to cool. The product was
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analyzed by 1H NMR and GPC. The monomer conversion was
determined to be approximately 91% by NMR, thus resulting in an Mw
of 15,553 g/mol. By integrating the peaks associated with the benzyl
group (7.1−7.4 ppm) and the hydroxyl group in the PHEA repeat unit
(δ = 4.8 ppm), the Mn(NMR) is found to be 15,961 g/mol. The
molecular number and polydispersity index were determined by GPC
to be 26,676 Mn and 1.24, respectively.
Synthesis of PHEA Star. A typical PHEA star synthesis is carried
out as follows. The synthesis of PHEA star was conducted using the
following stoichiometry: [PHEA 2]:[HEA]:[AIBN]:[XL] =
1:12:0.4:18. In brief, a 1.86 mL aliquot (250 mg equivalent) of the
solution above, AIBN (1.60 mg, 9.76 × 10−3 mol), methylene
bis(acrylamide) (77.09 mg, 0.5 mol), and 930 μL of DMSO were
added into a glass vial equipped with a magnetic stirrer bar and capped
with a rubber septum. The reaction mixture was deoxygenated for 30
min at 0 °C with nitrogen gas. The sealed deoxygenated reaction
vessel was placed in a preheated oil bath at 70 °C, and the
polymerization was carried for 24 h with stirring. Polymerization was
terminated by placing the vessel in ice to cool.
Purification was conducted by dialysis against water with a MWCO
of 14 kDa for 2 days and then lyophilization. The product was
analyzed by GPC, and its molecular number and polydispersity index
were determined to be 85,500 Mn and 2.18, respectively. With the
given Mn values from GPC, the star was calculated to have 12 arms. In
theory, the molecular weight of the star is 47,295 g/mol.
Analysis Methods. 1H Nuclear Magnetic Resonance Spectros-
copy. 1H NMR spectra were recorded at 400 MHz on a Bruker
UltraShield 400 MHz spectrometer running Bruker Topspin, version
1.3. Spectra were recorded in DMSO-d6.
Gel Permeation Chromatography (GPC). GPC was performed
using a Shimadzu modular system comprised of a SIL-20AD automatic
injector, a RID-10A differential refractive-index detector, and a 50 ×
7.8 mm guard column followed by three KF-805L columns (300 × 8
mm, bead size: 10 μm, pore size maximum: 5000 Å). N,N′
-Dimethylacetamide (DMAc, HPLC grade, 0.03% w/v LiBr) at 50
°C was used for the analysis with a flow rate of 1 mL min−1. Samples
were filtered through 0.45 μm PTFE filters before injection. The GPC
calibration was performed with narrow-polydispersity polystyrene
standards ranging from 500 to 2 × 106 g mol−1.
Dynamic Light Scattering (DLS). DLS was carried out on a
Malvern Zetasizer Nano ZS Series running DTS software (laser, 4
mW, λ = 633; angle 173°). The polydispersity index (PDI) used to
describe the average diameters and size distribution of prepared stars
was determined via a cumulants analysis of the measured intensity
autocorrelation function using the DTS software. Samples were filtered
using 0.45 μm PTFE syringe filter to remove contaminants/dust prior
to the measurement.
Fourier Transform Infrared Spectroscopy-Attenuated Total
Reflectance (FTIR-ATR). ATR-FTIR measurements were performed
using a Shimadzu IRTracer 100 Fourier transform infrared
spectrometer with a GladiATR 10 single reflection ATR accessory.
Spectra were obtained in the midinfrared region of 4000−600 cm−1 at
a resolution of 8 cm−1 (512 scans) and analyzed using LabSolution IR
software.
Thioflavin T Assay. Aliquots of IAPP (final concentration of 25
μM), ThT dye (25 μM), and PHEA polymers (5, 1, or 0.2 μM) were
added directly to wells of a black/clear bottom 96-well plate (Costar)
and mixed thoroughly. The final well volume of 100 μL was made up
using Milli-Q water where necessary. The plate was run on a
Flexstation 3 plate reader (Molecular Devices) with samples excited at
440 nm and the emission read at 485 nm every 5 min for a total of 14
h (169 readings).
Circular Dichroism (CD) Spectroscopy. Experiments were
performed on a Chirascan CD spectrometer (Applied Photophysics)
with spectra read from 190 to 260 nm. Prior to sample loading, a
baseline with no cuvette was run. Then, 300 μL of 25 μM IAPP in
Milli-Q water alone or in the presence of PHEA (5 μM), was placed in
a cuvette with a 0.1 cm path length, and CD analysis was run at 0, 2.5,
and 24 h time points. Between samples, cuvettes were washed more
than 5× with distilled water. Reads are an average of 3 repeats. Raw
data were offset to zero and normalized against the spectra of Milli-Q
water for IAPP spectra and against PHEA alone for IAPP-PHEA mixed
samples. Data were then deconvoluted with CDNN software to give a
final relative percentage content of secondary structure.
Transmission Electron Microscopy. Samples were placed in
Eppendorf tubes at a final IAPP concentration of 25 μM and
incubated for 24 h at 25 °C. An aliquot (10 μL) was placed on 400
mesh carbon-coated Formvar copper grids (ProSciTech) that were
glow-discharged to promote hydrophilicity. Samples were adsorbed
onto the grid for 60 s, then drawn off using filter paper. Grids were
washed twice with 10 μL of Milli-Q water. Five microliters of 1%
uranyl acetate (in water) was then utilized to twice-stain grids by
touching one droplet and immediately drawing the stain off, and then
placing the grid atop the second droplet to stain for 15 s. TEM images
were obtained on a Tecnai TF20 transmission electron microscope
(FEI) with an UltraScan 1000 (2k × 2k) CCD camera (Gatan).
Determination of Fibril Morphology. Fibril tracking and analysis
were performed with software FiberApp36 to determine the
morphology and mesoscopic parameters of persistence length (λ)
and contour length (l) of IAPP fibrils. FiberApp was developed from
statistical physics and enables structural analysis of tubular and
macromolecular objects. The persistence length λ reflects the stiffness
of a polymer and is mathematically defined via the bond correlation
function (BCF) in 3D or 2D as the length over which angular
correlations in the tangential direction decrease by a factor of e.37
Here, the λ values of IAPP fibrils were estimated using the BCF, mean-
squared end-to-end distance (MSED), and mean-squared midpoint
displacement (MSMD) methods and presented as averaged values
determined by the three methods. The contour length corresponds to
the end-to-end length of a polymer along its physical contour. The
values of persistence length and contour length were obtained based
on statistical analysis of 1,243 fibrils.
Cell Culture and Viability. Insulin-producing βTC6 cells (ATCC)
were cultured in complete DMEM (ATCC; 15% FBS). For viability
assays, a 96-well plate (Corning) was coated with 70 μL of 70 μg/mL
poly-D-lysine for >10 min; then, the wells were washed 3× in 100 μL
of HBSS. Cells were seeded at a density of ∼50,000 cells per well in
200 μL of complete media and incubated at 37 °C in 5% CO2 for 3
days. Fresh IAPP or mature IAPP amyloids (200 μM stock) were
preincubated together with PHEA polymers (40, 8, and 3.2 μM
stocks) at a 1:1 v/v ratio for 24 h at room temperature. Prior to cell
treatment, the media was aspirated, and the wells were washed 1× in
100 μL of HBSS. One micromolar propidium iodide (PI; AnaSpec)
dye solution was made up in complete media containing 1% penicillin/
streptomycin, and 150 μL aliquots were added to each of the wells.
The cells were returned to the incubator for 30 min to equilibrate with
the dye solution. Each sample treatment was then added to the wells in
triplicate, in addition to an IAPP control made up fresh immediately
prior to adding to the wells (final well volume: 200 μL; final IAPP
concentration: 25 μM). The cells were imaged on an Operetta High-
Content Imaging System (PerkinElmer) utilizing standardized
excitation/emission settings for PI with images of five areas within a
single well taken every hour for 24 h. Total cell counts per well were
estimated using phase-contrast mapping within sampling areas. Cell
death over time was expressed as %PI positive cells within the total cell
count.
Ex Vivo Viability. C57BL/6 male mice (age 10−14-week-old) were
maintained at St. Vincent’s Institute animal care facility on a 12 h light-
dark cycle in a temperature-controlled room and obtained food and
water ad libitum. Uniformly sized mouse islets from C57BL/6 mice
were handpicked into 1 cm Petri dishes containing 1 mL of 25 μM
hIAPP, 5 μM PHEA, or a combination of both and cultured for 48 h.
At the end of the culture period, islets were dispersed with trypsin and
resuspended in 250 μL of hypotonic buffer containing 50 μg/mL of
propidium iodide, which stained nuclear DNA. The cells were
analyzed by fluorescence-activated cell sorter (FACS), and cell death
was identified by their subdiploid DNA content as previously
described.38 The study was conducted at St Vincent’s Institute
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Statistics. Where applicable, data were analyzed using a one-way
ANOVA with Tukey’s correction with p < 0.05 considered statistically
significant.
DMD Simulations and Simulation Setup. DMD is a special form
of molecular dynamics, where discrete step functions instead of
continuous functions are used to mimic the constraints. The united-
atom representation with all polar hydrogen and heavy atoms was used
to model IAPPs and PHEA polymers. An adapted Medusa force field35
with an implicit solvent model was used to describe the nonbonded
interatomic interactions, including van der Waals, solvation, hydrogen
bonding, and electrostatic terms. The Debye−Hückel approximation
with a Debye length of ∼10 Å was applied to capture the screened
electrostatic interactions. Anderson’s thermostat was used to maintain
temperature, which was fixed at 300 K in all simulations. The DMD
program is freely available to academic users at the Molecules in
Action Web site (http://moleculesinaction.com), and all simulation
parameters can be obtained upon request. Given the stochastic nature
in the dynamics of a multimolecular system and the nucleation-
dependent aggregation kinetics, we performed multiple independent
long simulations with different starting configurations (e.g., random-
ized velocities, intermolecular distances and orientations) to ensure
sufficient sampling and avoid potential bias associated with initial
configurations. Thermodynamic and kinetic prosperities were then
obtained by analyzing all the independent runs for each molecular
system.
All the PHEA model structures were constructed with the
Avogadro39 molecular builder software and energy minimized with
the MMFF94s force field.40 MedusaScore,41 an extension of the
Medusa force field,42 was adapted to model the polymers in addition
to IAPP. The MedusaScore was parametrized on a large set of ligands
and was transferrable to different molecular systems. The predictive
power of MedusaScore has been validated in various benchmark
studies, including recent community structure−activity resource
(CSAR) blind ligand−receptor docking prediction exercises.43,44
For each 2-arm PHEA (Figure S3A), we performed 20 independent
simulations at 300 K with different starting configurations. Each
independent simulation lasted 300 ns, and thus, an accumulative 6 μs
simulation was obtained for the polymer model. We used the last half
of all simulations and computed the radius of gyration (Rg) values of
the modeled polymers. For the 8-arm PHEA (Figure S3C), 20
Figure 1. Synthesis and preliminary characterization of PHEA stars via RAFT polymerization. (A) Synthesis of PHEA stars using a symmetrical
RAFT agent. (B) Gel permeation chromatograms for the PHEA arm (orange) and star (gray). (C) Size distribution by number from dynamic light
scattering for PHEA stars.
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independent simulations were performed at 300 K with different
starting configurations, each of which lasted 200 ns.
The IAPP (PDB ID: 2L86) structure was obtained from PDB.
Counterions Cl1− were introduced to achieve a neutral charge
condition if necessary. For systems containing six IAPPs (with and
without a 6-arm PHEA as shown in Figure S3B), the peptide
concentration was maintained by fixing the dimension of the
simulation box as 120 Å, and periodic boundary conditions were
applied. For each of the multimolecular systems, 20 independent
simulations starting with different intermolecular distances and
orientations were performed at 300 K, and each run lasted 100 ns.
Secondary structure analyses were performed using the dictionary
secondary structure of protein (DSSP) method. For each snapshot
structure, the secondary structure, such as helix, sheet, coil, and turn,
for each residue was obtained. An empirical sigmoidal function
= − + − − +y I I k t t I( )/(1 exp( ( )))max min 0 min (1)
was adopted to fit the kinetics of the total number of residues in the β-
sheet conformation, where fitting parameters A, B, t0, and k
corresponded to the max and min values of aggregation, the midpoint
time of aggregation, and the elongation rate, respectively. The lag time
was determined as
= −t t k2/lag 0
In the potential of mean force (PMF) calculation, normalized
sigmoidal function, Qfibrillization = 1/(1+ exp(−k(t − t0))), was used
to quantify the extent of fibrillization for each independent simulation.
For a given snapshot, the distribution of IAPP oligomers was analyzed,
where any two peptides interconnected by at least one intermolecular
heavy atom contact (the cutoff of 0.55 nm) was defined to belong to
an oligomer. The size of an oligomer, noligomer, was defined by the
number of IAPP peptides forming the aggregate. The two-dimensional
PMF (or effective free energy) was computed according to
= −K T P n QPMF ln ( , )B oligomer fibrillization (2)
where KB is the Boltzmann constant, T corresponds to the simulation
temperature 300 K, and P(noligomer, Qfibrillization) is the probability of
finding a peptide in an oligomer with the size of noligomer and the extent
of fibrillization Qfibrillization at the time.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of PHEA Stars. PHEA
stars were synthesized with constitutive elements similar to
those observed in small molecule aggregation promoters.
Specifically, the stars were designed to incorporate aromatic
rings (on the distal end of the star arms) and pendant hydroxyls
on the side chains of the arms. To actualize these design
criteria, we chose S,S′-dibenzyltrithiocarbonate (DBTC) as the
RAFT agent and employed in the polymerization of 2-
hydroxethyl acrylate (Figure 1A). The polymerization was
carried out in DMSO at 70 °C using AIBN as the radical
initiator. To provide a suitable array of arm molecular weights
for the subsequent star formation, we first synthesized three
PHEA homopolymers with varying degrees of polymerization
to approximately 80−90% conversion. The Mn of the
homopolymers was determined via 1H NMR analysis by
comparing integrals for the peaks at δ = 7.1−7.4 ppm
(corresponding to the benzyl leaving group of the RAFT
agent, i.e., the polymer end group) with the integral for the
peak corresponding to the hydroxyl group in the PHEA repeat
unit (δ = 4.8 ppm). These results agreed well with the
theoretical molecular weights determined from the ratio of the
monomer to RAFT agent (see Table S1). GPC analysis of the
various PHEA homopolymers revealed unimodal peaks with an
acceptable dispersity of 1.2−1.3, although of course the Mn
values from GPC differed considerably from those determined
above due to calibration of the GPC against polystyrene
standards.
The solutions of arm polymers (including unreacted HEA)
were then used to form the PHEA stars by adding
methylene(bis(acrylamide)) at various molar ratios and a
further aliquot of AIBN and then heating at 70 °C for 24 h.
Samples were taken periodically during the reaction with a
further aliquot of AIBN injected after 12 h. A library of different
core-cross-linked stars were formed with the results tabulated in
Table S2. It is worth noting that the symmetrical nature of the
RAFT agent used (DBTC) gave rise to arm polymer in which
the thiocarbonylthio moiety was in the middle of the polymer
chain. As such, subsequent introduction of the difunctional
monomer (to facilitate formation of the cross-linked core)
occurred in the middle of the arm polymer. The consequence
of this architecture is that the final stars had an arm molecular
weight that was half the value of the starting “arm” material. To
our knowledge, this is the first time that this approach (i.e., the
use of a symmetrical RAFT agent such as DBTC) has been
employed in the preparation of star polymers. The resulting star
polymers were analyzed by gel permeation chromatography to
identify the best conditions for star formation. For all systems,
there was a shift in the GPC trace for the PHEA homopolymer
to shorter retention times, reflecting successful chain extension,
with this shift typically most pronounced for higher ratios of
cross-linker to polymer (Figure 1B; for [P]:[M]:[X] = 1:12:16
and Mn(GPC)
arm = 14,500 g mol−1). Estimation of approximate
arm number could be made by dividing the Mn(GPC) for the star
by 1/2 Mn(GPC) for the arm. The factor of 1/2 is introduced
into this equation because of the symmetry of the chain transfer
agent, as noted above. For each series, higher ratios of cross-
linker led to higher arm numbers. It should be noted, however,
that these values are only indicative of the true arm number due
to the potential underestimation of molecular weight when
applying GPC to hyperbranched materials. Moreover, the
indicative nature of this approach is clearly evident in that the
arm number should only ever be even given the symmetrical
nature of the RAFT agent. Importantly, the use of DBTC as a
RAFT agent for the HEA polymerization and the subsequent
formation of star from DBTC-derived PHEA led to somewhat
broader molecular weight distributions than have been achieved
using other star polymer systems.33 Although there is evidence
in the literature that varying the solvent for star formation can
improve arm incorporation and minimize polydispersity,33 the
scope for optimization of the current system was limited by the
intransigent solubility of the stars in most solvents: we observed
that the resulting materials were soluble only in DMSO or
water. Even then, some difficulty was encountered when
attempting to redisperse the star in these solvents after
lyophilization. We attribute this effect to hydrogen bonding
between the arms and as such allowed a minimum of 72 h for
the polymer to equilibrate after redispersing in water.
From the GPC data, the star with the clearest shift to higher
molecular weight accompanied by maintenance of a relatively
unimodal molecular weight distribution was observed for the
system where Mn(GPC)
arm = 14,500 g mol−1 and [P]:[M]:[X] =
1:12:16. Analysis of this material by dynamic light scattering
(Figure 1C) indicated a number-average hydrodynamic radius
of approximately 9.8 nm for the stars when dispersed in water,
which is consistent with other water-soluble star polymers
synthesized via RAFT polymerization. Spectroscopic evaluation
of these same PHEA stars was also conducted with the
recorded 1H NMR spectrum confirming that the desired
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aromatic and hydroxyl moieties were present in the final
polymer structure (Figure 2A). FTIR analysis before and after
star formation provided further evidence of the high proportion
of OH groups in the star in addition to demonstrating the
presence of the methylene(bis(acrylamide)) linking groups in
the star core (Figure 2B). Specifically, the emergence of peaks
associated with amide CO stretch (1,645 cm−1) and amide
N−H stretch (1,547 cm−1) provide clear evidence that the
amide cross-linking groups were successfully incorporated into
the star structure.
Modulation of IAPP Fibrillization by PHEA Polymers.
The thioflavin T (ThT) assay utilizes the amyloidophilic ThT
dye to provide a measurement of both the extent and kinetics
of amyloid fibrillization over time. The control IAPP was shown
to fibrillate with a nucleation period of ∼2 h followed by an
exponential period of ∼12 h before reaching saturation at 14 h
(Figure 3A). Incubation of PHEA with IAPP at molar
concentrations of 1:5 and 1:25 had a promotional effect on
IAPP fibrillization both for the star NPs and their constituent
subunits, referred to as “arms” (Figure S1), with the largest
increase in ThT fluorescence observed at 1:5. Following the
trend of increasing fibrillization with increasing concentration
of PHEA, the energetically unfavorable nucleation period was
also shown to significantly decrease with increasing concen-
tration of PHEA, falling from ∼3.5 h in the IAPP control to less
than 30 min with the highest concentration of PHEA. The
reduction in IAPP lag time was also demonstrated through
circular dichroism (CD) spectroscopy, wherein the presence of
PHEA to IAPP at the 1:5 ratio notably promoted the
amyloidogenic conversion of random coil content to β-sheets
(Figures 3B and Figure S3). Over 2.5 h, β-sheet conversion in
IAPP:PHEA 1:5 (25−34%) was 2.3× more rapid than that of
IAPP alone (29−33%), and concordantly, IAPP contained 25%
higher β-sheet content at 24 h in the presence of PHEA (55%)
compared to that of IAPP alone (44%). This shift in
prototypical IAPP aggregation kinetics, in addition to the
Figure 2. (A) 1H NMR spectrum of purified PHEA stars recorded in DMSO-d6 (400 MHz). The phenyl end-groups are evident at δ = 7.2−7.3 ppm.
(B) FTIR-ATR spectra for the PHEA arm (orange) and star (blue).
Figure 3. (A) ThT fluorescence of IAPP in the presence of PHEA stars over 24 h. Dotted lines represent sigmoidal curve fitting (least-squares fit);
error is SEM (n = 2). (B) Secondary structure transitions in IAPP mapped by circular dichroism at 0, 2.5, and 24 h time points. Lines are intended to
guide the eye. The concentration of IAPP in all experiments is 25 μM.
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promotion of fibrillization overall, presents a case for rapid local
sequestration of IAPP seeds by PHEA, whereas a lower PHEA
concentration ratio would isolate aggregation “hotspots” and
thus limit fibril elongation but promote coaggregation and thus
enhance fibrillization at higher PHEA concentrations.
Stelliform Amyloid Formation and Amyloid Remodel-
ing by PHEA. Transmission electron microscopy (TEM)
imaging complemented ThT and CD analyses for fibrillating
IAPP, allowing further analysis of persistence and contour
length of amyloid fibrils generated after 24 h in aqueous
solution in the presence and absence of PHEA. After 24 h,
IAPP amyloidogenesis reached the saturation phase, and long,
semiflexible fibrils can be observed by TEM with some shorter
species still present (Figure 4A). Once fibril elongation and 3D
cross-linking occurred at >5 days of amyloidogenesis, amyloids
formed in-solution hydrogels, and generally, shorter species
were absent.45 “Stelliform amyloids” were observed when
PHEA was incubated with IAPP at a 1:5 molar ratio (Figure
4A). These amyloids were characterized by a central nucleation
“core”, ranging from smaller clusters of 50−150 nm to
micrometers in diameter. Fibrils of low persistence (average
of 891.9 nm compared with that of 2,885 ± 60 nm for the IAPP
control6,7) and contour length (<1,350 nm) were additionally
observed radiating out from the core, forming the full stelliform
structure of ∼0.5 μm in diameter for smaller cores and
micrometers in diameter for larger cores with some macro-
scopic aggregates visible in solution (Figure 4A).
With lower concentrations of PHEA, the fibrillization
products generally trended toward matching the structural
morphology of IAPP alone (Figure 4B). IAPP amyloid fibrils
with significantly reduced contour lengths were produced with
increasing PHEA concentration, indicating polyphenol-like
stabilization of growing fibrils through H-bonding; hydrophobic
and π−π interactions by PHEA46 may have terminated fibril
elongation, resulting in a fibril population with predominantly
low contour lengths. As fibril elongation is mediated by amyloid
seeds, the extensive exponential periods observed in the ThT
assay (Figure 3A) could be indicative of the PHEA-IAPP
Figure 4. (A) TEM imaging of fibrillating IAPP (IAPP) and mature IAPP amyloids (Amyloid) in the presence and absence of PHEA stars after 24 h
incubation. Stelliform amyloids are seen at PHEA:IAPP 1:5. Scale = 100 nm. (B) Structural analysis of amyloid fibrils visualized in (A). IAPP
concentration in all experiments is 25 μM.
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complex rapidly sequestering amyloid seeds to render large
populations of shorter fibrils, thus depleting the available
seeding population to perform elongation. Interestingly,
however, the shift in fibril persistence length induced by stars
versus arms varied greatly; stars induced softer fibrils, whereas
those generated in the presence of arms were notably stiffer.
The capacity of PHEA to remodel IAPP amyloids was also
assessed after coincubation for 24 h and demonstrated a similar
trend. Amyloids were reduced in persistence length upon
exposure to PHEA stars with the most notable effect seen as
soft, limp fibrils “bundling” at PHEA:IAPP 1:5. Conversely,
negligible amyloid remodeling was observed in the presence of
PHEA arms. These observations could be attributed to the
differences in morphology and surface physicochemical proper-
ties of the stars and arms.
Stelliform IAPP Amyloids Are Cytoprotective in Vitro
and ex Vivo. IAPP-mediated cytotoxicity was assessed in an
insulin-producing pancreatic β-cell line over a 24 h period
(Figure 5A) and ex vivo in mouse islets after 48 h (Figure 5B).
PHEA stars were completely biocompatible at all concen-
trations tested. In vitro, IAPP alone typically began to induce
cytotoxicity at ∼6 h post-treatment with cell death progressing
exponentially up until the 20−24 h mark to an end point
toxicity value of 38%. When incubated with IAPP at 1:25 and
1:125 ratios, PHEA stars delayed the progression of IAPP
toxicity by ∼2 h and reduced IAPP-mediated toxicity overall
compared to that of the IAPP control. However, with PHEA
stars:IAPP 1:5, cells were 94% viable after 24 h, and low levels
of cytotoxicity were only observed more than 15 h post
incubation. Per their aromatic structures,31 PHEA arms
successfully mitigated IAPP cytotoxicity at all concentrations
tested (Figure S2). The cytoprotective capacity of PHEA stars
at a 1:5 ratio to IAPP was also seen ex vivo, where mouse islets
treated with IAPP in the presence of the highest concentration
of PHEA stars (∼8% relative cell death) demonstrated a
significant reduction in toxicity compared to that of IAPP alone
(64%) after 48 h treatment.
The near-complete mitigation in IAPP-mediated toxicity
observed both in vitro and ex vivo when IAPP was incubated
with PHEA stars correlated with stelliform amyloid formation
at the PHEA:IAPP ratio of 1:5, as observed in Figure 4A. Likely
the key to the cytoprotective nature of stelliform amyloids lies
first in their mechanism of formation and additionally in terms
of the structure itself. First, oligomeric and low-order
protofibrillar species formed as intermediates during IAPP
amyloidogenesis are widely considered responsible for the
majority of IAPP-mediated cytotoxicity3 with far less toxicity
attributed to amyloid fibrils.28 Seeding of IAPP oligomers to the
plasma membrane of pancreatic β-cells resulted in destabiliza-
tion of the lipid membrane47 and cell death through “lipid
stripping”.48 Concordantly, rapid sequestering of toxic low-
order IAPP species through the formation of stelliform
amyloids mediated by PHEA stars would reduce the local
population of toxic species around the cell membrane.
Lastly, it has also been purported that the cytotoxicity of
amyloid fibrils is mediated through partitioning of the
hydrophobic, stiff fibrils into the cell membrane, leading to
disruption of the membrane and production of radical oxygen
species.47,49,50 The structure of stelliform amyloids, with a
compact core and vastly reduced persistence and contour
Figure 5. Protective effect of PHEA stars against IAPP-mediated cytotoxicity in pancreatic beta cells and islets. (A) In vitro cytotoxicity of fibrillating
IAPP and mature IAPP amyloids in the presence and absence of PHEA in βTC6 cells over 24 h. Error = SEM (n = 3). (B) Ex vivo cytotoxicity of
fibrillating IAPP and IAPP:PHEA at a 1:5 molar ratio in mouse islets after 48 h incubation. Flow cytometry data is representative of n = 5
experiments summarized in the graph. Error = SEM. ****p < 0.0001, one-way ANOVA with Tukey’s correction.
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lengths of radiating fibrils, would be unable to effectively
partition into the lipid bilayer51 and would also readily form a
protein corona52,53 within the extracellular milieu through
electrostatic and hydrophobic interactions, further limiting any
amyloid contact with cellular membranes. Importantly, we
observed complete protection from IAPP-induced cell death in
primary mouse islets treated with PHEA stars at a 1:5 molar
ratio.
In Silico Study of the PHEA Polymers and Their
Effects on IAPP Aggregation. To complement the
experimental findings, we examined the structural properties
of model PHEA polymers by all-atom DMD simulations35 (see
Experimental Methods, ESI). We first studied 2-arm PHEA
polymers (Figure S4A) with different degrees of polymerization
(DP) and computed their corresponding radius of gyration
(Rg) values (Figure S4D). The data revealed an approximately
linear dependence of Rg on DP (up to ∼40, Figure S4D),
suggesting that the PHEA stars were rather rigid. The
autocorrelation analysis of the polymer dynamics in simulations
resulted in an estimated Kuhn length of ∼36 repeats (Figure
Figure 6. Aggregation free energy landscapes of IAPP without (A) and with (B) PHEA. Three-dimensional potentials of mean force (PMFs) with
respect to IAPP oligomer size and degree of fibrillization were used to derive the free energy landscapes in front and top views. Snapshot structures
with IAPP in cartoon and PHEA polymers in stick are shown to illustrate the basins and saddles of the energy landscapes.
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S4E), which confirmed the rigidity of the PHEA stars. To
evaluate the structure and dynamics of PHEA stars, we studied
an 8-arm PHEA model with molecular compositions
resembling the experimental data (Figure S4C) in all-atom
DMD simulations. A rapid equilibration in terms of Rg and
ellipticity was observed (Figure S4F). The average Rg of the 8-
arm polymer was ∼4.5 nm, consistent with the experimentally
measured hydrodynamic radii (Figure 1C). The high ellipticity
value (close to 1) suggests that the 8-arm PHEA adopted a
nonspherical conformation as illustrated by a typical snapshot
3D structure (e.g., the inset of Figure S4F). Because of the high
rigidity, the interactions between different arms were found
minimal beyond the covalent cross-links. Therefore, the all-
atom DMD simulations revealed a different morphology of the
PHEA stars from that of PAMAM dendrimers, which feature a
micellar structure with a porous interior for encapsulating small
molecules54 and IAPP peptides.26
To provide molecular insight into IAPP-PHEA binding and
its effect on IAPP self-association, we performed DMD
simulations on two sets of molecular systems with one
containing six IAPP peptides along with a 6-arm PHEA
polymer (Figure S4B) and another of six peptides alone as the
control (see Experimental Methods in the ESI). We first
monitored the size of the largest IAPP aggregates as a function
of the simulation time and noted that the presence of PHEA
indeed accelerated the self-association clusters in silico (Figure
S5A). On the basis of the last 25 ns of the simulations where
the largest IAPP aggregates were formed, the binding
probability of each IAPP residue with PHEA indicated that
both polar and nonpolar residues of IAPP could bind PHEA,
though hydrophobic and aromatic residues showed a slightly
higher binding propensity (Figure S5B). As a result, the
generally nonspecific attraction between IAPP and PHEA led to
the accumulation of peptides on PHEA arms, and the increased
local peptide concentration accelerated the aggregation of IAPP
consistently with a previous coarse-grained computational
study.55 We also examined the secondary structure of IAPPs
and their binding with PHEA along the simulation trajectories
(e.g., one of the independent simulations shown in Figure S6),
where a general trend of correlation between IAPP-PHEA
binding and β-sheet formation in IAPP aggregates was evident.
Comparison-average secondary structure contents of the last 25
ns between simulations with and without PHEA (Figure S5C
and D) suggest that the PHEA binding did not significantly
affect the structures of the aggregates other than accelerated
IAPP self-association (Figure S4A).
Next, the kinetics of β-sheet formation were analyzed for
simulations of IAPPs with and without PHEA. The total
number of IAPP residues in the β-sheet conformation followed
sigmoidal-like kinetics (i.e., a lag phase followed by rapid
growth/elongation and saturation as in Figure S7A) resembling
experimentally observed aggregation kinetics. As expected for a
nucleation-dependent process, each of the independent
simulations rendered different lag times and elongation rates
(see the fitting analysis in the Experimental Methods). The
presence of PHEA significantly reduced the aggregation lag
times (Figure S7B) and broadened the distribution of the
elongation rates (Figure S7C), further suggesting that PHEA
binding accelerated the nucleation of β-sheet aggregates and
induced heterogeneity in β-sheet elongation, respectively.
Additionally, the potential of mean force (PMF; i.e., the
effective aggregate free energy landscape in Figure 6) was
computed with respect to the size of IAPP oligomers, noligomer,
and the degree of IAPP fibrillization, Qfibrillization (for details, see
Experimental Methods in the ESI). Two major basins, one
corresponding to IAPP monomers and oligomers with little β-
sheets (e.g., highlighted as a,b in Figure 6A and α,β in Figure
6B) and the other denoting IAPP aggregates with high amounts
of β-sheets (e.g., e,f in Figure 6A and ε,ζ in Figure 6B), could be
observed in both IAPP aggregation free energy landscapes with
and without PHEA stars. The saddles connecting the two
basins corresponded to the aggregation pathways and
intermediates (e.g., c,d in Figure 6A and γ,δ in Figure 6B).
The presence of the PHEA star rendered the non-β-sheet basin
shallower and the saddle broader (i.e., more pathways/routes
toward final β-rich aggregates in Figure 6B), which accounted
for the reduced aggregation lag times (Figure S7B) and
heterogeneity in β-sheet elongation rates (Figure S7C).
■ CONCLUSIONS
Inspired by the mechanism of Pmel17 amyloidogenesis, we
have developed and established that a polymeric star nano-
particle, PHEA, is capable of mitigating IAPP-mediated toxicity
both in vitro and ex vivo through PHEA-mediated promotion
of IAPP aggregation and formation of a unique “stelliform
amyloid” morphology. Unlike the porous PAMAM-OH
dendrimers, which inhibited both IAPP aggregation and toxicity
through peptide sequestration,26 the possession of high rigidity,
long arm length, and rich aromatic moieties of PHEA stars
facilitated rapid deposition and fibrillization of IAPP monomers
into amyloid fibrils. Subsequently, this amyloid structure
elicited significantly reduced toxicity in a pancreatic β-cell line
and in mouse islets when compared to the long, semiflexible
fibrils typically formed by IAPP. In light of the observation that
both PHEA arms and stars elevated IAPP aggregation while
mitigating IAPP toxicity, whereas dendrimers and hyper-
branched polymers have been predominantly shown in the
literature to inhibit amyloid protein aggregation,11−18,21−26 it is
plausible to attribute the observed phenomenon chiefly to the
structure and physicochemical properties of the PHEA.
Nonetheless, the shape/morphology of the PHEA stars was
likely a contributing factor in the IAPP-PHEA interaction, as
reflected by the difference in IAPP fibril stiffness associated with
PHEA stars versus arms. Shortening of the oligomer lifetime
through amyloid aggregation promotion represents a potential
strategy to be explored within the larger context of amyloid
research,56 although implementation of such a strategy in vivo
remains a challenge given the stochastic nature of secondary
nucleation of amyloid proteins. This study has shed new light
on the IAPP structure−toxicity relationship and presents an
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A.; Wang, Q.; Schmidt, M. R.; Lurz, R.; Anwyl, R.; Schnoegl, S.;
Fan̈drich, M.; Frank, R. F.; Reif, B.; Günther, S.; Walsh, D. M.;
Wanker, E. E. Small-molecule conversion of toxic oligomers to
nontoxic β-sheet−rich amyloid fibrils. Nat. Chem. Biol. 2011, 8, 93−
101.
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Chapter Five: Conclusions 
Amyloidosis, with its associated dysfunction and damage elicited to cells and tissues, is a 
hallmark of a number of metabolic and neurodegenerative diseases.1 IAPP represents an 
understudied amyloidogenic peptide, with regards to its role within the scope of pancreatic β-
cell failure and T2D, and beyond, as circulating toxic amyloid species translocate throughout 
the body.2 This thesis presented a streamlined biophysical, biochemical and toxicological 
investigation of IAPP amyloidosis, IAPP species and their biological interactions within a 
tightly controlled in vitro environment towards facilitating the design of effective anti-
amyloidosis agents. 
For assigning the associated toxicity of amyloidosis to specific pathway species, the ‘oligomer 
hypothesis’ has long been the reigning paradigm.3 This theory was largely based on studies 
that pertained to well-characterized amyloid species such as Aβ and αSyn, whose slow 
fibrillization kinetics allow for more facile gating and consequent interrogation of discrete 
monomeric, oligomeric and fibrillar populations comparative to the more rapidly aggregating 
IAPP. Characterization of IAPP amyloid pathway species in Chapter Two of this thesis 
ultimately aligned with this hypothesis: through the effective in vitro isolation of intermediate 
populations sans foreign stabilizing agents, early intermediate species elicited significantly 
higher cytotoxicity in primary cells comparative to mature amyloid species. Additionally, in 
Chapter Two, the impact of model proteins, lipids and ultrasmall membranes on amyloidosis 
was explored in vitro, demonstrating that each biomolecule had the capacity to modulate IAPP 
fibrillization, yet was unable to ameliorate its intrinsic cytotoxicity. IAPP interfaced with these 
model interactors adopted novel morphologies, potentiating an array of native states of IAPP 
in a biological milieu, beyond the fibrillar structures prepared in absence of interacting factors 
in vitro. Notably, utilizing model proteins with analogous molecular weights and globular 
structures yet opposing charges further demonstrated that the charge of IAPP interactors is not 
a major factor impacting the cytotoxic behavior of the net positively charged IAPP fibrillating 
species. Consequently, targeting cationic anti-amyloid agents towards net negatively charged 
amyloids, such as Aβ and αSyn, may not be a strategy worth the cytotoxic trade-off of the 
cationic agents themselves.  
Thus, two key findings in Chapter Two – the cytotoxicity of fibrillating IAPP species nullified 
upon reaching the mature amyloid state, and the charges of interactors of fibrillating IAPP 
having negligible impact on toxicity mitigation therein – advised the strategic approach utilized 
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for mitigation of IAPP-mediated cytotoxicity: firstly, enhancing the fibrillization of IAPP in 
order to reduce the half-life of toxic intermediate species through their incorporation into 
nontoxic mature amyloid morphologies, and, secondly, providing a neutral charge to the anti-
amyloid agent utilized for superior biocompatibility. Consequently, the novel synthesis of 
‘PHEA’ star polymers, designed with aromatic moieties and terminal hydroxyls to maximize 
amyloid contact, resulted in near-complete mitigation of IAPP-associated cytotoxicity in 
pancreatic β-cells in vitro and in mouse islets ex vivo. Indeed, cytotoxic IAPP intermediates 
were effectively scavenged from solution by PHEA stars, with the hydrophobic-hydrophobic 
IAPP-star binding interactions effectively facilitated by the rigid star polymer branches – 
further providing a scaffold for rapid fibril propagation to generate nontoxic ‘stelliform’ 
amyloids. Thus, the promotion of IAPP fibrillization presents an alternative approach to 
aggregation inhibition as the predominant anti-IAPP amyloidosis strategy currently employed. 
Moreover, star polymers represent an inexpensive and highly tunable class of nanomaterials to 
be further explored as anti-amyloidosis agents. 
Though this thesis has established fibrillating IAPP species as the major cytotoxic species 
within the amyloid pathway, and thus through bypassing the toxic intermediate stage via a 
‘fibrillization promotion’ strategy IAPP-associated toxicity can be effectively ameliorated, the 
role of the amyloid fibril in IAPP pathogenesis should not be so readily discarded. While the 
‘oligomer hypothesis’ can be correlated to cell dysfunction and tissue damage in the short term, 
the research presented herein underscores a longer-term impact of amyloid plaques in vivo. The 
binding and remodeling of IAPP amyloid fibrils by model proteins in Chapter Two conferred 
a protective effect against low-level amyloid-associated cytotoxicity in vitro – again, regardless 
of charge – demonstrated, for the first time, the potential biological impact of an ‘amyloid-
protein corona.’ Association of a single protein, from either a native or foreign source, has been 
demonstrated to significantly impact a nanomaterial’s biological properties. For example, Aβ 
amyloid fibril association with human immunodeficiency virus envelope protein Tat highly 
enhances the neurotoxicity of the complex beyond the capacity of either ligand alone4 – 
accordingly, endogenously available clusterin, upregulated in AD, has been found enriched in 
Aβ plaques in vivo, impacting both their localization and pathology.5 Upon further 
interrogation within a complex biological milieu in Chapter Three, it was revealed through 
biophysical and proteomic analyses that IAPP amyloid forms extensive, nonuniform coronae 
of proteins involved in a number of biological niches, with fibrillar conformations and 
structural plasticity pertaining to the most favorable binders while no trends were observed in 
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the charge or hydrophobicity of coronal proteins, further supporting observations in Chapter 
Two. Remarkably, variation in coronal proteins was seen when amyloids were exposed to the 
same media under different biological conditions, implicating both a complex architecture of 
permanent-transient interactors, and, consequently, a unique biological identity conferred to 
plaques localized to different areas of the body.  
The ‘amyloid-protein corona’ studies in Chapters Two and Three support in vivo observations 
of protein enrichment to amyloid plaques, giving detailed context to clinical profiles. 
Chaperone proteins and proteolytic species found highly localized to amyloid deposits, as 
observed in Liao and colleagues’ proteomic analysis of plaque-enriched proteins within AD 
patient tissues,6 could present a failed mechanism by the body to disaggregate amyloid fibrils, 
resulting instead in a highly proteolytic environment that likely impacts the local populations 
of circulating protein. Such ‘downstream’ effects would not be observed in short term studies, 
where the duration of experiments is within hours to days in vitro. Indeed, rodents, as the 
predominant animal model utilized in in vivo studies of amyloidosis, have a lifespan of a mere 
couple of years, whereas insoluble amyloid plaques in human tissues can exist for decades.7 
Thus, amyloid fibrils and plaques – and, by extension, the amyloid-protein corona – may 
facilitate long term pathologic effect, through disruption and destabilization of the local 
microenvironment rather than the short-term damage elicited by fibrillating species. Thus, 
Chapter Four’s landmark, comprehensive study into amyloid-protein corona formation in 
biological media provides new insights into potential amyloid interactors, illustrating a 
complex network of proteins with diverse functions that exemplify how pancreatic and extra-
pancreatic amyloid plaques exposed to different environmental conditions and localized 
concentrations of circulating protein may impact numerous biological processes in the 
surrounding milieu. With further quantitative in vitro analyses complemented by isolation and 
characterization of plaques from different in vivo microenvironments, new pathologies of 
amyloid-associated disease could be revealed. For example, the role of the protein corona on 
the cross-seeding of amyloid proteins, and the metal hosting capacity of amyloid fibrils and 
plaques modulated by their dynamic protein corona, are two significant topics to be fully 
elucidated towards understanding the implications of amyloidogenesis in in vivo environments.  
Lastly, in a follow-up study to elucidating the amyloid-protein corona in complex environs in 
Chapter Three, the candidate sought to characterize the protein corona of IAPP oligomers in 
biological media. Curiously, intermediate species of IAPP displayed very little binding to the 
oligomer-specific antibody A11 when exposure occurred under flow conditions. This data is 
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not presented herein as the results were inconclusive, but serve to underline a key point: that 
the breadth of conformations adopted by IAPP intermediate species, such as the novel 
biannular oligomer morphology identified herein, highlight challenges inherent in the 
application of (largely conformation-specific)8 targeting antibodies against amyloidosis. The 
recent revival of Biogen’s anti-amyloidosis drug towards FDA approval and commercialization 
has reinvigorated interest in the amyloid hypothesis of pathogenicity in neurodegenerative and 
metabolic disease: however, our understanding into amyloid-associated pathologies needs to 
continue to evolve in order for treatment strategies to effectively combat amyloid diseases. 
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Supporting Information  
Model Interactions of Amyloid Protein Species 
Figure S1: A. Two morphologies of off-pathway IAPP amyloid particulates identified during 
intermediate profiling study. Scale = 100 nm. B. Example of a biannular oligomer identified in 
oligomerized Aβ1-42 after incubation for 24 h at 4 oC in aqueous solution. Scale = 50 nm. 
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Figure S2: Cytotoxicity (as determined by PI positive cells) and ThT fluorescence intensity in the 
absence (A) and presence (B) of ThT dye in HUVECs treated with IAPP species (25 µM) over 24 
h, n = 3. Unpaired t-tests using Holm-Sidak’s method for multiple comparisons confirmed no 
significant difference in endpoint cytotoxicity between ThT+ and ThT- sets, and all ThT+ datasets 
were significantly differentiated from ThT- datasets by ThT fluorescence intensity. 
 
 
Figure S3: Fluorescence microscopy of IAPP species (25 µM), either fresh (lyophilized 
monomers), oligos (low order aggregates, pre-incubated for 4 h in aqueous at 4 oC) and amyloid 
(mature fibrils, pre-incubated for ~2 weeks in aqueous at room temperature) added to HUVECs and 
immediately imaged (T = 0 h). Propidium iodide (PI) indicates dead cell nuclei, and the formation 
of β-rich amyloid is probed by thioflavin T (ThT). Scale = 100 µm. 
Figure S4: TEM image of LPC micelles at 2 mM (>CMC). Scale = 10 nm. Reproduced by permission 
of the PCCP Owner Societies from Xing, Y.; Pilkington, E. H.; Wang, M.; Nowell, C. J.; Käkinen, 
A.; Sun, Y.; Wang, B.; Davis, T. P.; Ding, F.; Ke, P. C., Lysophosphatidylcholine modulates the 
aggregation of human islet amyloid polypeptide. Phys. Chem. Chem. Phys. 2017, 19, 30627-30635. 
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Blue-Native polyacrylamide gel electrophoresis (PAGE) and analysis 
Blue-Native PAGE allowed the examination of protein complex formation between IAPP 
amyloid fibrils (0.9 mg/mL) and FBS, which were pre-incubated (2% and 50%, in water) for 
2 h. A 15 µL aliquot of each sample was mixed 1:1 with chilled Native PAGE sample buffer 
and then transferred to 4-15% gel (Mini-Protean TGX). Blue-Native PAGE was performed at 
4
 °
C, pH = 8.3, using sequential buffer steps: briefly, Tris/Glycine buffer was supplemented
with Coomassie Brilliant Blue G-250 at either 0.02%, 0.002%, or omitted, with each buffer 
solution utilized in this order during the assay. For protein binding capacity a densitometry of 
lane and well band profiles, normalized against background intensity, was performed using 
ImageJ. The experiment was performed and analyzed in duplicate. All materials listed were 
sourced from BioRad. 
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Circular dichroism spectroscopy 
Structural changes in bovine serum albumin (BSA), the most abundant protein species in FBS 
medium, were examined upon its interaction with IAPP fibrils. BSA (0.1 mg/mL) was 
exposed to IAPP amyloid fibrils (>1 week old, in water; 0.1 mg/mL) for 24 h, and CD spectra 
of BSA were obtained at different timepoints using an Aviv Model 410 CD 
spectrophotometer (Biomedical, Inc.). The spectra were recorded over a wavelength range of 
190~260 nm, with a 1 nm step size and a scanning speed of 15 nm/min at room temperature. 
The final spectra were baseline-corrected and IAPP amyloid spectrum subtracted where 






nLC-MS/MS queries, analysis and informatics 
Analysis of nLC-MS/MS data utilizing custom R
1
 scripts are as follows. Briefly, the
combined summary files were used to plot peptide sequences identified, ratio of MS/MS 
identified: MS/MS submitted, the number of peaks and the mass standard deviation (ppm). 
Protein ID, protein name, gene name and sequence were extracted from the same uniprot 
reference proteome (Bos taurus) using seqinr
2
 and primary sequence dependent
characteristics (GRAVY, pI, MW) were calculated using alakazam.
3
 Using protein ID as a
key, the calculated values were extracted from the processed reference proteome for those 
proteins identified in the combined proteinGroup file to create a final data frame for plotting 
of identification overlaps and trends in GRAVY/pI/MW as well as amino acid composition of 
sequences for selected protein subsets (seqinr, ggplot2, gridExtra, VennDiagram).
4-6 
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Figure S1. Protein deposition on IAPP-functionalized QCM sensors (n = 4), as illustrated by 
frequency and dissipation shift after sequential introduction of IAPP amyloid and FBS. 
Figure S2. Optimization of centrifugal capture (CC) methodology, demonstrating retention 
of IAPP amyloid on high molecular weight filter surface (n = 6) with only low nonspecific 
binding of FBS proteins (n = 8) after four spin-wash cycles. Error is SEM. 
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Figure S3a. LC-MS/MS chromatogram showing correlation between independent 
experiments of A (n = 6, overlaid). 
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Figure S3b. LC-MS/MS chromatogram showing correlation between independent 
experiments of AF (n = 6, overlaid). 
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Figure S3c. LC-MS/MS chromatogram showing correlation between independent 
experiments of F (n = 12, overlaid). 
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Figure S3d. LC-MS/MS chromatogram showing correlation between independent 
experiments of AE (n = 4, overlaid). 
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Figure S3e. LC-MS/MS chromatogram showing correlation between independent 
experiments of EF (n = 4, overlaid). 
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Figure S4. MS/MS spectrum identified by MaxQuant/Andromeda as a tryptic peptide of 
Amyloid Precursor Protein (APP, uniprot IDs Q28053, A4_BOVIN). Full sequence with 
identified peptide emphasized in red is overlaid onto the MaxQuant annotated MS/MS 
visualization, including matched fragments for the b and y ion series. 
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Figure S5a. The GRAVY/molecular weight (MW) relationships for unique amyloid-corona 
proteins (yellow markers, unique AF) and unique FBS-only proteins (blue markers, F) for CC 
experiments. All plots are overlaid onto the Bos taurus proteome background (gray). Top: 
points labelled are GRAVY ≤ -1.5 and ≥ 0.5, MW ≥ 6E+5. Bottom: points labelled are
GRAVY (same as top) and MW ≥ 2E+5.
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Figure S5b. The GRAVY/molecular weight (MW) relationships for unique amyloid-corona 
proteins (yellow markers, AE) and unique control proteins (blue markers, EF) for QCM 
experiments (AE/EF) are shown. Plots are overlaid onto the Bos taurus proteome background 
(gray). Top: points labelled are outside ranges GRAVY ≥ 0.5 and GRAVY ≤ -1.5, MW ≥ 
6E
+5





Figure S6: Blue-Native PAGE demonstrates sequestering of FBS proteins through corona 
formation on IAPP amyloids. A: Representative gel of n = 2 runs. Lanes are as follows: (1) 
IAPP amyloid (0.9 mg/mL); (2) IAPP amyloid + 2% FBS; (3) 2% FBS control; (4) IAPP 
amyloid + 10% FBS; (5) 10% FBS control. B: Intensity profile of sample wells. C: 
Comparison of maximum intensity measured within sample lanes (excluding well); error = 
SEM.  
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Figure S7. Centrifugal capture (CC) method amyloid and serum corona (AF) STRING 
(string-db.org)
7,8
 protein network (molecular action) produced using database and
experimental interactors, with a minimum interaction score of 0.400 and no additional 
interactors, against a whole Bos taurus genome background. Enrichment analysis and 
molecular action legends are included, in addition to predicted action effects – positive 
(arrowhead), negative (endpoint line), unspecified (endpoint circle). 
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Figure S8a. Enriched gene ontology (GO) molecular function terms for proteins identified in 
AE (red) and AF (blue) experiments. Enrichment was performed using the STRING resource. 
Plot was generated in R using ggplot (see scatter plot code below). Point size is scaled to 
log(false.discovery.rate). 
Figure S8b. Enriched gene ontology (GO) KEGG pathway terms for proteins identified in 
AE (red) and AF (blue) experiments. Enrichment was performed using the STRING resource. 
Plot was generated in R using ggplot (see scatter plot code below). Point size is scaled to 
log(false.discovery.rate). 
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Figure S8c. Enriched gene ontology (GO) molecular functions for Catalytic activity (green) 
and hydrolase activity (blue), with the KEGG pathway for Complement and coagulation 
cascades also included (red). Enrichment was performed using the STRING resource. 
Enrichment analysis and molecular action legends are included, in addition to predicted 
action effects – positive (arrowhead), negative (endpoint line), unspecified (endpoint circle). 
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Figure S9. Structures of top AF proteins. Alpha-actinin-4 (a), protein AMBP (b), 
neuropilin in either close (c) or open state (d), laminin subunit alpha 2 (orange) (e), SPARC 
(f), and IQ motif containing GTPase activating protein 1 (g) are shown in cartoon 
representations. The missing structures are represented by dashed lines. 
Figure S10. Structures of top AE proteins. Serum albumin (a), thrombospondin-1 (b), and 
cartilage oligomeric matrix protein (c) are shown in cartoon representations. The missing 





















Figure S11. Structures of top FBS proteins. Serum albumin (a), cataytic domain of the 
Cone cGMP-specific 3′,5′-cyclic phosphodiesterase alpha-subunit (b), alpha-1-antiproteinase (c), 
Lactoperoxidase (d), NADH-ubiquinone oxido-reductase 75 from CroyEM (e), Hemiferrin 
(f), and thrombin domain of Prothrombin (g) are shown in cartoon representations. 
Fig S12. (A) CD spectra of BSA (0.1 mg/mL) upon its interaction with IAPP amyloid fibrils 
(0.1 mg/mL) after 15 min of incubation. (B) Changing intensity of CD spectra of BSA 
interacting with IAPP fibrils at 208 nm (one of two signature peaks of alpha helices) up to 24 




Table S1. Top 10 FBS proteins from a LC-MS method9. 






themeTIFF <- theme(legend.text = element_text(size = 16), legend.title=element_text(size=16), 
axis.title=element_text(size=18), 
    legend.key.size = unit(0.8, "cm"), axis.text.x = element_text(face = "bold", angle=0, vjust=0.5, 
size=16), 
    axis.text.y = element_text(face = "bold", size=16), title = element_text(size=18)) 
###molecular function### 
AE <- read.csv("./input/string_input/2018_03_05_STRING_analysis/AE/enrichment.Function.tsv", sep="\t", 
header=TRUE) 
AF <- read.csv("./input/string_input/2018_03_05_STRING_analysis/AF/enrichment.Function.tsv", sep="\t", 
header=TRUE) 
###KEGG### 
# FBS protein name PDB ID # Residues Net Charge 





Catalytic domain: 3JWQ (536-
855) 
855 -23
3 Alpha-1-antiproteinase 1QLP (46-415) (human: 72%) 416 -9
4 Plasminogen N/A 812 5 
5 Lactoperoxidase 2IPS (118-712) 712 11 




5O31 (24-727) 727 -9
8 Alpha-2-HS-glycoprotein N/A 359 -13
9 Hemiferrin 1H76 (1-215) (rat: 70%) 216 2 
10 Prothrombin 





AE_kegg <- read.csv("./input/string_input/2018_03_05_STRING_analysis/AE/enrichment.KEGG.tsv", sep="\t", 
header=TRUE) 
AF_kegg <- read.csv("./input/string_input/2018_03_05_STRING_analysis/AF/enrichment.KEGG.tsv", sep="\t", 
header=TRUE) 
###select columns and add ID### 
AE <- AE[,c(2,3,4)] 
AF <- AF[,c(2,3,4)] 
AE$ID <- "AE" 
AF$ID <- "AF" 
AE_kegg <- AE_kegg[,c(2,3,4)] 
AF_kegg <- AF_kegg[,c(2,3,4)] 
AE_kegg$ID <- "AE" 
AF_kegg$ID <- "AF" 
###combined dataframes### 
COMB <- rbind(AE, AF) 
COMB_kegg <- rbind(AE_kegg, AF_kegg) 
###plots### 
tiff("./output/molecular_function_figure.tiff", height=900, width=1500) 
a <- ggplot(COMB) 
a <- a + geom_point(aes(reorder(pathway.description, observed.gene.count), observed.gene.count, 
   size = log(false.discovery.rate), fill=ID), pch=21, alpha=0.5) 
a <- a + theme_bw() + themeTIFF + coord_flip()  
a <- a + xlab("Pathway description") + ylab("Observed gene count") 
plot(a) 
dev.off() 
tiff("./output/kegg_figure.tiff", height=700, width=1500) 
a <- ggplot(COMB_kegg) 
a <- a + geom_point(aes(reorder(pathway.description, observed.gene.count), observed.gene.count, 
   size = log(false.discovery.rate), fill=ID), pch=21, alpha=0.5) 
a <- a + theme_bw() + themeTIFF + coord_flip() 
a <- a + xlab("Pathway description") + ylab("Observed gene count") 
plot(a) 
dev.off() 
MaxQuant parameter set 1 (Bos taurus): 
Parameter Value 
Version 1.6.0.16 
User name GUSTAFOJ 
Machine name IOR268965 
Date of writing 02/19/2018 12:26:38 
Fixed modifications Carbamidomethyl (C) 
Include contaminants TRUE 
PSM FDR 0.01 
Protein FDR 0.01 
Site FDR 0.01 
Use Normalized Ratios For Occupancy TRUE 
Min. peptide Length 5 
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Min. score for unmodified peptides 0 
Min. score for modified peptides 40 
Min. delta score for unmodified peptides 0 
Min. delta score for modified peptides 6 
Min. unique peptides 0 
Min. razor peptides 1 
Min. peptides 1 
Use only unmodified peptides and TRUE 
Modifications included in protein quantification Oxidation (M);Acetyl (Protein N-term) 
Peptides used for protein quantification Razor 
Discard unmodified counterpart peptides TRUE 
Label min. ratio count 2 
Use delta score FALSE 
iBAQ FALSE 
iBAQ log fit FALSE 
Match between runs FALSE 
Find dependent peptides FALSE 
Fasta file E:\MaxQuant\fasta_files\2018_02_19\UP000009136_9913.fasta 
Decoy mode revert 
Include contaminants TRUE 
Advanced ratios TRUE 
Fixed andromeda index folder 
Temporary folder 
Combined folder location 
Second peptides TRUE 
Stabilize large LFQ ratios TRUE 
Separate LFQ in parameter groups FALSE 
Require MS/MS for LFQ comparisons TRUE 
Calculate peak properties FALSE 
Main search max. combinations 200 
Advanced site intensities TRUE 
LFQ norm for sites and peptides FALSE 
Write msScans table TRUE 
Write msmsScans table TRUE 
Write ms3Scans table TRUE 
Write allPeptides table TRUE 
Write mzRange table TRUE 
Write pasefMsmsScans table TRUE 
Write accumulatedPasefMsmsScans table TRUE 
Max. peptide mass [Da] 4600 
Min. peptide length for unspecific search 8 
Max. peptide length for unspecific search 25 
Razor protein FDR TRUE 
Disable MD5 FALSE 
Max mods in site table 3 
Match unidentified features FALSE 
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MS/MS tol. (FTMS) 20 ppm 
Top MS/MS peaks per Da interval. (FTMS) 12 
Da interval. (FTMS) 100 
MS/MS deisotoping (FTMS) TRUE 
MS/MS deisotoping tolerance (FTMS) 7 
MS/MS deisotoping tolerance unit (FTMS) ppm 
MS/MS higher charges (FTMS) TRUE 
MS/MS water loss (FTMS) TRUE 
MS/MS ammonia loss (FTMS) TRUE 
MS/MS dependent losses (FTMS) TRUE 
MS/MS recalibration (FTMS) FALSE 
MS/MS tol. (ITMS) 0.5 Da 
Top MS/MS peaks per Da interval. (ITMS) 8 
Da interval. (ITMS) 100 
MS/MS deisotoping (ITMS) FALSE 
MS/MS deisotoping tolerance (ITMS) 0.15 
MS/MS deisotoping tolerance unit (ITMS) Da 
MS/MS higher charges (ITMS) TRUE 
MS/MS water loss (ITMS) TRUE 
MS/MS ammonia loss (ITMS) TRUE 
MS/MS dependent losses (ITMS) TRUE 
MS/MS recalibration (ITMS) FALSE 
MS/MS tol. (TOF) 40 ppm 
Top MS/MS peaks per Da interval. (TOF) 10 
Da interval. (TOF) 100 
MS/MS deisotoping (TOF) TRUE 
MS/MS deisotoping tolerance (TOF) 0.01 
MS/MS deisotoping tolerance unit (TOF) Da 
MS/MS higher charges (TOF) TRUE 
MS/MS water loss (TOF) TRUE 
MS/MS ammonia loss (TOF) TRUE 
MS/MS dependent losses (TOF) TRUE 
MS/MS recalibration (TOF) FALSE 
MS/MS tol. (Unknown) 0.5 Da 
Top MS/MS peaks per Da interval. (Unknown) 8 
Da interval. (Unknown) 100 
MS/MS deisotoping (Unknown) FALSE 
MS/MS deisotoping tolerance (Unknown) 0.15 
MS/MS deisotoping tolerance unit (Unknown) Da 
MS/MS higher charges (Unknown) TRUE 
MS/MS water loss (Unknown) TRUE 
MS/MS ammonia loss (Unknown) TRUE 
MS/MS dependent losses (Unknown) TRUE 
MS/MS recalibration (Unknown) FALSE 
Site tables Oxidation (M)Sites.txt 
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MaxQuant parameter set 2 (Homo sapiens): 
Parameter Value 
Version 1.6.0.16 
User name GUSTAFOJ 
Machine name IOR268965 
Date of writing 02/27/2018 14:12:31 
Fixed modifications Carbamidomethyl (C) 
Include contaminants TRUE 
PSM FDR 0.01 
Protein FDR 0.01 
Site FDR 0.01 
Use Normalized Ratios For Occupancy TRUE 
Min. peptide Length 5 
Min. score for unmodified peptides 0 
Min. score for modified peptides 40 
Min. delta score for unmodified peptides 0 
Min. delta score for modified peptides 6 
Min. unique peptides 0 
Min. razor peptides 1 
Min. peptides 1 
Use only unmodified peptides and TRUE 
Modifications included in protein quantification Oxidation (M);Acetyl (Protein N-term) 
Peptides used for protein quantification Razor 
Discard unmodified counterpart peptides TRUE 
Label min. ratio count 2 
Use delta score FALSE 
iBAQ FALSE 
iBAQ log fit FALSE 
Match between runs FALSE 
Find dependent peptides FALSE 
Fasta file E:\MaxQuant\fasta_files\2018_02_23\UP000005640_9606.fasta 
Decoy mode revert 
Include contaminants TRUE 
Advanced ratios TRUE 
Fixed andromeda index folder 
Temporary folder 
Combined folder location 
Second peptides TRUE 
Stabilize large LFQ ratios TRUE 
Separate LFQ in parameter groups FALSE 
Require MS/MS for LFQ comparisons TRUE 
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Calculate peak properties FALSE 
Main search max. combinations 200 
Advanced site intensities TRUE 
LFQ norm for sites and peptides FALSE 
Write msScans table TRUE 
Write msmsScans table TRUE 
Write ms3Scans table TRUE 
Write allPeptides table TRUE 
Write mzRange table TRUE 
Write pasefMsmsScans table TRUE 
Write accumulatedPasefMsmsScans table TRUE 
Max. peptide mass [Da] 4600 
Min. peptide length for unspecific search 8 
Max. peptide length for unspecific search 25 
Razor protein FDR TRUE 
Disable MD5 FALSE 
Max mods in site table 3 
Match unidentified features FALSE 
MS/MS tol. (FTMS) 20 ppm 
Top MS/MS peaks per Da interval. (FTMS) 12 
Da interval. (FTMS) 100 
MS/MS deisotoping (FTMS) TRUE 
MS/MS deisotoping tolerance (FTMS) 7 
MS/MS deisotoping tolerance unit (FTMS) ppm 
MS/MS higher charges (FTMS) TRUE 
MS/MS water loss (FTMS) TRUE 
MS/MS ammonia loss (FTMS) TRUE 
MS/MS dependent losses (FTMS) TRUE 
MS/MS recalibration (FTMS) FALSE 
MS/MS tol. (ITMS) 0.5 Da 
Top MS/MS peaks per Da interval. (ITMS) 8 
Da interval. (ITMS) 100 
MS/MS deisotoping (ITMS) FALSE 
MS/MS deisotoping tolerance (ITMS) 0.15 
MS/MS deisotoping tolerance unit (ITMS) Da 
MS/MS higher charges (ITMS) TRUE 
MS/MS water loss (ITMS) TRUE 
MS/MS ammonia loss (ITMS) TRUE 
MS/MS dependent losses (ITMS) TRUE 
MS/MS recalibration (ITMS) FALSE 
MS/MS tol. (TOF) 40 ppm 
Top MS/MS peaks per Da interval. (TOF) 10 
Da interval. (TOF) 100 
MS/MS deisotoping (TOF) TRUE 
MS/MS deisotoping tolerance (TOF) 0.01 
MS/MS deisotoping tolerance unit (TOF) Da 
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MS/MS higher charges (TOF) TRUE 
MS/MS water loss (TOF) TRUE 
MS/MS ammonia loss (TOF) TRUE 
MS/MS dependent losses (TOF) TRUE 
MS/MS recalibration (TOF) FALSE 
MS/MS tol. (Unknown) 0.5 Da 
Top MS/MS peaks per Da interval. (Unknown) 8 
Da interval. (Unknown) 100 
MS/MS deisotoping (Unknown) FALSE 
MS/MS deisotoping tolerance (Unknown) 0.15 
MS/MS deisotoping tolerance unit (Unknown) Da 
MS/MS higher charges (Unknown) TRUE 
MS/MS water loss (Unknown) TRUE 
MS/MS ammonia loss (Unknown) TRUE 
MS/MS dependent losses (Unknown) TRUE 
MS/MS recalibration (Unknown) FALSE 
Site tables Oxidation (M)Sites.txt 
Complete script used to generate Rmarkdown html report: 
--- 
title: "Supplementary data analysis methods - Profiling the Serum Protein Corona of Human IAPP Amyloid" 
output:  
  html_document: 
    toc: true 
    toc_depth: 2 
    toc_float: TRUE 
    self_contained: no 



























```{r setup, include=FALSE} 
###global settings### 
knitr::opts_chunk$set(echo = TRUE, cache=TRUE, autodep=TRUE) 
###installs### 
#install.packages(c("ggplot2", "gridExtra",  
#    "seqinr", "alakazam", 
#    "sqldf", "stringr",  
#    "ggrepel", "VennDiagram", 















The specific research questions addressed in this document include: 
1. Which proteins can be identified in IAPP amyloid-coronae formed in-solution (CC method)?
2. Which proteins can be identified in IAPP amyloid-coronae formed under micro-flow conditions (QCM method)?
3. What is the difference in protein corona composition for CC and QCM methods?
4. What proteins are identified for IAPP amyloid-only experiments?
This document details the combination, processing and presentation of summary and proteinGroup text files 
resulting from MaxQuant Andromeda database queries, where each experiment type was pooled to maximise 
identifications (e.g. A1+A2+A3....). 
Independent searches were performed for selected experiment types (e.g. AF, F). 
*** 
# Analysis notes 
## General information 
- MaxQuant peptide identifications used a fasta file containing all reviewed and unreviewed Bos taurus entries
available as a reference proteome @
ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/reference_proteomes/Eukaryota/.
- Reviewed + unreviewed entries included to maximise identifications.
- Database 1: UP000009136_9913.fasta dated 21/12/2017.
- Database 2: UP000005640_9606.fasta dated 21/12/2017.
- Whole proteome of Bos taurus as plotting background (same fasta as above, 9136_9913).
- nLC-MS chromatograms imported from a separate R script (provided at the end of this document).
- Protein network analysis images were imported from a manual analysis using the online resource STRING
(v10.5).
- STRING resource link - see https://string-db.org/cgi/input.pl





themeTIFF <- theme(legend.text = element_text(size = 16), legend.title=element_text(size=16), 
axis.title=element_text(size=18), 
 legend.key.size = unit(0.8, "cm"), axis.text.x = element_text(face = "bold", angle=0, vjust=0.5, size=16), 
 axis.text.y = element_text(face = "bold", size=16), title = element_text(size=18)) 
``` 
*** 
# Experiment key 
| ID | Method   | Meaning | 
|:----------:|-------------|------------------------------| 
|A   | CC | Control - Amyloid only | 
|F   | CC | Control - FBS only  | 
|AF  | CC | Amyloid + FBS  | 
|EF  | QCM | Control - FBS only | 
|AE    | QCM | Amyloid + FBS | 
*** 
# Combined MaxQuant files 
## Summary files 
Function to combine MaxQuant summary files for analysis of the nLC-MS/MS data. 
This analysis includes: 
- Peptide sequences identified,
- Ratio of MS/MS identified : MS/MS submitted,
- The number of peaks, and
- The mass standard deviation (ppm)
```{r sum} 
###set path### 
path = "./input/IAPP" 
###GETsummaries### 
GETsummaries <- function(x){ 
  #see https://stackoverflow.com/questions/4876813/using-r-to-list-all-files-with-a-specified-extension 
  sum_files <- list.files(path = x, pattern = "summary.txt", recursive=TRUE, include.dirs=TRUE, ignore.case = 
TRUE) 
  complete_summary <- data.frame() 
  for (i in sum_files){ 
    #see https://stackoverflow.com/questions/8996134/extract-vectors-from-strsplit-list-without-using-a-loop 
    Experiment <- rapply(strsplit(i, "/"), function(a) a[1]) 
    summary <- read.csv(paste(x, "/", i, sep=""), sep="\t", header=TRUE) 
    summary <- summary[summary$Raw.file!="Total",] 
    summary$Experiment <- Experiment 
    id <- rapply(strsplit(as.character(summary$Raw.file), "_"), function(a) a[4]) 
    exp <- rapply(strsplit(as.character(summary$Raw.file), "_"), function(a) a[6]) 
    ID_EXP <- paste(id, exp, sep="-") 
    summary$ID_EXP <- ID_EXP 
    complete_summary <- rbind(summary, complete_summary) 
    } 
  return(complete_summary) 
} 
summaries <- GETsummaries(path) 
``` 
## Summary file plot 
```{r sumplot} 
tiff(file=paste("./output/summary_plots.tiff", sep=""), width=600, height=1000) 
#see https://www.statmethods.net/advgraphs/layout.html 
a <- ggplot(summaries) 
b <- a + geom_bar(stat="identity", aes(ID_EXP, Peptide.Sequences.Identified, fill=Experiment)) 
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b <- b + expand_limits(y=0) + coord_flip() + xlab("Experimental ID") + theme_bw() 
#see http://www.cookbook-r.com/Graphs/Legends_(ggplot2)/ 
b <- b + guides(fill=FALSE) 
c <- a + geom_bar(stat="identity", aes(ID_EXP, MS.MS.Identified..../MS.MS.Submitted, fill=Experiment)) 
c <- c + expand_limits(y=0) + coord_flip() + xlab("Experimental ID") + theme_bw() + guides(fill=FALSE) 
d <- a + geom_bar(stat="identity", aes(ID_EXP, Mass.Standard.Deviation..ppm., fill=Experiment)) 
d <- d + expand_limits(y=0) + coord_flip() + xlab("Experimental ID") + theme_bw() 
e <- a + geom_bar(stat="identity", aes(ID_EXP, Peaks, fill=Experiment)) 
e <- e + expand_limits(y=0) + coord_flip() + xlab("Experimental ID") + theme_bw() + guides(fill=FALSE) 
grid.arrange(b, c, e, d, ncol=2, nrow=2) 
dev.off() 
``` 
The number of peptide sequences identified (top left), ratio of MS/MS identified : MS/MS submitted (top right), the 





## proteinGroup files 
Function to combine MaxQuant outputs for subsequent analyses. 
The Experiment ID (see Experiment key) is added to the dataframe here to allow subsetting of the data. 
```{r group} 
GETgroups <- function(x){ 
  #see https://stackoverflow.com/questions/4876813/using-r-to-list-all-files-with-a-specified-extension 
  prot_files <- list.files(path = x, pattern = "proteinGroups.txt", recursive=TRUE, include.dirs=TRUE, 
ignore.case=TRUE) 
  complete_group <- data.frame() 
  count <- 0 
  for (i in prot_files){ 
    #see https://stackoverflow.com/questions/8996134/extract-vectors-from-strsplit-list-without-using-a-loop 
    Experiment <- rapply(strsplit(i, "/"), function(a) a[1]) 
    prot_group <- read.csv(paste(x, "/", i, sep=""), sep="\t", header=TRUE) 
    prot_group$Experiment <- Experiment 
    count <- count + nrow(prot_group) 
    print(paste("Experiment ", Experiment, " identified ", count, " proteins", sep="")) 
    count <- 0 
    complete_group <- rbind(prot_group, complete_group) 
  } 
  return(complete_group) 
} 
protgroups <- GETgroups(path) 
``` 
The unique Experiments included in the final proteinGroups data frame are `r unique(protgroups$Experiment)`. 
The total identifications for each appear in the table below. 
```{r} 
###count Experiment-specific ID### 
table(protgroups$Experiment) 
``` 
# Uniprot database 
## Load database 
Here, the Bos taurus uniprot database file "UP000009136_9913.fasta"" is loaded and the protein ID, protein 
name, gene name and sequence are extracted. 
```{r up} 
###read uniprot fasta file using seqinr function read.fasta### 
UP <- read.fasta(file="./input/fasta/UP000009136_9913.fasta", seqtype="AA", as.string=TRUE) 
###function to extract sequences and annotations from fasta files### 
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GetAnnotSeqFASTA <- function(x){ 
  UP_sequence <- unlist(getSequence(x, as.string=TRUE)) 
  UP_annotations <- unlist(getAnnot(x, as.string=TRUE)) 
  ProtName <- rapply(strsplit(UP_annotations, "IN ", fixed=TRUE), function(a) a[2]) 
  UP_prot_name <- rapply(strsplit(ProtName, " OS", fixed=TRUE), function(a) a[1]) 
  Gene <- rapply(strsplit(UP_annotations, "GN=", fixed=TRUE), function(a) a[2]) 
  UP_gene <- rapply(strsplit(Gene, " ", fixed=TRUE), function(a) a[1]) 
  UP_prot_ID <- rapply(strsplit(UP_annotations, "|", fixed=TRUE), function(a) a[2]) 
  return(data.frame(UP_prot_ID, UP_prot_name, UP_gene, UP_sequence)) 
} 
###apply function to extract sequences and annotations### 
dataUP <- GetAnnotSeqFASTA(UP) 
str(dataUP) 
``` 
This uniprot Bos taurus reference proteome contains `r nrow(dataUP)` proteins. 
## Filter database 
These are the amino acid counts across the proteome: 
```{r upfilter} 
#see https://stackoverflow.com/questions/19476210/counting-the-number-of-each-letter-in-a-vector-of-strings 
table(unlist(strsplit(as.character(dataUP$UP_sequence), ""), use.names=FALSE)) 
``` 
To allow the package functions to work properly when calculating sequence dependent values - isoelectric point 
(pI), molecular weight (MW) and Grand Average of Hydropathy (GRAVY) - U, B and X residues need to be 
removed. 
```{r} 
###remove U, B and X containing sequences### 
#see https://stackoverflow.com/questions/6650510/remove-rows-from-data-frame-where-a-row-match-a-string 
dataUP <- dataUP[!(str_count(as.character(dataUP$UP_sequence), "U")>=1),] 
dataUP <- dataUP[!(str_count(as.character(dataUP$UP_sequence), "B")>=1),] 
dataUP <- dataUP[!(str_count(as.character(dataUP$UP_sequence), "X")>=1),] 
``` 
Following removal of U, B and X containing sequences the Uniprot database contains `r nrow(dataUP)` proteins. 
## Calculate protein characteristics 
Now the pI, MW and GRAVY can be calculated. 
```{r} 
###string split uniprot sequences and calculate GRAVY, pI and MW### 
split_SEQ <- strsplit(as.character(dataUP$UP_sequence), "") 
dataUP$pI <- unlist(lapply(split_SEQ, computePI)) 
dataUP$MW <- unlist(lapply(split_SEQ, pmw)) 
dataUP$GRAVY <- gravy(dataUP$UP_sequence) 
``` 
# Protein filtering and ID matching 
Here, entries with greater than, or equal to, 1 unique peptide are retained. In addition, the first protein ID in the 
"Protein.IDs"" column is extracted and used from here on. 
```{r extract} 
###Proteins with >= 1 unique peptide retained### 
protgroupsMOD <- protgroups[protgroups$Unique.peptides >= 1,] 
###Multiple entries for protein IDs removed - first entry retained### 
protgroupsMOD$Prot_ID <- rapply(strsplit(as.character(protgroupsMOD$Protein.IDs),";"), function(a) a[1]) 
``` 
The extracted protein ID in the combined MaxQuant protein groups summary is then used to match to the uniprot 
dataframe protein ID and extract the GRAVY, pI and MW values for these entries. 
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```{r} 
###EXTRACT by matching Prot_ID in "protgroupsMOD" dataframe to UP_prot_ID from "dataUP"### 
#see https://www.r-bloggers.com/manipulating-data-frames-using-sqldf-a-brief-overview/ 
extract <- sqldf("select * from dataUP inner join protgroupsMOD on protgroupsMOD.Prot_ID = 
dataUP.UP_prot_ID") 
``` 
Final count of protein IDs: 
```{r} 
###count Experiment-specific ID### 
table(extract$Experiment) 
``` 
# Data subsets 
These data subsets are used for the plots generated by this script. 
```{r subsets} 
###combined experiment subsets### 
Q_AF_F <- extract[extract$Exp=="AF" | extract$Exp=="F",] 
Q_AE_EF <- extract[extract$Experiment=="AE" | extract$Experiment=="EF",] 
Q_AF_AE <- extract[extract$Exp=="AF" | extract$Exp=="AE",] 
Q_AF_AE_EF_F <- extract[extract$Experiment=="AF" | extract$Experiment=="AE" | extract$Experiment=="EF" | 
extract$Experiment=="F",] 
###single experiment subsets### 
Q_A <- extract[extract$Experiment=="A",] 
Q_F <- extract[extract$Experiment=="F",] 
Q_AF <- extract[extract$Experiment=="AF",] 
Q_EF <- extract[extract$Experiment=="EF",] 
Q_AE <- extract[extract$Experiment=="AE",] 
###venn subsets### 
vA <- Q_A[,"UP_prot_ID"] 
vF <- Q_F[,"UP_prot_ID"] 
vAF <- Q_AF[,"UP_prot_ID"] 
vAE <- Q_AE[,"UP_prot_ID"] 
vEF <- Q_EF[,"UP_prot_ID"] 
``` 
*** 
# General considerations 
## Count across samples 
```{r} 
counts <- data.frame(table(extract$Prot_ID)) 





tiff("./output/all_sample_count_prot_ID.tiff", height=300, width=300) 
a = ggplot(counts, aes(Count)) + geom_histogram(binwidth=1, col="black", fill="blue", alpha=0.5) 
a = a + geom_hline(yintercept=c(10,50,100,200,300,400), col="red", linetype="dashed") 









## Overrepresented proteins across samples 
```{r} 
###find proteins across all experiments### 
##list these proteins for 4/5 occurrences### 
overlap <- rbind(counts[counts$Count==4,],counts[counts$Count==5,]) 
overlap_match <- data.frame() 
for(i in overlap$Entry){ 
  data <- extract[extract$Prot_ID==i,] 
  data <- cbind(data, rep(i, nrow(data))) 
  overlap_match <- rbind(data, overlap_match) 
} 
ID_count <- data.frame(table(overlap_match$Prot_ID)) 
ID_count <- ID_count[ID_count$Freq>=1,] 
ID_count <- ID_count[ order(-ID_count$Freq), ] 
colnames(ID_count) <- c("Protein_ID", "Count") 
``` 
There were `r nrow(ID_count)` proteins that were identified across 4 or more experiment types (N = 5 total). 
```{r} 
IDs <- ID_count[ID_count$Count==5,] 
IDmatch <- data.frame() 
for(i in IDs$Protein_ID){ 
  data <- dataUP[dataUP$UP_prot_ID==i,] 
  data$Protein_ID <- i 
  IDmatch <- rbind(data, IDmatch) 
} 
COUNT5 <- data.frame(IDmatch$UP_prot_ID, IDmatch$Protein_ID, IDmatch$UP_prot_name) 
colnames(COUNT5) <- c("UP_prot_ID", "Protein_ID", "UP_prot_name") 
COUNT5 
``` 
## Count (independent AF searches) 
```{r} 
path <- "./input/IAPP_independent_searches/" 
###function to extract proteinGroup files from independent Andromeda searches### 
GETindependent <- function(x){ 
#see https://stackoverflow.com/questions/4876813/using-r-to-list-all-files-with-a-specified-extension 
  files_IND <- list.files(path = x, pattern = "proteinGroups.txt", recursive=TRUE, include.dirs=TRUE, 
ignore.case=TRUE) 
  complete_group <- data.frame() 
  for (i in files_IND){ 
#see https://stackoverflow.com/questions/8996134/extract-vectors-from-strsplit-list-without-using-a-loop 
    Experiment <- rapply(strsplit(i, "/"), function(a) a[1]) 
    prot_group <- read.csv(paste(x, "/", i, sep=""), sep="\t", header=TRUE) 
    prot_group$Experiment <- Experiment 
    complete_group <- rbind(prot_group, complete_group) 
  } 
  return(complete_group) 
} 
###modify data frame### 
protgroups_IND <- GETindependent(path) 
protgroups_IND$Prot_ID <- rapply(strsplit(as.character(protgroups_IND$Protein.IDs),";"), function(a) a[1]) 
###check experiments included### 
table(protgroups_IND$Experiment) 
###subset based on experiment### 
AF1 <- protgroups_IND[protgroups_IND$Experiment == "AF_1",] 
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AF2 <- protgroups_IND[protgroups_IND$Experiment == "AF_2",] 
AF3 <- protgroups_IND[protgroups_IND$Experiment == "AF_3",] 
AF4 <- protgroups_IND[protgroups_IND$Experiment == "AF_4",] 
AF5 <- protgroups_IND[protgroups_IND$Experiment == "AF_5",] 
AF6 <- protgroups_IND[protgroups_IND$Experiment == "AF_6",] 
F1 <- protgroups_IND[protgroups_IND$Experiment == "F_1_156",] 
F2 <- protgroups_IND[protgroups_IND$Experiment == "F_1_164",] 
F3 <- protgroups_IND[protgroups_IND$Experiment == "F_1_170",] 
F4 <- protgroups_IND[protgroups_IND$Experiment == "F_2_156",] 
F5 <- protgroups_IND[protgroups_IND$Experiment == "F_2_170",] 
F6 <- protgroups_IND[protgroups_IND$Experiment == "F_3_180",] 
F7 <- protgroups_IND[protgroups_IND$Experiment == "F_4_180",] 
F8 <- protgroups_IND[protgroups_IND$Experiment == "F_5_180",] 
F9 <- protgroups_IND[protgroups_IND$Experiment == "F_6_180",] 
###AF venn subsets### 
vAF1 <- AF1[,"Prot_ID"] 
vAF2 <- AF2[,"Prot_ID"] 
vAF3 <- AF3[,"Prot_ID"] 
vAF4 <- AF4[,"Prot_ID"] 
vAF5 <- AF5[,"Prot_ID"] 
vAF6 <- AF6[,"Prot_ID"] 
###F venn subsets### 
vF1 <- F1[,"Prot_ID"] 
vF2 <- F2[,"Prot_ID"] 
vF3 <- F3[,"Prot_ID"] 
vF4 <- F4[,"Prot_ID"] 
vF5 <- F5[,"Prot_ID"] 
vF6 <- F6[,"Prot_ID"] 
vF7 <- F7[,"Prot_ID"] 
vF8 <- F8[,"Prot_ID"] 
vF9 <- F9[,"Prot_ID"] 
#see https://stackoverflow.com/questions/25019794/venn-diagram-with-item-labels 
venn <- venn.diagram(list(AF1 = vAF1, AF2 = vAF2, AF3 = vAF3, AF4 = vAF4, AF5 = vAF5), 
      fill = c("red", "blue", "green", "yellow", "purple"),  
      alpha = 0.4, lwd = 1, cex = 1, cat.cex = 1, filename = NULL) 




venn <- venn.diagram(list(AF2 = vAF2, AF3 = vAF3, AF4 = vAF4, AF5 = vAF5, AF6= vAF6), 
      fill = c("blue", "green", "yellow", "purple", "brown"),  
      alpha = 0.4, lwd = 1, cex = 1, cat.cex = 1, filename = NULL) 




venn <- venn.diagram(list(F1 = vF1, F2 = vF2, F3 = vF3, F4 = vF4, F5 = vF5), 
      fill = c("blue", "green", "yellow", "purple", "orange"),  
      alpha = 0.4, lwd = 1, cex = 1, cat.cex = 1, filename = NULL) 




venn <- venn.diagram(list(F3 = vF3, F4 = vF4, F5 = vF5, F6 = vF6, F7 = vF7), 
      fill = c("yellow", "purple", "orange", "brown", "pink"),  
      alpha = 0.4, lwd = 1, cex = 1, cat.cex = 1, filename = NULL) 
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venn <- venn.diagram(list(F5 = vF5, F6 = vF6, F7 = vF7, F8 = vF8, F9 = vF9), 
      fill = c("orange", "brown", "pink", "gray", "darkblue"),  
      alpha = 0.4, lwd = 1, cex = 1, cat.cex = 1, filename = NULL) 












## Global faceted analysis of variables 
### Unique peptides vs peptides 
```{r} 
#see http://ggplot2.tidyverse.org/reference/facet_grid.html 
b <- ggplot(extract) 
b <- b + geom_point(aes(Unique.peptides, Peptides), alpha=0.7, pch=21, fill="gray") 
b <- b + facet_grid(. ~ Experiment) 
b <- b + theme_bw() + theme(axis.text.x = element_text(angle=90, vjust=0.5)) 
plot(b) 
``` 
### GRAVY vs pI 
```{r} 
c <- ggplot(extract) 
c <- c + geom_point(aes(GRAVY, pI), alpha=0.7, pch=21, fill="gray") 
c <- c + facet_grid(. ~ Experiment) 
c <- c + theme_bw() 
plot(c) 
``` 
### GRAVY vs MW 
```{r} 
d <- ggplot(extract) 
d <- d + geom_point(aes(GRAVY, MW), alpha=0.7, pch=21, fill="gray") 
d <- d + facet_grid(. ~ Experiment) 
d <- d + theme_bw() + scale_y_continuous(limits=c(0,1E+6)) 
plot(d) 
``` 
# Question 1 - CC coronae 
## Overlap of AF/F protein IDs 
Comparing FBS only (F), with IAPP amyloids exposed to FBS (AF). These samples were prepared with 1 MDa 
molecular weight cut-off (MWCO) spin columns (CC method). 
The identification overlap was as follows: 
```{r} 
#see https://stackoverflow.com/questions/25019794/venn-diagram-with-item-labels 
venn <- venn.diagram(list(F = vF, AF = vAF), fill = c("red", "blue"),  
  alpha = 0.4, lwd = 1, cex = 1.5, cat.cex = 1.5, filename = NULL) 
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## Unique AF proteins 
Here, plots are created that summarise the physico-chemical properties of proteins unique to the AF samples, 
highlighting some potentially interesting amyloid binding proteins that could be investigated in future. 
Extracting unique entries from combined AF/F data: 
```{r} 
#see https://stackoverflow.com/questions/16905425/find-duplicate-values-in-r 
AF_F_ID_count <- data.frame(table(Q_AF_F$Prot_ID)) 
AF_F_ID_count <- AF_F_ID_count[AF_F_ID_count$Freq==1,] 
###extract unique entries for AF and F### 
AF_F_unique <- data.frame() 
for(i in AF_F_ID_count$Var1){ 
  data <- Q_AF_F[Q_AF_F$Prot_ID==i,] 
  data <- cbind(data, i) 





Confirming Venn diagram counts: 
```{r} 
AF_F_unique_count <- data.frame(table(AF_F_unique$Experiment)) 
colnames(AF_F_unique_count) <- c("Prot_ID", "Count") 
AF_F_unique_count 
``` 
Extract unique AF proteins and export these for STRING network analysis: 
```{r} 
###create subset dataframe### 
AF <- AF_F_unique[AF_F_unique$Experiment=="AF",] 
F <- AF_F_unique[AF_F_unique$Experiment=="F",] 
#see http://r.789695.n4.nabble.com/write-text-file-as-output-without-quotes-td888020.html 
write.table(AF$Prot_ID, "./output/exp_AF_protlist.txt", sep="\t", quote=FALSE, row.names = FALSE, col.names = 
FALSE) 
``` 
The top 12 unique AF proteins, based on unique peptide count were: 
```{r} 
#see https://stackoverflow.com/questions/1296646/how-to-sort-a-dataframe-by-columns 
uniqueAF_sort <- AF[ order(-AF$Unique.peptides), ] 
uniqueAF_sort <- data.frame(uniqueAF_sort$Prot_ID, uniqueAF_sort$UP_prot_name, 
uniqueAF_sort$Unique.peptides) 
colnames(uniqueAF_sort) <- c("Protein ID", "Protein name", "Unique peptides") 
uniqueAF_sort[1:12,] 
``` 
## Unique AF/F amino acid composition 





propAF <- data.frame() 
for (i in AF_F_unique$UP_sequence){ 
  seq_vec <- unlist(strsplit(as.character(i), "")) 
  info <- AAstat(seq_vec, plot=FALSE) 
  all <- AF_F_unique[AF_F_unique$UP_sequence==i,] 
  summary <- cbind(all, info$Prop$Aliphatic, info$Prop$Aromatic, info$Prop$Non.polar, 
    info$Prop$Polar, info$Prop$Charged, info$Prop$Basic, info$Prop$Acidic) 
  propAF <- rbind(summary, propAF) 
} 
###uniprot### 
propUP <- data.frame() 
for (i in dataUP$UP_sequence){ 
  seq_vec <- unlist(strsplit(as.character(i), "")) 
  info <- AAstat(seq_vec, plot=FALSE) 
  all <- dataUP[dataUP$UP_sequence==i,] 
  summary <- cbind(all, info$Prop$Aliphatic, info$Prop$Aromatic, info$Prop$Non.polar, 
    info$Prop$Polar, info$Prop$Charged, info$Prop$Basic, info$Prop$Acidic) 
  propUP <- rbind(summary, propUP) 
} 
###subset based on specific columns### 




###update column names### 
colnames(propAF) <- c("UP_prot_ID", "UP_prot_name", "UP_gene", "Experiment", "Prot_ID", "Aliphatic", 
      "Aromatic", "NonPolar", "Polar", "Charged", "Basic", "Acidic") 
colnames(propUP) <- c("UP_prot_ID", "UP_prot_name", "UP_gene", "UP_sequence", "pI", "MW", "GRAVY", 
"Aliphatic",  
      "Aromatic", "NonPolar", "Polar", "Charged", "Basic", "Acidic") 
###plots### 
a <- ggplot(propUP) + geom_point(aes(NonPolar, Acidic), col="gray", alpha=0.4) 
a <- a + geom_point(data=propAF[propAF$Experiment=="F",], aes(NonPolar, Acidic), fill = "blue", pch=21) 
a <- a + geom_point(data=propAF[propAF$Experiment=="AF",], aes(NonPolar, Acidic), fill = "yellow", pch=21) 
a <- a + theme_bw() + coord_fixed() 
plot(a) 
``` 
## Unique AF proteins (GRAVY/pI + proteome) 
Here, the Bos taurus proteome (gray) is overlaid with all unique FBS only proteins (F, blue), as well as those 
proteins unique to amyloid + FBS (AF, yellow). Labels are gene names, outside the box indicated on the plot. 
The top panel labels unique AF proteins outside the boundaries indicated by the highlighted blue box. The 
bottom panel labels unique AF proteins (GRAVY <=-1 and GRAVY >=0 and pI <= 4.5 and pI >= 7). 
```{r} 
###plot### 
tiff("./output/AF_unique_GRAVY_pI_BosT.tiff", width=2500, height=5000, res=300) 
#themes, see #http://ggplot2.tidyverse.org/reference/theme.html 
#geom_rect, see - https://stackoverflow.com/questions/4733182/how-to-highlight-time-ranges-on-a-plot 
a <- ggplot(dataUP) 
a <- a + geom_point(data=dataUP, aes(GRAVY, pI), col="gray", alpha=0.1) 
a <- a + geom_point(data=F, aes(GRAVY, pI), pch=21, size=5, fill="blue") 
a <- a + geom_point(data=AF, aes(GRAVY, pI), pch=21, size=3, fill="yellow") 
a <- a + theme_bw() + themeTIFF + xlab("GRAVY") + ylab("pI") 
b <- a + geom_rect(data=data.frame(xmin=-1.5, xmax=0.5, ymin=4, ymax=10),  
    aes(xmin=xmin, xmax=xmax, ymin=ymin, ymax=ymax), 
    fill="lightblue", col="black", alpha=0.4,  
    inherit.aes = FALSE) 
b <- b + geom_label_repel(data=AF[AF$GRAVY<=-1.5 | AF$GRAVY>=0.5 | AF$pI<=4 | AF$pI>=10,], 
     aes(GRAVY, pI, label=UP_gene), size=4) 
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c <- a + scale_y_continuous(limits=c(4,10)) + scale_x_continuous(limits=c(-1.5,0.5)) 
c <- c + geom_rect(data=data.frame(xmin=-1, xmax=0, ymin=4.5, ymax=7),  
  aes(xmin=xmin, xmax=xmax, ymin=ymin, ymax=ymax), 
    fill="lightblue", col="black", alpha=0.4,  
    inherit.aes = FALSE) 
c <- c + geom_label_repel(data=AF[AF$GRAVY<=-1 | AF$GRAVY>=0 | AF$pI<=4.5 | AF$pI>=7,], 
     aes(GRAVY, pI, label=UP_gene), size=4) 
c <- c + guides(fill=FALSE) 






The following figure includes all AF and unique AF proteins, with the scatter markers size based on number of 
unique peptides. Unique AF proteins with >= 10 unique peptides (yellow) and all AF proteins with >= 20 unique 
peptides (white) are labelled. 
```{r} 
###plot### 
tiff("./output/AF_unique_GRAVY_pI_all_AF_unique_pep.tiff", width=700, height=700) 
d <- ggplot(Q_AF) + geom_point(aes(GRAVY, pI, size=Unique.peptides), col="blue") 
d <- d + geom_point(data=AF, aes(GRAVY, pI, size=Unique.peptides), col="yellow") 
d <- d + scale_x_continuous(limits=c(-1,0)) + scale_y_continuous(limits=c(4,7.5)) 
d <- d + geom_label_repel(data=Q_AF[Q_AF$Unique.peptides>=20,], aes(GRAVY, pI, label=UP_gene), size=3) 
d <- d + geom_label_repel(data=AF[AF$Unique.peptides>=10,], aes(GRAVY, pI, label=UP_gene), fill="yellow", 
size=3) 
d <- d + theme_bw() + themeTIFF + xlab("GRAVY") + ylab("pI") 
d <- d + theme(panel.background = element_rect(fill="gray"), panel.grid.minor = element_line(colour="gray"), 







## Unique AF proteins (GRAVY/MW + proteome) 
A matching overlay of unique F (blue) and unique AF (yellow) proteins against the Bos taurus proteome (gray) is 
shown below - plotting GRAVY and MW. Labels are gene names, with unique AF proteins labelled in both the top 
(>= 600 kDa) and bottom (>= 200 kDa) panel. GRAVY ranges for labelling are identical for both panels 
(GRAVY >= 0.5 & <= -1.5) 
```{r} 
###plot### 
tiff("./output/AF_unique_GRAVY_MW_BosT.tiff", width=2500, height=5000, res=300) 
a <- ggplot(dataUP) 
a <- a + geom_point(data=dataUP, aes(GRAVY, MW), col="gray", alpha=0.1) 
a <- a + geom_point(data=F, aes(GRAVY, MW), pch=21, size=5, fill="blue") 
a <- a + geom_point(data=AF, aes(GRAVY, MW), pch=21, size=3, fill="yellow", col="blue") 
a <- a + theme_bw() + themeTIFF + xlab("GRAVY") + ylab("MW") 
b <- a + geom_rect(data=data.frame(xmin=-1.5, xmax=0.5, ymin=0, ymax=6E+5),  
    aes(xmin=xmin, xmax=xmax, ymin=ymin, ymax=ymax), 
    fill="lightblue", col="black", alpha=0.4, inherit.aes = FALSE) 
b <- b + geom_label_repel(data=AF[AF$GRAVY<=-1.5 | AF$GRAVY>=0.5 | AF$MW>=6E+5,], 
     aes(GRAVY, MW, label=UP_gene), size=4) 
c <- a + scale_y_continuous(limits=c(0,6E+5)) + scale_x_continuous(limits=c(-1.5,0.5)) 
c <- c + geom_label_repel(data=AF[AF$GRAVY<=-1.5 | AF$GRAVY>=0.5 | AF$MW>=2E+5,], 
     aes(GRAVY, MW, label=UP_gene), size=4) 
c <- c + guides(fill=FALSE) 







# Question 2 - QCM coronae  
## Overlap of AE/EF protein IDs 
The identification overlap was as follows: 
```{r} 
#see https://stackoverflow.com/questions/25019794/venn-diagram-with-item-labels 
venn <- venn.diagram(list(AE = vAE, EF = vEF), fill = c("yellow", "blue"),  
      alpha = 0.4, lwd = 1, cex = 1.5, cat.cex = 1.5, filename = NULL) 








## Overlay of unique AE/EF proteins 
```{r} 
#see https://stackoverflow.com/questions/16905425/find-duplicate-values-in-r 
AE_EF_ID_count <- data.frame(table(Q_AE_EF$Prot_ID)) 
AE_EF_ID_count <- AE_EF_ID_count[AE_EF_ID_count$Freq==1,] 
AE_EF_unique <- data.frame() 
for(i in AE_EF_ID_count$Var1){ 
  data <- Q_AE_EF[Q_AE_EF$Prot_ID==i,] 
  data <- cbind(data, i) 
  AE_EF_unique <- rbind(data, AE_EF_unique) 
} 
AE_EF <- data.frame(table(AE_EF_unique$Experiment)) 
AE_EF <- AE_EF[AE_EF$Freq>0,] 
colnames(AE_EF) <- c("Prot_ID", "Count") 
Q2_AE <- AE_EF_unique[AE_EF_unique$Experiment=="AE",] 
Q2_EF <- AE_EF_unique[AE_EF_unique$Experiment=="EF",] 
``` 
There were a total of `r nrow(Q_EF)` and `r nrow(Q_AE)` IDs for experiments EF and AE, respectively. 
Of these there were `r nrow(Q2_EF)` and `r nrow(Q2_AE)` unique protein identifications for EF and AE, 
respectively. 
The top 12 unique AE proteins, based on unique peptide count were: 
```{r} 
uniqueAE_sort <- Q2_AE[ order(-Q2_AE$Unique.peptides), ] 
uniqueAE_sort <- data.frame(uniqueAE_sort$Prot_ID, uniqueAE_sort$UP_prot_name, 
uniqueAE_sort$Unique.peptides) 
colnames(uniqueAE_sort) <- c("Protein ID", "Protein name", "Unique peptides") 
uniqueAE_sort[1:12,] 
``` 
Here, the protein list for unique AE proteins was exported for STRING DB analysis. 
```{r export_AE} 
#see http://r.789695.n4.nabble.com/write-text-file-as-output-without-quotes-td888020.html 
write.table(Q2_AE$Prot_ID, "./output/exp_AE_protlist.txt", sep="\t", quote=FALSE, row.names = FALSE, 
col.names = FALSE) 
``` 
The unique EF proteins were: 
```{r} 
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uniqueEF_sort <- Q2_EF[ order(-Q2_EF$Unique.peptides), ] 
uniqueEF_sort <- data.frame(uniqueEF_sort$Prot_ID, uniqueEF_sort$UP_prot_name, 
uniqueEF_sort$Unique.peptides) 
colnames(uniqueEF_sort) <- c("Protein ID", "Protein name", "Unique peptides") 
uniqueEF_sort 
``` 
## Unique AE/EF amino acid composition 
Concept inspired by a table in the following reference -> DOI:10.1039/C7EN00466D (see 
http://pubs.rsc.org/en/content/articlehtml/2017/en/c7en00466d) 
```{r} 
propAE <- data.frame() 
for (i in AE_EF_unique$UP_sequence){ 
 seq_vec <- unlist(strsplit(as.character(i), "")) 
  info <- AAstat(seq_vec, plot=FALSE) 
  all <- AE_EF_unique[AE_EF_unique$UP_sequence==i,] 
  summary <- cbind(all, info$Prop$Aliphatic, info$Prop$Aromatic, info$Prop$Non.polar, 
    info$Prop$Polar, info$Prop$Charged, info$Prop$Basic, info$Prop$Acidic) 
  propAE <- rbind(summary, propAE) 
} 
###subset and rename columns### 
propAE <- propAE[,c(1,2,3,40,41,43,44,45,46,47,48,49)] 
###check column names### 
colnames(propAE) 
###update column names### 
colnames(propAE) <- c("UP_prot_ID", "UP_prot_name", "UP_gene", "Experiment", "Prot_ID", "Aliphatic", 
      "Aromatic", "NonPolar", "Polar", "Charged", "Basic", "Acidic") 
###plots### 
a <- ggplot(propUP) + geom_point(aes(NonPolar, Acidic), col="gray", alpha=0.4) 
a <- a + geom_point(data=propAE[propAE$Experiment=="AE",], aes(NonPolar, Acidic), fill = "yellow", pch=21) 
a <- a + geom_point(data=propAE[propAE$Experiment=="EF",], aes(NonPolar, Acidic), fill = "blue", pch=21) 
a <- a + theme_bw() + coord_fixed() 
plot(a) 
``` 
## Unique AE/EF proteins (GRAVY/pI/MW + proteome) 
Here, the Bos taurus proteome (gray) is overlaid with unique AE (yellow) and unique EF (blue) proteins - plotting 
GRAVY/pI and GRAVY/MW. 
```{r} 
tiff("./output/AE_EF_unique_GRAVY_pI_BosT.tiff", width=2500, height=5000, res=300) 
#themes, see #http://ggplot2.tidyverse.org/reference/theme.html 
d <- ggplot(dataUP) 
d <- d + geom_point(aes(GRAVY, pI), size=1, col="gray", alpha=0.5) 
d <- d + geom_point(data=Q2_EF, aes(GRAVY, pI), pch=21, fill="blue", size=5) 
d <- d + geom_point(data=Q2_AE, aes(GRAVY, pI), pch=21, fill="yellow", size=3) 
d <- d + xlab("GRAVY") + ylab("pI") + theme_bw() + themeTIFF  
#geom_rect, see - https://stackoverflow.com/questions/4733182/how-to-highlight-time-ranges-on-a-plot 
e <- d + geom_rect(data=data.frame(xmin=-1.5, xmax=0.5, ymin=4, ymax=10),  
    aes(xmin=xmin, xmax=xmax, ymin=ymin, ymax=ymax), 
    fill="lightblue", col="black", alpha=0.4, inherit.aes = FALSE) 
e <- e + geom_label_repel(data=Q2_AE[Q2_AE$pI>=10 | Q2_AE$pI<=4 | Q2_AE$GRAVY>=0.5 | 
Q2_AE$GRAVY<=-1.5,],  
     aes(GRAVY, pI, label=UP_gene), size=4) 
f <- d + scale_x_continuous(limits=c(-1.5,1)) + scale_y_continuous(limits=c(4,10)) 
f <- f + geom_rect(data=data.frame(xmin=-1, xmax=0, ymin=4.5, ymax=8.5),  
    aes(xmin=xmin, xmax=xmax, ymin=ymin, ymax=ymax), 
    fill="lightblue", col="black", alpha=0.4, inherit.aes = FALSE) 
f <- f + geom_label_repel(data=Q2_AE[Q2_AE$pI>=8.5 | Q2_AE$pI<=4.5 | Q2_AE$GRAVY>=0 | 
Q2_AE$GRAVY<=-1,],  
     aes(GRAVY, pI, label=UP_gene), size=4) 








tiff("./output/AE_EF_unique_GRAVY_MW_BosT.tiff", width=2500, height=5000, res=300) 
#themes, see #http://ggplot2.tidyverse.org/reference/theme.html 
d <- ggplot(dataUP) 
d <- d + geom_point(aes(GRAVY, MW), size=1, col="gray", alpha=0.5) 
d <- d + geom_point(data=Q2_EF, aes(GRAVY, MW), pch=21, fill="blue", size=5) 
d <- d + geom_point(data=Q2_AE, aes(GRAVY, MW), pch=21, fill="yellow", size=3) 
d <- d + xlab("GRAVY") + ylab("MW") + theme_bw() + themeTIFF 
#geom_rect, see - https://stackoverflow.com/questions/4733182/how-to-highlight-time-ranges-on-a-plot 
e <- d + geom_rect(data=data.frame(xmin=-1.5, xmax=0.5, ymin=0, ymax=600000),  
    aes(xmin=xmin, xmax=xmax, ymin=ymin, ymax=ymax), 
    fill="lightblue", col="black", alpha=0.4, inherit.aes = FALSE) 
e <- e + geom_label_repel(data=Q2_AE[Q2_AE$MW>=6E+5 | Q2_AE$GRAVY>=0.5 | Q2_AE$GRAVY<=-1.5,], 
     aes(GRAVY, MW, label=UP_gene), size=4) 
f <- d + scale_y_continuous(limits=c(0,600000)) 
f <- f + geom_label_repel(data=Q2_AE[Q2_AE$MW>=3E+5 | Q2_AE$GRAVY>=0.5 | Q2_AE$GRAVY<=-1.5,], 
     aes(GRAVY, MW, label=UP_gene), size=4) 







# Question 3 - CC vs QCM 
## Overlap of AF/AE protein IDs 
The next comparison of interest was to consider the difference, if any, between the amyloids + FBS prepared by 
either the CC method (AF) or the QCM method (AE). 
The identification overlap for these experiments was as follows: 
```{r} 
#see https://stackoverflow.com/questions/25019794/venn-diagram-with-item-labels 
venn <- venn.diagram(list(AF = vAF, AE = vAE), fill = c("red", "blue"),  
      alpha = 0.4, lwd = 1, cex = 2.5, cat.cex = 2.5, filename = NULL) 








There were a total of `r nrow(Q_AF)` and `r nrow(Q_AE)` IDs for experiments AF and AE, respectively. 
If we consider the Venn diagram showing the four experiments F/AF/AE/EF, we can identify those proteins 
unique to AF/AE. 
```{r} 
#see https://stackoverflow.com/questions/25019794/venn-diagram-with-item-labels 
venn <- venn.diagram(list(AF = vAF, AE = vAE, F=vF, EF=vEF), fill = c("red", "blue", "green", "yellow"), 
      alpha = 0.4, lwd = 1, cex = 1.5, cat.cex = 1.5, filename = NULL) 










# Question 4 - Control nLC-MS/MS 
## A 
Amyloid only control for CC method. 
Sample A nLC-MS/MS analyses identified a total of `r nrow(Q_A)` proteins. 
These proteins were: 
```{r}  
Q_A_sort <- Q_A[ order(-Q_A$Unique.peptides), ] 
A_list <- data.frame(Q_A_sort$Prot_ID, Q_A_sort$UP_prot_name, Q_A_sort$Unique.peptides) 
colnames(A_list) <- c("Protein ID", "Protein name", "Unique peptides") 
A_list[1:12,] 
``` 
The identification overlap for A/F/AF was: 
```{r}  
#see https://stackoverflow.com/questions/25019794/venn-diagra♣m-with-item-labels 
venn <- venn.diagram(list(A = vA, F = vF, AF=vAF), fill = c("green", "blue", "yellow"),  
      alpha = 0.4, lwd = 1, cex = 2.5, cat.cex = 2.5, filename = NULL) 








## A (using human .fasta file) 
```{r} 
A_human <- read.csv("./input/Ahuman/combined/txt/proteinGroups.txt", sep="\t", header=TRUE) 
A_human$Prot_ID <- rapply(strsplit(as.character(A_human$Protein.IDs),";"), function(a) a[1]) 
A_human$Prot_name <- rapply(strsplit(as.character(A_human$Protein.names),";"), function(a) a[1]) 
``` 
Sample A nLC-MS/MS analyses using a human fasta file for the Andromeda search identified a total of `r 
nrow(A_human)` proteins. 
The top 12 proteins in this list, based on unique peptides counts, were: 
```{r} 
A_human_sort <- A_human[ order(-A_human$Unique.peptides), ] 
A_human_sort <- data.frame(A_human_sort$Prot_ID, A_human_sort$Prot_name, 
A_human_sort$Unique.peptides) 




# Extract data consistency check 
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Random subset of 30 rows from extract dataframe checked to make sure that IDs, names and sequences align 
correctly. 
```{r} 
# see https://stackoverflow.com/questions/8273313/sample-random-rows-in-dataframe 
CHECK <- extract[sample(nrow(extract), 30), ] 
write.table(CHECK, "./output/extract_consistency_check.txt", sep="\t") 
``` 
*** 
# Check of MaxQuant parameters 
This section checks the consistency of the parameters used for MaxQuant. 
```{r} 
path <- "./input/IAPP" 
GETparameters <- function(x){ 
  #see https://stackoverflow.com/questions/4876813/using-r-to-list-all-files-with-a-specified-extension 
  parameter_files <- list.files(path = x, pattern = "parameters.txt", recursive=TRUE, include.dirs=TRUE, 
ignore.case = TRUE) 
  complete_parameters <- data.frame() 
  complete_parameters <- read.csv(paste(x, "/", parameter_files[[1]], sep=""), sep="\t", header=TRUE)$Parameter 
  for (i in parameter_files){ 
    #see https://stackoverflow.com/questions/8996134/extract-vectors-from-strsplit-list-without-using-a-loop 
    Experiment <- rapply(strsplit(i, "/"), function(a) a[1]) 
    parameters <- read.csv(paste(x, "/", i, sep=""), sep="\t", header=TRUE) 
    colnames(parameters) <- c("Parameter", Experiment) 
    # see http://www.r-tutor.com/r-introduction/data-frame/data-frame-column-slice 
    complete_parameters <- cbind(complete_parameters, parameters[2]) 
  } 
  return(complete_parameters) 
} 
parameters <- GETparameters(path) 
#see https://stackoverflow.com/questions/28628384/count-number-of-unique-values-per-row 
apply(parameters[,2:6], 1, function(x)length(unique(x))) 
``` 





# Chromatogram plotting script 



























#these vignettes, documentation and examples were used in writing of the code provided below. 
################################################################### 
###############set data directory and file_type#################### 
###mzR can load many file types - this code was written for mzML### 
################################################################### 
#path <- "./Converted_RAW_files/" 
#file_type <- ".mzML" 
################################################# 
####################lcms_vis##################### 
###FUNCTION TO CREATE TIC CHROMATOGRAM OUTPUTS### 
################################################# 
#lcms_vis <- function(x){ 
#  #see https://stackoverflow.com/questions/4876813/using-r-to-list-all-files-with-a-specified-extension 
#  files <- list.files(path = x, pattern= paste("\\", file_type, sep="")) 
#  complete_TIC_data <- data.frame() 
#  for (i in files){ 
#    #see https://stackoverflow.com/questions/8996134/extract-vectors-from-strsplit-list-without-using-a-loop 
#    id <- rapply(strsplit(i, "_"), function(a) a[6]) 
#    ID <- rapply(strsplit(id, ".m"), function(a) a[1]) 
#    #see https://stackoverflow.com/questions/18115550/how-to-combine-two-or-more-columns-in-a-dataframe-
into-a-new-column-with-a-new-n 
#    uniqueID <- paste(rapply(strsplit(i,"_"), function(a) a[4]),"_", ID, sep="") 
#    #see https://stackoverflow.com/questions/9756360/r-split-character-data-into-numbers-and-letters 
#    replicate <- as.numeric(str_extract(ID, "[0-9]+")) 
#    experiment <- (str_extract(ID, "[aA-zZ]+")) 
#    #see https://www.rdocumentation.org/packages/xcms/versions/1.48.0/topics/xcmsRaw 
#    data <- xcmsRaw(paste(path, i, sep=""), profstep = 1, profmethod = "bin", profparam = list(), 
#   includeMSn=FALSE, mslevel=NULL, scanrange=NULL) 
#    tiff(file=paste("./chromatograms/", uniqueID, "_combined_chromatograms.tiff", sep=""), width=1500, 
height=750) 
#    #see https://www.statmethods.net/advgraphs/layout.html 
#    par(mfrow=c(1,2)) 
#    plotChrom(data, base=TRUE) 
#    plotChrom(data, base=FALSE) 
#    dev.off() 
#    TIC <- data.frame(uniqueID, ID, experiment, replicate, data@scantime, data@tic) 
#    complete_TIC_data <- rbind(complete_TIC_data, TIC) 
#  } 
#  return(complete_TIC_data) 
#} 
################################ 
###Process selected directory### 
################################ 
#DATA <- lcms_vis(path) 
#write.table(DATA, "./complete_TIC_data.txt", sep="\t") 
################################### 
###Create combined chromatograms### 
################################### 
#for (i in unique(DATA$experiment)){ 
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#  plotDATA <- subset(DATA, DATA$experiment==i) 
#  pdf(paste("./chromatogram_overlays/chromatograms_",i,".pdf",sep=""), width=15, height=15) 
#  #see http://ggplot2.tidyverse.org/reference/scale_brewer.html 
#  a = ggplot(plotDATA, aes(data.scantime, data.tic)) + geom_line(alpha=0.5, aes(col=as.character(replicate))) 
#  #see https://stackoverflow.com/questions/14622421/how-to-change-legend-title-in-ggplot 
#  a = a + ggtitle(paste("LC-MS/MS chromatograms for ", i, " experiments", sep=""))  
#  a = a + xlab("Scan time") + ylab("total ion count (TIC)") + labs(color="Experiment No.")  
#  #see http://ggplot2.tidyverse.org/reference/theme.html 
#  a = a + theme_bw() + theme(legend.text = element_text(size = 20), legend.title=element_text(size=25),  
#   axis.title=element_text(size=25), legend.key.size = unit(0.8, "cm"), 
#   axis.text.x = element_text(size=20), axis.text.y = element_text(size=20), 
#   plot.title = element_text(size=25)) 
#  plot(a) 







## General attributions 
|Description                |Link                                                                                                                               | 
|---------------------------|---------------------------------------------------------------------------------------------------------------------| 
|Rmarkdown basics           |http://rmarkdown.rstudio.com/authoring_basics.html     
| 
|Rmarkdown format           |http://rmarkdown.rstudio.com/markdown_document_format.html    
| 
|In-line R code             |http://rmarkdown.rstudio.com/lesson-4.html    
| 
|Degree symbol    |https://stackoverflow.com/questions/26234119/how-can-i-write-a-degree-symbol-in-
rmarkdown2-for-html-and-pdf-output   | 
|Tables    |https://stackoverflow.com/questions/19997242/simple-manual-rmarkdown-tables-that-look-
good-in-html-pdf-and-docx   | 
|Tables    |https://www.rstudio.com/wp-content/uploads/2015/03/rmarkdown-reference.pdf 
| 
|Table dimensions       |https://stackoverflow.com/questions/27219629/how-to-control-cell-width-in-pandoc-
markdown-table         | 
|Rmarkdown themes    |http://rmarkdown.rstudio.com/html_document_format.html  
| 
|Rmarkdown image formatting |https://stackoverflow.com/questions/15625990/how-to-set-size-for-local-image-
using-knitr-for-markdown   | 
|Image formatting     |https://stackoverflow.com/questions/24677642/centering-image-and-text-in-r-markdown-
for-a-pdf-report          | 
|css fonts       |https://stackoverflow.com/questions/29274501/r-markdown-changing-font-size-and-font-
type-in-html-output      | 
|css style      |https://stackoverflow.com/questions/30446905/rmarkdown-font-size-and-header  
| 
|css body/TOC modifications |https://rpubs.com/stevepowell99/floating-css  
| 
|TOC     |https://stackoverflow.com/questions/42546001/how-to-change-colors-and-attributes-of-
table-of-contents-in-r-markdown-html-docu?rq=1 | 
|reshape    |https://www.statmethods.net/management/reshape.html 
| 
|ggrepel  |https://cran.r-project.org/web/packages/ggrepel/vignettes/ggrepel.html  
| 
|themes                     |http://ggplot2.tidyverse.org/reference/theme.html  
| 
|geom_rect   |https://stackoverflow.com/questions/4733182/how-to-highlight-time-ranges-on-a-plot 
| 
|ggplot theme               |https://rstudio-pubs-
static.s3.amazonaws.com/3364_d1a578f521174152b46b19d0c83cbe7e.html    | 
|Stand alone error          |https://github.com/rstudio/rmarkdown/issues/228     
| 
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|Subsetting    |http://adv-r.had.co.nz/Subsetting.html  
| 
|TIFF resolution    |https://www.r-bloggers.com/high-resolution-figures-in-r/ & https://stat.ethz.ch/pipermail/r-
help/2010-August/250893.html    | 
Additional attributions appear throughout this document. Citations, session information and package links appear 
below. 




## Package links 
| Name | URL | 
|:----------|-------------------------------------------| 
|gridExtra  |https://CRAN.R-project.org/package=gridExtra                    | 
|ggplot2    |http://ggplot2.org                                              | 
|seqinr    |https://cran.r-project.org/web/packages/seqinr/                  | 
|alakazam  |http://doi.org/10.1126/scitranslmed.3008879                      | 
|sqldf     |https://CRAN.R-project.org/package=sqldf                         | 
|ggrepel   |https://CRAN.R-project.org/package=ggrepel                       | 
|VennDiagram|https://cran.r-project.org/web/packages/VennDiagram/index.html  | 
|stringr    |https://cran.r-project.org/web/packages/stringr/index.html      | 
|reshape2 |https://cran.r-project.org/web/packages/reshape2/ | 
|xcms |https://bioconductor.org/packages/release/bioc/html/xcms.html         | 
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(th) Mn (GPC) PDI 
PHEA 1 38:1:0.1 88 4373 4141 8276 1.30 
PHEA 2 75:1:0.1 85 7728 7716 14688 1.18 
PHEA 3 144:1:0.1 91 15961 15553 26676 1.24 
a  Conversion % was calculated using the following equation: X = [1 – [(I5.9)/(I4.6-4.9)]] × 100% 
b Mn determined by NMR were calculated by the equation: Mn = MWDBTC +  (NHEA x MWHEA) 
where repeating units of HEA (NHEA) was calculated from the integrals of the two peak areas 
from 7.1-7.4 ppm and 4.6-4.9 ppm. NHEA = (I4.6-4.8 x 5)/(I7.1-7.4) 
c Theoretical Mw was determine by the equation: MWDBTC + (conversion/100) × (n HEA / n 
DBTC ) × MWHEA 
Table S2.  Summary of PHEA star formation of varying lengths of homopolymer and XL 







Mn homopolymer ᵝ 
(GPC) 




Arm number  
2* Mn star/Mn homopolymer
1 4373 8300 1:6:4 0 1.30 
1-4-2 4373 8300 1:6:4 2 11500 1.34 3 
1-4-6 4373 8300 1:6:4 6 11500 1.34 3 
1-4-12 4373 8300 1:6:4 12 13400 1.45 3 
1-4-24 4373 8300 1:6:4 24 14800 1.49 4 
1-4-24* 4373 8300 1:6:4 24 15600 1.51 4 
1 4373 8300 1:6:8 0 1.30 
1-8-2 4373 8300 1:6:8 2 10200 1.28 2 
1-8-6 4373 8300 1:6:8 6 18200 1.65 4 
1-8-12 4373 8300 1:6:8 12 26500 1.70 6 
1-8-24 4373 8300 1:6:8 24 31200 1.75 8 
1-8-24* 4373 8300 1:6:8 24 40100 1.60 10 
1 4373 8300 1:6:16 0 1.30 
1-16-2† 4373 8300 1:6:16 2 48300 1.92 12 
2 7728 14700 1:12:4 0 1.24 
2-4-2 7728 14700 1:12:4 2 17400 1.32 2 
2-4-6 7728 14700 1:12:4 6 17700 1.44 2 
2-4-12 7728 14700 1:12:4 12 18600 1.46 3 
2-4-24 7728 14700 1:12:4 24 18600 1.47 3 
2-4-24* 7728 14700 1:12:4 24 18400 1.49 3 
2 7728 14700 1:12:8 0 1.24 
2-8-2 7728 14700 1:12:8 2 23000 1.37 3 
2-8-6 7728 14700 1:12:8 6 30400 1.53 4 
2-8-12 7728 14700 1:12:8 12 33000 1.54 4 
2-8-24 7728 14700 1:12:8 24 34200 1.56 5 
2-8-24* 7728 14700 1:12:8 24 33738 1.54 5 
2 7728 14700 1:12:16 0 1.24 
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2-16-2 7728 14700 1:12:16 2 50200 1.69 7 
2-16-6 7728 14700 1:12:16 6 70300 1.91 10 
2-16-12 7728 14700 1:12:16 12 78400 1.92 11 
2-16-24 7728 14700 1:12:16 24 82200 1.94 11 
2-16-24* 7728 14700 1:12:16 24 82800 1.98 11 
3 15961 26700 1:14:16 0 1.24 
3-16-2 15961 26700 1:14:16 2 52000 1.53 4 
3-16-6 15961 26700 1:14:16 6 66000 1.62 5 
3-16-12 15961 26700 1:14:16 12 66800 1.67 5 
3-16-24 15961 26700 1:14:16 24 71500 1.65 5 
3-16-24* 15961 26700 1:14:16 24 66800 1.67 5 
3 15961 26700 1:14:24 0 1.24 
3-24-2 15961 26700 1:14:24 2 69700 1.78 5 
3-24-6 15961 26700 1:14:24 6 102600 2.07 8 
3-24-12 15961 26700 1:14:24 12 106000 2.16 8 
3-24-24 15961 26700 1:14:24 24 116600 2.13 9 
3-24-24* 15961 26700 1:14:24 24 110000 2.26 8 
3 15961 26700 1:14:32 0 1.24 
3-32-2 15961 26700 1:14:32 2 123000 3.07 9 
3-32-6 15961 26700 1:14:32 6 143600 3.73 11 
3-32-12 15961 26700 1:14:32 12 160000 3.89 12 
3-32-24 15961 26700 1:14:32 24 172000 3.88 13 
3-32-24* 15961 26700 1:14:32 24 177900 4.24 13 
* indicates an addition of 1.7, 0.86 and 0.45 mg of AIBN in 4373, 7728 and 15961
homopolymer reaction mixtures respectively after 12 h of polymerization.
† After 2h of polymerization mixture formed a gel. 
ᵝ Value reported to nearest hundred 
Entry 2-16-24 conditions were implemented on a larger scale. 
188
Figure S1. Promotion of IAPP fibrillization and remodeling of IAPP amyloids by PHEA 
arms. Concentration of IAPP in all experiments is 25 µM. (A) ThT fluorescence of IAPP in 
the presence of PHEA arms over 24 h. Dotted lines represent sigmoidal curve fitting (least 
squares fit), error is SEM. (B) Secondary structure transitions in IAPP mapped by CD 
spectroscopy at 0, 2.5 and 24 h time points. Lines are intended to guide the eye. (C) TEM 
imaging of fibrillating IAPP (IAPP) and mature IAPP amyloids (Amyloid) in the presence 
and absence of PHEA arms after 24 h incubation. Scale = 100 nm. (D) Structural analysis of 
amyloid fibrils visualized in (C).   
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Figure S2. Protective effect of PHEA arms against IAPP-mediated cytotoxicity in βTC6 
pancreatic β-cells. 
Figure S3. Normalized circular dichroism spectra of IAPP (25 µM) alone and in the presence 
of PHEA stars and arms after incubation in Milli-Q water at 0, 2.5 and 24 h. 
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Figure S4. Simulations of various PHEA stars. (A-C) Chemical structures of the 2-arm, 6-
arm, and 8-arm PHEA modelled in simulations. (D) The radius of gyration (Rg) of 2-arm 
PHEA increased approximately linearly with the degree of polymerization n (up to ~ 40), 
suggesting the polymers are rather rigid. (E) Autocorrelation analysis of 2-arm PHEAs. The 
exponential fitting returned a persistence length of n~18 (i.e., corresponding to a Kuhn length 
of ~36), which confirmed the rigidity of PHEA polymers. (F) Time evolution of Rg and 
ellipticity of an 8-arm PHEA model depicted in panel (C). The equilibrated Rg of ~ 45Å is 
consistent with the experimentally measured hydrodynamic diameter of ~ 9.8 nm in Fig. 1C. 
A high ellipticity value suggests that the 8-arm PHEA adopted a non-spherical conformation 
(e.g., an equilibrated snapshot with three different views in the inset). Error bars indicate s.e. 
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Figure S5. Binding of IAPP with a PHEA star in simulations. (A) Time evolution of the size 
of the largest IAPP aggregates in DMD simulations of 6 IAPPs with and w/o the presence of 
a 6-arm PHEA. Error bars indicate s.e. (B) Binding probability of each IAPP residue with 
PHEA. Residues with the highest binding probabilities are highlighted in red. (C&D) The 
secondary structure contents in terms of β-sheets and helices of the equilibrated IAPP 
residues, averaged for the last 25 ns of the DMD simulations. 
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Figure S6. β-sheet formation in IAPP aggregates is correlated with their binding with PHEA. 
Secondary structure change of IAPP peptides (C1 ~ C6) is shown in the upper panel, while 
the PHEA-binding of each peptide is illustrated as red pixels in the bottom panel accordingly. 
Snapshots at the 36 ns and 79 ns are used to display the structure of the modeled system. It’s 
noticeable that one of the peptides (C5) is not clustered in the IAPP aggregate. 
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Figure S7. Binding with PHEA star reduced the aggregation lag time and induced the 
heterogeneity in the fibril elongation rate of IAPP self-association. (A) Time evolution of the 
total number of IAPP residues in β-sheet content with and w/o the presence of a 6-arm PHEA. 
(B-C) Distributions of the lag time and elongation rate of 20 independent simulations. 
194
195 
6.2. Complete Bibliography 
Pertaining to a complete list of references cited in this thesis, ordered alphabetically. 
References herein are numbered only as a visual and navigational aid – as such, citation 
numbers in this bibliography do not correspond to in-text citations in thesis chapters.  
(1) Abbott, A.; Dolgin, E., Leading Alzheimer's Theory Survives Drug Failure. Nature 2016, 540,
15-16.
(2) Abedini, A.; Cao, P.; Plesner, A.; He, M.; Derk, J.; Patil, S. A.; Rosario, R.; Lonier, J.; Song,
F.; Koh, H.; Li, H.; Raleigh, D. P.; Schmidt, A. M., RAGE binds preamyloid IAPP intermediates and
mediates pancreatic β cell proteotoxicity. J. Clin. Invest. 2018, 128, 682-698.
(3) Abedini, A.; Raleigh, D. P., The Role of His-18 in Amyloid Formation by Human Islet Amyloid
Polypeptide. Biochemistry 2005, 44, 16284-16291.
(4) Adamcik, J.; Jung, J.-M.; Flakowski, J.; De Los Rios, P.; Dietler, G.; Mezzenga, R.,
Understanding amyloid aggregation by statistical analysis of atomic force microscopy images. Nat.
Nanotechnol., 2010, 5, 423-428.
(5) Adamcik, J.; Mezzenga, R., Amyloid Polymorphism in the Protein Folding and Aggregation
Energy Landscape. Angew. Chem., Int. Ed. Engl. 2018, 57, 8370-8382.
(6) Adler-Abramovich, L.; Vaks, L.; Carny, O.; Trudler, D.; Magno, A.; Caflisch, A.; Frenkel, D.;
Gazit, E., Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat.
Chem. Biol. 2012, 8, 701-706.
(7) Aguilera, P.; Marcoleta, A.; Lobos-Ruiz, P.; Arranz, R.; Valpuesta, J. M.; Monasterio, O.;
Lagos, R., Identification of Key Amino Acid Residues Modulating Intracellular and In vitro Microcin
E492 Amyloid Formation. Front. Microbiol. 2016, 7, 35.
(8) Ahlschwede, K. M.; Curran, G. L.; Rosenberg, J. T.; Grant, S. C.; Sarkar, G.; Jenkins, R. B.;
Ramakrishnan, S.; Poduslo, J. F.; Kandimalla, K. K., Cationic carrier peptide enhances cerebrovascular
targeting of nanoparticles in Alzheimer's disease brain. Nanomedicine 2019, 16, 258-266.
(9) Akhavan, O.; Ghaderi, E.; Akhavan, A., Size-Dependent Genotoxicity of Graphene
Nanoplatelets in Human Stem Cells. Biomaterials 2012, 33, 8017-8025.
(10) Akhavan, O.; Ghaderi, E.; Hashemi, E.; Akbari, E., Dose-Dependent Effects of Nanoscale
Graphene Oxide on Reproduction Capability of Mammals. Carbon 2015, 95, 309-317.
(11) Alexandrescu, A. T., Amide Proton Solvent Protection in Amylin Fibrils Probed by Quenched
Hydrogen Exchange NMR. PLoS ONE 2013, 8, No. e56467.
(12) Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C., Factors Affecting the Clearance and
Biodistribution of Polymeric Nanoparticles. Mol. Pharmaceutics 2008, 5, 505-515.
196 
(13) Al-Garawi, Z. S.; McIntosh, B. A.; Neill-Hall, D.; Hatimy, A. A.; Sweet, S. M.; Bagley, M. C.;
Serpell, L. C., The Amyloid Architecture Provides a Scaffold for Enzyme-Like Catalysts. Nanoscale
2017, 9, 10773-10783.
(14) Allaire, J. J.; Xie, Y.; McPherson, J.; Luraschi, J.; Ushey, K.; Atkins, A.; Wickham, H.; Cheng,
J.; Chang, W. Rmarkdown: Dynamic Documents for R. https://CRAN.R-
project.org/package=rmarkdown (accessed Feb 19, 2018). 
(15) Altieri, F.; Di Stadio, C. S.; Severino, V.; Sandomenico, A.; Minopoli, G.; Miselli, G.; Di Maro,
A.; Ruvo, M.; Chambery, A.; Quagliariello, V.; Masullo, M.; Rippa, E.; Arcari, P., Anti-amyloidogenic
property of human gastrokine 1. Biochimie 2014, 106, 91-100.
(16) Andreetto, E.; Yan, L.-M.; Tatarek-Nossol, M.; Velkova, A.; Frank, R.; Kapurniotu, A.,
Identification of Hot Regions of the Aβ–IAPP Interaction Interface as High-Affinity Binding Sites in
both Cross- and Self-Association. Angew. Chem. Int. Ed., Engl. 2010, 49, 3081-3085.
(17) Arimon, M.; Grimminger, V.; Sanz, F.; Lashuel, H. A., Hsp104 Targets Multiple Intermediates
on the Amyloid Pathway and Suppresses the Seeding Capacity of Aβ Fibrils and Protofibrils. J. Mol.
Biol. 2008, 384, 1157-1173.
(18) Arya, S.; Kumari, A.; Dalal, V.; Bhattacharya, M.; Mukhopadhyay, S., Appearance of annular
ring-like intermediates during amyloid fibril formation from human serum albumin. Phys. Chem. Chem.
Phys. 2015, 17, 22862-22871.
(19) Aso, E.; Martinsson, I.; Appelhans, D.; Effenberg, C.; Benseny-Cases, N.; Cladera, J. C.;
Gouras, G.; Ferrer, I.; Klementieva, O., Poly(propylene imine) dendrimers with histidine-maltose shell
as novel type of nanoparticles for synapse and memory protection. Nanomedicine 2019, 17, 198-209.
(20) Audas, T. E.; Audas, D. E.; Jacob, M. D.; Ho, J. J. D.; Khacho, M.; Wang, M.; Perera, J. K.;
Gardiner, C.; Bennett, C. A.; Head, T.; Kryvenko, O. N.; Jorda, M.; Daunert, S.; Malhotra, A.; Trinkle-
Mulcahy, L.; Gonzalgo, M. L.; Lee, S., Adaptation to Stressors by Systemic Protein Amyloidogenesis.
Dev. Cell 2016, 39, 155-168.
(21) Auluck, P. K.; Chan, H. Y. E.; Trojanowski, J. Q.; Lee, V. M. Y.; Bonini, N. M., Chaperone
Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease. Science 2002, 295,
865-868.
(22) Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Weinreb, O.; Youdim, M. B. H., Physiological
and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic
use of iron-chelators. BMC Neurosci. 2008, 9 (Suppl 2), S2.
(23) Babych, M.; Bertheau-Mailhot, G.; Zottig, X.; Dion, J.; Gauthier, L.; Archambault, D.;
Bourgault, S., Engineering and evaluation of amyloid assemblies as a nanovaccine against the
Chikungunya virus. Nanoscale 2018, 10, 19547-19556.
(24) Badman, M. K.; Pryce, R. A.; Chargé, S. B. P.; Morris, J. F.; Clark, A., Fibrillar islet amyloid
polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation. Cell Tissue
Res. 1998, 291, 285-294.
197 
(25) Bag, N.; Ali, A.; Chauhan, V. S.; Wohland, T.; Mishra, A., Membrane destabilisation by
monomeric hIAPP observed by imaging fluorescence correlation spectroscopy. Chem. Commun. 2013,
49, 9155-9157.
(26) Ban, D. K.; Paul, S., Nano Zinc Oxide Inhibits Fibrillar Growth and Suppresses Cellular
Toxicity of Lysozyme Amyloid. ACS Appl. Mater. Interfaces 2016, 8, 31587-31601.
(27) Baptiste, A. gridExtra: Miscellaneous Functions for "Grid" Graphics. https://CRAN.R-
project.org/package=gridExtra.
(28) Barrajón-Catalán, E.; Herranz-López, M.; Joven, J.; Segura-Carretero, A.; Alonso-Villaverde,
C.; Menéndez, J. A.; Micol, V., Molecular Promiscuity of Plant Polyphenols in the Management of
Age-Related Diseases: Far Beyond Their Antioxidant Properties. Adv. Exp. Med. Biol. 2014, 824, 141-
159.
(29) Bartlett, A. I.; Radford, S. E., An expanding arsenal of experimental methods yields an
explosion of insights into protein folding mechanisms. Nat. Struc. Mol. Biol. 2009, 16, 582-588.
(30) Barton, S. M.; Janve, V. A.; McClure, R.; Anderson, A.; Matsubara, J. A.; Gore, J. C.; Pham,
W., Lipopolysaccharide Induced Opening of the Blood Brain Barrier on Aging 5XFAD Mouse Model.
J. Alzheimers Dis. 2019, 67, 503-513.
(31) Bauer, P. O.; Goswami, A.; Wong, H. K.; Kurosawa, M.; Yamada, M.; Miyazaki, H.;
Matsumoto, G.; Kino, Y.; Nagai, Y.; Nukina, N., Harnessing chaperone-mediated autophagy for the
selective degradation of mutant huntingtin protein. Nat. Biotechnol. 2010, 28, 256-263.
(32) Bellomo, G.; Bologna, S.; Gonnelli, L.; Ravera, E.; Fragai, M.; Lelli, M.; Luchinat, C.,
Aggregation kinetics of the Aβ1–40 peptide monitored by NMR. Chem. Commun. 2018, 54, 7601-7604.
(33) Benseny-Cases, N.; Klementieva, O.; Cladera, J., Dendrimers antiamyloidogenic potential in
neurodegenerative diseases. New J. Chem. 2012, 36, 211-216.
(34) Bergmann, S. R.; Ferguson, T. B.; Sobel, B. E., Effects of amphiphiles on erythrocytes,
coronary arteries, and perfused hearts. Am. J. Physiol. 1981, 240, H229-H237.
(35) Bertrand, N.; Grenier, P.; Mahmoudi, M.; Lima, E. M.; Appel, E. A.; Dormont, F.; Lim, J.-M.;
Karnik, R.; Langer, R.; Farokhzad, O. C., Mechanistic Understanding of In Vivo Protein Corona
Formation on Polymeric Nanoparticles and Impact on Pharmacokinetics. Nat. Commun. 2017, 8, No.
777.
(36) Betsholtz, C.; Christmansson, L.; Engström, U.; Rorsman, F.; Svensson, V.; Johnson, K. H.;
Westermark, P., Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains
differences in islet amyloid formation between species. FEBS Lett. 1989, 251, 261-264.
(37) Bieschke, J.; Herbst, M.; Wiglenda, M.; Friedrich, R. P.; Boeddrich, A.; Schiele, F.; Kleckers,
D.; del Amo, J. M. L.; Grüning, B. A.; Wang, Q.; Schmidt, M. R.; Lurz, R.; Anwyl, R.; Schnoegl, S.;
Fändrich, M.; Frank, R. F.; Reif, B.; Günther, S.; Walsh, D. M.; Wanker, E. E., Small-molecule
conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils. Nat. Chem. Biol. 2011, 8, 93-
101.
198 
(38) Bieschke, J.; Russ, J.; Friedrich, R. P.; Ehrnhoefer, D. E.; Wobst, H.; Neugebauer, K.; Wanker,
E. E., EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc.
Natl. Acad. Sci. U.S.A. 2010, 107, 7710-7715.
(39) Bilia, A. R.; Nardiello, P.; Piazzini, V.; Leri, M.; Bergonzi, M. C.; Bucciantini, M.; Casamenti,
F., Successful Brain Delivery of Andrographolide Loaded in Human Albumin Nanoparticles to
TgCRND8 Mice, an Alzheimer's Disease Mouse Model. Front. Pharmacol. 2019, 10, 910.
(40) Birol, M.; Kumar, S.; Rhoades, E.; Miranker, A. D., Conformational switching within dynamic
oligomers underpins toxic gain-of-function by diabetes-associated amyloid. Nat. Commun. 2018, 9,
1312.
(41) Blanco, L. P.; Evans, M. L.; Smith, D. R.; Badtke, M. P.; Chapman, M. R., Diversity,
Biogenesis and Function of Microbial Amyloids. Trends Microbiol. 2012, 20, 66-73.
(42) Bobylev, A. G.; Kraevaya, O. A.; Bobyleva, L. G.; Khakina, E. A.; Fadeev, R. S.; Zhilenkov,
A. V.; Mishchenko, D. V.; Penkov, N. V.; Teplov, I. Y.; Yakupova, E. I.; Vikhlyantsev, I. M.; Troshin,
P. A., Anti-amyloid activities of three different types of water-soluble fullerene derivatives. Colloids
Surf. B Biointerfaces 2019, 183, 110426.
(43) Bolisetty, S.; Harnau, L.; Jung, J.; Mezzenga, R., Gelation, Phase Behavior, and Dynamics of
β-Lactoglobulin Amyloid Fibrils at Varying Concentrations and Ionic Strengths. Biomacromolecules
2012, 13, 3241-3252.
(44) Bolisetty, S.; Mezzenga, R., Amyloid-carbon hybrid membranes for universal water
purification. Nat. Nanotechnol. 2016, 11, 365-372.
(45) Bongiovanni, M. N.; Aprile, F. A.; Sormanni, P.; Vendruscolo, M., A Rationally Designed
Hsp70 Variant Rescues the Aggregation-Associated Toxicity of Human IAPP in Cultured Pancreatic
Islet β-Cells. Int. J. Mol. Sci. 2018, 19, 1443.
(46) Borchi, E.; Bargelli, V.; Guidotti, V.; Berti, A.; Stefani, M.; Nediani, C.; Rigacci, S., Mild
exposure of RIN-5F β-cells to human islet amyloid polypeptide aggregates upregulates antioxidant
enzymes via NADPH oxidase-RAGE: An hormetic stimulus. Redox Biol. 2014, 2, 114-122.
(47) Brender, J. R.; Hartman, K.; Nanga, R. P. R.; Popovych, N.; de la Salud Bea, R.; Vivekanandan,
S.; Marsh, E. N. G.; Ramamoorthy, A., Role of Zinc in Human Islet Amyloid Polypeptide Aggregation.
J. Am. Chem. Soc. 2010, 132, 8973-8983.
(48) Breydo, L.; Newland, B.; Zhang, H.; Rosser, A.; Werner, C.; Uversky, V. N.; Wang, W., A
hyperbranched dopamine-containing PEG-based polymer for the inhibition of α-synuclein fibrillation.
Biochem. Biophys. Res. Commun. 2016, 469, 830-835.
(49) Bruno, E.; Pereira, C.; Roman, K. P.; Takiguchi, M.; Kao, P.-Y.; Nogaj, L. A.; Moffet, D. A.,
IAPP aggregation and cellular toxicity are inhibited by 1,2,3,4,6-penta-O-galloyl-β-D-glucose. Amyloid
2013, 20, 34-38.
(50) Cabaleiro-Lago, C.; Lynch, I.; Dawson, K. A.; Linse, S., Inhibition of IAPP and IAPP(20-29)
Fibrillation by Polymeric Nanoparticles. Langmuir 2009, 26, 3453-3461.
199 
(51) Cabaleiro-Lago, C.; Quinlan-Pluck, F.; Lynch, I.; Lindman, S.; Minogue, A. M.; Thulin, E.;
Walsh, D. M.; Dawson, K. A.; Linse, S., Inhibition of Amyloid β Protein Fibrillation by Polymeric
Nanoparticles. J. Am. Chem. Soc. 2008, 130, 15437-15443.
(52) Cadavez, L.; Montane, J.; Alzarraz-Vizán, G.; Visa, M.; Vidal-Fàbrega, L.; Servitja, M.;
Novials, A., Chaperones Ameliorate Beta Cell Dysfunction Associated with Human Islet Amyloid
Polypeptide Overexpression. PLoS ONE 2014, 9, e101797.
(53) Camargo, D. C. R.; Garg, D.; Buday, K.; Franko, A.; Camargo, A. R.; Schmidt, F.; Cox, S. J.;
Suladze, S.; Haslbeck, M.; Mideksa, Y. G.; Gemmecker, G.; Aichler, M.; Mettenleiter, G.; Schulz, M.;
Walch, A. K.; de Angelis, M. H.; Feige, M. J.; Sierra, C. A.; Conrad, M.; Tripsianes, K.; Ramamoorthy,
A.; Reif, B., hIAPP forms toxic oligomers in plasma. Chem. Commun. 2018, 54, 5426-5429.
(54) Cano, A.; Ettcheto, M.; Chang, J.-H.; Barroso, E.; Espina, M.; Kühne, B. A.; Barenys, M.;
Auladell, C.; Folch, J.; Souto, E. B.; Camins, A.; Turowski, P.; García, M. L., Dual-drug loaded
nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of
EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. J. Control. Release 2019, 301, 62-75.
(55) Cao, P.; Abedini, A.; Wang, H.; Tu, L.-T.; Zhang, X.; Schmidt, A. M.; Raleigh, D. P., Islet
amyloid polypeptide toxicity and membrane interactions. Proc. Natl. Acad. Sci. USA 2013, 110, 19279-
19284.
(56) Cao, P.; Raleigh, D. P., Analysis of the Inhibition and Remodeling of Islet Amyloid Polypeptide
Amyloid Fibers by Flavanols. Biochemistry 2012, 51, 2670-2683.
(57) Carrotta, R.; Canale, C.; Diaspro, A.; Trapani, A.; Biagio, P. L. S.; Bulone, D., Inhibiting effect
of α(s1)-casein on Aβ(1-40) fibrillogenesis. Biochim. Biophys. Acta 2012, 1820, 124-132.
(58) Casas, S.; Gomis, R.; Gribble, F. M.; Altirriba, J.; Knuutila, S.; Novials, A., Impairment of the
Ubiquitin-Proteasome Pathway is a Downstream Endoplasmic Reticulum Stress Response Induced by
Extracellular Human Islet Amyloid Polypeptide and Contributes to Pancreatic β-cell Apoptosis.
Diabetes 2007, 56, 2284-2294.
(59) Cedervall, T.; Lynch, I.; Lindman, S.; Berggård, T.; Thulin, E.; Nilsson, H.; Dawson, K. A.;
Linse, S., Understanding the Nanoparticle-Protein Corona Using Methods to Quantify Exchange Rates
and Affinities of Proteins for Nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 2050-2055.
(60) Chargé, S. B. P.; Esiri, M. M.; Bethune, C. A.; Hansen, B. C.; Clark, A., Apolipoprotein E is
Associated With Islet Amyloid and Other Amyloidoses: Implications for Alzheimer's Disease. J.
Pathol. 1996, 179, 443-447.
(61) Charif, D.; Lobry, J. R., SeqinR 1.0-2: a contributed package to the R project for statistical
computing devoted to biological sequences retrieval and analysis. In Structural approaches to sequence
evolution: Molecules, networks, populations, Bastolla, U.; Porto, M.; Roman, H. E.; Vendruscolo, M.,
Eds. Springer Verlag: New York, 2007.
(62) Chen, H. VennDiagram: Generate High-Resolution Venn and Euler Plots. https://CRAN.R-
project.org/package=VennDiagram.
200 
(63) Chen, J.; Armstrong, A. H.; Koehler, A. N.; Hecht, M. H., Small Molecule Microarrays Enable
the Discovery of Compounds that Bind the Alzheimer's Aβ Peptide and Reduce its Cytotoxicity. J. Am.
Chem. Soc. 2010, 132, 17015-17022.
(64) Chen, L.; Wei, Y.; Wang, X.; He, R., d-Ribosylated Tau forms globular aggregates with high
cytotoxicity. Cell. Mol. Life Sci. 2009, 66, 2559-2571.
(65) Chen, L.; Wei, Y.; Wang, X.; He, R., Ribosylation Rapidly Induces α-Synuclein to Form Highly
Cytotoxic Molten Globules of Advanced Glycation End Products. PLoS ONE 2010, 5, e9052.
(66) Chen, S. W.; Drakulic, S.; Deas, E.; Ouberai, M.; Aprile, F. A.; Arranz, R.; Ness, S.; Roodveldt,
C.; Guilliams, T.; De-Genst, E. J.; Klenerman, D.; Wood, N. W.; Knowles, T. P. J.; Alfonso, C.; Ricas,
G.; Abramov, A. Y.; Valpuesta, J. M.; Dobson, C. M.; Cremades, N., Structural characterization of
toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc. Natl. Acad. Sci.
U.S.A. 2015, 112, E1194-E2003.
(67) Cheng, C.-H.; Lin, K.-J.; Hong, C.-T.; Wu, D.; Chang, H.-M.; Liu, C.-H.; Hsiao, I.-T.; Yang,
C.-P.; Liu, Y.-C.; Hu, C.-J., Plasmon-Activated Water Reduces Amyloid Burden and Improves Memory
in Animals with Alzheimer's Disease. Sci. Rep. 2019, 9, 13252.
(68) Cheng, I. H.; Scearce-Levie, K.; Legleiter, J.; Palop, J. J.; Gerstein, H.; Bien-Ly, N.; Puoliväli,
J.; Lesné, S.; Ashe, K. H.; Muchowski, P. J.; Mucke, L., Accelerating Amyloid-β Fibrillization Reduces
Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models. J. Biol. Chem. 2007,
282, 23818-23828.
(69) Chien, V.; Aitken, J. F.; Zhang, S.; Buchanan, C. E.; Hickey, A.; Brittain, T.; Cooper, G. J.;
Loomes, K. M., The chaperone proteins HSP70, HSP40/DnaJ and GRP78/BiP suppress misfolding and
formation of β-sheet-containing aggregates by human amylin: a potential role for defective chaperone
biology in Type 2 diabetes. Biochem. J. 2010, 432, 113-121.
(70) Chimienti, F.; Favier, A.; Seve, M., ZnT-8, a pancreatic beta-cell-specific zinc transporter.
BioMetals 2005, 18, 313-317.
(71) Chiti, F.; Calamai, M.; Taddei, N.; Stefani, M.; Ramponi, G.; Dobson, C. M., Studies of the
aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc.
Natl. Acad. Sci. U.S.A. 2002, 99, 16419-16426.
(72) Chiti, F.; Dobson, C. M., Protein Misfolding, Functional Amyloid, and Human Disease. Annu.
Rev. Biochem. 2006, 75, 333-366.
(73) Choi, S. H.; Kim, Y. H.; Hebisch, M.; Sliwinski, C.; Lee, S.; D'Avanzo, C.; Chen, H.; Hooli,
B.; Asselin, C.; Muffat, J.; Klee, J. B.; Zhang, C.; Wainger, B. J.; Peitz, M.; Kovacs, D. M.; Woolf, C.
J.; Wagner, S. L.; Tanzi, R. E.; Kim, D. Y., A three-dimensional human neural cell culture model of
Alzheimer's disease. Nature 2014, 515, 274-278.
(74) Choi, S. H.; Kim, Y. H.; Quinti, L.; Tanzi, R. E.; Kim, D. Y., 3D culture models of Alzheimer’s
disease: a road map to a “cure-in-a-dish”. Mol. Neurodegener. 2016, 11, 75.
201 
(75) Chowdhury, S. R.; Agarwal, M.; Meher, N.; Muthuraj, B.; Iyer, P. K., Modulation of Amyloid
Aggregates into Nontoxic Coaggregates by Hydroxyquinoline Appended Polyfluorene. ACS Appl.
Mater. Interfaces 2016, 8, 13309-13319.
(76) Clinton, L. K.; Blurton-Jones, M.; Myczek, K.; Trojanowski, J. Q.; LaFerla, F. M., Synergistic
Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive
Decline. J. Neurosci. 2010, 30, 7281-7289.
(77) Cox, D.; Selig, E.; Griffin, M. D. W.; Carver, J. A.; Ecroyd, H., Small Heat-shock Proteins
Prevent α-Synuclein Aggregation via Transient Interactions and Their Efficacy Is Affected by the Rate
of Aggregation. J. Biol. Chem. 2016, 291, 22618-22629.
(78) Cox, J.; Mann, M., MaxQuant Enables High Peptide Identification Rates, Individualized
P.P.B.-Range Mass Accuracies and Proteome-Wide Protein Quantification. Nat. Biotechnol. 2008, 26,
1367-1372.
(79) De Baets, G.; Reumers, J.; Blanco, J. D.; Dopazo, J.; Schymkowitz, J.; Rousseau, F., An
Evolutionary Trade-Off between Protein Turnover Rate and Protein Aggregation Favors a Higher
Aggregation Propensity in Fast Degrading Proteins. PLoS Comput. Biol. 2011, 7, e1002090.
(80) De Baets, G.; Van Doorn, L.; Rousseau, F.; Shymkowitz, J., Increased Aggregation Is More
Frequently Associated to Human Disease-Associated Mutations Than to Neutral Polymorphisms. PLoS
Comput. Biol. 2015, 11, e1004374.
(81) Debnath, K.; Shekhar, S.; Kumar, V.; Jana, N. R.; Jana, N. R., Efficient Inhibition of Protein
Aggregation, Disintegration of Aggregates, and Lowering of Cytotoxicity by Green Tea Polyphenol-
Based Self-Assembled Polymer Nanoparticles. ACS Appl. Mater. Interfaces 2016, 8, 20309-20318.
(82) Despa, S.; Margulies, K. B.; Chen, L.; Knowlton, A. A.; Havel, P. J.; Taegtmeyer, H.; Bers, D.
M.; Despa, F., Hyperamylinemia Contributes to Cardiac Dysfunction in Obesity and Diabetes: A Study
in Humans and Rats. Circ. Res. 2012, 110, 598-608.
(83) Despa, S.; Margulies, K. B.; Chen, L.; Knowlton, A. A.; Havel, P. J.; Taegtmeyer, H.; Bers, D.
M.; Despa, F., Hyperamylinemia Contributes to Cardiac Dysfunction in Obesity and Diabetes: A Study
in Humans and Rats. Circ. Res. 2012, 110, 598-608.
(84) D'Este, L.; Wimalawansa, S. J.; Renda, T. G., Distribution of Amylin-Immunoreactive Neurons
in the Monkey Hypothalamus and their Relationships with the Histaminergic System. Arch. Histol.
Cytol. 2001, 64, 295-303.
(85) DeToma, A. S.; Salamekh, S.; Ramamoorthy, A.; Lim, M. H., Misfolded Proteins in
Alzheimer's Disease and Type II Diabetes. Chem. Soc. Rev. 2012, 41, 608-621.
(86) Dikic, I.; Elazar, Z., Mechanism and medical implications of mammalian autophagy. Nat. Rev.
Mol. Cell Biol. 2018, 19, 349-364.
(87) Ding, F.; Dokholyan, N., Emergence of Protein Fold Families through Rational Design. PLoS
Comput. Biol., 2006, 2, e85.
202 
(88) Ding, F.; Dokholyan, N., Incorporating Backbone Flexibility in MedusaDock Improves
Ligand-Binding Pose Prediction in the CSAR2011 Docking Benchmark. J. Chem. Inf. Model., 2013,
53, 1871-1879.
(89) Ding, F.; Radic, S.; Chen, R.; Chen, P.; Geitner, N. K.; Brown, J. M.; Ke, P. C., Direct
observation of a single nanoparticle-ubiquitin corona formation. Nanoscale 2013, 5, 9162-9169.
(90) Ding, F.; Tsao, D.; Nie, H.; Dokholyan, N. V., Ab initio folding of proteins with all-atom
discrete molecular dynamics. Structure, 2008, 16, 1010-1018.
(91) Dobson, C. M., Principles of protein folding, misfolding and aggregation. Semin. Cell Dev.
Biol. 2004, 15, 3-16.
(92) Docter, D.; Westmeier, D.; Markiewicz, M.; Stolte, S.; Knauer, S. K.; Stauber, R. H., The
Nanoparticle Biomolecule Corona: Lessons Learned – Challenge Accepted? Chem. Soc. Rev. 2015, 44,
6094-6121.
(93) Dodart, J.-C.; Bales, K. R.; Paul, S. M., Immunotherapy for Alzheimer's disease: will
vaccination work? Trends Mol. Med. 2003, 9, 85-87.
(94) Dominy, S. S.; Lynch, C.; Ermini, F.; Benedyk, M.; Marczyk, A.; Konradi, A.; Nguyen, M.;
Haditsch, U.; Raha, D.; Griffin, C.; Holsinger, L. J.; Arastu-Kapur, S.; Kaba, S.; Lee, A.; Ryder, M. I.;
Potempa, B.; Mydel, P.; Hellvard, A.; Adamowicz, K.; Hasturk, H.; Walker, G. D.; Reynolds, E. C.;
Faull, R. L. M.; Curtis, M. A.; Dragunow, M.; Potempa, J., Porphyromonas gingivalis in Alzheimer’s
disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv.
2019, 5, eaau3333.
(95) Dong, X.; Svantesson, T.; Sholts, S. B.; Wallin, C.; Jarvet, J.; Gräslund, A.; Wärmländer, S. K.
T. S., Copper ions induce dityrosine-linked dimers in human but not in murine islet amyloid polypeptide
(IAPP/amylin). Biochem. Biophys. Res. Communs. 2019, 510, 520-524.
(96) Dowding, J. M.; Song, W.; Bossy, K.; Karakoti, A.; Kumar, A.; Kim, A.; Bossy, B.; Seal, S.;
Ellisman, M. H.; Perkins, G.; Self, W. T.; Bossy-Wetzel, E., Cerium oxide nanoparticles protect against
Aβ-induced mitochondrial fragmentation and neuronal cell death. Cell Death Differ. 2014, 21, 1622-
1632.
(97) Drummond, E.; Wisniewski, T., Alzheimer’s disease: experimental models and reality. Acta
Neuropathol. 2017, 133, 155-175.
(98) Du, Z.; Gao, N.; Guan, Y.; Ding, C.; Sun, Y.; Ren, J.; Qu, X., Rational Design of a “Sense and
Treat” System to Target Amyloid Aggregates Related to Alzheimer’s Disease. Nano Res. 2018, 11,
1987-1997.
(99) Duan, M.; Fan, J.; Huo, S., Conformations of islet amyloid polypeptide monomers in a
membrane environment: implications for fibril formation. PLoS ONE 2012, 7, e47150.
(100) Dzwolak, W., Chirality and Chiroptical Properties of Amyloid Fibrils. Chirality 2014, 26, 580-
587.
203 
(101) Eisenberg, D.; Jucker, M., The amyloid state of proteins in human diseases. Cell 2012, 148,
1188-1203.
(102) Engel, M. F. M.; Khemtémourian, L.; Kleijer, C. C.; Meeldijk, H. J. D.; Jacobs, J.; Verkleij, A.
J.; de Kruijff, B.; Killian, J. A.; Höppener, J. W. M., Membrane Damage by Human Islet Amyloid
Polypeptide Through Fibril Growth at the Membrane. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 6033-
6038.
(103) Evgrafova, Z.; Voigt, B.; Roos, A. H.; Hause, G.; Hinderberger, D.; Balbach, J.; Binder, W. H.,
Modulation of amyloid β peptide aggregation by hydrophilic polymers. Phys. Chem. Chem. Phys. 2019,
21, 20999-21006.
(104) Ezzat, K.; Pernemalm, M.; Palsson, S.; Roberts, T. C.; Jarver, P.; Dondalska, A.; Bestas, B.;
Sobkowiak, M. J.; Levanen, B.; Skold, M.; Thompson, E. A.; Saher, O.; Kari, O. K.; Lajunen, T.;
Ekström, E. S.; Nilsson, C.; Ischenko, Y.; Malm, T.; Wood, M. J. A.; Power, U. F.; Masich, S.; Linden,
A.; Sandberg, J. K.; Lehtio, J.; Spetz, A.-L.; Andaloussi, S. E. L., The viral protein corona directs viral
pathogenesis and amyloid aggregation. Nat. Commun. 2018, 10, 2331.
(105) Faridi, A.; Sun, Y.; Okazaki, Y.; Peng, G.; Gao, J.; Käkinen, A.; Faridi, P.; Zhao, M.; Javed, I.;
Purcell, A. W.; Davis, T. P.; Lin, S.; Oda, R.; Ding, F.; Ke, P. C., Mitigating Human IAPP
Amyloidogenesis In Vivo with Chiral Silica Nanoribbons. Small 2018, 14, 1802825.
(106) Ferreira, J.; Syrett, J.; Whittaker, M. R.; Haddleton, D. M.; Davis, T. P.; Boyer, C., Optimizing
the generation of narrow polydispersity 'arm-first' star polymers made using RAFT polymerization.
Polym. Chem., 2011, 2, 1671-1677.
(107) Ferrier, G. J. M.; Pierson, A. M.; Bloom, S. R.; Girgis, S. I.; Legon, S., Expression of the rat
amylin (IAPP/DAP) gene. J. Mol. Endocrinol. 1989, 3, R1-4.
(108) Filipek, S.; Krzysko, K. A.; Fotiadis, D.; Liang, Y.; Saperstein, D. A.; Engel, A.; Palczewski,
K., A concept for G protein activation by G protein-coupled receptor dimers: the transducin/rhodopsin
interface. Photochem. Photobiol. Sci. 2004, 3, 628-638.
(109) Fischer, M.; Appelhans, D.; Schwarz, S.; Klajnert, B.; Bryszewska, M.; Voit, B.; Rogers, M.,
Influence of Surface Functionality of Poly(propylene imine) Dendrimers on Protease Resistance and
Propagation of the Scrapie Prion Protein. Biomacromolecules 2010, 11, 1314-1325.
(110) Flanagan, P.; Lionetti, F., Lysozyme Distribution in Blood. Blood 1955, 10, 497-501.
(111) Foote, M.; Zhou, Y., 14-3-3 proteins in neurological disorders. Int. J. Biochem. Mol. Biol. 2012,
3, 152-164.
(112) Fowler, D. M.; Koulov, A. V.; Alory-Jost, C.; Marks, M. S.; Balch, W. E.; Kelly, J. W.,
Functional Amyloid Formation within Mammalian Tissue. PLoS Biol. 2006, 4, 0100-0107.
(113) Fox, N.; Schrementi, J.; Nishi, M.; Ohagi, S.; Chan, S. J.; Heisserman, J. A.; Westermark, G.
T.; Leckström, A.; Westermark, P.; Steiner, D. F., Human islet amyloid polypeptide transgenic mice as
a model of non‐insulin‐dependent diabetes mellitus (NIDDM). FEBS Lett. 1993, 323, 40-44.
204 
(114) Friedlich, A. L.; Tanzi, R. E.; Rogers, J. T., The 5'-untranslated region of Parkinson's disease
α-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry 2007, 12,
222-223.
(115) Friedrich, R. P.; Tepper, K.; Rönicke, R.; Soom, M.; Westermann, M.; Reymann, K.; Kaether,
C.; Fändrich, M., Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ
pathogenicity. Proc. Natl. Acad. Sci. U.S.A. 2009, 107, 1942-1947.
(116) Galvagnion, C.; Buell, A. K.; Meisl, G.; Michaels, T. C. T.; Vendruscolo, M.; Knowles, T. P.
J.; Dobson, C. M., Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation.
Nat. Chem. Biol. 2015, 11, 229-234.
(117) Gao, M.; Estel, K.; Seeliger, J.; Friedrich, R. P.; Dogan, S.; Wanker, E. E.; Winter, R.;
Ebbinghaus, S., Modulation of human IAPP fibrillation: cosolutes, crowders and chaperones. Phys.
Chem. Chem. Phys. 2015, 17, 8338-8348.
(118) Gao, M.; Winter, R., The Effects of Lipid Membranes, Crowding and Osmolytes on the
Aggregation, and Fibrillation Propensity of Human IAPP. J. Diabetes Res. 2015, 2015, 849017.
(119) Gao, N.; Sun, H.; Dong, K.; Ren, J.; Duan, T.; Xu, C.; Qu, X., Transition-metal-substituted
polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer’s disease. Nat. Commun.
2014, 5, 3422.
(120) Ge, X.; Kakinen, A.; Gurzov, E. N.; Pang, L.; Pilkington, E. H.; Separovic, F.; Davis, T. P.;
Ke, P. C.; Ding, F., Zinc-coordination and C-peptide complexation: a potential mechanism for the
endogenous inhibition of IAPP aggregation. Chem. Commun. 2017, 53, 9394-9397.
(121) Geng, J.; Li, M.; Ren, J.; Wang, E.; Qu, X., Polyoxometalates as Inhibitors of the Aggregation
of Amyloid β Peptides Associated with Alzheimer's Disease. Angew. Chem. Int Ed., Engl. 2011, 50,
4184-4188.
(122) Ghavami, M.; Rezaei, M.; Ejtehadi, R.; Lofti, M.; Shokrgozar, M. A.; Emamy, B. A.; Raush,
J.; Mahmoudi, M., Physiological Temperature Has a Crucial Role in Amyloid Beta in the Absence and
Presence of Hydrophobic and Hydrophilic Nanoparticles. ACS Chem. Neurosci. 2013, 4, 375-378.
(123) Gianneli, M.; Yan, Y.; Polo, E.; Peiris, D.; Aastrup, T.; Dawson, K. A., Novel QCM-Based
Method to Predict In Vivo behaviour of nanoparticles. Proc. Technol. 2017, 27, 197-200.
(124) Glabe, C. G., Structural Classification of Toxic Amyloid Oligomers. J. Biol. Chem. 2008, 283,
29639-29643.
(125) Gladytz, A.; Abel, B.; Risselada, H. J., Gold-Induced Fibril Growth: The Mechanism of
Surface-Facilitated Amyloid Aggregation. Angew. Chem. Int. Ed., Engl. 2016, 55, 11242-11246.
(126) Glickman, M. H.; Ciechanover, A., The Ubiquitin-Proteasome Proteolytic Pathway:
Destruction for the Sake of Construction. Physiol. Rev. 2001, 82, 373-428.
(127) Gong, W.; Liu, Z. H.; Zeng, C. H.; Peng, A.; Chen, H. P.; Zhou, H.; Li, L. S., Amylin
Deposition in the Kidney of Patients With Diabetic Nephropathy. Kidney Int. 2007, 72, 213-218.
205 
(128) Govers, S. K.; Mortier, J.; Adam, A.; Aertsen, A., Protein aggregates encode epigenetic
memory of stressful encounters in individual Escherichia coli cells. PLoS Biol. 2018, 16, e2003853.
(129) Govindan, P. N.; Gurzov, E. N.; Chen, P.; Pilkington, E. H.; Stanley, W. J.; Litwak, S. A.;
Davis, T. P.; Ke, P. C.; Ding, F., Graphene Oxide Inhibits hIAPP Amyloid Fibrillation and Toxicity in
Insulin-Producing NIT-1 Cells. Phys. Chem. Chem. Phys. 2015, 18, 94-100.
(130) Govindan, P. N.; Jemec, D. B.; Ding, F., CSAR Benchmark of Flexible MedusaDock in
Affinity Prediction and Nativelike Binding Pose Selection. J. Chem. Inf. Model., 2016, 56, 1042-1052.
(131) Govindan, P. N.; Käkinen, A.; Pilkington, E. H.; Davis, T. P.; Ke, P. C.; Ding, F., Stabilizing
Off-pathway Oligomers by Polyphenol Nanoassemblies for IAPP Aggregation Inhibition. Sci. Rep.
2016, 6, 19463.
(132) Grey, M.; Linse, S.; Nilsson, H.; Brundin, P.; Sparr, E., Membrane Interaction of α-Synuclein
in Different Aggregation States. J. Parkinsons Dis. 2011, 1, 359-371.
(133) Gsponer, J.; Babu, M. M., Cellular Strategies for Regulating Functional and Nonfunctional
Protein Aggregation. Cell Reports 2012, 2, 1425-1437.
(134) Guariguata, L.; Whiting, D. R.; Hambleton, I.; Beagley, J.; Linnenkamp, U.; Shaw, J. E., Global
estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 2014,
103, 137-149.
(135) Guerreiro, L. H.; Da Silva, D.; Ricci-Junior, E.; Girard-Dias, W.; Mascarenhas, C. M.; Sola-
Penna, M.; Miranda, K.; Lima, L. M. T. R., Polymeric particles for the controlled release of human
amylin. Colloids Surf. B Biointerfaces 2012, 94, 101-106.
(136) Guivernau, B.; Bonet, J.; Valls-Comamala, V.; Bosch-Morató, M.; Godoy, J. A.; Inestrosa, N.
C.; Perálvarez-Martin, A.; Fernández-Busquets, X.; Andreu, D.; Oliva, B.; Muñoz, F. J., Amyloid-β
Peptide Nitrotyrosination Stabilizes Oligomers and Enhances NMDAR-Mediated Toxicity. J. Neurosci.
2016, 36, 11693-11703.
(137) Guo, C.; Côté, S.; Mousseau, N.; Wei, G., Distinct Helix Propensities and Membrane
Interactions of Human and Rat IAPP1–19 Monomers in Anionic Lipid Bilayers. J. Phys. Chem. B 2015,
119, 3366-3376.
(138) Gupta, N. T.; Vander Heiden, J. A.; Uduman, M.; Gadala-Maria, D.; Yaari, G.; Kleinstein, S.
H., Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data.
Bioinformatics 2015, 31, 3356-3358.
(139) Gursky, O., Lipids in Protein Misfolding. Springer: Cham, Switzerland, 2015; Vol. 855.
(140) Gurzov, E. N.; Wang, B.; Pilkington, E. H.; Chen, P.; Käkinen, A.; Stanley, W. J.; Litwak, S.
A.; Hanssen, E. G.; Davis, T. P.; Ding, F.; Ke, P. C., Inhibition of hIAPP Amyloid Aggregation and
Pancreatic β-Cell Toxicity by OH-Terminated PAMAM Dendrimer. Small 2016, 12, 1615-1626.
(141) Gustafsson, M.; Thyberg, J.; Näslund, J.; Eliasson, E.; Johansson, J., Amyloid fibril formation
by pulmonary surfactant protein C. FEBS Lett. 1999, 464, 138-142.
206 
(142) Haataja, L.; Gurlo, T.; Huang, C. J.; Butler, P. C., Islet Amyloid in Type 2 Diabetes, and the
Toxic Oligomer Hypothesis. Endocrine Rev. 2008, 29, 303-316.
(143) Hadjidemetriou, M.; Al-Ahmady, Z.; Mazza, M.; Collins, R. F.; Dawson, K.; Kostarelos, K.,
In Vivo Biomolecule Corona Around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid
Bilayer Nanoscale Vesicles. ACS Nano 2015, 9, 8142-8156.
(144) Halgren, T. A., MMFF VI. MMFF94s option for energy minimization studies. J. Comput.
Chem., 1999, 20, 720-729.
(145) Hanwell, M. D.; Curtis, D. E.; Lonie, D. C.; Vandermeersch, T.; Zurek, E.; Hutchison, G. R.,
Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminf.,
2012, 4, 17.
(146) Haque, E.; Kamil, M.; Hasan, A.; Irfan, S.; Sheikh, S.; Khatoon, A.; Nazir, A.; Mir, S. S.,
Advanced Glycation End Products (AGEs), Protein Aggregation and their Crosstalk: New Insight in
Tumorigenesis. Glycobiology 2019, cwz073.
(147) Hartl, F. U.; Bracher, A.; Hayer-Hartl, M., Molecular chaperones in protein folding and
proteostasis. Nature 2011, 475, 324-332.
(148) Hartter, E.; Svoboda, T.; Ludvik, B.; Schuller, M.; Lell, B.; Kuenburg, E.; Brunnbauer, M.;
Woloszczuk, W.; Prager, R., Basal and Stimulated Plasma Levels of Pancreatic Amylin Indicate Its Co-
Secretion With Insulin in Humans. Diabetologia 1991, 34, 52-54.
(149) Hatami, A.; Monjazeb, S.; Milton, S.; Glabe, C. G., Familial Alzheimer's Disease Mutations
within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β
Peptide. J. Biol. Chem. 2017, 292, 3172-3185.
(150) Hategan, A.; Bianchet, M. A.; Steiner, J.; Karnaukhova, E.; Masliah, E.; Fields, A.; Lee, M. H.;
Dickens, A., M.; Haughey, N.; Dimitriadis, E. K.; Nath, A., HIV Tat Protein and Amyloid-β Peptide
Form Multifibrillar Structures That Cause Neurotoxicity. Nat. Struct. Mol. Biol. 2017, 24, 379-386.
(151) Hatters, D. M.; Minton, A. P.; Howlett, G. J., Macromolecular Crowding Accelerates Amyloid
Formation by Human Apolipoprotein C-II. J. Biol. Chem. 2002, 277, 7824-7830.
(152) He, X.-P.; Deng, Q.; Cai, L.; Wang, C.-Z.; Zang, Y.; Li, J.; Chen, G.-R.; Tian, H., Fluorogenic
Resveratrol-Confined Graphene Oxide For Economic and Rapid Detection Of Alzheimer's Disease.
ACS Appl. Mater. Interfaces 2014, 6, 5379-5382.
(153) Hernández, M. G.; Aguilar, A. G.; Burillo, J.; Oca, R. G.; Manca, A. M.; Novials, A.; Alcarraz-
Vizan, G.; Guillén, C.; Benito, M., Pancreatic β cells overexpressing hIAPP impaired mitophagy and
unbalanced mitochondrial dynamics. Cell Death Dis. 2018, 9, 481.
(154) Hickey, A. J. R.; Bradley, J. W. I.; Skea, G. L.; Middleditch, M. J.; Buchanan, C. M.; Phillips,
A. R. J.; Cooper, G. J. S., Proteins Associated with Immunopurified Granules from a Model Pancreatic
Islet β-Cell System: Proteomic Snapshot of an Endocrine Secretory Granule. J. Proteome Res. 2009, 8,
178-186.
207 
(155) Hinault, M.-P.; Cuendet, A. F. H.; Mattoo, R. U. H.; Mensi, M.; Dietler, G.; Lashuel, H. A.;
Goloubinoff, P., Stable α-Synuclein Oligomers Strongly Inhibit Chaperone Activity of the Hsp70
System by Weak Interactions with J-domain Co-chaperones. J. Biol. Chem. 2010, 285.
(156) Hirakura, Y.; Yiu, W. W.; Yamamoto, A.; Kagan, B. L., Amyloid peptide channels: blockade
by zinc and inhibition by Congo red (amyloid channel block). Amyloid 2000, 7, 194-199.
(157) Hong, L.; Huang, H.-C.; Jiang, Z.-F., Relationship between amyloid-beta and the ubiquitin–
proteasome system in Alzheimer’s disease. Neurol. Res. 2014, 36, 276-282.
(158) Hsu, Y.-H.; Chen, Y.-W.; Wu, M.-H.; Tu, L.-H., Protein Glycation by Glyoxal Promotes
Amyloid Formation by Islet Amyloid Polypeptide. Biophys. J. 2019, 116, 2304-2313.
(159) Hu, J.; Qiao, R.; Whittaker, M. R.; Quinn, J. F.; Davis, T. P., Synthesis of Star Polymers by
RAFT Polymerization as Versatile Nanoparticles for Biomedical Applications. Aust. J. Chem., 2017,
doi: 10.1071/CH17391
(160) Huang, B.; He, J.; Ren, J.; Yan, X.-Y.; Zeng, C.-M., Cellular Membrane Disruption by Amyloid
Fibrils Involved Intermolecular Disulfide Cross-Linking. Biochemistry 2009, 48, 5794-5800.
(161) Huang, C. C.; Faber, P. W.; Persichetti, F.; Mittal, V.; Vonsattel, J.-P.; MacDonald, M. E.;
Gusella, J. F., Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of
Normal Polyglutamine Proteins. Somatic Cell Mol. Genet. 1998, 24, 217-233.
(162) Huang, C. J.; Haataja, L.; Gurlo, T.; Butler, A. E.; Wu, X.; Soeller, W. C.; Butler, P. C.,
Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of
polyubiquitinated proteins by human islet amyloid polypeptide. Am. J. Physiol. Endocrinol. Metab.
2007, 293, E1656-E1662.
(163) Huang, C.-J.; Lin, C.-Y.; Haataja, L.; Gurlo, T.; Butler, A. E.; Rizza, R. A.; Butler, P. C., High
Expression Rates of Human Islet Amyloid Polypeptide Induce Endoplasmic Reticulum Stress–
Mediated β-Cell Apoptosis, a Characteristic of Humans With Type 2 but Not Type 1 Diabetes. Diabetes
2007, 56, 2016-2027.
(164) Huang, H.; Li, P.; Zhang, M.; Yu, Y.; Huang, Y.; Gu, H.; Wang, C.; Yang, Y., Graphene
quantum dots for detecting monomeric amyloid peptides. Nanoscale 2017, 9, 5044-5048.
(165) Huang, J.; Liu, S.; Zhang, C.; Wang, X.; Pu, J.; Ba, F.; Xue, S.; Ye, H.; Zhao, T.; Li, K.; Wang,
Y.; Zhang, J.; Wang, L.; Fan, C.; Lu, T. K.; Zhong, C., Programmable and printable Bacillus subtilis
biofilms as engineered living materials. Nat. Chem. Biol. 2019, 15, 34-41.
(166) Ittner, A.; Chua, S. W.; Bertz, J.; Volkerling, A.; van der Hoven, J.; Gladbach, A.; Przybyla,
M.; Bi, M.; van Hummel, A.; Stevens, C. H.; Ippati, S.; Suh, L. S.; Macmillan, A.; Sutherland, G.; Kril,
J. J.; Silva, A. P. G.; Mackay, J. P.; Poljak, A.; Delerue, F.; Ke, Y. D.; Ittner, L. M., Site-specific
phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice. Science 2016, 354, 904-908.
(167) Jackson, K.; Barisone, G. A.; Diaz, E.; Jin, L.-W.; DeCarli, C.; Despa, F., Amylin Deposition
in the Brain: A Second Amyloid in Alzheimer Disease? Ann. Neurol. 2013, 74, 517-526.
208 
(168) Jacob, R. S.; Das, S.; Singh, N.; Patel, K.; Datta, D.; Sen, S.; Maji, S. K., Amyloids Are Novel
Cell-Adhesive Matrices. In Biochemical and Biophysical Roles of Cell Surface Molecules,
Chattopadhyay, K.; Basu, S., Eds. Springer: Singapore, 2018.
(169) Jaikaran, E. T. A. S.; Nilsson, M. R.; Clark, A., Pancreatic β-cell granule peptides form
heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem. J. 2004,
377, 709-716.
(170) Jain, R.; Khandelwal, G.; Roy, S., Unraveling the Design Rules in Ultrashort Amyloid-Based
Peptide Assemblies toward Shape-Controlled Synthesis of Gold Nanoparticles. Langmuir 2019, 35,
5878-5889.
(171) Jang, H. H., Regulation of Protein Degradation by Proteasomes in Cancer. J. Cancer Prev.
2018, 23, 153-161.
(172) Jansen, W. J.; Ossenkoppele, R.; Knol, D. L.; Tijms, B. M.; Scheltens, P.; Verhey, F. R. J.;
Visser, P. J.; The Amyloid Biomarker Study Group, Prevalence of Cerebral Amyloid Pathology in
Persons Without Dementia: A Meta-Analysis. J. Am. Med. Assoc. 2015, 313, 1924-1938.
(173) Javed, I.; Peng, G.; Xing, Y.; Yu, T.; Zhao, M.; Käkinen, A.; Faridi, A.; Parish, C. L.; Ding, F.;
Davis, T. P.; Ke, P. C.; Lin, S., Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold
nanoparticle dual strategy. Nat. Commun. 2019, 10, 3780.
(174) Javed, I.; Sun, Y.; Adamcik, J.; Wang, B.; Käkinen, A.; Pilkington, E. H.; Ding, F.; Mezzenga,
R.; Davis, T. P.; Ke, P. C., Cofibrillization of Pathogenic and Functional Amyloid Proteins with Gold
Nanoparticles against Amyloidogenesis. Biomacromolecules 2017, 18, 4316-4322.
(175) Javed, I.; Yu, T.; Peng, G.; Sánchez-Ferrer, A.; Faridi, A.; Käkinen, A.; Zhao, M.; Mezzenga,
R.; Davis, T. P.; Lin, S.; Ke, P. C., In Vivo Mitigation of Amyloidogenesis through
Functional−Pathogenic Double-Protein Coronae. Nano Lett. 2018, 18, 5797-5804.
(176) Jean, L.; Lee, C. F.; Hodder, P.; Hawkins, N.; Vaux, D. J., Dynamics of the formation of a
hydrogel by a pathogenic amyloid peptide: islet amyloid polypeptide. Sci. Rep. 2016, 6, 32124.
(177) Jha, S.; Patil, S. M.; Gibson, J.; Nelson, C. E.; Alder, N. N.; Alexandrescu, A. T., Mechanism
of Amylin Fibrillization Enhancement by Heparin. J. Biol. Chem. 2011, 286, 22894-22904.
(178) Jo, Y. H.; Jang, I. J.; Nemeno, J. G.; Lee, S.; Kim, B. Y.; Nam, B. M.; Yang, W.; Lee, K. M.
K., H.; Takebe, T.; Kim, Y. S.; Lee, J. I., Artificial Islets From Hybrid Spheroids of Three Pancreatic
Cell Lines. Transplant. Proc. 2014, 46, 1156-1160.
(179) John, T.; Gladytz, A.; Kubeil, C.; Martin, L. L.; Risselada, H. J.; Abel, B., Impact of
nanoparticles on amyloid peptide and protein aggregation: a review with a focus on gold nanoparticles.
Nanoscale 2018, 10, 20894-20913.
(180) Jollès, J.; Jollès, P., Lysozymes' esterase activity. FEBS Lett. 1983, 162, 120-121.
(181) Jurgens, C. A.; Toukatly, M. N.; Fligner, C. L.; Udayasankar, J.; Subramanian, S. L.; Zraika,
S.; Aston-Mourney, K.; Carr, D. B.; Westermark, P.; Westermark, G. T., β-Cell Loss and β-Cell
209 
Apoptosis in Human Type 2 Diabetes Are Related to Islet Amyloid Deposition. Am. J. Pathol. 2011, 
178, 2632-2640. 
(182) Kahn, S. E., The Importance of the β-Cell in the Pathogenesis of Type 2 Diabetes Mellitus. Am.
J. Med. 2000, 108, 2S-8S.
(183) Kahn, S. E.; Andrikopoulos, S.; Verchere, C. B., Islet Amyloid: A Long-Recognized But
Underappreciated Pathological Feature of Type 2 Diabetes. Diabetes 1999, 48, 241-253.
(184) Kahn, S. E.; Zraika, S.; Utzschneider, K. M.; Hull, R. L., The beta cell lesion in type 2 diabetes:
there has to be a primary functional abnormality. Diabetologia 2009, 52, 1003-1012.
(185) Käkinen, A.; Adamcik, J.; Wang, B.; Ge, X.; Mezzenga, R.; Davis, T. P.; Ding, F.; Ke, P. C.,
Nanoscale inhibition of polymorphic and ambidextrous IAPP amyloid aggregation with small
molecules. Nano Res. 2017, 11, 3636-3647.
(186) Käkinen, A.; Javed, I.; Faridi, A.; Davis, T. P.; Ke, P. C., Serum albumin impedes the amyloid
aggregation and hemolysis of human islet amyloid polypeptide and alpha synuclein. Biochim. Biophys.
Acta, Biomembranes 2018, 1860, 1803-1809.
(187) Kamata, K.; Mizukami, H.; Inaba, W.; Tsuboi, K.; Tateishi, Y.; Yoshida, T.; Yagihashi, S.,
Islet amyloid with macrophage migration correlates with augmented β-cell deficits in type 2 diabetic
patients. Amyloid 2014, 21, 191-201.
(188) Kawahara, M.; Kuroda, Y.; Arispe, N.; Rojas, E., Alzheimer's β-Amyloid, Human Islet Amylin,
and Prion Protein Fragment Evoke Intracellular Free Calcium Elevations by a Common Mechanism in
a Hypothalamic GnRH Neuronal Cell Line. J. Biol. Chem. 2000, 275, 14077-14083.
(189) Kayed, R.; Pensalfini, A.; Margol, L.; Sokolov, Y.; Sarsoza, F.; Head, E.; Hall, J.; Glabe, C.,
Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer. J. Biol.
Chem. 2009, 284, 4230-4237.
(190) Kayed, R.; Sokolov, Y.; Edmonds, B.; McIntire, T. M.; Milton, S. C.; Hall, J. E.; Glabe, C. G.,
Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid
Oligomers in Protein Misfolding Diseases. J. Biol. Chem. 2004, 279, 46363-46366.
(191) Ke, P. C.; Lin, S.; Parak, W. J.; Davis, T. P.; Caruso, F., A Decade of the Protein Corona. ACS
Nano 2017, 11, 11773-11776.
(192) Ke, P. C.; Pilkington, E. H.; Sun, Y.; Javed, I.; Käkinen, A.; Peng, G.; Ding, F.; Davis, T. P.,
Mitigation of Amyloidosis with Nanomaterials. Adv. Mater. 2019, 1901690.
(193) Ke, P. C.; Qiao, R., Carbon nanomaterials in biological systems. J. Phys. Condens. Matter
2007, 19, 373101.
(194) Ke, P. C.; Sani, M.-A.; Ding, F.; Käkinen, A.; Javed, I.; Separovic, F.; Davis, T. P.; Mezzenga,
R., Implications of peptide assemblies in amyloid diseases. Chem. Soc. Rev. 2017, 46, 6492-6531.
(195) Ke, P. C.; Sani, M.-A.; Ding, F.; Käkinen, A.; Javed, I.; Separovic, F.; Davis, T. P.; Mezzenga,
R., Implications of Peptide Assemblies in Amyloid Diseases. Chem. Soc. Rev. 2017, 46, 6492-6531.
210 
(196) Keller, A.; Fritzsche, M.; Yu, Y.-P.; Liu, Q.; Li, Y.-M.; Dong, M.; Besenbacher, F., Influence
of Hydrophobicity on the Surface-Catalyzed Assembly of the Islet Amyloid Polypeptide. ACS Nano
2011, 5, 2770-2778.
(197) Khemtémourian, L.; Doménech, E.; Doux, J. P. F.; Koorengevel, M. C.; Killian, J. A., Low pH
Acts as Inhibitor of Membrane Damage Induced by Human Islet Amyloid Polypeptide. J. Am. Chem.
Soc. 2011, 133, 15598-15604.
(198) Kim, D.; Kwon, H. J.; Hyeon, T., Magnetite/Ceria Nanoparticle Assemblies for Extracorporeal
Cleansing of Amyloid-β in Alzheimer's Disease. Adv. Mater. 2019, 31, e1807965.
(199) Kim, H. S.; Lee, S. H.; Choi, I., On-chip plasmonic immunoassay based on targeted assembly
of gold nanoplasmonic particles. Analyst 2019, 144, 2820-2826.
(200) Kim, H. Y.; Kim, H. V.; Jo, S.; Lee, J.; Choi, S. Y.; Kim, D. J.; Kim, Y., EPPS rescues
hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers
and plaques. Nat. Commun. 2015, 6, 8997.
(201) Kim, Y. S.; Liu, L.; Axelsen, P. H.; Hochstrasser, R. M., 2D IR Provides Evidence for Mobile
Water Molecules in β-Amyloid Fibrils. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 17751-17756.
(202) Kishimoto, T.; Soda, Y.; Matsuyama, Y.; Mizuno, K., An enzymatic assay for
lysophosphatidylcholine concentration in human serum and plasma. Clin. Biochem. 2002, 35, 411-416.
(203) Klajnert, B.; Appelhans, D.; Komber, H.; Morgner, N.; Schwarz, S.; Richter, S.; Brutschy, B.;
Ionov, M.; Tonkikh, A. K.; Bryszewska, M.; Voit, B., The Influence of Densely Organized Maltose
Shells on the Biological Properties of Poly(propylene imine) Dendrimers: New Effects Dependent on
Hydrogen Bonding. Chem. Eur. J. 2008, 14, 7030-7041.
(204) Kleinberg, D. L., Human α-Lactalbumin: Measurement in Serum and in Breast Cancer Organ
Cultures by Radioimmunoassay. Science 1975, 190, 276-278.
(205) Klementieva, O.; Aso, E.; Filippini, D.; Benseny-Cases, N.; Carmona, M.; Juvés, S.;
Appelhans, D.; Cladera, J.; Ferrer, I., Effect of Poly(propylene imine) Glycodendrimers on β‑Amyloid
Aggregation in Vitro and in APP/PS1 Transgenic Mice, as a Model of Brain Amyloid Deposition and
Alzheimer’s Disease. Biomacromolecules 2013, 14, 3570-3580.
(206) Klementieva, O.; Benseny-Cases, N.; Gella, A.; Appelhans, D.; Voit, B.; Cladera, J., Dense
Shell Glycodendrimers as Potential Nontoxic Anti-amyloidogenic Agents in Alzheimer's Disease.
Amyloid-Dendrimer Aggregates Morphology and Cell Toxicity. Biomacromolecules 2011, 12, 3903-
3909.
(207) Knowles, T. P. J.; Vendruscolo, M.; Dobson, C. M., The amyloid state and its association with
protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 2014, 15, 384-396.
(208) Koh, A.; Molinaro, A.; Ståhlman, M.; Khan, M. T.; Schmidt, C.; Mannerås-Holm, L.; Wu, H.;
Carreras, A.; Jeong, H.; Olofsson, L. E.; Bergh, P.-O.; Gerdes, V.; Hartstra, A.; de Brauw, M.; Perkins,
211 
R.; Nieuwdorp, M.; Bergström, G.; Bäckhed, F., Microbially Produced Imidazole Propionate Impairs 
Insulin Signaling through mTORC1. Cell 2018, 175, 947-961. 
(209) Kopito, R. R., Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000,
10, 524-530.
(210) Kostarelos, K., The long and short of carbon nanotube toxicity. Nat. Biotechnol. 2008, 26, 774-
776.
(211) Kuhn, D. M.; Sykes, C. E.; Geddes, T. J.; Jaunarajs, K. L. E.; Bishop, C., Tryptophan
hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin
deficits and non-motor symptoms in Parkinson's disease. J. Neurochem. 2011, 116, 426-437.
(212) Kumar, D. K. V.; Choi, S. H.; Washicosky, K. J.; Eimer, W. A.; Tucker, S.; Ghofrani, J.;
Lefkowitz, A.; McColl, G.; Goldstein, L. E.; Tanzi, R. E.; Moir, R. D., Amyloid-β peptide protects
against microbial infection in mouse and worm models of Alzheimer's disease. Sci. Transl. Med. 2016,
8, 340ra72.
(213) Kumar, S. T.; Meinhardt, J.; Fuchs, A.-K.; Aumüller, T.; Leppert, J.; Büchele, B.; Knüpfer, U.;
Ramachandran, R.; Yadav, J. K.; Prell, E.; Morgado, I.; Ohlenschläger, O.; Horn, U.; Simmet, T.;
Görlach, M.; Fändrich, M., Structure and Biomedical Applications of Amyloid Oligomer Nanoparticles.
ACS Nano 2014, 8, 11042-11052.
(214) Kumar, S.; Walter, J., Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation
of toxic aggregates in Alzheimer's disease. Aging 2011, 3, 803-812.
(215) Kumar, S.; Wirths, O.; Stüber, K.; Wunderlich, P.; Koch, P.; Theil, S.; Rezaei-Ghaleh, N.;
Zweckstetter, M.; Bayer, T. A.; Brüstle, O.; Thal, D. R.; Walter, J., Phosphorylation of the amyloid β-
peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol. 2016,
131, 525-537.
(216) Larson, J. L.; Miranker, A. D., The Mechanism of Insulin Action on Islet Amyloid Polypeptide
Fiber Formation. J. Mol. Biol. 2004, 335, 221-231.
(217) Leahy, J. L., Pathogenesis of Type 2 Diabetes Mellitus. Arch. Med. Res. 2005, 36, 197-209.
(218) Lee, M.; Wang, T.; Makhlynets, O. V.; Wu, Y.; Polizzi, N. F.; Wu, H.; Gosavi, P. M.; Stöhr,
J.; Korendovych, I. V.; DeGrado, W. F.; Hong, M., Zinc-Binding Structure of a Catalytic Amyloid
From Solid-State NMR. Proc. Natl. Acad. Sci. U.S.A. 2017, 114, 6191-6196.
(219) Lee, M.-C.; Yu, W.-C.; Shih, Y.-H.; Chen, C.-Y.; Guo, Z.-H.; Huang, S.-J.; Chan, J. C. C.;
Chen, Y.-R., Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β
derived diffusible ligands in Alzheimer’s disease. Sci. Rep. 2018, 8, 4772.
(220) Lee, S.; Lee, D.; Hong, C.-S.; Yang, J. E.; Kang, J. S.; Sung, Y.-E.; Paik, S. R., Alternative
Assembly of α-Synuclein Leading to Protein Film Formation and Its Application for Developing
Polydiacetylene-Based Sensing Materials. Langmuir 2019, 35, 11923-11931.
(221) Lemaire, K.; Ravier, M. A.; Schraenen, A.; Creemers, J. W. M.; Van de Plas, R.; Granvik, M.;
Van Lommel, L.; Waelkens, E.; Chimienti, F.; Rutter, G. A.; in't Veld, P. A.; Schuit, F. C., Insulin
212 
crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose 
homeostasis in mice. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 14872-14877. 
(222) Li, C.; Mezzenga, R., The interplay between carbon nanomaterials and amyloid fibrils in bio-
nanotechnology. Nanoscale 2013, 5, 6207-6218.
(223) Li, M.; Zhao, A.; Dong, K.; Li, W.; Ren, J.; Qu, X., Chemically exfoliated WS2 nanosheets
efficiently inhibit amyloid β-peptide aggregation and can be used for photothermal treatment of
Alzheimer’s disease. Nano Res. 2015, 8, 3216-3227.
(224) Li, N.; Luo, H.-C.; Yang, C.; Deng, J.-J.; Ren, M.; Xie, X.-Y.; Lin, D.-Z.; Yan, L.; Zhang, L.-
M., Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast
cells and promoting wound healing in diabetic rats. Int. J. Nanomedicine 2014, 9, 3377-3387.
(225) Li, X.-H.; Du, L.-L.; Cheng, X.-S.; Jiang, X.; Zhang, Y.; Lv, B.-L.; Liu, R.; Wang, J.-Z.; Zhou,
X.-W., Glycation exacerbates the neuronal toxicity of β-amyloid. Cell Death Dis. 2013, 4, e673.
(226) Li, Y.; Wang, L.; Lu, T.; Wei, Y.; Li, F., The Effects of Chondroitin Sulfate and Serum Albumin
on the Fibrillation of Human Islet Amyloid Polypeptide at the Phospholipid Membranes. Phys. Chem.
Chem. Phys. 2016, 18, 12000-12008.
(227) Li, Z.; Wang, C.; Wang, Z.; Zhu, C.; Li, J.; Sha, T.; Ma, L.; Gao, C.; Yang, Y.; Sun, Y.; Wang,
J.; Sun, X.; Lu, C.; Difiglia, D.; Mei, Y.; Ding, C.; Luo, S.; Dang, Y.; Ding, Y.; Fei, Y.; Lu, B., Allele-
selective lowering of mutant HTT protein by HTT–LC3 linker compounds. Nature 2019, 575, 203-209.
(228) Liao, L.; Cheng, D.; Wang, J.; Duong, D. M.; Losik, T. G.; Gearing, M.; Rees, H. D.; Lah, J.
J.; Levey, A. I.; Peng, J., Proteomic Characterization of Postmortem Amyloid Plaques Isolated by Laser
Capture Microdissection. J. Biol. Chem. 2004, 279, 37061-37068.
(229) Liberek, K.; Lewandowska, A.; Zietkiewicz, S., Chaperones in control of protein
disaggregation. EMBO J. 2008, 27, 328-335.
(230) Librizzi, F.; Carrotta, R.; Spigolon, D.; Bulone, D.; Biagio, P. L. S., α-Casein Inhibits Insulin
Amyloid Formation by Preventing the Onset of Secondary Nucleation Processes. J. Phys. Chem. Lett.
2014, 5, 3043-3048.
(231) Limbocker, R.; Chia, S.; Ruggeri, F. S.; Perni, M.; Cascella, R.; Heller, G. T.; Meisl, G.;
Mannini, B.; Habchi, J.; Michaels, T. C. T.; Challa, P. K.; Ahn, M.; Casford, S. T.; Fernando, N.; Xu,
C. K.; Kloss, N. D.; Cohen, S. I. A.; Kumita, J. R.; Cecchi, F.; Zasloff, M.; Linse, S.; Knowles, T. P. J.;
Chiti, F.; Vendruscolo, M.; Dobson, C. M., Trodusquemine enhances Aβ42 aggregation but suppresses
its toxicity by displacing oligomers from cell membranes. Nat. Commun. 2019, 10, 225.
(232) Little, W. C.; Schwartlander, R.; Smith, M. L.; Gourdon, D.; Vogel, V., Stretched Extracellular
Matrix Proteins Turn Fouling and Are Functionally Rescued by the Chaperones Albumin and Casein.
Nano Lett. 2009, 9, 4158-4167.
(233) Liu, C.; Zhang, Y., Nucleic acid-mediated protein aggregation and assembly. Adv. Protein
Chem. Struct. Biol. 2011, 84, 1-40.
213 
(234) Liu, J.; Li, L., Targeting Autophagy for the Treatment of Alzheimer’s Disease: Challenges and
Opportunities. Front. Mol. Neurosci. 2019, 12, 203.
(235) Liu, P.; Zhang, S.; Chen, M.-S.; Liu, Q.; Wang, C.; Wang, C.; Li, Y.-M.; Besenbacher, F.;
Dong, M., Co-Assembly of Human Islet Amyloid Polypeptide (hIAPP)/Insulin. Chem. Commun. 2012,
48, 191-193.
(236) Liu, X. G.; Lu, S.; Liu, D. Q.; Zhang, L.; Zhang, L. X.; Yu, X. L.; Liu, R. T., ScFv-conjugated
superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of
Parkinson's and Huntington's diseases. Brain Res. 2019, 1707, 141-153.
(237) Liu, Y.; Xu, L.-P.; Dai, W.; Dong, H.; Wen, Y.; Zhang, X., Graphene quantum dots for the
inhibition of β amyloid aggregation. Nanoscale 2015, 7, 19060-19065.
(238) Liu, Y.; Zhou, H.; Yin, T.; Gong, Y.; Yang, G.; Chen, L.; Liu, J., Quercetin-modified gold-
palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer's disease. J.
Colloid Interface Sci. 2019, 552, 388-400.
(239) Lopes, D. H. J.; Attar, A.; Nair, G.; Hayden, E. Y.; Du, Z.; McDaniel, K.; Dutt, S.; Bandmann,
H.; Bravo-Rodriguez, K.; Mittal, S.; Klärner, F.-G.; Wang, C.; Sanchez-Garcia, E.; Schrader, T.; Bitan,
G., Molecular Tweezers Inhibit Islet Amyloid Polypeptide Assembly and Toxicity by a New
Mechanism. ACS Chem. Biol. 2015, 10, 1555-1569.
(240) Lopes, D. H. J.; Meister, A.; Gohlke, A.; Hauser, A.; Blume, A.; Winter, R., Mechanism of
Islet Amyloid Polypeptide Fibrillation at Lipid Interfaces Studied by Infrared Reflection Absorption
Spectroscopy. Biophys. J. 2007, 93, 3132-3141.
(241) Lorenzo, A.; Razzaboni, B.; Weir, G. C.; Yankner, B. A., Pancreatic islet cell toxicity of amylin
associated with type-2 diabetes mellitus. Nature 1994, 368, 756-760.
(242) Lu, M.; Williamson, N.; Mishra, A.; Michel, C. H.; Kaminski, C. F.; Tunnacliffe, A.; Schierle,
G. S. K., Structural progression of amyloid-β Arctic mutant aggregation in cells revealed by
multiparametric imaging. J. Biol. Chem. 2018, 294, 1478-1487.
(243) Luca, S.; Yau, W.-M.; Leapman, R.; Tycko, R., Peptide Conformation and Supramolecular
Organization in Amylin Fibrils:  Constraints From Solid-State NMR. Biochemistry 2007, 46, 13505-
13522.
(244) Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A., Nanoparticle Size
and Surface Properties Determine the Protein Corona With Possible Implications for Biological
Impacts. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 14265-14270.
(245) Luo, J.; Wärmländer, S. K. T. S.; Gräslund, A.; Abrahams, J. P., Human lysozyme inhibits the
in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease. Chem.
Commun. 2013, 49, 6507-6509.
(246) Luo, J.; Wärmländer, S. K. T. S.; Gräslund, A.; Abrahams, J. P., Non-chaperone Proteins Can
Inhibit Aggregation and Cytotoxicity of Alzheimer Amyloid β Peptide. J. Biol. Chem. 2014, 289,
27766-27775.
214 
(247) Luo, Q.; Lin, Y.-X.; Yang, P.-P.; Wang, Y.; Qi, G.-B.; Qiao, Z.-Y.; Li, B.-N.; Zhang, K.; Zhang,
J.-P.; Wang, L.; Wang, H., A self-destructive nanosweeper that captures and clears amyloid β-peptides.
Nat. Commun. 2018, 9, 1802.
(248) Ly, H.; Despa, F., Hyperamylinemia as a Risk Factor for Accelerated Cognitive Decline in
Diabetes. Expert Rev. Proteomics 2015, 12, 575-577.
(249) Ma, X.; Zhou, P.; Kugelmass, A.; Toskic, D.; Warner, M.; Lee, L.; Fogaren, T.; Godara, A.;
Wang, M.; Li, Y.; Yang, L.; Xu, Q.; Comenzo, R. L., A novel xenograft mouse model for testing
approaches targeting human kappa light-chain diseases. Gene Ther. 2019, 26, 187-197.
(250) MacDonald, M. J.; Ade, L.; Ntambi, J. M.; Ansari, I.-U. H.; Stoker, S. W., Characterization of
Phospholipids in Insulin Secretory Granules and Mitochondria in Pancreatic Beta Cells and Their
Changes with Glucose Stimulation. J. Biol. Chem. 2015, 290, 11075-11092.
(251) Mahmoudi, M.; Akhavan, O.; Ghavami, M.; Rezaee, F.; Ghiasi, S. M. A., Graphene Oxide
Strongly Inhibits Amyloid Beta Fibrillation. Nanoscale 2012, 4, 7322-7325.
(252) Mäkimattila, S.; Fineman, M. S.; Yki-Järvinen, H., Deficiency of Total and Nonglycosylated
Amylin in Plasma Characterizes Subjects with Impaired Glucose Tolerance and Type 2 Diabetes. J.
Clin. Endocrinol. Metab. 2000, 85, 2822-2827.
(253) Malishev, R.; Arad, E.; Bhunia, S. K.; Shaham-Niv, S.; Kolusheva, S.; Gazit, E.; Jelinek, R.,
Chiral modulation of amyloid beta fibrillation and cytotoxicity by enantiomeric carbon dots. Chem.
Commun. 2018, 54, 7762-7765.
(254) Mansson, C.; Arosio, P.; Hussein, R.; Kampinga, H. H.; Hashem, R. M.; Boelens, W. C.;
Dobson, C. M.; Knowles, T. P. J.; Linse, S.; Emanuelsson, C., Interaction of the molecular chaperone
DNAJB6 with growing amyloid-beta 42 (Aβ42) aggregates leads to sub-stoichiometric inhibition of
amyloid formation. J. Biol. Chem. 2014, 289, 31066-31076.
(255) Masliah, E.; Rockenstein, E.; Veinbergs, I.; Sagara, Y.; Mallory, M.; Hashimoto, M.; Mucke,
L., β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse
model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98,
12245-12250.
(256) Mathers, C. D.; Loncar, D., Projections of Global Mortality and Burden of Disease from 2002
to 2030. PLoS Med. 2006, 3, 2011-2030.
(257) Matveyenko, A. V.; Butler, P. C., Islet Amyloid Polypeptide (IAPP) Transgenic Rodents as
Models for Type 2 Diabetes. ILAR J. 2006, 47, 225-233.
(258) Mayer, E. A.; Knight, R.; K., M. S.; Cryan, J. F.; Tillisch, K., Gut Microbes and the Brain:
Paradigm Shift in Neuroscience. J. Neurosci. 2014, 34, 15490-15496.
(259) McCarthy, J. M.; Appelhans, D.; Tarzelt, J.; Rogers, S. M., Nanomedicine for prion disease
treatment. Prion 2013, 7, 198-202.
215 
(260) McGlinchey, R. P.; Shewmaker, F.; McPhie, P.; Monterroso, B.; Thurber, K.; Wickner, R. B.,
The repeat domain of the melanosome fibril protein Pmel17 forms the amyloid core promoting melanin
synthesis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 13731-13736.
(261) Meier, J. J.; Kayed, R.; Lin, C.-Y.; Gurlo, T.; Haataja, L.; Jajasinghe, S.; Langen, R.; Glabe, C.
G.; Butler, P. C., Inhibition of human IAPP fibril formation does not prevent β-cell death: evidence for
distinct actions of oligomers and fibrils of human IAPP. Am. J. Physiol. Endocrinol. Metab. 2006, 291,
E1317-E1324.
(262) Meijnikman, A. S.; Gerdes, V. E.; Nieuwdorp, M.; Herrema, H., Evaluating Causality of Gut
Microbiota in Obesity and Diabetes in Humans. Endocr. Rev. 2018, 39, 133-153.
(263) Mendis, S. Global status report on noncommunicable diseases 2014; World Health
Organisation: Geneva, 2014.
(264) Meng, F.; Abedini, A.; Song, B.; Raleigh, D. P., Amyloid Formation by Pro-Islet Amyloid
Polypeptide Processing Intermediates: Examination of the Role of Protein Heparan Sulfate Interactions
and Implications for Islet Amyloid Formation in Type 2 Diabetes. Biochemistry 2007, 46, 12091-12099.
(265) Meng, F.; Marek, P.; Potter, K. J.; Verchere, C. B.; Raleigh, D. P., Rifampicin Does Not Prevent
Amyloid Fibril Formation by Human Islet Amyloid Polypeptide but Does Inhibit Thioflavin-T
Interactions: Implications for Mechanistic Studies of β-cell Death. Biochemistry 2008, 47, 6016-6024.
(266) Mi, W.; Pawlik, M.; Sastre, M.; Jung, S. S.; Radvinsky, D. S.; Klein, A. M.; Sommer, J.;
Schmidt, S. D.; Nixon, R. A.; Mathews, P. M.; Levy, E., Cystatin C inhibits amyloid-β deposition in
Alzheimer's disease mouse models. Nat. Genet. 2007, 39, 1440-1442.
(267) Mietlick-Baase, E. G., Amylin-mediated control of glycemia, energy balance, and cognition.
Physiol. Behav. 2016, 162, 130-140.
(268) Mirzabekov, T. A.; Lin, M.-C.; Kagan, B. L., Pore Formation by the Cytotoxic Islet Amyloid
Peptide Amylin. J. Biol. Chem. 1996, 271, 1988-1992.
(269) Moghimi, S. M.; Hunter, A. C.; Murray, J. C., Long-Circulating and Target-Specific
Nanoparticles: Theory to Practice. Pharmacol. Rev. 2001, 53, 283-318.
(270) Moir, R. D.; Lathe, R.; Tanzi, R. E., The antimicrobial protection hypothesis of Alzheimer's
disease. Alzheimers Dement. 2018, 14, 1602-1614.
(271) Moores, B.; Drolle, E.; Attwood, S. J.; Simons, J.; Leonenko, Z., Effect of Surfaces on Amyloid
Fibril Formation. PLoS ONE 2011, 6, e25954.
(272) Moreno-Gonzalez, I.; Soto, C., Misfolded Protein Aggregates: Mechanisms, Structures and
Potential for Disease Transmission. Semin. Cell Dev. Biol. 2011, 22, 482-487.
(273) Nakae, T.; Ishii, J.; Tokunaga, M., Subunit Structure of Functional Porin Oligomers That Form
Permeability Channels in the Outer Membrane of Escherichia coli. J. Biol. Chem. 1978, 254, 1457-
1461.
216 
(274) Nanga, R. P. R.; Brender, J. R.; Vivekanandan, S.; Ramamoorthy, A., Structure and membrane
orientation of IAPP in its natively amidated form at physiological pH in a membrane environment.
Biochim. Biophys. Acta 2011, 2011, 2337-2342.
(275) Neelov, I. M.; Janaszewska, A.; Klajnert, B.; Bryszewska, M.; Makova, N. Z.; Hicks, D.;
Pearson, H. A.; Vlaslov, G. P.; Ilyash, M. Y.; Dubrovskaya, N. M.; Tumanova, N. L.; Zhuravin, I. A.;
Turner, A. J.; Nalivaeva, N. N., Molecular Properties of Lysine Dendrimers and their Interactions with
Aβ-Peptides and Neuronal Cells. Curr. Med. Chem. 2013, 20, 134-143.
(276) Nerelius, C.; Gustafsson, M.; Nordling, K.; Larsson, A.; Johansson, J., Anti-Amyloid Activity
of the C-Terminal Domain of proSP-C against Amyloid β-Peptide and Medin. Biochemistry 2009, 48,
3778-3786.
(277) Neuhauser, N.; Michalski, A.; Scheltema, R. A.; Olsen, J. V.; Mann, M., Andromeda: A Peptide
Search Engine Integrated Into the MaxQuant Environment. J. Proteome Res. 2011, 10, 1794-1805.
(278) Nguyen, P. T.; Sharma, R.; Rej, R.; De Carufel, C. A.; Roy, R.; Bourgault, S., Low generation
anionic dendrimers modulate islet amyloid polypeptide self-assembly and inhibit pancreatic β-cell
toxicity. RSC Adv. 2016, 6, 76360-76369.
(279) Noble, W.; Hanger, D. P.; Miller, C. C. J.; Lovestone, S., The Importance of Tau
Phosphorylation for Neurodegenerative Diseases. Front. Neurol. 2013, 4, 83.
(280) Nowacka, O.; Shcharbin, D.; Klajnert-Maculewicz, B.; Bryszewska, M., Stabilizing effect of
small concentrations of PAMAM dendrimers at the insulin aggregation. Colloids Surf. B Biointerfaces
2014, 116, 757-760.
(281) O'Nuallain, B.; Williams, A. D.; Westermark, P.; Wetzel, R., Seeding Specificity in Amyloid
Growth Induced by Heterologous Fibrils. J. Biol. Chem. 2004, 279, 17490-17499.
(282) Ookoshi, T.; Hasegawa, K.; Ohhashi, Y.; Kimura, H.; Takahashi, N.; Yoshida, H.; Miyazaki,
R.; Goto, Y.; Naiki, H., Lysophospholipids induce the nucleation and extension of beta2-microglobulin-
related amyloid fibrils at a neutral pH. Nephrol. Dial. Transplant. 2008, 23, 3247-3255.
(283) Oskarsson, M. E.; Paulsson, J. F.; Schultz, S. W.; Ingelsson, M.; Westermark, P.; Westermark,
G. T., In Vivo Seeding and Cross-Seeding of Localized Amyloidosis. Am. J. Pathol. 2015, 185, 834-
846.
(284) Oskarsson, M. E.; Singh, K.; Wang, J.; Vlodavsky, I.; Li, J.-P.; Westermark, G. T., Heparan
Sulfate Proteoglycans are important for Islet Amyloid Formation and Islet Amyloid Polypeptide-
Induced Apoptosis. J. Biol. Chem. 2015, 290, 15121-15132.
(285) Oslakovic, C.; Cedervall, T.; Linse, S.; Dahlbäck, B., Polystyrene Nanoparticles Affecting
Blood Coagulation. Nanomedicine 2012, 8, 981-986.
(286) Owen, M. C.; Gnutt, D.; Gao, M.; Wärmländer, S. K. T. S.; Jarvet, J.; Gräslund, A.; Winter, R.;
Ebbinghaus, S.; Strodel, B., Effects of in vivo conditions on amyloid aggregation. Chem. Soc. Rev.
2019, 48, 3946-3996.
217 
(287) Padrick, S. B.; Miranker, A. D., Islet amyloid: phase partitioning and secondary nucleation are
central to the mechanism of fibrillogenesis. Biochemistry 2002, 41, 4694-4703.
(288) Pansierei, J.; Gerstenmayer, M.; Lux, F.; Mériaux, S.; Tillement, O.; Forge, V.; Larrat, B.;
Marquette, C., Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review.
Nanomaterials 2018, 8, 740.
(289) Pansierei, J.; Plissonneau, M.; Stransky-Heilkron, N.; Dumoulin, M.; Heinrich-Balard, L.;
Rivory, P.; Morfin, J.-F.; Toth, E.; Saraiva, M. J.; Allémann, E.; Tillement, O.; Forge, V.; Lux, F.;
Marquette, C., Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a
nanobody for amyloid plaques targeting. Nanomedicine 2017, 12, 1675-1687.
(290) Park, H.; Oh, J.; Shim, G.; Cho, B.; Chang, Y.; Kim, S.; Baek, S.; Kim, H. S.; Shin, J.; Choi,
H.; Yoo, J.; Kim, J.; Jun, W.; Lee, M.; Lengner, C.; Oh, Y.-K.; Kim, J., In vivo neuronal gene editing
via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's
disease. Nat. Neurosci. 2019, 22, 524-528.
(291) Park, J.-S.; Kim, D.-H.; Yoon, S.-Y., Regulation of amyloid precursor protein processing by its
KFERQ motif. BMB Rep. 2016, 49, 337-342.
(292) Park, Y. J.; Woo, M., Pancreatic β cells: Gatekeepers of type 2 diabetes. J. Cell Biol. 2019, 218,
1094.
(293) Patil, S. M.; Xu, S.; Sheftic, S. R.; Alexandrescu, A. T., Dynamic α-Helix Structure of Micelle-
bound Human Amylin. J. Biol. Chem. 2009, 284, 11982-11991.
(294) Peinado, J. R.; Sami, F.; Rajpurohit, N.; Lindberg, I., Blockade of islet amyloid polypeptide
fibrillation and cytotoxicity by the secretory chaperones 7B2 and proSAAS. FEBS Lett. 2013, 587,
3406-3411.
(295) Peng, S.; Fitzen, M.; Jörnvall, H.; Johansson, J., The extracellular domain of Bri2 (ITM2B)
binds the ABri peptide (1–23) and amyloid β-peptide (Aβ1–40): Implications for Bri2 effects on
processing of amyloid precursor protein and Aβ aggregation. Biochem. Biophys. Res. Commun. 2010,
393, 356-361.
(296) Peng, S.; Glennert, J.; Westermark, P., Medin-amyloid: A recently characterized age-associated
arterial amyloid form affects mainly arteries in the upper part of the body. Amyloid 2005, 12, 96-102.
(297) Peters, T. W.; Rardin, M. J.; Czerwieniec, G.; Evani, U. S.; Reis-Rodrigues, P.; Lithgow, G. J.;
Mooney, S. D.; Gibson, B. W.; Hughes, R. E., Tor1 regulates protein solubility in Saccharomyces
cerevisiae. Mol. Biol. Cell 2012, 23, 4679-4688.
(298) Peterson, S. A.; Klabunde, T.; Lashuel, H. A.; Purkey, H.; Sacchettini, J. C.; Kelly, J. W.,
Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad.
Sci. U.S.A. 1998, 95, 12956-12960.
(299) Pilkington, E. H.; Gurzov, E. N.; Käkinen, A.; Litwak, S. A.; Stanley, W. J.; Davis, T. P.; Ke,
P. C., Pancreatic β-Cell Membrane Fluidity and Toxicity Induced by Human Islet Amyloid Polypeptide
Species. Sci. Rep. 2016, 6, 21274.
218 
(300) Pilkington, E. H.; Gustafsson, O. J. R.; Xing, Y.; Hernandez-Fernaud, J.; Zampronio, C.;
Käkinen, A.; Faridi, A.; Ding, F.; Wilson, P.; Ke, P. C.; Davis, T. P., Profiling the Serum Protein Corona
of Fibrillar Human Islet Amyloid Polypeptide. ACS Nano 2018, 12, 6066-6078.
(301) Pilkington, E. H.; Lai, M.; Ge, X.; Stanley, W. J.; Wang, B.; Wang, M.; Käkinen, A.; Sani, M.-
A.; Whittaker, M. R.; Gurzov, E. N.; Ding, F.; Quinn, J. F.; Davis, T. P.; Ke, P. C., Star Polymers
Reduce Islet Amyloid Polypeptide Toxicity via Accelerated Amyloid Aggregation. Biomacromolecules
2017, 18, 4249-4260.
(302) Pilkington, E. H.; Xing, Y.; Wang, B.; Käkinen, A.; Wang, M.; Davis, T. P.; Ding, F.; Ke, P.
C., Effects of Protein Corona on IAPP Amyloid Aggregation, Fibril Remodelling, and Cytotoxicity.
Sci. Rep. 2017, 7, 2455.
(303) Pillay, K.; Govender, P., Amylin Uncovered: A Review on the Polypeptide Responsible for
Type II Diabetes. Biomed Res. Int. 2013, 2013, 826706.
(304) Pisani, C.; Gaillard, J.-C.; Odorico, M.; Nyalosaso, J. L.; Charnay, C.; Guari, Y.; Chopineau,
J.; Devoisselle, J.-M.; Armengaud, J.; Prat, O., The Timeline of Corona Formation Around Silica
Nanocarriers Highlights the Role of the Protein Interactome. Nanoscale 2017, 9, 1840-1851.
(305) Poduslo, J. F.; Hultman, K. L.; Curran, G. L.; Preboske, G. M.; Chamberlain, R.; Marjanska,
M.; Garwood, M.; Jack Jr., C. R.; Wengenack, T. M., Targeting vascular amyloid in arterioles of
Alzheimer disease transgenic mice with amyloid β protein antibody-coated nanoparticles. J.
Neuropathol. Exp. Neurol. 2011, 70, 653-661.
(306) Ponomarenko, E. A.; Poverennaya, E. V.; Ilgisonis, E. V.; Pyatnitskiy, M. A.; Kopylov, A. T.;
Zgoda, V. G.; Lisitsa, A. V.; Archakov, A. I., The Size of the Human Proteome: The Width and Depth.
Int. J. Anal. Chem. 2016, 2016, 7436849.
(307) Porat, Y.; Kolusheva, S.; Jelinek, R.; Gazit, E., The Human Islet Amyloid Polypeptide Forms
Transient Membrane-Active Prefibrillar Assemblies. Biochemistry 2003, 42, 10971-10977.
(308) Press, M.; Jung, T.; König, J.; Grune, T.; Höne, A., Protein aggregates and proteostasis in aging:
Amylin and β-cell function. Mech. Ageing Dev. 2019, 177, 46-54.
(309) Pyle, E.; Kalli, A. C.; Amillis, S.; Hall, Z.; Lau, A. M.; Hanyaloglu, A. C.; Diallinas, G.; Byrne,
B.; Politis, A., Structural Lipids Enable the Formation of Functional Oligomers of the Eukaryotic Purine
Symporter UapA. Cell Chem. Biol. 2018, 25, 840-848.
(310) Qiao, R.; Ke, P. C., Lipid-Carbon Nanotube Self-Assembly in Aqueous Solution. J. Am. Chem.
Soc. 2006, 128, 13656-13657.
(311) Qin, J.; Cho, M.; Lee, Y., Ultrasensitive Detection of Amyloid-β Using Cellular Prion Protein
on the Highly Conductive Au Nanoparticles–Poly(3,4-ethylene dioxythiophene)–Poly(thiophene-3-
acetic acid) Composite Electrode. Anal. Chem. 2019, 91, 11259-11265.
(312) Qiu, W. Q.; Wallack, M.; Dean, M.; Liebson, E.; Mwamburi, M.; Zhu, H., Association between
Amylin and Amyloid-β Peptides in Plasma in the Context of Apolipoprotein E4 Allele. PLoS ONE
2014, 9, e88063.
219 
(313) Quist, A.; Doudevski, I.; Lin, H.; Azimova, R.; Ng, D.; Frangione, B.; Kagan, B.; Ghiso, J.;
Lal, R., Amyloid ion channels: A common structural link for protein-misfolding disease. Proc. Natl.
Acad. Sci. U.S.A. 2005, 102, 10427-10432.
(314) R Core Team, R: A Language and Environment for Statistical Computing. https://www.R-
project.org/ (accessed Feb 19, 2018).
(315) Radic, S.; Davis, T. P.; Ke, P. C.; Ding, F., Contrasting effects of nanoparticle-protein attraction
on amyloid aggregation. RSC Adv., 2015, 5, 105489-105498 (2015)
(316) Rahman, M.; Zetterberg, H.; Lendel, C.; Härd, T., Binding of Human Proteins to Amyloid-β
Protofibrils. ACS Chem. Biol. 2015, 10, 766-774.
(317) Raleigh, D.; Zhang, X.; Hastoy, B.; Clark, A., The β-Cell Assassin: IAPP Cytotoxicity. J. Mol.
Endocrinol. 2017, 59, R121-R140.
(318) Raman, B.; Ban, T.; Sakai, M.; Pasta, S. Y.; Ramakrishna, T.; Naiki, H.; Goto, Y.; Rao, C. M.,
αB-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid β-peptide
and β2-microglobulin. Biochem. J. 2005, 392, 573-581.
(319) Rappsilber, J.; Mann, M.; Ishihama, Y., Protocol for Micro-Purification, Enrichment, Pre-
Fractionation and Storage of Peptides for Proteomics Using StageTips. Nat. Protoc. 2007, 8, 1896-
1906.
(320) Rawat, A.; Maity, B. K.; Chandra, B.; Maiti, S., Aggregation-induced conformation changes
dictate islet amyloid polypeptide (IAPP) membrane affinity. Biochim. Biophys. Acta 2018, 1860, 1734-
1740.
(321) Reches, M.; Gazit, E., Casting metal nanowires within discrete self-assembled peptide
nanotubes. Science 2003, 300, 625-627.
(322) Ren, J. M.; McKenzie, T. G.; Fu, Q.; Wong, E. H. H.; Xu, J.; An, Z.; Shanmugam, S.; Davis,
T. P.; Boyer, C.; Qiao, G. C., Star Polymers. Chem. Rev. 2016, 116, 6743-6836.
(323) Reumers, J.; Maurer-Stroh, S.; Schymkowitz, J.; Rousseau, F., Protein sequences encode
safeguards against aggregation. Hum. Mutat. 2009, 30, 431-437.
(324) Rezaei-Ghaleh, N.; Amininasab, M.; Kumar, S.; Walter, J.; Zweckstetter, M., Phosphorylation
modifies the molecular stability of β-amyloid deposits. Nat. Commun. 2016, 7, 11359.
(325) Ritzel, R. A.; Meier, J. J.; Lin, C.-Y.; Veldhuis, J. D.; Butler, P. C., Human Islet Amyloid
Polypeptide Oligomers Disrupt Cell Coupling, Induce Apoptosis, and Impair Insulin Secretion in
Isolated Human Islets. Diabetes 2007, 56, 65-71.
(326) Rogers, J. T.; Randall, J. D.; Cahill, C. M.; Eder, P. S.; Huang, X.; Gunshin, H.; Leiter, L.;
McPhee, J.; Sarang, S. S.; Utsuki, T.; Greig, N. H.; Lahiri, D. K.; Tanzi, R. E.; Bush, A. I.; Giordani,
T.; Gullans, S. R., An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's
amyloid precursor protein transcript. J. Biol. Chem. 2002, 277, 45518-45528.
(327) Romero, D.; Kolter, R., Functional amyloids in bacteria. Int. Microbiol. 2014, 17, 65-73.
220 
(328) Rosas, P. C.; Nagaraja, G. M.; Kaur, P.; Panossia, A.; Wickman, G.; Garcia, L. R.; Al-Khamis,
F. A.; Asea, A. A. A., Hsp72 (HSPA1A) Prevents Human Islet Amyloid Polypeptide Aggregation and
Toxicity: A New Approach for Type 2 Diabetes Treatment. PLoS ONE 2016, 11, e0149409.
(329) Rothe, S.; Prakash, A.; Tyedmers, J., The Insoluble Protein Deposit (IPOD) in Yeast. Front.
Mol. Neurosci. 2018, 11, 237.
(330) Rousseau, F.; Schymkowitz, J.; Serrano, L., Protein aggregation and amyloidosis: confusion of
the kinds? Curr. Opin. Struct. Biol. 2006, 16, 118-126.
(331) Sade, D.; Shaham-Niv, S.; Arnon, Z. A.; Tavassoly, O.; Gazit, E., Seeding of proteins into
amyloid structures by metabolite assemblies may clarify certain unexplained epidemiological
associations. Open Biol. 2018, 8, 170229.
(332) Sadik, G.; Tanaka, T.; Kato, K.; Yamamori, H.; Nessa, B. N.; Morihara, T.; Takeda, M.,
Phosphorylation of tau at Ser214 mediates its interaction with 14‐3‐3 protein: implications for the
mechanism of tau aggregation. J. Neurochem. 2009, 108, 33-43.
(333) Sakagashira, S.; Hiddinga, H. J.; Tateishi, K.; Sanke, T.; Hanabusa, T.; Nanjo, K.; Eberhardt,
N. L., S20G Mutant Amylin Exhibits Increased in Vitro Amyloidogenicity and Increased Intracellular
Cytotoxicity Compared to Wild-Type Amylin. Am. J. Pathol. 2000, 157, 2101-2109.
(334) Sanati, M.; Khodagholi, F.; Ghasemi, F.; Gholami, M.; Kebriaeezadeh, A.; Sabzevari, O.;
Hajipour, M. J.; Imani, M.; Mahmoudi, M.; Sharifzadeh, M., Impact of Gold Nanoparticles on Amyloid
β-Induced Alzheimer’s Disease in a Rat Animal Model: Involvement of STIM Proteins. ACS Chem.
Neurosci. 2019, 10, 2299-2309.
(335) Sanke, T.; Hanabusa, T.; Nakano, Y.; Oki, C.; Okai, K.; Nishimura, S.; Kondo, M.; Nanjo, K.,
Plasma Islet Amyloid Polypeptide (Amylin) Levels and Their Responses to Oral Glucose in Type 2
(Non-Insulin-Dependent) Diabetic Patients. Diabetologia 1991, 34, 129-132.
(336) Saptarshi, S. R.; Duschi, A.; Lopata, A. L., Interaction of nanoparticles with proteins: relation
to bio-reactivity of the nanoparticle. J. Nanobiotechnol. 2013, 11, No. 26.
(337) Sasahara, K.; Morigaki, K.; Shinya, K., Amyloid aggregation and deposition of human islet
amyloid polypeptide at membrane interfaces. FEBS J. 2014, 281, 2597-2612.
(338) Scherbaum, W. A., The role of amylin in the physiology of glycemic control. Exp. Clin.
Endocrinol. Diabetes 1998, 106, 97-102.
(339) Schmitz, O.; Brock, B.; Rungby, J., Amylin Agonists: A Novel Approach in the Treatment of
Diabetes. Diabetes 2004, 53, S233-S238.
(340) Schubert, D.; Behl, C.; Lesley, R.; Brack, A.; Dargusch, R.; Sagara, Y.; Kimura, H., Amyloid
peptides are toxic via a common oxidative mechanism. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1989-
1993.
(341) Sciacca, M. F. M.; Milardi, D.; Messina, G. M. L.; Marletta, G.; Brender, J. R.; Ramamoorthy,
A.; La Rosa, C., Cations as Switches of Amyloid-Mediated Membrane Disruption Mechanisms:
Calcium and IAPP. Biophys. J. 2013, 104, 173-184.
221 
(342) Seeliger, J.; Weise, K.; Opitz, N.; Winter, R., The effect of Aβ on IAPP aggregation in the
presence of an isolated β-cell membrane. J. Mol. Biol. 2012, 421, 348-363.
(343) Seino, S.; Study Group of Comprehensive Analysis of Genetic Factors in Diabetes Mellitus, T.,
S20G mutation of the amylin gene is associated with Type II diabetes in Japanese. Diabetologia 2001,
44, 906-909.
(344) Serebryany, E.; Woodard, J. C.; Adkar, B. V.; Shabab, M.; King, J. A.; Shakhnovich, E. I., An
Internal Disulfide Locks a Misfolded Aggregation-prone Intermediate in Cataract-linked Mutants of
Human γD-Crystallin. J. Biol. Chem. 2016, 291, 19172-19183.
(345) Serpooshan, V.; Mahmoudi, M.; Zhao, M.; Wei, K.; Sivanesan, S.; Motamedchaboki, K.;
Malkovskiy, A. V.; Goldstone, A. B.; Cohen, J. E.; Yang, P. C.; Rajadas, J.; Bernstein, D.; Woo, Y. J.;
Ruiz-Lozano, P., Protein Corona Influences Cell–Biomaterial Interactions in Nanostructured Tissue
Engineering Scaffolds. Adv. Funct. Mater. 2015, 25, 4379-4389.
(346) Sheikh, A. M.; Michikawa, M.; Kim, S. U.; Nagai, A., Lysophosphatidylcholine increases the
neurotoxicity of Alzheimer’s amyloid β1-42 peptide: Role of oligomer formation. Neuroscience 2015,
292, 159-169.
(347) Sheikh, A. M.; Nagai, A., Lysophosphatidylcholine modulates fibril formation of amyloid beta
peptide. FEBS J. 2011, 278, 634-642.
(348) Shen, Y.; Posavec, L.; Bolisetty, S.; Hilty, F. M.; Nyström, G.; Kohlbrecher, J.; Hilbe, M.;
Rossi, A.; Baumgartner, J.; Zimmermann, M. B.; Mezzenga, R., Amyloid fibril systems reduce,
stabilize and deliver bioavailable nanosized iron. Nat. Nanotechnol. 2017, 12, 642-647.
(349) Shtilerman, M. D.; Ding, T. D.; Lansbury, P. T., Molecular Crowding Accelerates Fibrillization
of α-Synuclein:  Could an Increase in the Cytoplasmic Protein Concentration Induce Parkinson's
Disease? Biochemistry 2002, 41, 3855-3860.
(350) Siekierska, A.; De Baets, G.; Reumers, J.; Gallardo, R.; Rudyak, S.; Broersen, K.; Couceiro, J.;
Van Durme, J.; Schymkowitz, J.; Rousseau, F., α-Galactosidase Aggregation Is a Determinant of
Pharmacological Chaperone Efficacy on Fabry Disease Mutants. J. Biol. Chem. 2012, 287, 28386-
28397.
(351) Sipe, J. D.; Benson, M. D.; Buxbaum, J. N.; Ikeda, S.-I.; Merlini, G.; Saraiva, M. J. M.;
Westermark, P., Nomenclature 2014: Amyloid fibril proteins and clinical classification of the
amyloidosis. Amyloid 2014, 21, 221-224.
(352) Smith, C. A.; Want, E. J.; O'Maille, G.; Abagyan, R.; Siuzdak, G., XCMS: Processing Mass
Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and
Identification. Anal. Chem. 2006, 78, 779-787.
(353) Smith, D. P.; Ciccotosto, G. D.; Tew, D. J.; Fodero-Tavoletti, M. T.; Johanssen, T.; Masters,
C. L.; Barnham, K. J.; Cappai, R., Concentration Dependent Cu2+ Induced Aggregation and Dityrosine
Formation of the Alzheimer's Disease Amyloid-β Peptide. Biochemistry 2007, 46, 2881-2891.
222 
(354) Solassol, J.; Crozet, C.; Perrier, V.; Leclaire, J.; Béranger, F.; Caminade, A.-M.; Meunier, B.;
Dormont, D.; Majoral, J.-P.; Lehmann, S., Cationic phosphorus-containing dendrimers reduce prion
replication both in cell culture and in mice infected with scrapie. J. Gen. Virol. 2004, 85, 1791-1799.
(355) Soldi, G.; Bemporad, F.; Torrassa, S.; Relini, A.; Ramazzotti, M.; Taddei, N.; Chiti, F.,
Amyloid Formation of a Protein in the Absence of Initial Unfolding and Destabilization of the Native
State. Biophys. J. 2005, 89, 4234-4244.
(356) Sonawane, S. K.; Ahmad, A.; Chinnathambi, S., Protein-Capped Metal Nanoparticles Inhibit
Tau Aggregation in Alzheimer's Disease. ACS Omega 2019, 4, 12833-12840.
(357) Song, Q.; Huang, M.; Yao, L.; Wang, X.; Gu, X.; Chen, J.; Chen, J.; Huang, J.; Hu, Q.; Kang,
T.; Rong, Z.; Qi, H.; Zheng, G.; Chen, H.; Gao, X., Lipoprotein-Based Nanoparticles Rescue the
Memory Loss of Mice with Alzheimer’s Disease by Accelerating the Clearance of Amyloid-Beta. ACS
Nano 2014, 8, 2345-2359.
(358) Sörgjerd, K. M.; Zako, T.; Sakono, M.; Stirling, P. C.; Leroux, M. R.; Saito, T.; Nilsson, P.;
Sekimoto, M.; Saido, T. C.; Maeda, M., Human Prefoldin Inhibits Amyloid-β (Aβ) Fibrillation and
Contributes to Formation of Nontoxic Aβ Aggregates. Biochemistry 2013, 52, 3532-3542.
(359) Sorokina, S. A.; Stroylova, Y. Y.; Shifrina, Z. B.; Muronetz, V. I., Disruption of Amyloid Prion
Protein Aggregates by Cationic Pyridylphenylene Dendrimers. Macromol. Biosci. 2016, 16, 266-275.
(360) Sorrentino, V.; Romani, M.; Mouchiroud, L.; Beck, J. S.; Zhang, H.; D'Amico, D.; Moullan,
N.; Potenza, F.; Schmid, A. W.; Rietsch, S.; Counts, S. E.; Auwerx, J., Enhancing mitochondrial
proteostasis reduces amyloid-β proteotoxicity. Nature 2017, 552, 187-193.
(361) Sparr, E.; Engel, M. F. M.; Sakharov, D. V.; Sprong, M.; Jacobs, J.; de Kruijff, B.; Höppener,
J. W. M.; Killian, J. A., Islet Amyloid Polypeptide-Induced Membrane Leakage Involves Uptake of
Lipids by Forming Amyloid Fibres. FEBS Lett. 2004, 577, 117-120.
(362) Srodulski, S.; Sharma, S.; Bachstetter, A. B.; Brelsford, J. M.; Pascual, C.; Xie, X. S.; Saatman,
K. E.; Van Eldik, L. J.; Despa, F., Neuroinflammation and neurologic deficits in diabetes linked to brain
accumulation of amylin. Mol. Neurodegener. 2014, 9, 30.
(363) Stanley, W. J.; Litwak, S. A.; Quah, H. S.; Tan, S. M.; Kay, T. W.; Tiganis, T.; de Haan, J. B.;
Thomas, H. E.; Gurzov, E. N., Inactivation of Protein Tyrosine Phosphatases Enhances Interferon
Signaling in Pancreatic Islets. Diabetes, 2015, 64, 2489-2496.
(364) Stanyon, H. F.; Viles, J. H., Human Serum Albumin Can Regulate Amyloid-β Peptide Fiber
Growth in the Brain Interstitium. J. Biol. Chem. 2012, 2012, 28163-28168.
(365) Stine, W. B.; Dahlgren, K. N.; Krafft, G. A.; LaDu, M. J., In Vitro Characterization of
Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis. J. Biol. Chem. 2003, 278,
11612-11622.
(366) Stine, W. B.; Jungbauer, L.; Yu, C.; LaDu, M. J., Preparing Synthetic Aβ in Different
Aggregation States. Methods Mol. Biol. 2011, 670, 13-32.
223 
(367) Sun, Y.; Käkinen, A.; Xing, Y.; Pilkington, E. H.; Davis, T. P.; Ke, P. C.; Ding, F., Nucleation
of β-rich oligomers and β-barrels in the early aggregation of human islet amyloid polypeptide. Biochim.
Biophys. Mol. Basis Dis. 2019, 1865, 434-444.
(368) Supattapone, S.; Nguyen, H.-O. B.; Cohen, F. E.; Prusiner, S. B.; Scott, M. R., Elimination of
prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. U.S.A. 1999,
96, 14529-14534.
(369) Supattapone, S.; Wille, H.; Uyechi, L.; Sarfar, J.; Tremblay, P.; Szoka, F. C.; Cohen, F. E.;
Prusiner, S. B.; Scott, M. R., Branched Polyamines Cure Prion-Infected Neuroblasoma Cells. J. Virol.
2001, 75, 3453-3461.
(370) Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.;
Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K. P.; Kuhn, M.; Bork, P.; Jensen, L. J.; von Mering, C.,
STRING v10: Protein-Protein Interaction Networks, Integrated Over the Tree of Life. Nucleic Acids
Res. 2015, 43, D447-D452.
(371) Szklarczyk, D.; Morris, J. H.; Cook, H.; Kuhn, M.; Wyder, S.; Simonovic, M.; Santos, A.;
Doncheva, N. T.; Roth, A.; Bork, P.; Jensen, L. J.; von Mering, C., The STRING Database in 2017:
Quality-Controlled Protein–Protein Association Networks, Made Broadly Accessible. Nucleic Acids
Res. 2017, 45, D362-D368.
(372) Tamamis, P.; Adler-Abramovich, L.; Reches, M.; Marshall, K.; Sikorski, P.; Serpell, L.; Gazit,
E.; Archontis, G., Self-Assembly of Phenylalanine Oligopeptides: Insights from Experiments and
Simulations. Biophys. J. 2009, 96, 5020-5029.
(373) Tang, F.; Li, L.; Chen, D., Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and
Drug Delivery. Adv. Mater. 2012, 24, 1504-1534.
(374) Teo, J.; McCarroll, J. A.; Boyer, C.; Youkhana, J.; Sagnella, S. M.; Duong, H. T. T.; Liu, J.;
Sharbeen, G.; Goldstein, D.; Davis, T. P.; Kavallaris, M.; Phillips, A. P., A Rationally Optimized
Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in
Vivo. Biomacromolecules 2016, 17, 2337-2351.
(375) Törnquist, M.; Michaels, T. C. T.; Sanagavarapu, K.; Yang, X.; Meisl, G.; Cohen, S. I. A.;
Knowles, T. P. J.; Linse, S., Secondary nucleation in amyloid formation. Chem. Commun. 2018, 54,
8667-8684.
(376) Trigo, D.; Nadais, A.; da Cruz e Silva, O. A. B., Unravelling protein aggregation as an ageing
related process or a neuropathological response. Ageing Res. Rev. 2019, 51, 67-77.
(377) Tuttle, M. D.; Comellas, G.; Nieuwkoop, A. J.; Covell, D. J.; Berthold, D. A.; Kloepper, K. D.;
Courtney, J. M.; Kim, J. K.; Barclay, A. M.; Kendall, A.; Wan, W.; Stubbs, G.; Schwieters, C. D.; Lee,
V. M. Y.; George, J. M.; Rienstra, C. M., Solid-State NMR Structure of a Pathogenic Fibril of Full-
Length Human α-Synuclein. Nat. Struc. Mol. Biol. 2016, 23, 409-415.
224 
(378) Umahara, T.; Uchihara, T.; Tsuchiya, K.; Nakamura, A.; Iwamoto, T.; Ikeda, K.; Takasaki, M.,
14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer’s disease.
Acta Neuropathol. 2004, 108, 279-286.
(379) Usov, I.; Mezzenga, R., FiberApp: An Open-Source Software for Tracking and Analyzing
Polymers, Filaments, Biomacromolecules and Fibrous Objects. Macromolecules 2015, 48, 1269-1280.
(380) Uversky, V. N.; Cooper, M. E.; Bower, K. S.; Li, J.; Fink, A. L., Accelerated α-synuclein
fibrillation in crowded milieu. FEBS Lett. 2002, 515, 99-103.
(381) Vaiana, S. M.; Ghirlando, R.; Yau, W.-M.; Eaton, W. A.; Hofrichter, J., Sedimentation Studies
on Human Amylin Fail to Detect Low-Molecular-Weight Oligomers. Biophys. J. 2008, 94, L45-L47.
(382) Van der Munnik, N. P.; Moss, M. A.; Uline, M. J., Obstacles to translating the promise of
nanoparticles into viable amyloid disease therapeutics. Phys. Biol. 2019, 16, 021002.
(383) van Diggelen, F.; Tepper, A. W. J. W.; Apetri, M. M.; Otzen, D. E., α-Synuclein Oligomers: A
Study in Diversity. Isr. J. Chem. 2016, 57, 699-723.
(384) Vetri, V.; Foderà, V., The route to protein aggregate superstructures: Particulates and amyloid-
like spherulites. FEBS Lett. 2015, 589, 2448-2463.
(385) Vidal, J.; Verchere, C. B.; Andrikopoulos, S.; Wang, F.; Hull, R. L.; Cnop, M.; Olin, K. L.;
LeBoeuf, R. C.; O'Brien, K. D.; Chait, A.; Kahn, S. E., The Effect of Apolipoprotein E Deficiency on
Islet Amyloid Deposition in Human Islet Amyloid Polypeptide Transgenic Mice. Diabetologia 2003,
46, 71-79.
(386) Viles, J. H., Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper,
zinc and iron in Alzheimer's, Parkinson's and prion diseases. Coord. Chem. Rev. 2012, 256, 2271-2284.
(387) Vogiatzi, T.; Xilouri, M.; Vekrellis, K.; Stefanis, L., Wild Type α-Synuclein Is Degraded by
Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells. J. Biol. Chem. 2008, 283,
23542-23556.
(388) Wadghiri, Y. Z.; Sigurdsson, E. M.; Sadowski, M.; Elliott, J. I.; Li, Y.; Scholtzova, H.; Tang,
C. Y.; Aguinaldo, G.; Pappolla, M.; Duff, K.; Wisniewski, T.; Turnbull, D. H., Detection of Alzheimer's
amyloid in transgenic mice using magnetic resonance microimaging. Magn. Res. Med. 2003, 50, 293-
302.
(389) Wadman, M.; Servick, K., Alzheimer’s drug resurrected, as company claims clinical benefits.
Science 2019.
(390) Walkey, C. D.; Chan, C. W., Understanding and Controlling the Interaction of Nanomaterials
With Proteins in a Physiological Environment. Chem. Soc. Rev. 2012, 41, 2780-2799.
(391) Walsh, D. M.; Selkoe, D. J., Aβ Oligomers - a decade of discovery. J. Neurochem. 2007, 101,
1172-1184.
(392) Wang, B.; Geitner, N. K.; Davis, T. P.; Ke, P. C.; Ladner, D. L.; Ding, F., Deviation from the
Unimolecular Micelle Paradigm of PAMAM Dendrimers Induced by Strong Interligand Interactions J.
Phys. Chem. C, 2015, 119, 19475-19484.
225 
(393) Wang, B.; Pilkington, E. H.; Sun, Y.; Davis, T. P.; Ke, P. C.; Ding, F., Modulating protein
amyloid aggregation with nanomaterials. Environ. Sci. Nano, 2017, 4, 1772-1783.
(394) Wang, J.; Liu, L.; Ge, D.; Zhang, H.; Feng, Y.; Zhang, Y.; Chen, M.; Dong, M., Differential
Modulating Effect of MoS2 on Amyloid Peptide Assemblies. Chem. Eur. J. 2018, 24, 3397-3402.
(395) Wang, M.; Käkinen, A.; Pilkington, E. H.; Davis, T. P.; Ke, P. C., Differential Effects of Silver
and Iron Oxide Nanoparticles on IAPP Aggregation and Toxicity. Biomater. Sci. 2017, 5, 485-493.
(396) Wang, M.; Sun, Y.; Cao, X.; Peng, G.; Javed, I.; Käkinen, A.; Davis, T. P.; Lin, S.; Liu, J.;
Ding, F.; Ke, P. C., Graphene quantum dots against human IAPP aggregation and toxicity in vivo.
Nanoscale 2018, 10, 19995-20006.
(397) Wang, X.; Zhou, Y.; Ren, J.-J.; Hammer, N. D.; Chapman, M. R., Gatekeeper residues in the
major curlin subunit modulate bacterial amyloid fiber biogenesis. Proc. Natl. Acad. Sci. U.S.A. 2010,
107, 163-168.
(398) Wang, Y.; Mandelkow, E., Degradation of tau protein by autophagy and proteasomal pathways.
Biochem. Soc. Trans. 2012, 40, 644-652.
(399) Weids, A. J.; Ibstedt, S.; Tamás, M. J.; Grant, C. M., Distinct stress conditions result in
aggregation of proteins with similar properties. Sci. Rep. 2016, 6, 24554.
(400) Westermark, P.; Andersson, A.; Westermark, G. T., Islet Amyloid Polypeptide, Islet Amyloid,
and Diabetes Mellitus. Physiol. Rev. 2011, 91, 795-826.
(401) Westermark, P.; Li, Z.-C.; Westermark, G. T.; Leckström, A.; Steiner, D. F., Effects of beta
cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett. 1996, 379,
203-206.
(402) Westermark, P.; Skinner, M.; Cohen, A. S., The P-Component of Amyloid of Human Islets of
Langerhans. Scand. J. Immunol. 1975, 4, 95-97.
(403) Wickham, H. ggplot2: Elegant Graphics for Data Analysis. http://ggplot2.org.
(404) Wilhelmus, M. M. M.; Boelens, W. C.; Otte-Höller, I.; Kamps, B.; de Waal, R. M. W.; Verbeek,
M. M., Small heat shock proteins inhibit amyloid-β protein aggregation and cerebrovascular amyloid-
β protein toxicity. Brain Res. 2006, 1089, 67-78.
(405) Willander, H.; Presto, J.; Askarieh, G.; Biverstal, H.; Frohm, B.; Knight, S. D.; Johansson, J.;
Linse, S., BRICHOS domains efficiently delay fibrillation of amyloid β-peptide. J. Biol. Chem. 2012,
287, 31608-31617.
(406) Wojtas, A. M.; Kang, S. S.; Olley, B. M.; Gatherer, M.; Shinohara, M.; Loranzo, P. A.; Liu, C.
C.; Kurti, A.; Baker, K. E.; Dickson, D. W.; Yue, M.; Petrucelli, L.; Bu, G.; Carare, R. O.; Fryer, J. D.,
Loss of Clusterin Shifts Amyloid Deposition to the Cerebrovasculature via Disruption of Perivascular
Drainage Pathways. Proc. Natl. Acad. Sci. U.S.A. 2017, 114, E6962-E6971.
(407) Woodruff, J. B.; Hyman, A. A.; Boke, E., Organization and Function of Non-dynamic
Biomolecular Condensates. Trends Biochem. Sci. 2018, 43, 81-94.
226 
(408) Wördehoff, M. M.; Bannach, O.; Shaykhalishahi, H.; Kulawik, A.; Schiefer, S.; Willbold, D.;
Hoyer, W.; Birkmann, E., Single Fibril Growth Kinetics of α-Synuclein. J. Mol. Biol. 2015, 427, 1428-
1435.
(409) Wu, Y.; Hudson, J. S.; Lu, Q.; Moore, J. M.; Mount, A. S.; Rao, A. M.; Alexov, E.; Ke, P. C.,
Coating Single-Walled Carbon Nanotubes with Phospholipids. J. Phys. Chem. B 2006, 110, 2475-2478.
(410) Xing, Y.; Pilkington, E. H.; Wang, M.; Nowell, C. J.; Käkinen, A.; Sun, Y.; Wang, B.; Davis,
T. P.; Ding, F.; Ke, P. C., Lysophosphatidylcholine modulates the aggregation of human islet amyloid
polypeptide. Phys. Chem. Chem. Phys. 2017, 19, 30627-30635.
(411) Xu, J.; Reumers, J.; Couceiro, J. R.; De Smet, F.; Gallardo, R.; Rudyak, S.; Cornelis, A.;
Rozenski, J.; Zwolinska, A.; Marine, J.-C.; Lambrechts, D.; Suh, Y.-A.; Rousseau, F.; Schymkowitz,
J., Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol.
2011, 7, 285-295.
(412) Yamamoto, S.; Hasegawa, K.; Yamaguchi, I.; Tsutsumi, S.; Kardos, J.; Goto, Y.; Gejyo, F.;
Naiki, H., Low Concentrations of Sodium Dodecyl Sulfate Induce the Extension of β2-Microglobulin-
Related Amyloid Fibrils at a Neutral pH. Biochemistry 2004, 43, 11075-11082.
(413) Yan, P.; Bero, A. W.; Cirrito, J. R.; Xiao, Q.; Hu, X.; Wang, Y.; Gonzales, E.; Holtzman, D.
M.; Lee, J.-M., Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice. J.
Neurosci. 2009, 29, 10706-10714.
(414) Yerbury, J. J.; Kumita, J. R.; Meehan, S.; Dobson, C. M.; Wilson, M. R., α2-Macroglobulin
and Haptoglobin Suppress Amyloid Formation by Interacting with Prefibrillar Protein Species. J. Biol.
Chem. 2009, 284, 4246-4254.
(415) Yerbury, J. J.; Poon, S.; Meehan, S.; Thompson, B.; Kumita, J. R.; Dobson, C. M.; Wilson, M.
R., The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with
prefibrillar structures. FASEB J. 2007, 21, 2312-2322.
(416) Yin, S.; Biedermannova, L.; Vondrasek, J.; Dokholyan, N. V., MedusaScore: An Accurate
Force-Field Based Scoring Function for Virtual Drug Screening. J. Chem. Inf. Model. 2008, 48, 1656-
1662.
(417) Yoo, B. K.; Xiao, Y.; McElheny, D.; Ishii, Y., E22G Pathogenic Mutation of β‐Amyloid (Aβ)
Enhances Misfolding of Aβ40 by Unexpected Prion-like Cross Talk between Aβ42 and Aβ40. J. Am.
Chem. Soc. 2018, 140, 2781-2784.
(418) Yoo, S. I.; Yang, M.; Brender, J. R.; Subramanian, V.; Sun, K.; Joo, N. E.; Jeong, S.-H.;
Ramamoorthy, A.; Kotov, N. A., Inhibition of Amyloid Peptide Fibrillation by Inorganic Nanoparticles:
Functional Similarities with Protein. Angew. Chem. Int. Ed., Engl. 2011, 50, 5110-5115.
(419) Yoshimura, Y.; Lin, Y.; Yagi, H.; Lee, Y.-H.; Kitayama, H.; Sakurai, K.; Masatomo, S.; Ogi,
H.; Naiki, H.; Goto, Y., Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates
from their kinetics of formation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 14446-14451.
227 
(420) Young, I. D.; Ailles, L.; Narindrasorasak, S.; Tan, R.; Kisilevsky, R., Localization of the
Basement Membrane Heparan Sulfate Proteoglycan in Islet Amyloid Deposits in Type II Diabetes
Mellitus. Arch. Pathol. Lab. Med. 1992, 116, 951-954.
(421) Young, L. M.; Cao, P.; Raleigh, D. P.; Ashcroft, A. E.; Radford, S. E., Ion Mobility
Spectrometry-Mass Spectrometry Defines the Oligomeric Intermediates in Amylin Amyloid Formation
and the Mode of Action of Inhibitors. J. Am. Chem. Soc. 2014, 136, 660-670.
(422) Young, L. M.; Mahood, R. A.; Saunders, J. C.; Tu, L.-H.; Raleigh, D. P.; Radford, S. E.;
Ashcroft, A. E., Insights Into the Consequences of Co-Polymerisation in the Early Stages of IAPP and
Aβ Peptide Assembly From Mass Spectrometry. Analyst 2015, 140, 6990-6999.
(423) Yu, Y.-P.; Zhang, S.; Liu, Q.; Li, Y.-M.; Wang, C.; Besenbacher, F.; Dong, M., 2D Amyloid
Aggregation of Human Islet Amyloid Polypeptide at the Solid-Liquid Interface. Soft Matter 2012, 8,
1616-1622.
(424) Zhang, C.; Wan, X.; Zheng, X.; Shao, X.; Liu, Q.; Zhang, Q.; Qian, Y., Dual-functional
nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials 2014,
35, 456-465.
(425) Zhang, Q.; Bolisetty, S.; Cao, Y.; Handschin, S.; Adamcik, J.; Peng, Q.; Mezzenga, R.,
Selective and Efficient Removal of Fluoride from Water: In Situ Engineered Amyloid Fibril/ZrO2
Hybrid Membranes. Angew. Chem. Int. Ed., Engl. 2019, 58, 6012-6016.
(426) Zhang, S.; Andreasen, M.; Nielson, J. T.; Liu, L.; Nielson, E. H.; Song, J.; Ji, G.; Sun, F.;
Skrydstrup, T.; Besenbacher, F.; Nielson, N. C.; Otzen, D. E.; Dong, M., Coexistence of ribbon and
helical fibrils originating from hIAPP20-29 revealed by quantitative nanomechanical atomic force
microscopy. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 2798-2803.
(427) Zhang, S.; Liu, H.; Chuang, C. L.; Li, X.; Au, M.; Zhang, L.; Phillips, A. R. J.; Scott, D. W.;
Cooper, G. J. S., The pathogenic mechanism of diabetes varies with the degree of overexpression and
oligomerization of human amylin in the pancreatic islet β cells. FASEB J. 2014, 28, 5083-5096.
(428) Zhang, W.; Christofferson, A. J.; Besford, Q. A.; Richardson, J. J.; Guo, J.; Ju, Y.; Kempe, K.;
Yarovsky, I.; Caruso, F., Metal-dependent inhibition of amyloid fibril formation: synergistic effects of
cobalt–tannic acid networks. Nanoscale 2019, 11, 1921-1928.
(429) Zhang, Y.-J.; Gendron, T. F.; Xu, Y.-F.; Ko, L.-W.; Yen, S.-H.; Petrucelli, L., Phosphorylation
regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal
fragments. Mol. Neurodegener. 2010, 5, 33.
(430) Zhao, J.; Gao, W.; Yang, Z.; Li, H.; Gao, Z., Nitration of amyloid-β peptide (1–42) as a
protective mechanism for the amyloid-β peptide (1–42) against copper ion toxicity. J. Inorg. Biochem.
2019, 190, 15-23.
(431) Zheng, X.; Baker, H.; Hancock, W. S.; Fawaz, F.; McCaman, M.; Pungor Jr., E., Proteomic
analysis for the assessment of different lots of fetal bovine serum as a raw material for cell culture. Part
228 
IV. Application of proteomics to the manufacture of biological drugs. Biotechnol. Progr. 2006, 22,
1294-1300.
(432) Zhou, L.; Chen, Z.; Dong, K.; Yin, M.; Ren, J.; Qu, X., DNA‐Mediated Construction of Hollow
Upconversion Nanoparticles for Protein Harvesting and Near‐Infrared Light Triggered Release. Adv.
Mater. 2014, 26, 2424-2430.
(433) Zhu, B.; Jiang, L.; Huang, T.; Zhao, Y.; Liu, T.; Li, X.; Campos, A.; Pomeroy, K.; Masliah, E.;
Zhang, D.; Xu, H., ER-associated degradation regulates Alzheimer's amyloid pathology and memory
function by modulating γ-secretase activity. Nat. Commun. 2017, 8, 1472.
(434) Zhu, X.; Wen, Y.; Zhao, Y.; Liu, Y.; Sun, J.; Liu, J.; Chen, L., Functionalized chitosan-modified
defect-related luminescent mesoporous silica nanoparticles as new inhibitors for hIAPP aggregation.
Nanotechnology 2019, 30, 315705.
(435) Zimmerman, S. B.; Trach, S. O., Estimation of macromolecule concentrations and excluded
volume effects for the cytoplasm of Escherichia coli. J. Mol. Biol. 1991, 222, 599-620.
(436) Zraika, S.; Hull, R. L.; Verchere, C. B.; Clark, A.; Potter, K. J.; Fraser, P. E.; Kahn, S. E., Toxic
oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?
Diabetologia 2010, 53, 1046-1056.
